

WO 2012/165914 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(10) International Publication Number
WO 2012/165914 A2

(43) International Publication Date
6 December 2012 (06.12.2012)

(51) International Patent Classification:
A61K 31/357 (2006.01) A61K 31/015 (2006.01)
A61K 31/343 (2006.01) A61P 3/00 (2006.01)
A61K 31/35 (2006.01)

(21) International Application Number:
PCT/KR2012/004366

(22) International Filing Date:
1 June 2012 (01.06.2012)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
61/492,143 1 June 2011 (01.06.2011) US

(71) Applicant (for all designated States except US): **GREEN CROSS CORPORATION [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHOI, Soongyu [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). SONG, Kwang-Seop [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). LEE, Suk Ho [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). KIM, Min Ju [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). SEO, Hee Jeong [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). PARK, Eun-Jung [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). KONG, Young-gyu [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). PARK, So Ok [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). KANG, Hyunku [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). JUNG, Myung Eun [KR/KR]; #303, Bojeong-**

dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). **LEE, Kinam [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). KIM, Hyun Jung [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). LEE, Jun Sung [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). LEE, Min Woo [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). KIM, Mi-Sooon [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). HONG, Dong Ho [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR). KANG, Misuk [KR/KR]; #303, Bojeong-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-770 (KR).**

(74) Agent: **FIRSTLAW P.C.; Trust Tower, 275-7 Yangjae-Dong, Seocho-Ku, Seoul 137-739 (KR).**


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS

FIG. 1



(57) Abstract: The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.



Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

DESCRIPTION**NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS****FIELD OF THE INVENTION**

5

The present invention relates to a novel compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating diabetes.

BACKGROUND OF THE INVENTION

The prevalence of diabetes has become an increasing concern to the world's population. An estimated 285 million people, corresponding to 6.4% of the world's adult population, will live with diabetes in 2010. The number is expected to grow to 438 million by 2030, corresponding to 7.8% of the adult population. Diabetes is characterized by a chronic metabolic disorder that is caused by failure of the body to produce insulin and/or an inability of the body to respond adequately to circulating insulin. Secreted by the pancreas, insulin increases the ability of tissue to absorb blood glucose. Accordingly, disruption of insulin function results in the high level of blood glucose that is commonly associated with diabetic patients. There are two generally recognized form of diabetes: Type 1 diabetes, or insulin-dependent diabetes mellitus (IDDM), is characterized as an autoimmune disease involving pancreatic β -cells, while type 2 diabetes, or noninsulin-dependent diabetes mellitus (NIDDM), is characterized by β -cell dysfunction and insulin resistance. Type 2 diabetes is the most prevalent abnormality of glucose homeostasis, accounting for approximately 90-95% of all cases of diabetes. The diabetes has been widespread throughout the whole world due to ageing populations and rapid cultural changes such as increasing urbanization, dietary change, decreased physical activity and other unhealthy behavioral patterns.

The burden of diabetes is driven by vascular complications such as cardiovascular disease, stroke, nephropathy, retinopathy, renal failure, and lower limb infection and gangrene. Although these complications result from multiple metabolic disorders, hyperglycemia is considered as the main cause of both the vascular consequences of the disease and the progressive nature of diabetes itself. Most harmful of all is that high glucose levels aggravate insulin resistance, impair β -cell function and

finally contribute to β -cell apoptosis. The loss of β -cell function deteriorates hyperglycemia, resulting in a vicious cycle that culminates in the abject destruction of the β -cells. The United Kingdom Prevention of Diabetes Study (UKPDS) showed that incremental reductions in glycosylated hemoglobin (HbA1C) lowered the risk of 5 diabetes-related events [Stratton, I. M. *et al. Br. Med. J.* **2000**, *321*, 405-412]. Thus, it is recommended that patients with type 2 diabetes should reduce HbA1C values to 7% and less.

The most important strategy for treatment of type 2 diabetes involves lifestyle interventions that promote body weight loss, leading to an improvement in glycemic 10 control. In case lifestyle interventions are not enough for the management of diabetes, an extensive range of antidiabetic drugs might be considered for the treatment of the condition (monotherapies and combination therapies). These therapies target the liver to reduce glucose output, small intestine to decrease glucose absorption, adipose deposits or muscle to elevate glucose cellular uptake or to promote glucose metabolism, serum 15 proteases to prolong incretin action, and the pancreas to enhance insulin release. Despite the wide range of antihyperglycemic agent, it is difficult for many patients to achieve HbA1C target level. In a study reviewing diabetic patients for control of vascular risk factors, only 37.0% of participants achieved the target goal of HbA1C level of less than 7.0% [Saydah, S. H. *et al. J. Am. Med. Assoc.* **2004**, *291*, 335-342]. In addition, current 20 therapies have limited durability and/or are associated with significant side effects such as gastrointestinal intolerance, hypoglycemia, weight gain, lactic acidosis and edema. Thus, significant unmet medical needs still remain for the treatment of diabetes. In particular, safer, better tolerated medications which provide increased efficacy and long-term durability are desired.

25 The obvious need for new approaches to treat patients with uncontrolled type 2 diabetes has promoted continuous exploration of alternative targets in organs involved in maintenance of glucose homeostasis. In the context of type 2 diabetes, renal glucose reabsorption contributes to plasma glucose levels and the concomitant microvascular complications. Evaluation of molecular targets available in the kidney (a major 30 unexploited contributor to glucose homeostasis) stimulated interest in the development of a new class of antihyperglycemic agents that promote urinary glucose excretion. Inhibitors of the SGLT2 prevent renal glucose reabsorption from the glomerular filtrate and provide an insulin-independent way of controlling hyperglycemia.

35 Sodium-dependent glucose cotransporters (SGLTs) couple the transport of glucose against a concentration gradient with the simultaneous transport of Na^+ down a concentration gradient. Two important SGLT isoforms have been cloned and identified

as SGLT1 and SGLT2. SGLT1 is located in the gut, kidney, and heart where its expression regulates cardiac glucose transport. SGLT1 is a high-affinity, low-capacity transporter and therefore accounts for only a small fraction of renal glucose reabsorption. In contrast, SGLT2 is a low-affinity, high-capacity transporter located exclusively at the 5 apical domain of the epithelial cells in the early proximal convoluted tubule. In healthy individuals, greater than 99% of the plasma glucose that filtered in the kidney glomerulus is reabsorbed, resulting in less than 1% of the total filtered glucose being excreted in urine. It is estimated that 90% of renal glucose reabsorption is facilitated by SGLT2; the remaining 10% is likely mediated by SGLT1 in the late proximal straight 10 tubule. Genetic mutations in SGLT2 lead to increased renal glucose excretion of as much as 140 g/day depending on the mutation with no apparent adverse effects on carbohydrate metabolism. Since SGLT2 appears to be responsible for the majority of renal glucose reabsorption based on human mutation studies, it has become a target of therapeutic interest [Lee, J. *et al.* *Bioorg. Med. Chem.* **2010**, *18*, 2178-2194; van den 15 Heuvel, L. P. *et al.* *Hum. Genet.* **2020**, *111*, 544-547].

Phlorizin was isolated from the root bark of the apple tree and evaluated as the first SGLT inhibitor. Despite antidiabetic potency of phlorizin, its metabolic instability due to β -glucosidase cleavage in the intestinal tract has prevented its development as a drug for the treatment of diabetes. Subsequently, T-1095, by Tanabe Seiyaku, was 20 reported as the first orally absorbable SGLT2 inhibitor, overcoming the disadvantage of phlorizin. T-1095 was absorbed in the intestine and converted to an active form, T-1095A. Following the discovery of T-1095, O-aryl glucosides such as sergliflozin and remogliflozin advanced furthest in clinical trials. Again, concern regarding gut β -glucosidase-mediated degradation, resulted in developing sergliflozin A and 25 remogliflozin A being administered as the ethyl carbonate prodrugs sergliflozin and remogliflozin, respectively. Subsequent endeavors to identify SGLT2 inhibitors suitable for oral administration without the need for a prodrug led to the discovery of C-aryl glucoside-derived SGLT2 inhibitors. C-aryl glucoside appears to have drug-like properties with enhanced chemical stability of the glucosidic bond. Extensive SAR 30 studies by Bristol-Myers Squibb identified dapagliflozin, a potent, selective SGLT2 inhibitor for the treatment of type 2 diabetes. At present, dapagliflozin is the most advanced SGLT2 inhibitor in clinical trials and is believed to be the first SGLT2 inhibitor to go to market [Meng, W. *et al.* *J. Med. Chem.* **2008**, *51*, 1145-1149]. On the other hand, Mitsubishi Tanabe Pharma, in collaboration with Johnson & Johnson, is 35 developing canagliflozin, another novel C-aryl glucoside-derived SGLT2 inhibitor [Tanabe Seiyaku, WO2008013321].

Considering the important impact of diabetes on public health and unmet medical needs of current therapy, it is no surprise that SGLT2 inhibitors are currently interesting topics of studies, which were published in the following review articles [Washburn, W. N. *Expert Opin. Ther. Patents*, **2009**, *19*, 1485-1499; Washburn, W. N. *J. Med. Chem.* **2009**, *52*, 1785-1794].

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a novel compound bearing a diphenylmethane moiety of formula I, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, which is effective as SGLT2 inhibitor, useful for the prevention and/or treatment of metabolic disorders, particularly diabetes.

It is another object of the present invention to provide a method for preparing the inventive compound.

It is another object of the present invention to provide a pharmaceutical composition for preventing or treating metabolic disorders, particularly diabetes.

It is yet another object of the present invention to provide a method for preventing or treating a metabolic disorder, particularly diabetes, in a mammal.

It is still another object of the present invention to provide a method for inhibiting sodium-dependent glucose cotransporter 2 (SGLT2) in a mammal.

It is a further object of the present invention to provide a use of the inventive compound.

In accordance with one aspect of the present invention, there is provided a compound of formula I, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein formula I is as defined herein.

In accordance with another aspect of the present invention, there is provided a method for preparing the compound of formula I-a of claim 1, comprising:

(a) reacting a compound of formula II with a compound of formula III to obtain a compound of formula IV; and

(b) deprotecting and reducing the compound of formula IV to obtain a compound of formula I-a, wherein formulae II, III, IV and I-a are as defined herein.

In accordance with another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating a metabolic disorder, comprising as an active ingredient the compound of formula I, or a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutically acceptable carrier.

In accordance with yet another aspect of the present invention, there is provided a

method for preventing or treating a metabolic disorder in a mammal, which comprises administering the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof to the mammal.

In accordance with still another aspect of the present invention, there is provided a method for inhibiting sodium-dependent glucose cotransporter 2 (SGLT2) in a mammal, which comprises administering the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof to the mammal.

In accordance with a further aspect of the present invention, there is provided a use of the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof for the manufacture of a medicament for preventing or treating a metabolic disorder.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "alkyl" refers to a straight or branched chain saturated hydrocarbon radical. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl and hexyl.

As used herein, the term "substituted alkyl" refers to a straight or branched chain saturated hydrocarbon radical, which is optionally substituted by one or more substituents selected from the group consisting of C₁₋₃ alkyl optionally having one to three fluorine substituents, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₂ alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, ureido, nitro, cyano and halogen.

As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond. Examples of "alkenyl" as used herein include, but are not limited to, ethenyl and propenyl.

As used herein, the term "substituted alkenyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond, which has optional substituents selected from the group consisting of C₁₋₃ alkyl optionally having one to three fluorine substituents, amino, aryl, cyano and halogen.

As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond. Examples of "alkynyl" as used herein include, but are not limited to, acetylenyl and 1-propynyl.

As used herein, the term "substituted alkynyl" refers to a straight or branched

chain hydrocarbon radical having at least one carbon-carbon triple bond, optionally having one or more substituents selected from the group consisting of C₁₋₃ alkyl optionally having one to three fluorine substituents, amino, aryl and halogen.

As used herein, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).

As used herein, the term "carbocycle" refers to a non-aromatic cyclic hydrocarbon radical composed of three to seven carbon atoms. Five-to seven-membered rings may contain a double bond in the ring structure. Exemplary "carbocycle" groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, 10 cyclohexyl and cycloheptyl.

As used herein, the term "substituted carbocycle" refers to a non-aromatic cyclic hydrocarbon radical composed by three to seven carbon atoms, which is optionally substituted with one or more substituents selected from the group consisting of C₁₋₃ alkyl optionally having one to three fluorine substituents, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₂ 15 alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heterocyclic, aminosulfonyl, sulfonylamino, carboxamide, nitro, ureido, cyano and halogen.

As used herein, the term "aryl" refers to an optionally substituted benzene ring or refers to a ring system which may result by fusing one or more optional substituents. Exemplary optional substituents include substituted C₁₋₃ alkyl, substituted C₂₋₃ alkenyl, substituted C₂₋₃ alkynyl, heteroaryl, heterocyclic, aryl, alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, 25 carboxamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido. Such a ring or ring system may be optionally fused to aryl rings (including benzene rings) optionally having one or more substituents, carbocycle rings or heterocyclic rings. Examples of "aryl" groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, indanyl, anthracyl or phenanthryl, as well as 30 substituted derivatives thereof.

As used herein, the term "heteroaryl" refers to an optionally substituted monocyclic five to six-membered aromatic ring containing one or more heteroatomic substitutions selected from S, SO, SO₂, O, N, or N-oxide, or refers to such an aromatic ring fused to one or more rings such as heteroaryl rings, aryl rings, heterocyclic rings, or 35 carbocycle rings (e.g., a bicyclic or tricyclic ring system), each having optional substituents.

Examples of optional substituents are selected from the group consisting of substituted C₁₋₃ alkyl, substituted C₂₋₃ alkenyl, substituted C₂₋₃ alkynyl, heteroaryl, heterocyclic, aryl, C₁₋₃ alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, 5 sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen or ureido. Examples of "heteroaryl" groups used herein include, but are not limited to, benzoimidazolyl, benzothiazolyl, benzoisothiazolyl, benzothiophenyl, benzopyrazinyl, benzotriazolyl, benzo[1,4]dioxanyl, benzofuranyl, 9H-a-carbolinyl, cinnolinyl, furanyl, furo[2,3-10 b]pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoxazolyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, indolizinyl, naphthyridinyl, oxazolyl, oxothiadiazolyl, oxadiazolyl, phthalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl, phenazinyl, pyrazolyl, pyridyl, pyrazolopyrimidinyl, pyrrolizinyl, pyridazyl, pyrazinyl, pyrimidyl, 4-oxo-1, 2-dihydro-4H-pyrrolo[3,2,1-ij]-quinolin-4-yl, quinoxalinyl, quinazolinyl, quinolinyl, 15 quinolizinyl, thiophenyl, triazolyl, triazinyl, tetrazolopyrimidinyl, triazolopyrimidinyl, tetrazolyl, thiazolyl, thiazolidinyl, and substituted versions thereof.

As used herein, the term "heterocyclic" refers to a three to seven-membered ring containing one or more heteroatomic moieties selected from S, SO, SO₂, O, N, or N-oxide, optionally substituted with one or more substituents selected from the group which includes substituted C₁₋₃ alkyl, substituted C₂₋₃ alkenyl, substituted C₂₋₃ alkynyl, heteroaryl, heterocyclic, aryl, C₁₋₃ alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, and ureido. Such a ring can be saturated or have one or more degrees of unsaturation. Such a ring may be optionally fused to one or more "heterocyclic" ring(s), aryl ring(s), heteroaryl ring(s) or carbocycle ring(s), each having optional substituents.

Examples of "heterocyclic" moieties include, but are not limited to, 1,4-dioxanyl, 30 1,3-dioxanyl, pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, imidazolidine-2,4-dione piperidinyl, piperazinyl, piperazine-2,5-dionyl, morpholinyl, dihydropyranyl, dihydrocinnolinyl, 2,3-dihydrobenzo [1,4] dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]-dioxepinyl, tetrahydropyranyl, 2,3-dihydrofuranyl, 2,3-dihydrobenzofuranyl, dihydroisoxazolyl, tetrahydrobenzodiazepinyl, tetrahydroquinolinyl, tetrahydrofuranyl, 35 tetrahydronaphthyridinyl, tetrahydropurinyl, tetrahydrothiopyranyl, tetrahydrothiophenyl, tetrahydroquinoxalinyl, tetrahydropyridinyl, tetrahydrocarbolinyl,

4H-benzo[1,3]-dioxinyl, benzo[1,3]dioxonyl, 2,2-difluorobenzo-[1,3]-dioxonyl, 2,3-dihydro-phthalazine-1,4-dionyl, and isoindole-1,3-dionyl.

As used herein, the term "alkoxy" refers to the group -OR_a, where R_a is alkyl as defined above. Exemplary alkoxy groups useful in the present invention include, but are not limited to, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and t-butoxy.

As used herein the term "aralkoxy" refers to the group -OR_aR_b, wherein R_a is alkyl and R_b is aryl as defined above.

As used herein the term "aryloxy" refers to the group -OR_b, wherein R_b is aryl as defined above.

As used herein, the term "mercapto" refers to the group -SH.

As used herein, the term "sulfanyl" refers to the group -SR_c, wherein R_c is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "sulfinyl" refers to the group -S-(O)R_c, wherein R_c is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "sulfonyl" refers to the group -S(O)₂R_c, wherein R_c is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "oxo" refers to the group =O.

As used herein, the term "hydroxy" refers to the group -OH.

As used herein, the term "amino" refers to the group -NH₂. The amino group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "cyano" refers to the group -CN.

As used herein, the term "aminosulfonyl" refers to the group -S(O)₂NH₂. The aminosulfonyl group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "sulfonylamino" refers to the group -NHS(O)₂R_c wherein R_c is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "carboxyamide" refers to the group -NHC(O)R_c wherein R_c is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "carboxy" refers to the group -C(O)OH. The carboxy

group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "aminocarbonyl" refers to the group -C(O)NH₂. The aminocarbonyl group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "ureido" refers to the group -NHC(O)NHR_d wherein R_d is hydrogen, alkyl, carbocycle or aryl as defined above.

As used herein, the term "guanidino" refers to the group -NHC(=NH)NH₂.

As used herein, the term "acyl" refers to the group -C(O)R_e, wherein R_e is alkyl, carbocycle, or heterocyclic as defined herein.

As used herein, the term "aryloyl" refers to the group -C(O)R_b, wherein R_b is aryl as defined herein.

As used herein, the term "heteroaroyl" refers to the group -C(O)R_f, wherein R_f is heteroaryl as defined herein.

As used herein, the term "acyloxy" refers to the group -OC(O)R_e, wherein R_e is alkyl, carbocycle, or heterocyclic as defined herein.

As used herein, the term "aryloxy" refers to the group -OC(O)R_b, wherein R_b is aryl as defined herein.


As used herein, the term "heteroaroyloxy" refers to the group -OC(O)R_f, wherein R_f is heteroaryl as defined herein.

It is to be understood that the present invention also includes a pharmaceutically acceptable salt and an addition salt of the inventive compound, such as a hydrochloride, hydrobromide or trifluoroacetate addition salt and a sodium, potassium and magnesium salt.

Further, it should be construed that the present invention also includes prodrugs of the inventive compound. The term "prodrug" refers to a pharmacologically inactive compound that is converted to an active drug by a metabolic biotransformation. Examples of the prodrug include carrier-linked prodrugs (e.g., ester analogs), and bioprecursor prodrugs. Those skilled in the art can easily design and prepare suitable prodrugs based on the inventive compound.

The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are incorporated within the scope of the present invention.


In one aspect of the present invention, the compound of the present invention has the following structure:



wherein,

X is oxygen or sulfur;

Y is C₁₋₇ alkyl, C₂₋₇ alkenyl, C₂₋₇ alkynyl, C₁₋₇ alkoxy, C₁₋₇ alkoxy-C₁₋₇ alkyl, C₁₋₇ alkylsulfinyl, C₁₋₇ alkylsulfonyl, or C₁₋₇ alkylthio;
5 ring A is



said R_{1a}, R_{1b}, R_{4a}, R_{4b} and W being each independently selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, cyano, nitro, amino, carboxy, C₁₋₇ alkyl, C₂₋₇ alkenyl, C₂₋₇ alkynyl, C₁₋₇ alkoxy, C₁₋₇ alkoxy-C₁₋₇ alkyl, C₂₋₇ alkenyl-C₁₋₇ alkoxy, C₂₋₇ alkynyl-C₁₋₇ alkoxy, C₃₋₁₀ cycloalkyl, C₅₋₁₀ cycloalkenyl, C₃₋₁₀ cycloalkyloxy, phenyl-C₁₋₇ alkoxy, mono- or di-C₁₋₇ alkylamino, C₁₋₇ alkanoyl, C₁₋₇ alkanoylamino, C₁₋₇ alkoxycarbonyl, carbamoyl, mono- or di-C₁₋₇ alkylcarbamoyl, C₁₋₇ alkylsulfonylamino, phenylsulfonylamino, C₁₋₇ alkylsulfanyl, C₁₋₇ alkylsulfinyl, C₁₋₇ alkylsulfonyl, C₆₋₁₄ arylsulfanyl, C₆₋₁₄ arylsulfonyl, C₆₋₁₄ aryl, 5 to 13-membered heteroaryl, or 5 to 10-membered heterocycloalkyl,
10

said R₂ being each independently hydroxy, C₁₋₇ alkyl, or C₁₋₇ alkoxy,



said n being an integer of 0 to 3,

said Z₁, Z₂, and Z₃ being each independently -CH₂-, -CH=, -(CO)-, -O-, -S-, -

15 NH-, or -N=, and

said p being an integer of 1 to 3;


ring B is




with the proviso that when ring A is A-1, then ring B is B-2,
wherein,

- said R_{5a}, R_{5b}, R_{6a}, and R_{6b} being each independently selected from the group
5 consisting of hydrogen, halogen, hydroxy, mercapto, cyano, nitro, amino, carboxy, oxo,
C₁₋₇alkyl, C₁₋₇alkylthio, C₂₋₇alkenyl, C₂₋₇alkynyl, C₁₋₇alkoxy, C₁₋₇alkoxy-C₁₋₇alkyl, C₂₋₇
alkenyl-C₁₋₇alkyloxy, C₂₋₇alkynyl-C₁₋₇alkyloxy, C₃₋₁₀cycloalkyl, C₃₋₇cycloalkylthio, C₅₋₁₀
cycloalkenyl, C₃₋₁₀cycloalkyloxy, C₃₋₁₀cycloalkyloxy-C₁₋₇alkoxy, phenyl-C₁₋₇alkyl, C₁₋₇
alkylthio-phenyl, phenyl-C₁₋₇alkoxy, mono- or di-C₁₋₇alkylamino, mono- or di-C₁₋₇
10 alkylamino-C₁₋₇alkyl, C₁₋₇alkanoyl, C₁₋₇alkanoylamino, C₁₋₇alkylcarbonyl, C₁₋₇
alkoxycarbonyl, carbamoyl, mono- or di-C₁₋₇alkylcarbamoyl, C₁₋₇alkylsulfonylamino,
phenylsulfonylamino, C₁₋₇alkylsulfinyl, C₆₋₁₄arylsulfanyl, C₆₋₁₄arylsulfonyl, C₆₋₁₄aryl, 5
to 13-membered heteroaryl, 5 to 10-membered heterocycloalkyl, 5 to 10-membered
heterocycloalkyl-C₁₋₇alkyl, or 5 to 10-membered heterocycloalkyl-C₁₋₇alkoxy, and
15 said ring C being C₃₋₁₀cycloalkyl, C₅₋₁₀cycloalkenyl, C₆₋₁₄aryl, 5 to 13-membered
heteroaryl, or 5 to 10-membered heterocycloalkyl;
said alkyl, alkenyl, alkynyl; or alkoxy is optionally substituted with at least one
substituent selected from the group consisting of halogen, hydroxy, cyano, nitro, amino,
mercapto, C₁₋₇alkyl, and C₂₋₇alkynyl; and
20 said cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocycloalkyl is optionally
substituted with at least one substituent selected from the group consisting of halogen,
hydroxy, cyano, nitro, amino, mercapto, C₁₋₄alkyl, and C₁₋₄alkoxy.


- In one embodiment of the present invention, ring A-2 may be selected from the
25 group consisting of:





In another embodiment of the present invention, ring B-1 may be selected from the group consisting of:


5



in which R₇ is hydrogen, or C₁₋₇ alkyl, and
R_{8a} and R_{8b} are each independently C₁₋₇ alkyl, or R_{8a} and R_{8b} are connected to form

a 5 to 10-membered heterocycloalkyl.

In yet another embodiment of the present invention, ring B-2 may be selected from the group consisting of:



In a preferred embodiment of the present invention, ring A is a benzene, indane, indene, dihydrobenzofuran, dihydroisobenzofuran, benzofuran, dihydrobenzothiophene, benzothiophene, tetrahydronaphthalene, dihydronaphthalene, chroman, chromene, isochroman, isochromene, benzodioxole, benzodioxane, benzoazoxazine, tetrahydroquinoline, tetrahydroquinoxaline, tetrahydroisoquinoline, indazole, indole, indoline, benzoimidazole, benzoazazole, benzothiazole, benzotriazole, quinazoline, quinoxaline, cinnoline, phthalazine, or benzotriazine ring, which is optionally substituted with a substituent as defined herein.

15

In a preferred embodiment of the present invention, ring B is a quinoline, quinoxaline, 3,4-dihydro-2H-benzo[b][1,4]dioxepine, 2,3-dihydrobenzo[b]thiophene, indazole, indole, 2,3-dihydrobenzo[b][1,4]dioxine, benzodioxole, indane, tetrahydronaphthalene, 3,4-dihydro-2H-thiochromene, dihydrobenzofuran, benzo[d][1,3]oxathiole, tetrahydroquinoline, or 3,4-dihydro-2H-benzo[b][1,4]oxazine ring, which is optionally substituted with a substituent as defined herein.

Compounds especially useful in the present invention are selected from the group consisting of:

25 (1) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-

4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(2) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(3) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(4) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(5) (2S,3R,4R,5S,6R)-2-(7-fluoro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

10 (6) (2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(6-(4-methoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran-3,4,5-triol;

(7) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

15 (8) (2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(9) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(10) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

20 (11) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(12) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

25 (13) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-methoxybenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(14) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethylbenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(15) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

30 (16) (2S,3R,4R,5S,6R)-2-(6-(4-ethylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(17) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

35 (18) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(19) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)chroman-5-yl)-6-

(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(20) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

5 (21) (2S,3R,4R,5S,6R)-2-(5-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(22) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

10 (23) (2S,3R,4R,5S,6R)-2-(5-(4-(ethoxybenzyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(24) (2S,3R,4R,5S,6R)-2-(5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(25) (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-methyl-5-(thiophen-3-yl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

15 (26) (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-methyl-5-(thiophen-2-yl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(27) (2S,3R,4R,5S,6S)-2-(7-bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol;

20 (28) (2S,3R,4R,5S,6R)-2-(8-chloro-7-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(29) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

25 (30) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(31) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

30 (32) (2S,3R,4R,5S,6R)-2-(6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(33) (2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

35 (34) (2S,3R,4R,5S,6R)-2-(2-(allyloxy)-4-chloro-5-(4-methoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;

(35) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-

(methylthio)tetrahydro-2H-pyran-3,4,5-triol;

(36) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triol;

(37) (2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-5-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;

(38) (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;

(39) (2S,3R,4R,5S,6S)-2-(2-(allyloxy)-4-chloro-5-(4-methoxybenzyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol;

10 (40) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(dimethylamino)benzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(41) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-vinylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

15 (42) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(43) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-vinylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(44) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

20 (45) ((2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-cyclopropylbenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(46) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-(trifluoromethyl)benzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

25 (47) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-chlorobenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(48) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(trifluoromethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(49) (2S,3R,4S,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-methyltetrahydro-2H-pyran-3,4,5-triol;

30 (50) (2S,3R,4R,5S,6S)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(fluoromethyl)tetrahydro-2H-pyran-3,4,5-triol;

(51) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(1-hydroxyethyl)tetrahydro-2H-pyran-3,4,5-triol;

35 (52) (2S,3R,4R,5S,6S)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(difluoromethyl)tetrahydro-2H-pyran-3,4,5-triol;

(53) (2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-7-methyl-2,3-dihydrobenzofuran-

4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(54) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

5 (55) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(56) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(57) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-cyclopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

10 (58) (2S,3R,4R,5S,6R)-2-(4-chloro-2-methyl-5-(4-propylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(59) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

15 (60) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(61) (2S,3R,4R,5S,6R)-2-(7-chloro-2-methyl-6-(4-vinylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(62) ((2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

20 (63) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(64) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(methylamino)benzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 2,2,2-trifluoroacetate

25 (65) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(methylamino)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 2,2,2-trifluoroacetate

(66) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

30 (67) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(68) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(69) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;

35 (70) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triol;

- (71) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-((S)-methylsulfinyl)tetrahydro-2H-pyran-3,4,5-triol;
- (72) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;
- 5 (73) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (74) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- 10 (75) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2,3-dimethoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (76) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-3-hydroxy-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- 15 (77) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-3-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (78) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-(methylthio)benzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- 20 (79) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-cyclopropylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (80) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- 25 (81) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (82) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- 30 (83) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (84) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- 35 (85) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (86) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (87) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-cyclopropylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- 40 (88) (2S,3R,4R,5S,6R)-2-(9-chloro-8-(4-ethoxybenzyl)-3,4-dihydro-2H-

benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(89) (2S,3R,4R,5S,6R)-2-(9-chloro-8-(4-ethylbenzyl)-3,4-dihydro-2H-
benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(90) (2S,3R,4R,5S,6R)-2-(6-benzyl-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-
5 (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(91) 1-((7-chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-
yl)methyl)phenyl)ethanone;
(92) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(1-hydroxyethyl)benzyl)-2,3-
10 dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(93) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(1-fluoroethyl)benzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(94) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-vinylbenzyl)-2,3-dihydrobenzofuran-4-
yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
15 (95) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(96) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-cyclopropylbenzyl)benzofuran-7-yl)-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
20 (97) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(2-hydroxypropan-2-yl)benzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(98) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(difluoromethyl)benzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
25 (99) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(1,1-difluoroethyl)benzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(100) (2S,3R,4R,5S,6R)-2-(6-(4-cyclopropylbenzyl)-7-methyl-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
30 (101) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(2-hydroxybut-3-yn-2-yl)benzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(102) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(prop-1-en-2-yl)benzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
35 (103) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropylbenzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(104) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethynylbenzyl)-2,3-
dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
(105) 4-((7-chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-

yl)methyl)benzonitrile;

(106) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-propylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

5 (107) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol;

(108) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(methylthio)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(109) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(dimethylamino)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

10 (110) (2S,3R,4R,5S,6R)-2-(4-chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(111) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-hydroxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

15 (112) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(3-hydroxypropoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(113) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-propoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

20 (114) 4-chloro-5-(4-methoxybenzyl)-7-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one;

(115) (2S,3R,4R,5S,6R)-2-(4-chloro-3-hydroxy-5-(4-methoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(116) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-(dimethylamino)benzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

25 (117) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(2-cyclopropoxymethoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(118) (2S,3R,4R,5S,6R)-2-(6-(4-(azetidin-1-yl)benzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

30 (119) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(trifluoromethoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(120) 2-(4-((7-chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methyl)phenyl)acetonitrile;

35 (121) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(oxetan-3-yloxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(122) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropoxybenzyl)-2,3-

- dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (123) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(cyclopropylthio)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (124) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((5-methoxythiophen-2-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (125) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-methoxybenzyl)chroman-8-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;
- (126) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (127) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (128) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (129) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethylbenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (130) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (131) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (132) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (133) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (134) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (135) (2S,3R,4R,5S,6R) -2-(4-chloro-5-(4-ethoxybenzyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (136) (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(pyrrolidin-1-yl)benzyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (137) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (138) (2S,3R,4R,5S,6R) -2-(4-chloro-5-(4-ethoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (139) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (140) (2S,3R,4R,5S,6R) -2-(7-chloro-6-(4-ethoxybenzyl)-3,3-dimethyl-2,3-

dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(141) 7-chloro-6-(4-ethoxybenzyl)-4-(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one

(142) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-3-methoxy-2,3-

5 dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(143) (2S,3R,4R,5S,6R)-2-(7-cyclopropyl-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(144) (2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-7-propyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

10 (145) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((1,2,3,4-tetrahydroquinolin-7-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(146) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

15 (147) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(cyclopentyloxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(148) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopentylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

20 (149) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclobutoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(150) (2S,3R,4R,5S,6R)-2-(6-(4-tert-butylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

25 (151) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclobutylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;

(152) (2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(153) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

30 (154) (2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(155) (2S,3R,4R,5S,6R)-2-(6-(4-(azetidin-1-yl)benzyl)-7-chloro-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

35 (156) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzo[b]thiophen-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(157) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)thiochroman-5-yl)-6-

(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(158) (2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(3-(4-methoxybenzyl)-4-methyl-5,6,7,8-tetrahydronaphthalen-1-yl)tetrahydro-2H-pyran-3,4,5-triol;

(159) (2S,3R,4R,5S,6R)-2-(4-chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol; and

(160) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.

10 The inventive compound of formula I is effective as an inhibitor against sodium-dependent glucose cotransporter (SGLT2), thereby preventing or treating a metabolic disease.

15 Accordingly, the present invention provides a pharmaceutical composition for preventing or treating a metabolic disorder, which comprises the compound of formula I, or a pharmaceutically acceptable salt or a prodrug thereof as an active ingredient, and a pharmaceutically acceptable carrier.

The metabolic disorder may be diabetes, cardiovascular disease, or hypertension, preferably diabetes.

20 Further, the present invention provides a method for preventing or treating a metabolic disorder in a mammal, which comprises administering the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof to the mammal.

Also, the present invention provides a method for inhibiting SGLT2 in a mammal, which comprises administering the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof to the mammal.

25 The pharmaceutical composition may be administered orally or parenterally, e.g., intramuscularly or subcutaneously. The formulation for oral administration may take various forms such as a syrup, tablet, capsule, cream and lozenge. A syrup formulation will generally contain a suspension or solution of the compound or its salt in a liquid carrier, e.g., ethanol, peanut oil, olive oil, glycerine or water, optionally with 30 a flavoring or coloring agent. When the composition is in the form of a tablet, any one of pharmaceutical carriers routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. When the composition is in the form of a capsule, any of the routine encapsulation procedures may be employed, e.g., using the aforementioned carriers in a hard gelatin capsule shell. When the composition is 35 formulated in the form of a soft gelatin shell capsule, any of the pharmaceutical carrier

routinely used for preparing dispersions or suspensions may be prepared using an aqueous gum, cellulose, silicate or oil. The formulation for intramuscular or subcutaneous administration may take a liquid form such as a solution, suspension and emulsion which includes aqueous solvents such as water, physiological saline and 5 Ringer's solution; or lipophilic solvents such as fatty oil, sesame oil, corn oil and synthetic fatty acid ester.

Preferably the composition is formulated in a specific dosage form for a particular patient.

Each dosage unit for oral administration contains suitably from 0.1 mg to 500 10 mg, and preferably from 1 mg to 100 mg of the compound of formula I or its pharmaceutically acceptable salt or prodrug.

The suitable daily dosage for oral administration is about 0.01 mg/kg body weight to 40 mg/kg body weight of the compound of formula I or its pharmaceutically acceptable salt or prodrug, and may be administered 1 to 6 times a day, depending on 15 the patient's condition.


The present invention further provides a use of the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof for the manufacture of a medicament for preventing or treating a metabolic disorder, particularly diabetes.

20 The compounds of present invention may be prepared by several synthetic procedures. The compounds of the present invention and the preparation thereof will be better understood in connection with the following synthetic schemes, which are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.

25


GENERAL SYNTHETIC SEQUENCE

Some particular compounds of the present invention such as compounds of formula I-a can be prepared by a) reacting a compound of formula II with a compound of 30 formula III to obtain a compound of formula IV; and (b) deprotecting and reducing the compound of formula IV to obtain a compound of formula I-a,




5 wherein, X, ring A and ring B are same as defined herein, Hal is halogen, and PG is trimethylsilyl or benzyl.


In one embodiment of the present invention, step (b) is carried out by deprotecting the compound of formula IV to obtain a compound of formula V, and reducing the 10 compound of formula V to obtain the compound of formula I-a, when PG is trimethylsilyl:



In another embodiment of the present invention, step (b) is carried out by reducing the compound of formula **IV** to obtain a compound of formula **VI**, and deprotecting the compound of formula **VI** to obtain the compound of formula **I-a**, when PG is benzyl:




Hereinafter, the particular examples of the procedure are described in detail.




Scheme 1

A general synthetic route to desired compound I-5 is illustrated in Scheme 1. Metal-halogen exchange of halogenated compound I-2, followed by addition of the nascent organo metallic compound to persilylated gluconolactone or thiogluconolactone (*Tetrahedron Lett.* 1981, 22, 5061-5062; *J. Med. Chem.* 2010, 53, 3247-3261) I-1, produces a mixture of the corresponding lactol I-3, which is converted *in situ* to the desilylated *O*-methyl lactol by treatment with methansulfonic acid in methanol at cold conditions (-78 ~ -40 °C). The reduction of the anomeric methoxy group of lactol I-4 using triethylsilane and boron trifluoride diethyl etherate is performed to generate the corresponding mixture of α,β-isomers. The required β-isomers I-5 are resolved by selective crystallization of peracetylated mixtures or prep. HPLC (reverse phase) of final compounds.



Scheme 2


Perbenzylated gluconolactone or thiogluconolactone (*Tetrahedron Lett.* 1981, 22, 5061-5062; *J. Med. Chem.* 2010, 53, 3247-3261) **II-1**, instead of persilylated gluconolactone or thiogluconolactone **I-1**, is also used to prepare the corresponding lactols **II-3**, which are reduced using triethylsilane and boron trifluoride diethyl etherate. Deprotection of benzyl groups is performed using Pd/C under hydrogen atmosphere or BCl_3 at low temperature ($< 0^\circ\text{C}$).



Scheme 3


A key intermediate **4** is prepared from compound **1** through three steps. The starting material **1** is converted into the corresponding 5-acetylated intermediate **2** by the Friedel-Crafts reaction with acetyl anhydride in quantitative yield. The methyl ketone compound **2** is brought into haloform reaction to obtain benzoic acid **3** at heating conditions (55°C). Bromination of the benzoic acid **3** with bromine and AgNO_3 gives the 2,5-dibromide intermediate **4** in acidic conditions.

The dibrominated benzoic acid **4** is converted to the corresponding acyl chloride **5**, which is used for the Friedel-Crafts acylation of compound **III-1** to provide the desired diarylketone **III-2**. Reduction of diarylketone **III-2** by triethylsilane in the presence of boron trifluoride etherate provides aglycon **III-3**. Alternatively, another desired aglycons **III-6** are also synthesized through Weinreb amide **9**, which is prepared from the acid **4** by treatment of *N,O*-dimethylhydroxylamine hydrochloride, HOBT, EDCI and NMM under mild conditions in good yield. Reaction of Weinreb amide **9** with proper organometallic nucleophiles, such as Grignard reagents **III-4**, produces the desired ketones **III-5**. Finally, the diarylketones **III-5** are reduced by triethylsilane in the presence of boron trifluoride etherate to yield aglycon **III-6**.



Scheme 4


Persilylated lactone **12** is coupled with aglycons **IV-1** (**III-3** or **III-6** in Scheme 3), prepared in Scheme 3, by lithium-halogen exchange reaction at low temperature (-78 °C). The produced lactols **IV-2** are converted *in situ* to the desilylated *O*-methyl lactols by treatment with methansulfonic acid in methanol at cold conditions (-78 ~ -40 °C). The reduction of the anomeric methoxy group of lactol **IV-3** using triethylsilane and boron trifluoride diethyl etherate is performed to generate the corresponding tetraol, and then the required β-isomers (**IV-4**) are separated by prep HPLC equipped with a reverse phase column. The derivative **IV-4** is debrominated to produce another derivative **IV-5** by hydrogenation with a palladium catalyst.




Scheme 5

Aglycons **V-1** (**III-3** or **III-6** in Scheme 3), prepared in Scheme 3, are incorporated into perbenzylated lactone **13** by lithium-halogen exchange reaction at low temperature (-78 °C). The produced lactols are reduced using triethylsilane and boron trifluoride diethyl etherate to provide bromide intermediates **V-2**, which are used as starting materials for further derivatizations, as illustrated in Scheme 5. The bromo substituent of intermediate **V-2** is converted into a chloro substituent **V-3** by the treatment of Cu(I)Cl at heating conditions (120 °C) in quantitative yield. The bromide intermediate **V-2** is lithiated with n-BuLi and subsequently reacted with *N*-fluorobenzenesulfonimide at low temperature (-78 °C) to afford the corresponding fluoride compound **V-5**. The lithiation of the bromide **V-2** followed by the treatment of iodomethane is also applied to prepare a methyl substituted derivative **V-7**. The bromide **V-2** is lithiated and treated with DMF to give a corresponding benzaldehyde, which is reacted with DAST ((diethylamino)sulfur trifluoride) to produce a difluoromethyl substituted compound **V-9**. The benzaldehyde is converted to a benzyl alcohol with NaBH₄, and the benzyl alcohol is treated with DAST to give a monofluoromethyl substituted compound **V-11**. Benzyl groups are deprotected by hydrogenation using Pd/C under hydrogen atmosphere and then the required β-isomers (**V-4**, **V-6**, **V-8**, **V-10**, **V-12**) are separated by prep HPLC equipped with a reverse phase column.

[Case A]




[Case B]



Scheme 6


A glycon moieties **VI-2**, containing an allyloxy group, are prepared from an acid **21** (refer to Scheme 8). The acid **21** is changed into the corresponding acyl chloride with oxalyl chloride, and subsequently coupled with substituted benzenes through the Friedel-Crafts acylation. The produced ketones **VI-1** are reduced by triethylsilane in
5 the presence of boron trifluoride etherate to yield aglycons **VI-2**. The aglycon **VI-2** is lithiated by treatment of n-BuLi and coupled with persilylated lactone to produce an α,β-mixture of lactol, which is converted into a desilylated *O*-methyl lactol **VI-3** by methanesulfonic acid. The anomeric methoxy group of compound **VI-3** is reduced using triethylsilane and boron trifluoride etherate. After peracetylation, the resulting
10 tetraacetate is recrystallized from ethanol to a pure β-anomer **VI-5**. Hydrolysis of compound **VI-5** with NaOMe generates a tetraol **VI-6** in quantitative yield. The tetraols **VI-6** are protected by treatment with benzyl bromide and NaH for next reactions. Finally, an allyl group of the perbenzylated intermediate **VI-7** is reductively
15 deprotected with NaBH₄ and a catalytic amount of Pd(PPh₃)₄ to yield the key intermediate **VI-8**, containing phenol moiety.

Case B, in Scheme 6, represents another route to a key intermediate **VI-10**, which also includes phenol moiety. The same starting material **21** is used to prepare desired ketones **VI-9** through Weinreb-amide, and then the similar reactions (from **VI-1** to **VI-8**, in Case A) are applied to produce **VI-10** from **VI-9**.



Scheme 7

The key intermediate **VII-1** (VI-8 or VI-10), prepared in Scheme 6, is selectively brominated at an *ortho*-position of the hydroxyl group by molecular bromine in acetic acid medium. Potassium carbonate mediated *O*-alkylation of phenol **VII-1** with proper bromoalcohols is carried out under mild heating conditions to give corresponding phenol ethers **VII-3**. The hydroxyl group of compound **VII-3** is replaced with chlorine using triphenylphosphine and CCl_4 to produce chlorinated compound **VII-4**. Treatment of n-BuLi produces heterocyclic compounds **VII-5**, such as dihydrobenzofuran, via cyclization of aryl bromide onto alkyl chloride. Debenzylation is carried out using Pd/C under hydrogen atmosphere to give final products **VII-6**.




Scheme 8

Commercially available cyanide **36** is used as a starting material. The selective


monobromination of compound **36** with NBS in acetonitrile is promoted by CF₃SO₃H. Phenol protection of compound **37** is carried out efficiently with allyl bromide in the presence of K₂CO₃. The resulting compound **38** is hydrolyzed with sodium hydroxide in aqueous ethanol, and subsequently converted to the corresponding methylester **39** using SOCl₂ and methanol. The silyl-protected alcohol **41** is prepared by reduction of the ester **39** with LiBH₄, and subsequent silylation of the resulting alcohol **40** with *tert*-butyldiphenylchlorosilane (TBDPSCl) in the presence of imidazole.

After lithiation of bromide **41** using n-BuLi, the lithiated aromatic compound is added to perbenzylated gluconolactone to generate a α,β-isomer mixture of the lactols **42**. The anomeric alcohol is reduced using triethylsilane and boron trifluoride diethyl etherate, and subsequently the selective deprotection of allyl group is performed by treatment of NaBH₄ and Pd(PPh₃)₄ to yield the key intermediate **44**. A heterocyclic intermediate **VIII-5** is prepared by the general procedure, described in Scheme 7 (from **VII-1** to **VII-5**). The cleavage of silyl ether **VIII-5** to alcohol **VIII-6** using TBAF is followed by replacement of a hydroxyl group with a bromine atom by treatment of PBr₃ in the presence of a catalytic amount of pyridine to produce the corresponding benzylbromide **VIII-7**. Proper phenylboronic acids are coupled with the benzylbromide **VIII-7**, through palladium-catalyzed reaction, Suzuki coupling, to provide compounds **VIII-8**, which are debenzylated using Pd/C under hydrogen atmosphere to yield final products **VIII-9**.

[Case A]




[Case B]



Scheme 9


A commercially available acid **51** is converted to the corresponding methyl ester **52** using MeI and K₂CO₃. The nitro group of **52** is changed to an amine group **53** by catalytic reduction under hydrogen atmosphere. Bromination of **53** is performed using
5 a brominating agent such as NBS to obtain compound **54**. The amine compound **54** is diazotized with NaNO₂ in acidic conditions, and then chlorinated with Cu(I)Cl to give compound **55**. Hydrolysis of compound **55** in basic conditions produces the benzoic acid **56**, which is reduced to the benzyl alcohol **57** with borane dimethylsulfide complex.
10 Silyl protection of the benzyl alcohol **57** is carried out using *tert*-butyldiphenylchlorosilane (TBDPSCl) in the presence of imidazole to provide a key intermediate **58**.

As shown in Case B (Scheme 9), another key intermediate **IX-2** is prepared from the acid **56**, which is already mentioned in Case A (Scheme 9). The acid **56** is converted to the corresponding acyl chloride **59** using oxalyl chloride and DMF as a
15 catalyst, and subsequently coupled with *N,O*-dimethylhydroxylamine hydrochloride to give Weinreb-amide **60**. Reaction of Weinreb amide **60** with proper organometallic nucleophiles, such as Grignard reagents, produces the diarylketones **IX-1**. On the other hand, the acyl chloride **59** is directly converted into the diarylketone **IX-1** through
20 the Friedel-Crafts reaction. The treatment of triethylsilane and boron trifluoride etherate reduces the ketone **IX-1** to provide the desired aglycon **IX-2**.




Scheme 10

The bromide **58**, prepared in Scheme 9, is lithiated with n-BuLi and is added to perbenzylated gluconolactone, and the resulting lactol is subsequently reduced and demethylated with NaSEt to provide compound **62**, containing a phenol moiety. A bromine atom is incorporated into the *ortho*-position of the phenol using bromine in acetic acid to provide bromophenol **63**. *O*-Alkylation of bromophenol **63** with a proper bromoalcohol is carried out under basic conditions to give the corresponding phenol ether **X-1**. The intermediate **X-1** can be converted into the final tetraol **X-3** via **X-2** (refer to Scheme 7 and Scheme 8).




Lithiation of the bromide **IX-2**, prepared in Scheme 9 [Case B], is followed by the coupling reation with perbenzylated gluconolactone to generate a mixture of lactol **XI-1**. Reduction of an anomeric hydroxyl group with Et_3SiH in the presence of $\text{BF}_3\cdot\text{OEt}_2$, and subsequent demethylation of **XI-2** using NaSEt produces the intermediate **XI-3**, containing a phenol group. Monobromination with bromine in an acidic medium provides an *ortho*-bromophenol compound **XI-4**. The treatment of a proper bromophenol and a base produces *O*-alkylated intermediate **XI-5**, which is cyclized by the same procedures used in Scheme 7 to generate compound **XI-6**. Deprotection of **XI-6** is performed using Pd/C under hydrogen atmosphere, and followed by chromatographical purification (reverse phase) to yield final compound **XI-7**.



Scheme 12


Another synthetic route through the ring-closing metathesis (RCM) is also developed to generate various heterobicyclic moieties, as shown in Scheme 12. 5 Compound 71 is treated with excess n-BuLi to produce an intermediate 82 containing an *o*-hydroxystyrene moiety. The phenol group of 82 is alkylated with allyl bromide under basic conditions, and followed by RCM using Grubb's 2nd generation catalyst to give a cyclized alkenyl compound 84. Hydrogenation using Pd/C under hydrogen atmosphere is performed for debenzylation and alkene reduction to yield a final 10 compound E023.




Scheme 13

The key intermediate **VII-3**, referred to in Scheme 7, is used for preparing other heterobicyclic moieties, as shown in Scheme 13. Palladium-catalyzed intramolecular etherification using a dialkylphosphinobiaryl ligand is applied to cyclization of **VII-3**. The produced heterobicycles **XIII-1** are subsequently debenzylated by hydrogenation to give final products **XIII-2**.

[Case A]



[Case B]




Scheme 14

Synthetic routes of other aglycons, containing various heterobicyclic moieties, are illustrated in Scheme 14. In Case A (Scheme 14), a branched heterobicyclic

moiety is prepared from compound **38** (refer to Scheme 8). Intramolecular cyclization of an allyl group generates a methyl-branched dihydrobenzofuran moiety of compound **87**. Subsequent hydrolysis with NaOH in aqueous ethanol produces the corresponding acid **88**. Treatment of oxalyl chloride in the presence of a catalytic amount of DMF 5 yields the acyl chloride, which is coupled with an aryl compound through the Friedel-Crafts reaction to generate the diarylketone **89**. Reduction of the ketone **89** with Et₃SiH and BF₃·OEt₂ gives the desired aglycon **90**. This aglycon **90** is coupled with the gluconolactone, deprotected, reduced, and purified to the final compound **E014** (refer to Scheme 1).

10 In Case B (Scheme 14), a benzothiophene moiety is prepared from compound **38** (refer to Scheme 8). Intramolecular migration of an allyl group by microwave radiation is performed to produce the key intermediate **91**. Compound **91** is coupled with dimethylthiocarbamoyl chloride in basic conditions to generate a thionoester **92**, which is converted into the corresponding thiocarbamate **93** through the Newman-Kwart rearrangement in heating conditions. Hydrolysis of **93** is followed by allylation 15 in the presence of K₂CO₃ to give compound **94**. The cyano group of compound **94** is efficiently converted to the corresponding methyl ester **95** by conventional procedures. Intramolecular cyclization of compound **95** by Grubb's 2nd generation catalyst generates a benzothiophene moiety **96**, which is treated with NaOH in aqueous ethanol and oxalyl 20 chloride to produce the corresponding acyl chloride. Friedel-Crafts acylation of the acyl chloride with an aryl compound generates the diarylketone **98**. Reduction of the ketone **98** with Et₃SiH and BF₃·OEt₂ gives the desired aglycon **99**. This aglycon **99** is coupled with the gluconolactone, deprotected, reduced, and purified to the final compound **E048** (refer to Scheme 1).


25



Scheme 15

As shown in Scheme 15, various phenyl moieties can be incorporated into the


benzyl bromide intermediates (**106** in Case A; **111** in Case B). Halogenated compounds (**100** or **107**) are lithiated with n-BuLi and followed by coupling with perbenzylated lactone **13**. The resulting lactols (**101** or **108**) are reduced by Et₃SiH and BF₃OEt₂. Deprotection of compound **102** and **109** is accomplished by TBAF-mediated desilylation to produce benzyl alcohols **103** and **110**. After esterification of compound **103** by benzyl chloride in the presence of pyridine, the required β -isomer **104** is resolved by selective crystallization from isopropanol. The β -isomer **104** is hydrolyzed by LiOH to give benzyl alcohol **105**. The benzyl alcohols (**105** and **110**) are brominated by treatment of PBr₃ with pyridine to generate the corresponding benzyl bromides (**106** and **111**). The Suzuki cross-coupling reaction between the benzyl bromides (**106** and **111**) and proper phenylboron compounds (Commercially unavailable phenylboron compounds are prepared in Scheme 16) produces the diphenylmethyl intermediates (**XV-1** or **XV-3**). Debenzylation of compound **XV-1** and **XV-3** is achieved by hydrogenation with Pd/C under hydrogen atmosphere or the treatment of BCl₃ at low temperature. Crude products are purified by prep HPLC equipped with a reverse phase column to provide pure β -isomers (**XV-2** or **XV-4**).



Scheme 16


20

Commercially available anilines **XVI-1** can be converted into the corresponding bromides **XVI-2** through the Sandmeyer reaction with NaNO₂ and CuBr. Palladium catalyzed borylation of **XVI-2** with bis(pinacolato)diboron is performed to generate the desired phenylboronic ester **XVI-3**. The boronic esters **XVI-3** are used for the Suzuki cross-coupling reaction mentioned in Scheme 8, 10 and 15.



Scheme 17


The starting bromides **XVII-1**, prepared by the known procedure
 5 (WO2008/101939, Example V), are used to provide arylphenyl linked compounds
XVII-2 through the Suzuki cross-coupling reaction with proper boronic acids.
 Deacetylation of compounds **XVII-2** with NaOMe produces final products **XVII-3**.




Scheme 18

As shown in Scheme 18 and 19, the main sugar core is changed from D-glucose to L-xylose. A morpholino amide **134** is provided from L-xylose **133** through the known procedures (WO 2009/014970 A1). A halogenated aglycon is coupled by the treatment of n-BuLi with the morpholino amide **134** to generate a ketone **135**, which is subsequently reduced to the corresponding alcohol, key intermediate **136**, by NaBH₄. In acidic conditions, the furanose **136** is changed to a pyranose, and then acetylated by a

conventional procedure to give a peracetylated compound **137**. A thiomethyl group is directly incorporated into the intermediate **137** by the treatment of thiourea and TMSOTf, followed by addition of MeI and DIPEA. The resulting methanthiopyranose **138** is deacetylated using NaOMe to give the final product **E095**. On the other hand, a methoxypyranose **140** is prepared via a bromide **139**. The treatment of intermediate **137** with HBr in acetic acid provides the xylopyranosyl bromide **139**, which is converted into the corresponding methoxypyranose **140** with ZnO in methanol. Deacetylation with NaOMe is achieved to yield the final product **E096**. The synthetic route for a compound **E097**, an isomer of methoxypyranose **E096**, is illustrated in Scheme 19. Peracetylated isomeric intermediate **143** is separated from **140** by prep HPLC equipped with a reverse column.




Scheme 19



As shown in Scheme 20, isodihydrobenzofuran moiety is prepared from 6-bromophthalide **144**. Reduction of compound **144** by DIBAL-H produces a lactol **145**. Ring-opening of the lactol **145** by addition of a Grignard reagent generates compound **XX-1**, and then alcohols are protected with TIPSCl and TIPSOTf in order to provide the aglycon **XX-2**. The resulting bromide **XX-2** is lithiated and coupled with persilylated lactone **12** to yield the corresponding lactol **XX-3**. Reduction of the lactol and desilylation is achieved by the treatment of Et_3SiH and $\text{BF}_3 \cdot \text{OEt}_2$, and subsequently acetylated with Ac_2O in basic conditions to provide peracetylated intermediate **XX-4**. The remained protection group of **XX-4** is deprotected by TBAF. Dehydration-

cyclization of the produced diol **XX-5** with *p*-TsCl generates an isodihydrofuran moiety of compound **XX-6**. Deacetylation and purification by prep HPLC equipped with a reverse column yields the required products **XX-7**.

5



Scheme 21

As shown in Scheme 21, various substituents, such as acetyl, hydroxyethyl, vinyl and cyclopropyl, are incorporated into para-position of the non-substituted phenyl ring (*Bioorg. Med. Chem. Lett.* 2011, 21, 4465-4470).

EXPERIMENTAL SECTION

As used herein the symbols and conventions used describing the processes, schemes and examples of the present invention are consistent with those used in the contemporary scientific literature, for example, the *Journal of the American Chemical Society* or the *Journal of Biological Chemistry*.

	Hz (Hertz)	T LC (thin layer chromatography)
10	T _r (retention time)	RP (reverse pH ase)
	MeOH (methanol)	i -PrOH (isopropanol)
	TFA (trifluoroacetic acid)	TEA (triethylamine)
	EtOH (ethanol)	THF (tetrahydrofuran)
	DMSO (dimethylsulfoxide)	EtOAc (ethyl acetate)
15	DCM (dichloromethane)	HOAc (acetic acid)
	DMF (<i>N,N</i> -dimethylformamide)	Ac (acetyl)
	CDI (1,1-carbonyldiimidazole)	Bn (benzyl)
	TES (Triethylsilyl)	NBS (<i>N</i> -Bromosuccinimide)
	HOBt (1-hydroxybenzotriazole)	
20	Boc (<i>tert</i> -butyloxycarbonyl)	
	mCPBA (meta-chloroperbenzoic acid)	
	NMM (<i>N</i> -methyl morpholine)	
	TBAF (tetra- <i>n</i> -butylammonium fluoride)	
	DMAP (4-dimethylaminopyridine)	
25	HPLC (high performance liquid chromatography)	
	EDCI (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride)	
	DME (1,2-dimethoxyethane)	
	AIBN (2,2'-azobis(2-methylpropionitrile))	
	DIEA (<i>N,N'</i> -diisopropylethylamine)	
30	TIPSCl (triisopropylsilyl chloride)	
	TIPSOTf (triisopropylsilyl trifluoromethanesulfonate)	
	TMSI (iodotrimethylsilane)	
	TMSOTf (trimethylsilyl trifluoromethanesulfonate)	
	DDQ (2,3-dichloro-5,6-dicyano- <i>p</i> -benzoquinone)	
35	DAST (diethylaminosulfur trifluoride)	
	NMP (1-methyl-2-pyrrolidinone)	


MW (microwave irradiation)

All reactions are conducted under an inert atmosphere at room temperature (rt or r.t.), unless otherwise noted. *n*-Butyllithium (Aldrich) was titrated with *N*-benzylbenzamide as indicator. All reagents were purchased at the highest commercial quality and used without further purification, unless otherwise indicated. All experiment involving moisture- and/or air-sensitive compounds were performed in oven- and/or flame-dried glassware with rubber septa under a positive pressure of nitrogen using standard Schlenck technique. Microwave reaction was conducted with a Biotage Initiator microwave reactor. NMR spectra were obtained on a Varian 400-MR (400 MHz ¹H, 100 MHz ¹³C) spectrometer or a Bruker Ultrashield 400 plus (400 MHz ¹H, 100 MHz ¹³C) spectrometer. NMR spectra were recorded in ppm (δ) relative to tetramethylsilane ($\delta = 0.00$) as an internal standard unless otherwise stated and are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, m = multiplet, and br = broad), coupling constant, and integration. ¹³C NMR spectra were referenced to the residual chloroform-*d*₁ ($\delta = 77.0$) or DMSO-*d*₆ ($\delta = 39.7$). Mass spectra were obtained with an Agilent 6110 quadruple LC-MSD (ESI+). High resolution mass spectra were obtained on a Jeol JMS-700 Mstation (10 kV, HFAB). Optical rotations were obtained on a Rudolph Autopol III digital polarimeter. Preparative HPLC purifications were performed on a Gilson purification system. For preparative HPLC, *ca.* 100 mg of a product was injected in 1 mL of methanol onto a SunFire Prep C18 OBD 5 μ m 30x100 mm Column with a 30 min gradient from 5 to 90% acetonitrile in water and a 45 mL/min flow rate. Biotage SP1 and Isolera purification systems were used for normal phase column chromatography with ethyl acetate and hexane. Flash chromatography was performed using E. Merck 230-400 mesh silica gel according to the procedure of Still *et al* (*J. Org. Chem.* **43**, 2923, 1978). Reactions were monitored by either thin-layer chromatography (TLC) on 0.25 mm E. Merck silica gel plates (60F-254) using UV light and *p*-anisaldehyde solution as visualizing agents or HPLC analysis on an Agilent 1200 series system.

The following synthetic schemes are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.

35

Preparation of the intermediates:




1-(2,3-Dihydro-1H-inden-5-yl)ethanone (2)

A mixture of indane (1, 12.25 mL, 0.10 mol) and Ac₂O (11.34 mL, 0.12 mol) was added dropwise for 1 h to a slurry of AlCl₃ (26.7 g, 0.2 mol) in DCM (100 mL) at 0 °C. The reaction mixture was warmed up to room temperature and stirred for 15 h. The mixture was cooled to 0 °C and quenched by slow addition of water (20~30 mL) and 1 M HCl (50 mL). The organic layer was separated, washed with brine and saturated NaHCO₃ solution, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The crude product **2** was dried under high vacuum and used without further purification (16.1 g, 0.10 mol, 100%).

¹H NMR (400 MHz, CDCl₃) δ 7.82 (s, 1H), 7.76 (d, *J* = 7.6 Hz, 1H), 7.29 (d, *J* = 7.6 Hz, 1H), 2.95 (t, *J* = 7.6 Hz, 4H), 2.58 (s, 3H), 2.12 (m, 2H); [M+H]⁺ 161.

15



2,3-Dihydro-1H-indene-5-carboxylic acid (3)

Bromine (20.5 mL, 0.4 mol) was added to a solution of KOH (72.9 g, 1.3 mol) in water (250 mL) at 0 °C. To the resulting solution was slowly added compound **2** (16.0 g, 0.1 mol) at 0 °C. The reaction mixture was heated at 55 °C overnight and quenched with Na₂S₂O₃ (14.8 g, 0.094 mol). The mixture was acidified to pH 2~3 with conc. HCl (40~50 mL). The precipitate was collected by filtration, and washed with water. The crude product **3** was dried under high vacuum and used without further purification (15.4 g, 0.095 mol, 95%).


25 ¹H NMR (400 MHz, CDCl₃) δ 10.89 (br s, -COOH, 1H), 7.95 (s, 1H), 7.90 (d, *J* = 8.0 Hz, 1H), 7.30 (d, *J* = 8.0 Hz, 1H), 2.97 (t, *J* = 7.6 Hz, 4H), 2.13 (m, 2H); [M+H]⁺ 163.



4,7-Dibromo-2,3-dihydro-1H-indene-5-carboxylic acid (4)

To a mixture of compound **3** (5.0 g, 30.8 mmol) and conc. HNO_3 (20.0 mL) in acetic acid (92 mL) was added dropwise bromine (4.6 mL, 62.1 mmol) and AgNO_3 (12.3 g, 72.6 mmol) in water (31 mL). After stirring at rt overnight, the reaction was quenched with brine (250 mL), and the mixture was extracted with ethyl acetate (450 mL). The organic layer was washed with brine, dried over anhydrous MgSO_4 , filtered and concentrated *in vacuo*. The crude product **4** was dried under high vacuum and used without further purification (8.5 g, 26.7 mmol, 87%).

10 ^1H NMR (400 MHz, CDCl_3) δ 7.96 (s, 1H), 3.16-3.09 (m, 4H), 2.16 (m, 2H); $[\text{M}+\text{H}]^+$ 321.



15 (4,7-Dibromo-2,3-dihydro-1H-inden-5-yl)(4-methoxyphenyl)methanone (5-1)

To a mixture of the crude acid **4** (12.1 g, 37.9 mmol) and catalytic amounts of DMF (0.45 mL) in DCM (63 mL) was added dropwise oxalyl chloride (4.95 mL, 56.8 mmol) at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at rt for 3 h and evaporated *in vacuo* to provide a crude acyl chloride (compound **5**). To a solution of compound **5** in DCM (67 mL) was added anisole (4.23 mL, 38.8 mmol) at 0 °C. After stirring for 5 min, AlCl_3 (5.2 g, 38.8 mmol) was added portionwise. The reaction mixture was warmed up to rt and stirred at rt overnight. After cooling to 0 °C, the reaction mixture was quenched with saturated NH_4Cl solution (50 mL) and extracted with DCM (100 mL). The organic layer was washed with brine, dried over anhydrous MgSO_4 , filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **5-1** (3.9 g, 9.5 mmol, 25%).

30 ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, $J = 11.6$ Hz, 2H), 7.26 (s, 1H), 6.94 (d, $J = 12.0$ Hz, 2H), 3.88 (s, 3H), 3.14-3.08 (m, 4H), 2.19 (m, 2H); $[\text{M}+\text{H}]^+$ 411.



4,7-Dibromo-5-(4-methoxybenzyl)-2,3-dihydro-1H-indene (6)

To a solution of ketone **5-1** (3.9 g, 9.5 mmol) in CH₂Cl₂/CH₃CN (31 mL/31 mL) were added triethylsilane (4.8 mL, 28.5 mmol) and boron trifluoride diethyl etherate (3.7 mL, 28.5 mmol) at 0 °C under nitrogen atmosphere. The mixture was warmed up to room temperature slowly and stirred at room temperature for 15 h. To the mixture was added saturated K₂CO₃ solution (50 mL) slowly and the mixture was extracted with EtOAc (100 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the desired product **6** (3.2 g, 8.1 mmol, 85%).


¹H NMR (400 MHz, CDCl₃) δ 7.11 (d, *J* = 8.8 Hz, 2H), 7.07 (s, 1H), 6.84 (d, *J* = 8.8 Hz, 2H), 3.99 (s, 2H), 3.79 (s, 3H), 3.06 (t, *J* = 7.8 Hz, 2H), 3.02 (t, *J* = 7.6 Hz, 2H), 2.11 (m, 2H).

15




(4,7-Dibromo-2,3-dihydro-1H-inden-5-yl)(4-ethoxyphenyl)methanone (7)

¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.8 Hz, 2H), 7.26 (s, 1H), 6.92 (d, *J* = 9.2 Hz, 2H), 4.11 (q, *J* = 7.2 Hz, 2H), 3.14-3.06 (m, 4H), 2.21-2.14 (m, 2H), 1.45 (t, *J* = 6.8 Hz, 3H); [M+H]⁺ 425.



4,7-Dibromo-5-(4-ethoxybenzyl)-2,3-dihydro-1H-indene (8)

¹H NMR (400 MHz, CDCl₃) δ 7.09 (d, *J* = 8.8 Hz, 2H), 7.07 (s, 1H), 6.82 (d, *J* = 8.8 Hz, 2H), 4.01 (q, *J* = 7.2 Hz, 2H), 3.98 (s, 2H), 3.08-2.98 (m, 4H), 2.12(m, 2H), 1.40 (t, *J* = 7.2 Hz, 3H).



4,7-Dibromo-N-methoxy-N-methyl-2,3-dihydro-1H-indene-5-carboxamide (9)

To a solution of acid **4** (4.8 g, 15.0 mmol) in CH₂Cl₂ (80 mL) were added EDCI (3.83 g, 20 mmol), HOBT (2.70 g, 20 mmol), NMM (8.8 mL, 80 mmol) and *N,O*-dimethylhydroxylamine-HCl (1.95 g, 20 mmol) at rt. The mixture was stirred at rt overnight. The reaction mixture was quenched with water (50 mL) and extracted with DCM (100 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **9** (0.27 g, 0.73 mmol, 7%).


10 ¹H NMR (400 MHz, CDCl₃) δ 7.26 (s, 1H), 3.51 (s, 3H), 3.36 (s, 3H), 3.10-3.04 (m, 4H), 2.14(m, 2H); [M+H]⁺ 364.



15 (4,7-Dibromo-2,3-dihydro-1H-inden-5-yl)(4-ethylphenyl)methanone (10)

To a solution of amide **9** (0.27 g, 0.73 mmol) in anhydrous THF (2.7 mL) was added dropwise 4-ethylphenylmagnesium bromide (3.65 mL of 0.5 M in THF, 1.83 mol) at 0 °C under nitrogen atmosphere. The mixture was warmed up to room temperature slowly and stirred at room temperature for 15 h. The reaction mixture was quenched with 1 M HCl solution (10 mL) and extracted with EtOAc (20 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **10** (0.25 g, 0.62 mmol, 85%).


25 [M+H]⁺ 409.



4,7-Dibromo-5-(4-ethylbenzyl)-2,3-dihydro-1H-indene (11)

¹H NMR (400 MHz, CDCl₃) δ 7.11 (d, *J* = 3.2 Hz, 4H), 7.09 (s, 1H), 4.02 (s, 2H), 3.08-2.99 (m, 4H), 2.62 (q, *J* = 7.6 Hz, 2H), 2.14(m, 2H), 1.22 (t, *J* = 7.2 Hz, 3H).


5



(3R,4S,5R,6R)-2-(7-Bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-3,4,5-tris(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)tetrahydro-2H-pyran-2-ol (14)

To a solution of bromide **6** (0.92 g, 2.32 mmol) in anhydrous THF (12.3 mL) was added dropwise *n*-BuLi (2.5 M in hexane, 1.21 mL, 3.02 mmol) at -78 °C under nitrogen atmosphere, and the mixture was stirred for 0.5-1 h at the same temperature. Then a solution of TMS-protected gluconolactone (1.41 g, 3.02 mmol) in THF (6 mL) was added dropwise, and the mixture was stirred for 3 h at the same temperature. The reaction mixture was quenched with saturated NH₄Cl solution (15 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to provide the crude intermediate **14**, which was used without further purification (2.03 g, 2.59 mmol, 111%). TLC (10% EtOAc/hexane) R_f=0.33.

20




(3R,4S,5S,6R)-2-(7-Bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol (15)

To a solution of crude alcohol **14** (2.03 g) in anhydrous THF (11.9 mL) were added CH₃SO₃H (0.6 N in MeOH, 7.0 mL, 4.18 mmol) at -78 °C under nitrogen atmosphere. The mixture was slowly warmed up to -40 °C for 2 h. The reaction mixture was quenched with saturated NaHCO₃ solution (15 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over anhydrous

MgSO₄, filtered and concentrated *in vacuo* to provide the crude intermediate **15**, which was used without further purification (0.94 g, 1.85 mmol, 80%). [M-OMe]⁺ 477.

5




(3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-2-(7-bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran-2-ol (16)

To a solution of bromide **6** (3.21 g, 8.10 mmol) in anhydrous THF (28.3 mL) was added dropwise *n*-BuLi (2.5 M in hexane, 3.40 mL, 8.51 mmol) at -78 °C under nitrogen atmosphere, and the mixture was stirred for 0.5-1 h at the same temperature. Then a solution of perbenzylated gluconolactone **13** (4.37 g, 8.10 mmol) in THF (9.6 mL) was added dropwise, and the mixture was stirred for 3 h at the same temperature. The reaction mixture was quenched with saturated NH₄Cl solution (30 mL) and extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to provide the crude intermediate **16**, which was used without further purification (6.96 g, 8.13 mmol, 100%).

TLC (25% EtOAc/hexane) R_f=0.24; [M+H]⁺ 877.

20




(2R,3R,4R,5S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(7-bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran (17)

To a solution of the intermediate **16** (6.96 g, 8.13 mmol) in CH₂Cl₂ (40.1 mL) were added triethylsilane (3.24 mL, 16.2 mmol) and boron trifluoride diethyl etherate (2.55 mL, 16.2 mmol) at -60 °C under nitrogen atmosphere. The mixture was warmed up to -30 °C for 3 h. To the mixture was added saturated K₂CO₃ solution (50 mL) slowly and the mixture was extracted with EtOAc (100 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by

silica gel column chromatography to provide the desired intermediate **17** (2.87 g, 3.42 mmol, 42%).

TLC (25% EtOAc/hexane) R_f =0.53; $[M+Na]^+$ 863.


5



(2R,3R,4R,5S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran (**18**)

To a solution of the intermediate **17** (0.76 g, 0.91 mmol) in DMF (3.8 mL) were added Cu(I)Cl (2.24 g, 22.6 mmol). The mixture was stirred at 120 °C for 4 h. The reaction mixture was quenched with brine (50 mL) and extracted with EtOAc (50 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to provide the crude intermediate **18**, which was used without further purification (0.77 g, 0.97 mmol, 106%).


15 $[M+Na]^+$ 817.



20 (2R,3R,4R,5S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(7-fluoro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran (**19**)

To a solution of the intermediate **17** (1.01 g, 1.2 mmol) in anhydrous THF (12.0 mL) were added dropwise *n*-BuLi (2.5 M in hexane, 0.77 mL, 1.92 mmol) at -78 °C under nitrogen atmosphere, and the mixture was stirred for 20 min at the same temperature. Then a solution of *N*-fluorobenzenesulfonimide (0.68 g, 2.16 mmol) in THF (3.0 mL) was added dropwise, and the mixture was stirred for 1 h at the same temperature. The reaction mixture was quenched with saturated NaCl solution (10 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to provide the crude

intermediate **19**, which was used without further purification (0.95 g, 1.21 mmol, 101%).
 $[M+Na]^+$ 801.




5

(2R,3R,4R,5S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(6-(4-methoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran (20)

To a solution of the intermediate **17** (0.95 g, 1.13 mmol) in anhydrous THF (12.0 mL) were added dropwise *n*-BuLi (2.5 M in hexane, 0.72 mL, 1.81 mmol) at -78 °C under nitrogen atmosphere, and the mixture was stirred for 0.5 h at the same temperature. Then a solution of iodomethane (0.13 mL, 2.03 mmol) in THF (1.0 mL) was added dropwise, and the mixture was slowly warmed up to 0 °C for 3 h. The reaction mixture was quenched with 1 M HCl solution (30 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to provide the crude intermediate **20**, which was used without further purification (0.88 g, 1.13 mmol, 100%).

$[M+Na]^+$ 797.



20


4-(Allyloxy)-5-bromo-2-chlorobenzoic acid (21)

A mixture of compound **38** (15.6 g, 57.4 mmol) and NaOH (80.0 g, 2.11 mol) in EtOH (220 mL) and water (110 mL) was stirred for 6 hours under reflux. The cooled mixture was concentrated *in vacuo* and diluted with water (400 mL). The mixture was cooled down to 5 °C and acidified with conc. HCl. The precipitated solid was collected by filtration. The solid was dissolved with EtOAc and washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to provide a crude product **21** (17.0 g, 100%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.30 (s, 1H), 6.96 (s, 1H), 6.10-6.01 (m, 1H),

5.52 (dq, $J = 8.6, 0.8$ Hz, 1H), 5.39 (dq, $J = 8.6, 0.8$ Hz, 1H), 4.68 (dt, $J = 4.6, 1.6$ Hz, 2H).

5




4-(Allyloxy)-5-bromo-2-chloro-N-methoxy-N-methylbenzamide (22)

To a suspension of 4-(allyloxy)-5-bromo-2-chlorobenzoic acid **21** (5.0 g, 17.2 mmol) in CH₂Cl₂ (50 mL) were added *N,N*-dimethylhydroxylamine HCl (2.1 g, 20.6 mmol), EDCI (4.9 g, 25.8 mmol), HOBT (4.7 g, 34.4 mmol) and NMM (9.5 mL, 86.0 mmol). The reaction mixture was stirred at rt for 15 hours and evaporated *in vacuo* to remove volatiles. The mixture was extracted with EtOAc / H₂O (100 mL / 100 mL). The organic layer was dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was triturated with hexane (100 mL) and stirred at r.t. for 30 min. The solid was precipitated, filtered, washed with hexane (50 mL) and dried under high vacuum to obtain the desired product (5.5 g, 95%).


¹H NMR (400 MHz, CDCl₃) δ 7.57 (s, 1H), 6.93 (s, 1H), 6.15-6.01 (m, 1H), 5.53 (ddd, $J = 17.3$ Hz, 3.0 Hz, 1.7 Hz, 1H), 5.39 (ddd, $J = 10.6$ Hz, 2.8 Hz, 1.4 Hz, 1H), 4.70 (dt, $J = 4.2$ Hz, 1.6 Hz, 2H), 3.57 (br s, 3H), 3.35 (br s, 3H); [M+Na]⁺ 334.

20



(3R,4S,5S,6R)-2-(2-(Allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol (23)


Compound **23** was prepared in Scheme 14 from 4-(allyloxy)-5-bromo-2-chlorobenzoic acid (**21**).



(3R,4R,5S,6R)-2-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (24)

To a solution of crude compound **23** (7.14 g 14.4 mmol) in CH₂Cl₂ / CH₃CN (75 mL / 75 mL) were added triethylsilane (4.6 mL, 28.9 mmol) and boron trifluoride diethyl etherate (3.6 mL, 28.9 mmol) at -55 °C. The mixture was allowed to slowly warm to 0 °C. To a mixture was added *aq.* saturated NaHCO₃ solution (75 mL) to quench the reaction and the mixture was evaporated *in vacuo* to remove CH₂Cl₂ and CH₃CN. The mixture was extracted with EtOAc (100 mL x 2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude (3R,4R,5S,6R)-2-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (**24**, 6.36 g) was carried on to the next step without further purification.


15



(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (25)

To a solution of crude compound **24** (6.36 g) in CH₂Cl₂ (100 mL) were added Ac₂O (13.0 mL, 137.0 mmol), Et₃N (20.0 mL, 137.0 mmol) and catalytic amount of DMAP at 0 °C. The mixture was stirred at 0 °C for 15 min and at room temperature for 3 hours. The mixture was concentrated under reduced pressure to remove volatiles. The residue was diluted with EtOAc (50 mL), washed with H₂O (100 mL), *aq.* 1 N HCl solution (100 mL) and brine (100 mL) successively. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was recrystallized with EtOH (50 mL). The desired product was precipitated and the precipitate was collected by filtration and washed with cold EtOH (50 mL) and dried under high vacuum to obtain the title compound **25** (1.37 g).

$[M+Na]^+$ 655.




5 (2S,3S,4R,5R,6R)-2-(2-(Allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran (26)

To a suspension of acetate **25** (1.37 g, 2.16 mmol) in MeOH (50 mL) was added NaOMe (25 wt % in MeOH, 0.5 mL) at room temperature. The mixture was stirred at room temperature for 1 hour. Glacial AcOH was added to the mixture to acidify the 10 mixture. The mixture was concentrated under a reduced pressure. The crude ((*2S,3R,4R,5S,6R*)-2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (**25-1**) was carried on to the next step without further purification.

To a solution of the crude compound **25-1** and benzyl bromide (2.6 mL, 21.6 mmol) in THF/DMF (30 mL / 10 mL) was added NaH (60% dispersion in mineral oil, 1.3 g, 32.4 mmol) portionwise at 0 °C. The reaction mixture was gradually raised to room temperature and stirred at r.t. for 15 hour. The mixture was cooled to 0 °C and aqueous saturated NH₄Cl solution (150 mL) was added to the mixture. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over 20 anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified using normal phase column chromatography to provide the desired product **26** (1.50 g, 85% (2-steps)).


1H NMR (400 MHz, CDCl₃) δ 7.49-7.23 (m, 14H), 7.21-7.11 (m, 5H), 7.08-7.03 (m, 3H), 6.83 (d, *J* = 6.4 Hz, 2H), 6.71 (d, *J* = 8.8 Hz, 2H), 6.02-5.91 (m, 1H), 5.38 (d, *J* = 17.2 Hz, 1H), 5.18 (d, *J* = 10.4 Hz, 1H), 4.80 (s, 2H), 4.76 (d, *J* = 11.2 Hz, 1H), 4.61-4.48 (m, 7H), 3.95-3.86 (m, 5H), 3.79-3.72 (m, 2H), 3.64-3.56 (m, 4H), 1.25 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 847.



5-Chloro-4-(4-ethoxybenzyl)-2-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenol (27)

To a suspension of compound **26** (1.50 g, 1.82 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.22 g, 0.18 mmol) in THF (20 mL) was added NaBH₄ (0.56 g, 14.6 mmol) at 0 °C. The mixture was warmed up to r.t. slowly and stirred at r.t. for 12 hours. The reaction mixture was cooled to 0 °C and aqueous saturated NH₄Cl solution (50 mL) was added to the mixture. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified using normal phase column chromatography to provide the title product **27** (0.98 g, 68%).

¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 1H), 7.38-7.18 (m, 16H), 7.17-7.11 (m, 2H), 7.03-6.91 (m, 5H), 6.88 (s, 1H), 6.75-6.68 (m, 2H), 4.94-4.79 (m, 3H), 4.59-4.42 (m, 4H), 4.31 (d, *J* = 9.2 Hz, 1H), 4.02-3.82 (m, 5H), 3.79-3.63 (m, 5H), 3.57-3.49 (m, 1H), 1.38 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 807.




2-Bromo-3-chloro-4-(4-ethoxybenzyl)-6-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenol (28)

To a solution of phenol **27** (0.98 g, 1.24 mmol) in AcOH (12 mL) were added Et₃N (0.37 mL, 1.86 mmol) and bromine (77 μL, 1.50 mmol) at 0 °C. The mixture was stirred at 0 °C for 5 min and at room temperature for 12 hours. The reaction mixture was cooled to 0 °C and aqueous saturated NH₄Cl solution (30 mL) was added to the mixture. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with H₂O (50 mL x 2), aqueous saturated NaHCO₃ solution (100 mL), dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The crude 2-bromo-3-chloro-4-(4-ethoxybenzyl)-6-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-

(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenol (**28**, 1.08 g) was carried on to the next step without further purification.

$[M+Na]^+$ 885.


5



3-(2-Bromo-3-chloro-4-(4-ethoxybenzyl)-6-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenoxy)propan-1-ol (29)

10 To a suspension of crude compound **28** (1.33 g, 1.54 mmol) and K_2CO_3 (0.322 g, 2.31 mmol) in acetone (20 mL) was added 3-bromopropanol (0.30 mL, 2.31 mmol) at r.t. The mixture was stirred at 55 °C for 15 hours. The reaction mixture was cooled to r.t and filtered off to remove inorganic salts. The filtrate was concentrated *in vacuo*. The residue was purified using normal phase column chromatography to provide the title product **29** (1.47 g, 100%).

15 1H NMR (400 MHz, $CDCl_3$) δ 7.38-7.22 (m, 13H), 7.21-7.11 (m, 6H), 7.03 (d, J = 8.6 Hz, 2H), 6.80 (d, J = 6.7 Hz, 2H), 6.73 (d, J = 8.6 Hz, 2H), 4.90 (s, 2H), 4.87 (d, J = 10.8 Hz, 1H), 4.61 (d, J = 10.8 Hz, 1H), 4.59-4.42 (m, 3H), 4.10-3.94 (m, 6H), 3.93-3.75 (m, 5H), 3.55-3.49 (m, 3H), 2.33 (dd, J = 6.9 Hz, 5.3 Hz, 1H), 2.11 (quint, J = 6.0 Hz, 2H), 1.97-1.93 (m, 2H), 1.38 (t, J = 7.0 Hz, 3H); $[M+Na]^+$ 943.




20 (2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-bromo-4-chloro-2-(3-chloropropoxy)-5-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran (29-1)

To a suspension of bromide **29** (1.47 g, 1.59 mmol) in CH_3CN (25 mL) were added triphenylphosphine (1.1 g, 3.98 mmol) and CCl_4 (2.5 mL) at r.t. The mixture was stirred at 55 °C for 3 hours. The reaction mixture was cooled to r.t and concentrated *in*

vacuo. The residue was purified using normal phase column chromatography to provide the desired product **29-1** (1.03 g, 70%).

¹H NMR (400 MHz, CDCl₃) δ 7.33-7.22 (m, 13H), 7.21-7.10 (m, 6H), 7.02 (d, *J* = 8.6 Hz, 2H), 6.80 (d, *J* = 6.7 Hz, 2H), 6.71 (d, *J* = 8.6 Hz, 2H), 4.89 (s, 2H), 4.87 (d, *J* = 11.0 Hz, 1H), 4.63 (d, *J* = 10.8 Hz, 1H), 4.55-4.43 (m, 4H), 4.10-4.03 (m, 4H), 3.99-3.91 (m, 4H), 3.88-3.65 (m, 7H), 2.21-2.04 (m, 2H), 1.38 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 961.



10


5-Chloro-6-(4-ethoxybenzyl)-8-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)chroman (30)

To a solution of chloride **29-1** (1.03 g, 1.09 mmol) in THF (30 mL) was added *n*-BuLi (2.5 M in hexane, 0.87 mL, 2.18 mmol) at -78 °C. The mixture was allowed to slowly warm to r.t. and stirred at r.t. for 12 hours. To the mixtures was added aqueous saturated NH₄Cl solution (50 mL). The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified using normal phase column chromatography to provide the title product **30** (255 mg, 28%).

20

¹H NMR (400 MHz, CDCl₃) δ 7.35-7.23 (m, 13H), 7.21-7.07 (m, 6H), 7.02 (d, *J* = 8.6 Hz, 2H), 6.80 (d, *J* = 6.7 Hz, 2H), 6.71 (d, *J* = 8.6 Hz, 2H), 4.96-4.83 (m, 3H), 4.68-4.61 (m, 2H), 4.49 (dd, *J* = 12.6 Hz, 11.6 Hz, 2H), 4.09-3.91 (m, 8H), 3.83-3.69 (m, 4H), 3.61-3.54 (m, 2H), 2.76 (t, *J* = 6.7 Hz, 2H), 1.98-1.83 (m, 2H), 1.34 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 847.

25




(4-(Allyloxy)-5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone (31)

To solution of Weinreb amide **22** (4.5 g, 13.4 mmol) in THF (100 mL) was added 4-ethylphenylmagnesium bromide (0.5 M in THF, 50.8 mL, 26.9 mmol) at 0 °C. The reaction mixture was warmed up to r.t. slowly and stirred at r.t. for 15 hours. To the reaction mixture was added aqueous saturated NH₄Cl solution (100 mL). The mixture 5 was extracted with EtOAc (100 mL). The organic layer was dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was triturated with hexane (100 mL) and stirred at r.t. for 30 min. The solid was precipitated, filtered, washed with hexane (50 mL) and dried under high vacuum to obtain the title product (4.30 g, 73%).

10 ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 6.5 Hz, 2H), 7.62 (s, 1H), 7.25 (d, *J* = 8.0 Hz, 2H), 6.98 (s, 1H), 6.18-6.03 (m, 1H), 5.55 (ddd, *J* = 17.3 Hz, 3.0 Hz, 1.7 Hz, 1H), 5.41 (ddd, *J* = 10.6 Hz, 2.8 Hz, 1.4 Hz, 1H), 4.71 (dt, *J* = 4.2 Hz, 1.6 Hz, 2H), 2.77 (q, *J* = 7.6 Hz, 2H), 1.30 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 379.


15



2-Bromo-3-chloro-4-(4-ethylbenzyl)-6-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenol (32)

To a mixture of 5-chloro-4-(4-ethylbenzyl)-2-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenol (3.0 g, 3.90 mmol) and TEA (1.63 mL) in acetic acid (20.1 mL) was added dropwise bromine (0.30 mL, 5.85 mmol) at 0 °C under nitrogen atmosphere. After stirring for 2 h at rt, the reaction mixture was quenched with saturated NH₄Cl solution (50 mL) and extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by 20 silica gel column chromatography to provide the compound **32** (2.99 g, 3.53 mmol, 90%).


25 [M+Na]⁺ 871.



2-(2-Bromo-3-chloro-4-(4-ethylbenzyl)-6-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenoxy)ethanol (33)

To a mixture of the intermediate **32** (2.99 g, 3.53 mmol) and K₂CO₃ (0.73 g, 5.29 mmol) in acetone (35 mL) was added 2-bromoethanol (0.38 mL, 5.29 mmol) at rt. After stirring for 15 h at 50 °C, the reaction mixture was cooled to rt. The precipitate was removed by filtration and the filtrate was concentrated *in vacuo*. The residue was dissolved in EtOAc (100 mL), washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to provide the crude intermediate **33**, which was used without further purification (3.04 g, 3.41 mmol, 97%).


[M+Na]⁺ 915.



15 (2R,3R,4R,5S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-bromo-4-chloro-2-(2-chloroethoxy)-5-(4-ethylbenzyl)phenyl)tetrahydro-2H-pyran (34)

To a solution of the intermediate **33** (3.04 g, 3.41 mmol) were added triphenylphosphine (2.23 g, 8.52 mmol) and CCl₄ (3.7 mL). After stirring for 2 h at 55 °C, the solvent was evaporated off. The residue was dissolved in EtOAc (100 mL), washed with saturated NaHCO₃ solution, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **34** (1.62 g, 1.78 mmol, 52%).


[M+Na]⁺ 933.



4-Chloro-5-(4-ethylbenzyl)-7-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran (35)

To a solution of the intermediate **34** (1.18 g, 1.30 mmol) in anhydrous THF (15 mL) was added dropwise *n*-BuLi (2.5 M in hexane, 0.78 mL, 1.94 mmol) at -78 °C under nitrogen atmosphere. The mixture was slowly warmed up to rt and stirred overnight. The reaction mixture was quenched with 1 M HCl solution (10 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to provide the crude intermediate **35**, which was used without further purification (1.03 g, 1.30 mmol, 100%).

[M+Na]⁺ 817.




5-Bromo-2-chloro-4-hydroxybenzonitrile (37)

To a solution of 2-chloro-4-hydroxybenzonitrile (10 g, 65.1 mmol) in CH₃CN (200 mL) was added CF₃SO₃H (6.33 g, 71.6 mmol) and NBS (16.2 g, 94.1 mmol) at -30 °C. After being stirred for 18 hours at room temperature, the mixture was quenched with *aq.* saturated NaHSO₄ solution and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford the product **37** (10.5 g, 66%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 7.17 (s, 1H); [M+H]⁺ 232.

25




4-(Allyloxy)-5-bromo-2-chlorobenzonitrile (38)

A mixture of compound **37** (20.5 g, 88.1 mmol), allyl bromide (11.2 mL, 132

mmol) and K_2CO_3 (24.4 g, 176 mmol) in acetone (440 mL) was stirred for 3 hours under reflux. The mixture was filtrated and concentrated *in vacuo*. The resultant was partitioned between EtOAc and water. The organic layer was washed with brine, dried over $MgSO_4$, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford the product **38** (15.6 g, 65%) as a white solid.

¹H NMR (400 MHz, $CDCl_3$) δ 7.82 (s, 1H), 7.00 (s, 1H), 6.09-5.99 (m, 1H), 5.51 (dq, $J = 8.6, 0.8$ Hz, 1H), 5.30 (dq, $J = 8.6, 0.8$ Hz, 1H), 4.68 (dt, $J = 4.6, 1.6$ Hz, 2H); $[M+H]^+$ 272.

10




Methyl 4-(allyloxy)-5-bromo-2-chlorobenzoate (39)

To a solution of compound **21** (17.0 g, 58.0 mmol) in MeOH (380 mL) was added dropwise $SOCl_2$ (21.1 mL, 291 mmol) at 0 °C under an atmosphere of nitrogen. The mixture was stirred at 0 °C for 30 min and then, stirred at 0 °C for 14 hours. The mixture was concentrated *in vacuo* and poured into *aq.* saturated $NaHCO_3$ solution and extracted with EtOAc. The organic layer was washed with brine, dried over $MgSO_4$, filtered and concentrated *in vacuo* to provide the crude product **39** (17.7 g, 99%) as a white solid.

¹H NMR (400 MHz, $CDCl_3$) δ 8.14 (s, 1H), 6.93 (s, 1H), 6.10-6.00 (m, 1H), 5.50 (dq, $J = 8.6, 0.8$ Hz, 1H), 5.37 (dq, $J = 8.6, 0.8$ Hz, 1H), 4.66 (dt, $J = 4.6, 1.6$ Hz, 2H), 3.91 (s, 3H); $[M+H]^+$ 305.

25




(4-(Allyloxy)-5-bromo-2-chlorophenyl)methanol (40)

To a solution of compound **40** (17.7 g, 58.0 mmol) in THF (230 mL) was added dropwise $LiBH_4$ (2.0 M in THF, 72.5 mL, 145 mmol) at 0 °C under an atmosphere of nitrogen. The mixture was stirred for 30 min at 0 °C and then, stirred for 5 hours under reflux. To a cooled mixture was added MeOH (50 mL) at 0 °C and extracted with EtOAc. The organic layer was washed with brine, dried over $MgSO_4$, filtered and

concentrated *in vacuo* to provide the crude product **40** (16.2 g, 100%) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.66 (s, 1H), 6.89 (s, 1H), 6.10-6.03 (m, 1H), 5.49 (dq, *J* = 8.6, 0.8 Hz, 1H), 5.34 (dq, *J* = 8.6, 0.8 Hz, 1H), 4.69 (d, *J* = 3.6 Hz, 2H), 4.60 (dt, *J* = 4.6, 1.6 Hz, 2H).

5




(4-(Allyloxy)-5-bromo-2-chlorobenzyl)(tert-butyl)diphenylsilane (41)

To a mixture of compound **40** (16.2 g, 58.0 mmol) and imidazole (5.17 g, 75.8 mmol) in THF (116 mL) was added *tert*-butyldiphenylchlorosilane (TBDPSCl) (19.4 mL, 75.8 mmol) dropwise at 0 °C under an atmosphere of nitrogen. The mixture was stirred at room temperature for 4 hours. To the mixture was added water (100 mL) and extracted with EtOAc (100 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the desired TBDPS-protected product **41** (26.6 g, 88%) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.80 (s, 1H), 7.69-7.67 (m, 4H), 7.44-7.37 (m, 6H), 6.83 (s, 1H), 6.10-6.00 (m, 1H), 5.49 (dq, *J* = 8.6, 0.8 Hz, 1H), 5.33 (dq, *J* = 8.6, 0.8 Hz, 1H), 4.72 (s, 2H), 4.59 (dt, *J* = 4.6, 1.6 Hz, 2H), 1.11 (s, 9H); [M+Na]⁺ 515.

20



((2R,3R,4R,5S)-5-((3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-4-(allyloxy)-2-chlorobenzyl)(tert-butyl)diphenylsilane (43)

Step 1) To a solution of bromide compound **41** (5.53 g, 10.7 mmol) in THF (60 mL) at -78 °C under an atmosphere of nitrogen was added dropwise *n*-butyllithium (2.5 M in hexane, 4.66 mL, 11.67 mmol), and the mixture was stirred for 40 min at the same temperature. Then a solution of benzyl-protected gluconolactone (5.24 g, 9.73 mmol) in THF (10 mL) was added dropwise, and the mixture was stirred for 2 hours at the same temperature. The reaction mixture was quenched by addition of saturated ammonium chloride. After completing the addition, the solution was gradually raised to room


temperature. The organic layer was separated and the aqueous layer was extracted with EtOAc. The organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to afford the compound **42** (9.57 g), which was carried on to the next step without further purification.

5 [M+Na]⁺ 997.

Step 2) To a solution of crude compound **42** (6.57 g, 6.73 mmol) in CH₂Cl₂ (42 mL) were added triethylsilane (1.61 mL, 10.0 mmol) and boron trifluoride diethyl etherate (1.26 mL, 10.0 mmol) at -60 °C. The mixture was allowed to slowly warm to -20 °C. To a mixture was added *aq.* saturated K₂CO₃ solution (20 mL) to quench the reaction and extracted with EtOAc (100 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **43** (1.81 g, 27%) as colorless oil.

10 [M+Na]⁺ 981.

15



6-((3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-2-bromo-4-((tert-butyldiphenylsilyloxy)methyl)-3-chlorophenol (45)


Step 1) To a mixture of compound **43** (1.81 g, 1.88 mmol) and Pd(PPh₃)₄ (427 mg, 0.37 mmol) in THF (25 mL) was added NaBH₄ (569 mg, 15.0 mmol) at 0 °C under an atmosphere of nitrogen. The mixture was stirred for 20 hours at room temperature. To the mixture was quenched with *aq.* saturated NH₄Cl solution. The mixture was extracted with EtOAc. The organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to provide the compound **44** (1.5 g, 86%), which was carried on to the next step without further purification.

20 [M+Na]⁺ 941.

Step 2) To a solution of compound **44** (2.19 g, 2.38 mmol) in AcOH (12 mL) were added TEA (0.497 mL, 3.57 mmol) and Br₂ (0.146 mL, 2.85 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 15 min and at room temperature for 3 hours. To a mixture was added saturated ammonium chloride and extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the

product **45** (2.05 g, 79%) as colorless oil.

[M+Na]⁺ 1019.



5

((2R,3R,4R,5S)-5-((3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-3-bromo-2-chloro-4-(2-chloroethoxy)benzyloxy)(tert-butyl)diphenylsilane (46)


Step 1) A mixture of compound **45** (2.0 g, 1.85 mmol), 2-bromoalcohol (0.196 mL, 2.77 mmol) and K₂CO₃ (511 mg, 3.70 mmol) in acetone (10 mL) was stirred for 18 hours under reflux. The mixture was filtrated and concentrated *in vacuo*. The resultant was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude product **45-1** (1.9 g, 100%) as brown oil.

15

[M+Na]⁺ 1063.

Step 2) A mixture of compound **45-1** (2.4 g, 2.3 mmol), triphenylphosphine (1.50 g, 5.76 mmol) and CCl₄ (2.40 mL, 27.6 mmol) in CH₃CN (23 mL) was stirred for 2 hours under reflux. The mixture was concentrated *in vacuo*. The resultant was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue purified by silica gel column chromatography to provide the product **46** (1.3 g, 53%) as colorless oil.

[M+Na]⁺ 1081.




25

((7-((3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-4-chloro-2,3-dihydrobenzofuran-5-yl)methoxy)(tert-butyl)diphenylsilane

(47)

To a solution of compound **46** (1.3 g, 1.22 mmol) in THF (12 mL) was added dropwise *n*-butyllithium (2.5 M in hexane, 0.73 mL, 1.83 mmol) at -78 °C under an atmosphere of nitrogen. The mixture was stirred for 18 hours at -78 °C to 5 °C. The mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **47** (827 mg, 71%) as colorless oil, which was contained a major β-isomer as a α:β=1:3 ratio.

¹H NMR (400 MHz, CDCl₃) δ 7.72-7.69 (m, 4H), 7.50 (s, 1H), 7.40-7.27 (m, 18H), 7.22-7.15 (m, 6H), 6.92-6.99 (m, 2H), 4.98-4.87 (m, 3H), 4.82-4.72 (m, 2H), 4.66-4.41 (m, 7H), 4.032 (d, *J* = 11.2 Hz, 1 H), 3.86-3.59 (m, 6H), 3.14-3.09 (m, 2H), 1.10 (s, 9H); [M+Na]⁺ 967.




15

(7-((3S,4R,5R,6R)-3,4,5-Tris(benzylxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-4-chloro-2,3-dihydrobenzofuran-5-yl)methanol (48)

To a solution of compound **47** (827 mg, 0.87 mmol) in THF (4.0 mL) was added dropwise tetra-*n*-butylammonium fluoride (1.0 M in THF, 2.17 mL, 2.17 mmol) at 0 °C. After being stirred for 2 hours at room temperature, the mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **48** (578 mg, 93%) as a white solid.

[M+Na]⁺ 729.

25




7-((3S,4R,5R,6R)-3,4,5-Tris(benzylxy)-6-(benzyloxymethyl)-tetrahydro-2H-

pyran-2-yl)-5-(bromomethyl)-4-chloro-2,3-dihydrobenzofuran(49)

To a solution of compound **48** (578 mg, 0.81 mmol) in Et₂O (14 mL) was added pyridine (0.007 mL, cat.) and phosphorus tribromide (0.038 mL, 0.40 mmol) at 0 °C under an atmosphere of nitrogen. After being stirred for 20 hours at room temperature, 5 the mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to provide the crude product **49** (654 mg) as yellow oil.




10




4-Chloro-5-(4-methoxybenzyl)-7-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran (50)

To a mixture of compound **49** (623 mg, 0.81 mmol), K₂CO₃ (447 mg, 3.24 mmol) and 4-methoxyphenyl boronic acid (306 mg, 2.02 mmol) in acetone (7.5 mL) and H₂O (2.5 mL) was added bis(triphenylphosphine)palladium chloride (56 mg, 0.08 mmol) at 0 °C under atmosphere of nitrogen. The mixture was stirred at 0 °C for 30 min and then, stirred at room temperature for 16 hours. The mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered 15 and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **50** (407 mg, 62%) as colorless oil.



25




Methyl 3-methoxy-2-nitrobenzoate (52)

To a mixture of 3-methoxy-2-nitrobenzoic acid (25.0 g, 126 mmol) and K₂CO₃ (35.0 g, 253 mmol) in DMF (126 mL) was added MeI (15.8 mL, 253 mmol) at room temperature. The mixture was stirred at room temperature for 2 hours. To the mixture

was poured the water (200 mL) and then stirred at 5 °C for 30 min. The precipitated solid was collected by filtration, washed with water and hexane. The solid was dried under reduced pressure to afford the compound **52** in a crude form (26.2 g, 98%) as a white solid.


5 ¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, *J*= 8.2, 1.2 Hz, 1H), 7.50 (t, *J*= 8.2 Hz, 1H), 7.26 (dd, *J*= 8.2, 1.2 Hz, 1H), 3.39 (s, 3H), 3.99 (s, 3H); [M+Na]⁺ 235.



10 Methyl 2-amino-3-methoxybenzoate (53)

A suspension of compound **52** (26.2 g, 124 mmol) and Pd/C (10 wt. %, 6.0 g) in THF (400 mL) and MeOH (200 mL) was stirred under an atmosphere of H₂ at room temperature for 18 hours. EtOAc (300 mL) was added to the mixture and filtered through a Celite pad. The filtrate was concentrated *in vacuo* to provide the crude product **53** (22.4 g, 99%) as colorless oil.

15 ¹H NMR (400 MHz, CDCl₃) δ 7.47 (dd, *J*= 8.2, 1.2 Hz, 1H), 6.85 (dd, *J*= 8.2, 1.2 Hz, 1H), 6.58 (t, *J*= 8.2 Hz, 1H), 6.00 (brs, 2H), 3.87 (s, 3H); [M+H]⁺ 182.




20 Methyl 2-amino-5-bromo-3-methoxybenzoate (54)

To a solution of compound **53** (22.4 g 123 mmol) in DMF (250 mL) was added *N*-bromosuccinimide (21.9 g, 123 mmol) portionwise at 0 °C. The mixture was stirred at 0 °C for 0.5 h. To the mixture was added water and extracted with EtOAc (500 mL x 2).

25 The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the desired compound **54** (27.5 g, 86%) as a white solid.

30 ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J*= 2.2 Hz, 1H), 6.90 (d, *J*= 2.2 Hz, 1H), 6.03 (brs, 1H), 3.87 (s, 3H); [M+H]⁺ 260.




Methyl 5-bromo-2-chloro-3-methoxybenzoate (55)

To a solution of compound **54** (27.0 g, 103 mmol) in H₂O (70 mL) and conc.HCl (70 mL) was added dropwise a solution of NaNO₂ (21.5 g, 311 mmol) in H₂O (50 mL) at 0 °C. After being stirred for 1 hour, a solution of Cu(I)Cl in conc.HCl (80 mL) was added to the reaction mixture dropwise at 0 °C. The mixture was stirred at room temperature for 18 hours. To the mixture was added water (300 mL) and extracted with EtOAc (500 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product **55** was dried under high vacuum and used without further purification (29.0 g, 100%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 2.4 Hz, 1H), 7.16 (d, *J* = 2.4 Hz, 1H), 3.93 (s, 36H), 3.92(s, 3H); [M+H]⁺ 278.


15



5-Bromo-2-chloro-3-methoxybenzoic acid (56)

To a solution of compound **55** (25.0 g, 89.4 mmol) in THF (100 mL), H₂O (100 mL) and MeOH (100 mL) was added *aq.* 5 N NaOH dropwise at 0 °C. The mixture was stirred at room temperature for 1 hour. Conc. HCl was added to the mixture to acidify and the mixture was extracted with EtOAc (500 mL x 2). The combined organic layers were dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude acid **56** (22.6 g, 96%) as an orange solid.


¹H NMR (400 MHz, CDCl₃) δ 7.55 (s, 1H), 7.13 (s, 1H), 3.89 (s, 3H); [M+H]⁺ 265.



(5-Bromo-2-chloro-3-methoxyphenyl)methanol (57)

To a solution of acid **56** (10.1 g, 38.0 mmol) in THF (100 mL) was added boron trifluoride-dimethylsulfide (14.4 mL, 152 mmol) dropwise at 0 °C under an atmosphere of nitrogen. The mixture was stirred at room temperature for 18 hours. MeOH was added to the reaction mixture dropwise at 0 °C. The mixture was extracted with EtOAc/H₂O (150 mL/150 mL), dried over MgSO₄, filtered, and concentrated *in vacuo* to provide the crude alcohol **57** (9.50 g, 100%) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, *J* = 2.2 Hz, 1H), 7.01 (d, *J* = 2.2 Hz, 1H), 4.77 (s, 2H), 3.91 (s, 3H); [M+Na]⁺ 273.




(5-Bromo-2-chloro-3-methoxybenzyloxy)(tert-butyl)diphenylsilane (58)

To a mixture of alcohol **57** (6.49 g, 25.8 mmol) and imidazole (2.30 g, 33.5 mmol) in THF (50 mL) was added TBDPSCl (8.59 mL, 33.5 mmol) dropwise at 0 °C under an atmosphere of nitrogen. The mixture was stirred at room temperature for 5 hours. To the mixture was added water (100 mL) and extracted with EtOAc (100 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the desired TBDPS-protected product **58** (9.60 g, 75%) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.70-7.67 (m, 4H), 7.52-7.51 (m, 1H), 7.46-7.37 (m, 6H), 6.99 (d, *J* = 2.4 Hz, 1H), 4.78 (s, 2H), 3.88 (s, 3H), 1.21 (s, 9H).


25



5-Bromo-2-chloro-3-methoxybenzoyl chloride (59)

To a solution of compound **56** (3.82 g, 14.3 mmol) in CH₂Cl₂ (63 mL) was added dropwise DMF (0.20 mL) and (COCl)₂ (1.63 mL, 18.7 mmol) at 0 °C under an atmosphere of nitrogen. After being stirred for 20 hours at room temperature, the mixture was concentrated *in vacuo* to provide the crude acid chloride **59**, which was 5 used for the next reaction without further purification.

¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 2.4 Hz, 1H), 7.16 (d, *J* = 2.4 Hz, 1H), 3.93 (s, 3H), 3.92 (s, 3H).




10

5-Bromo-2-chloro-N,3-dimethoxy-N-methylbenzamide (60)

To a solution of acid chloride **59** (3.41 g, 14.3 mmol) in CH₂Cl₂ (70 mL) was added dropwise *N,O*-dimethylhydroxylamine hydrochloride (4.18 g, 42.9 mmol) at 0 °C under an atmosphere of nitrogen. Then, TEA (12.0mL, 85.8 mmol) was added to the 15 mixture at 0 °C. After being stirred for 18 hours, the mixture was partitioned between EtOAc (150 mL) and water (100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford the product **60** (3.45 g, 80%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.08 (s, 2H), 3.92 (s, 3H), 3.51 (s, 3H), 3.37 (s, 20 3H); [M+H]⁺ 308.



25


(5-Bromo-2-chloro-3-methoxyphenyl)(4-ethylphenyl)methanone (61)

To a solution of compound **60** (3.45 g, 11.2 mmol) in THF (44 mL) was added dropwise 4-ethoxyphenyl magnesium bromide (0.5 M in THF, 44.8 mL, 22.4 mmol) at 0 °C under an atmosphere of nitrogen. After being stirred for 15 hours at room temperature, the mixture was quenched with 1 N HCl (10 mL). The mixture was extracted with EtOAc (100 mL). The organic layer was dried over MgSO₄, filtered, and 30 concentrated *in vacuo*. The residue was purified by silica gel column chromatography to

afford the product **61** (3.92 g, 99%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 8.4 Hz, 2H), 7.16 (d, *J* = 2.2 Hz, 1H), 7.08 (d, *J* = 2.2 Hz, 1H), 3.95 (s, 3H), 2.72 (q, *J* = 7.6 Hz, 2H), 1.27 (t, *J* = 7.6 Hz, 3H); [M+H]⁺ 353.

5




1-(4-Ethylbenzyl)-5-bromo-2-chloro-3-methoxybenzene (**62**)

To a solution of compound **61** (4.45 g, 12.6 mmol) in CH₂Cl₂ (80 mL) was added dropwise triethylsilane (6.00 mL, 37.8 mmol) and boron trifluoride diethyl etherate (4.67 mL, 37.8 mmol) at 0 °C under an atmosphere of nitrogen. After being stirred for 5 hours at room temperature, the mixture was quenched with *aq.* saturated K₂CO₃ solution (30 mL) and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford the product **62** (2.40 g, 56%) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.14-7.08 (m, 4H), 6.93 (q, *J* = 2.4 Hz, 2H), 4.04 (s, 2H), 3.88 (s, 3H), 2.62 (q, *J* = 7.6 Hz, 2H), 1.22 (t, *J* = 7.6 Hz, 3H); [M+H]⁺ 339.



20



(3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-2-(3-((tert-butyldiphenylsilyloxy)methyl)-4-chloro-5-methoxyphenyl)tetrahydro-2H-pyran-2-ol (**61-1**)

To a solution of bromide compound **58** (8.69 g, 17.7 mmol) in THF (80 mL) at -78 °C under an atmosphere of nitrogen was added dropwise *n*-butyllithium (2.5 M in hexane, 7.73 mL, 19.3 mmol), and the mixture was stirred for 40 min at the same temperature. Then a solution of benzyl-protected gluconolactone (8.67 g, 16.1 mmol) in THF (20 mL) was added dropwise, and the mixture was stirred for 2 hours at the same

temperature. The reaction mixture was quenched by addition of saturated ammonium chloride. After complete addition, the solution was gradually raised to room temperature. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to yield the title compound **61-1** (15.0 g), which was carried on to the next step without further purification.




10

2-Bromo-5-((tert-butyldiphenylsilyloxy)methyl)-6-chloro-3-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenol (63)


Step 1) To a solution of crude compound **61-1** (15.0 g, 16.1 mmol) in CH₂Cl₂ (100 mL) were added triethylsilane (5.14 mL, 32.2 mmol) and boron trifluoride diethyl etherate (4.04 mL, 32.2 mmol) at -60 °C. The mixture was allowed to slowly warm to -20 °C for 5 hours. To a mixture was added *aq.* saturated K₂CO₃ solution (30 mL) to quench the reaction and extracted with EtOAc (150 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product **61-2** (6.83 g) was carried on to the next step without further purification.

20




Step 2) A mixture of crude compound **61-2** (6.83 g, 7.31 mmol) and sodium ethanethiolate (1.84 g, 21.9 mmol) in DMF (36 mL) was stirred for 6 hours at 90 °C. To a mixture was added 1 N HCl (50 mL) and extracted EtOAc (100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product **62** (5.32 g) was carried on to the next step without further purification.

25




Step 3) To a solution of compound **62** (5.32 g, 5.76 mmol) in AcOH (28 mL) were added TEA (1.2 mL, 8.64 mmol) and Br₂ (0.295 mL, 5.76 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 15 min and at room temperature for 3 hours. To a mixture was added saturated ammonium chloride and extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated

in vacuo. The residue was purified by silica gel column chromatography to provide the product **63** (5.08 g, 31%) as colorless oil.




5




((2R,3R,4R,5S)-5-((3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-4-bromo-2-chloro-3-(2-chloroethoxy)benzyloxy)(tert-butyl)diphenylsilane (64)

10 Step 1) A mixture of compound **63** (2.90 g, 2.9 mmol), 2-bromoalcohol (0.308 mL, 4.35 mmol) and K₂CO₃ (801 mg, 5.80 mmol) in acetone (15 mL) was stirred for 17 hours under reflux. The mixture was filtrated and concentrated *in vacuo*. The resultant was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude product **63-1** (2.92 g, 96%) as colorless oil.


15



Step 2) A mixture of compound **63-1** (2.90 g, 2.78 mmol), triphenylphosphine (1.83 g, 6.95 mmol) and CCl₄ (2.90 mL, 3.36 mmol) in CH₃CN (27 mL) was stirred for 2 hours under reflux. The mixture was concentrated *in vacuo*. The resultant was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **64** (2.76 g, 93%) as colorless oil.



25




((4-((3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-7-chloro-2,3-dihydrobenzofuran-6-yl)methoxy)(tert-butyl)diphenylsilane

(65)

To a solution of compound **64** (2.70 g, 2.54 mmol) in THF (25 mL) was added dropwise *n*-butyllithium (2.5 M in hexane, 2.03 mL, 5.08 mmol) at -78 °C under an atmosphere of nitrogen. The mixture was stirred for 18 hours at -78 °C to 5 °C. The mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **65** (1.87 g, 77%) as colorless oil, which contained a major β-isomer as a α:β=1:3 ratio.

¹H NMR (400 MHz, CDCl₃) δ 7.72-7.69 (m, 4H), 7.41-7.28 (m, 22H), 7.22-7.16 (m, 4H), 6.90 (dd, *J* = 7.4, 1.4 Hz, 1H), 5.00-4.90 (m, 3H), 4.84-4.77 (m, 2H), 4.71-4.60 (m, 2H), 4.54-4.51 (m, 4H), 4.44-4.37 (m, 1H), 4.22 (d, *J* = 9.6 Hz, 1H), 3.93 (d, *J* = 10.4 Hz, 1H), 3.81-3.68 (m, 5H), 3.27-3.06 (m, 2H), 1.10 (s, 9H); [M+Na]⁺ 967.


15



(7-Chloro-4-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methanol
(66)

To a solution of compound **65** (1.80 g, 1.9 mmol) in THF (9.5 mL) was added dropwise tetra-*n*-butylammonium fluoride (1.0 M in THF, 4.75 mL, 4.75 mmol) at 0 °C. After being stirred for 2 hours at room temperature, the mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **66** (1.28 g, 94%) as colorless oil.


¹H NMR (400 MHz, CDCl₃) δ 7.36-7.27 (m, 12H), 7.24-7.17 (m, 6H), 7.01 (s, 1H), 6.90 (dd, *J* = 7.6, 1.6 Hz, 2H), 4.95 (ABq, Δν_{AB} = 12.5 Hz, *J*_{AB} = 11.2 Hz, 2H), 4.86 (d, *J* = 10.8 Hz, 1H), 4.72 (d, *J* = 6.8 Hz, 2H), 4.63 (d, *J* = 10.8 Hz, 1H), 4.57-4.53 (m, 3H), 4.49-4.42 (m, 1H), 4.20 (d, *J* = 9.6 Hz, 1H), 3.95 (d, *J* = 10.8 Hz, 1H), 3.81-3.72 (m, 4H), 3.57-3.50 (m, 2H), 3.32-3.24 (m, 1H), 3.17-3.08 (m, 1H), 1.7 (t, *J* = 6.6 Hz, 1H); [M+Na]⁺ 729.



6-(Bromomethyl)-7-chloro-4-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran (67)

5 To a solution of compound **66** (1.28 g, 1.80 mmol) in Et₂O (30 mL) was added pyridine (0.015 mL, cat.) and phosphorus tribromide (0.085 mL, 0.9 mmol) at 0 °C under an atmosphere of nitrogen. After being stirred for 20 hours at room temperature, the mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was
10 purified by silica gel column chromatography to provide the product **67** (1.42 g) as brown oil.

15 ¹H NMR (400 MHz, CDCl₃) δ 7.35-7.29 (m, 12H), 7.22-7.16 (m, 6H), 7.00 (s, 1H), 6.90 (dd, *J* = 6.4, 1.2 Hz, 2H), 4.95 (ABq, Δv_{AB} = 10.9 Hz, *J*_{AB} = 11.2 Hz, 2H),
4.87 (d, *J* = 10.8 Hz, 1H), 4.63 (d, *J* = 10.8 Hz, 1H), 4.60-4.48 (m, 5H), 4.34-4.37 (m, 1H), 4.16 (d, *J* = 9.2 Hz, 1H), 4.00 (d, *J* = 10.8 Hz, 1H), 3.80-3.70 (m, 4H), 3.56-3.49 (m, 2H), 3.29-3.20 (m, 1H), 3.10-3.02 (m, 1H); [M+Na]⁺ 791.




20 7-Chloro-6-(4-methoxybenzyl)-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran (68)

To a mixture of compound **67** (700 mg, 0.9 mmol), K₂CO₃ (497 mg, 3.6 mmol) and 4-methoxyphenyl boronic acid (341 mg, 2.25 mmol) in acetone (9.0 mL) and H₂O (3.0 mL) was added bis(triphenylphosphine)palladiumchloride (63 mg, 0.09 mmol) at 0 °C under atmosphere of nitrogen. The mixture was stirred at 0 °C for 30 min and then, stirred at room temperature for 16 hours. The mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to
25

provide the product **68** (340 mg, 46%) as colorless oil.

[M+Na]⁺ 819.

5



(3S,4R,5R,6R)-2-(3-(4-Ethylbenzyl)-4-chloro-5-methoxyphenyl)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran (69)


Step 1) To a solution of bromide compound **62** (2.40 g, 7.00 mmol) in THF (26.0 mL) at -78 °C under an atmosphere of nitrogen was added dropwise *n*-butyllithium (2.5 M in hexane, 2.94 mL, 7.35 mmol), and the mixture was stirred for 40 min at the same temperature. Then a solution of benzyl-protected gluconolactone (3.60 g, 6.70 mmol) in THF (8.8 mL) was added dropwise, and the mixture was stirred for 2 hours at the same temperature. The reaction mixture was quenched by addition of saturated ammonium chloride. After complete addition, the solution was gradually raised to room temperature. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to provide a mixture of lactol compounds (5.4 g), which was carried on to the next step without further purification.

[M+Na]⁺ 821.

Step 2) To a solution of the crude lactol compound (5.4 g, 6.70 mmol) in CH₂Cl₂ (27 mL) was added triethylsilane (2.14 mL, 13.4 mmol) and boron trifluoride diethyl etherate (1.65 mL, 13.4 mmol) at -60 °C. The mixture was allowed to slowly warm to -20 °C. To a mixture was added *aq.* saturated K₂CO₃ solution (20 mL) to quench the reaction and extracted with EtOAc (100 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **69** (3.96 g, 75%) as colorless oil.

For β anomer ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.270 (m, 12H), 7.23-7.15 (m, 8H), 7.10-7.07 (m, 4H), 6.90 (d, *J* = 1.4 Hz, 1H), 6.84 (d, *J* = 1.4 Hz, 1H), 6.39 (ABq, Δ*v*_{AB} = 10.8 Hz, *J*_{AB} = 11.0 Hz, 2H), 4.86 (d, *J* = 10.8 Hz, 1H), 4.77 (t, *J* = 10.8 Hz, 1H), 4.67-4.53 (m, 4H), 4.49-4.41 (m, 2H), 4.14 (t, *J* = 9.2 Hz, 1H), 3.97-3.86 (m, 1H), 3.79-3.74 (m, 6H), 3.65-3.56 (m, 1H), 3.52-3.43 (m, 1H), 2.57 (q, *J* = 7.6 Hz, 2H), 1.18 (t, *J* = 7.6 Hz, 3H);

For α anomer ^1H NMR (400 MHz, CDCl_3) δ 7.32-7.270 (m, 12H), 7.23-7.15 (m, 8H), 7.10-7.07 (m, 4H), 6.92 (d, $J = 1.4$ Hz, 1H), 6.88 (d, $J = 1.4$ Hz, 1H), 5.13 (d, $J = 4.8$ Hz, 1H), 4.86 (d, $J = 10.8$ Hz, 1H), 4.77 (t, $J = 10.8$ Hz, 1H), 4.67-4.53 (m, 4H), 4.49-4.41 (m, 2H), 4.14 (t, $J = 9.2$ Hz, 1H), 3.97-3.86 (1H, m), 3.77-3.74 (m, 4H), 3.71 (s, 3H), 3.65-3.56 (m, 1H), 3.52-3.43 (m, 1H), 2.52 (q, $J = 7.6$ Hz, 2H), 1.14 (t, $J = 7.6$ Hz, 3H); $[\text{M}+\text{Na}]^+$ 805.




10 3-((3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-5-(4-ethylbenzyl)-2-bromo-6-chlorophenol (70)

Step 1) A mixture of crude compound **69** (1.50 g, 1.91 mmol) and sodium sodium ethanethiolate (482 mg, 5.73 mmol) in DMF (9.5 mL) was stirred for 6 hours at 90 °C. To a mixture was added 1 N HCl (50 mL) and extracted EtOAc (100 mL). The organic layer was washed with brine, dried over MgSO_4 , filtered, and concentrated *in vacuo*. The crude phenol compound (1.50 g) was carried on to the next step without further purification.

$[\text{M}+\text{Na}]^+$ 791.

Step 2) To a solution of the crude phenol compound (1.49 g, 1.94 mmol) in AcOH (9.70 mL) were added TEA (0.405 mL, 2.91 mmol) and Br_2 (0.119 mL, 2.32 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 15 min and at room temperature for 3 hours. To a mixture was added saturated ammonium chloride and extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **70** (1.42 g, 86%) as colorless oil.

$[\text{M}+\text{Na}]^+$ 869.



(3S,4R,5R,6R)-2-(5-(4-Ethylbenzyl)-2-bromo-4-chloro-3-(2-chloroethoxy)phenyl)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran (71)

5 Step 1) A mixture of compound **70** (1.42 g, 1.67 mmol), 2-bromoalcohol (0.178 mL, 2.51 mmol) and K₂CO₃ (348 mg, 2.51 mmol) in acetone (20 mL) was stirred for 17 hours under reflux. The mixture was filtrated and concentrated *in vacuo*. The resultant was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude product **70-1**


10 (1.29 g, 86%) as colorless oil.

[M+Na]⁺ 913.

Step 2) A mixture of compound **70-1** (1.29 g, 1.44 mmol), triphenylphosphine (945 mg, 3.61 mmol) and CCl₄ (1.5 mL, 17.5 mmol) in CH₃CN (14 mL) was stirred for 2 hours under reflux. The mixture was concentrated *in vacuo*. The resultant was 15 partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue purified by silica gel column chromatography to provide the product **71** (1.16 g, 88%) as colorless oil.

[M+Na]⁺ 931.

20




4-((3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-6-(4-ethylbenzyl)-7-chloro-2,3-dihydrobenzofuran (72)

To a solution of compound **71** (1.16 g, 1.27 mmol) in THF (12.7 mL) was added 25 dropwise *n*-butyllithium (2.5 M in hexane, 1.27 mL, 3.17 mmol) at -78 °C under an atmosphere of nitrogen. The mixture was stirred for 18 hours at -78 °C to 5 °C. The mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue

was purified by silica gel column chromatography to provide the product **72** (493 mg, 48%) as brown oil.

[M+Na]⁺ 817.


5



(5-Bromo-2-chloro-3-methoxyphenyl)(4-ethoxyphenyl)methanone (73)

To a solution of acid **56** (4.9 g, 18.57 mmol) in CH₂Cl₂ (62 mL) were added oxalyl chloride (2.1 mL, 24.14 mmol) and catalytic amounts of DMF at room temperature. The mixture was stirred at room temperature for 3 hours. The mixture was evaporated *in vacuo* and dried under high vacuum. The crude acid chloride was dissolved with CH₂Cl₂ (93 mL) and cooled to 0 °C. To the mixture was added phenetole (2.4 mL, 18.57 mmol) at 0 °C and stirred at 0 °C for 5 min. To the reaction mixture was added AlCl₃ (2.7 g, 20.43 mmol) portionwise at 0 °C. The mixture was stirred at 0 °C for 30 min, warmed up to room temperature and stirred at room temperature for 15 hours. The mixture was poured into ice-water and extracted with CH₂Cl₂ (100 mL x 2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product **73** was dried under high vacuum and used without further purification (7.0 g).

20 [M+H]⁺ 368.




5-Bromo-2-chloro-1-(4-ethoxybenzyl)-3-methoxybenzene (74)


25 To a solution of methanone **73** (7.0 g, 18.94 mmol) in CH₂Cl₂/CH₃CN (60 mL/60 mL) were added triethylsilane (9.1 mL, 56.81 mmol) and boron trifluoride diethyl etherate (7.0 mL, 56.81 mmol) at 0 °C. The mixture was warmed up to room temperature slowly and stirred at room temperature for 15 hours. To the mixture was added aq. saturated K₂CO₃ solution (80 mL) slowly and extracted with EtOAc (100 mL x 2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in*

vacuo. The residue was purified by silica gel column chromatography to provide the desired product **74** (5.7 g, 87%).

¹H NMR (400 MHz, CDCl₃) δ 7.09-7.07 (m, 2H), 6.92 (d, *J* = 2.0 Hz, 1H), 6.88 (d, *J* = 2.0 Hz, 1H), 6.83-6.81 (m, 2H), 4.03-3.98 (m, 4H), 3.88 (s, 3H), 1.40 (t, *J* = 7.2 Hz, 3H).




10 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (75)




Step 1) (3R,4S,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol (**74-3**)

15 To a solution of bromide **74** (5.74 g, 16.14 mmol) in toluene / THF (72 mL / 36mL) at -78 °C under an atmosphere of nitrogen was added dropwise *n*-butyllithium (2.5 M in hexane, 7.8 mL, 19.36 mmol), and the mixture was stirred for 40 min at the same temperature. Then a solution of TMS-protected gluconolactone **74-1** (9.04 g, 19.36 mmol) in toluene (30 mL) was added dropwise, and the mixture was stirred for 1 hour at the same temperature. To a solution of crude alcohol **74-2** were added CH₃SO₃H (0.6 N in MeOH, 53.8 mL, 32.28 mmol) at -78 °C. The mixture was allowed to slowly warm to -40 °C. To a mixture was added *aq.* saturated NaHCO₃ solution (50 mL) to quench the reaction. After dilution with water, the mixture was stirred at room temperature for 30 min and extracted with EtOAc (100 mL). The organic layer was dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The (3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol **74-3** (6.6 g) was carried on to the next step without further purification.



Step 2) (3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (74-4)

To a solution of triol 74-3 (6.6 g, 14.14 mmol) in CH₂Cl₂/CH₃CN (70 mL/70 mL) were added triethylsilane (4.5 mL, 28.28 mmol) and boron trifluoride diethyl etherate (3.6 mL, 28.28 mmol) at -50 °C. The mixture was warmed up to 0 °C slowly and stirred at 0 °C for 2 hours. To the mixture was added aq. saturated NaHCO₃ solution (50 mL) slowly and extracted with EtOAc (100 mL x 2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was carried on to the next step without purification.




Step 3) (2S,3S,4S,5R,6R)-6-(Acetoxyethyl)-2-(4-chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-5-hydroxytetrahydro-2H-pyran-3,4-diyl diacetate (74-5)

To a solution of compound 74-4 (6.2 g) in CH₂Cl₂ (95 mL) were added Ac₂O (13.4 mL, 141.4 mmol), Et₃N (19.7 mL, 141.4 mmol) and catalytic amount of DMAP at 0 °C. The mixture was stirred at 0 °C for 15 min and at room temperature for 15 hours. The mixture was concentrated under reduced pressure to remove volatiles. The residue was diluted with EtOAc (200 mL), washed with H₂O (100 mL), aq. 1 N HCl solution (100 mL) and brine (100 mL) successively. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the α,β-isomer mixture of the title compound 74-4 (1.9 g). The anomeric mixture of 74-4 was recrystallized with EtOH (100 mL). The precipitate was collected by filtration and washed with cold EtOH (50 mL) and dried under high vacuum to obtain the title compound 74-5 (2.5 g, 26% (5-steps)).


¹H NMR (400 MHz, CDCl₃) δ 7.06-7.04 (m, 2H), 6.84 (d, *J* = 1.6 Hz, 1H), 6.81-6.79 (m, 2H), 6.67 (d, *J* = 2.0 Hz, 1H), 5.30-5.19 (m, 2H), 5.09 (t, *J* = 9.6 Hz, 1H), 4.31-4.25 (m, 2H), 4.15 (dd, *J* = 12.4, 2.4 Hz, 1H), 4.08-3.95 (m, 4H), 3.91 (s, 3H), 3.82-3.77 (m, 1H), 2.07 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H), 1.69 (s, 3H), 1.39 (t, *J* = 7.2 Hz, 3H);

[M+Na]⁺ 629.



Step 4) (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-
5 6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (**75**)

To a suspension of acetate **74-5** (2.5 g, 4.12 mmol) in MeOH (40 mL) was added NaOMe (25 wt % in MeOH, 0.75 mL) at room temperature. The mixture was stirred at room temperature for 1 hour. Glacial AcOH was added to the mixture to acidify the mixture. The mixture was concentrated under reduced pressure. The residue
10 was carried on to the next step without purification.




(2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(4-chloro-3-(4-
15 ethoxybenzyl)-5-methoxyphenyl)tetrahydro-2H-pyran (**76**)

To a solution of compound **75** (4.12 mmol) in DMF / THF (20 mL / 60 mL) at 0 °C under an atmosphere of nitrogen were added NaH (60% oil, 825 mg, 20.6 mmol) and benzyl bromide (4.9 mL, 41.2 mmol) dropwise, and the mixture was stirred for 16 hours at the room temperature. To the mixture was added water (20 mL) to quench the reaction. After dilution with water, the mixture was stirred at room temperature for 30 min and extracted with EtOAc (200 mL). The organic layer was dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **76** (3.0 g, 93%) as colorless oil.

[M+Na]⁺ 821.


25



2-Chloro-3-(4-ethoxybenzyl)-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenol (77)

A mixture of compound 76 (3.0 g, 3.82 mmol) in DMF (38 mL) was added 5 NaSEt (1.1 g, 13.35 mmol) at 90 °C. The mixture was stirred at 90 °C for 6 hours. To a mixture was added 1 N HCl (50 mL) and extracted EtOAc (200 mL). The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product 77 (3.0 g).


10 [M+Na]⁺ 807.



15 2-Bromo-6-chloro-5-(4-ethoxybenzyl)-3-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenol (78)

To a solution of compound 77 (2.36 g, 3.0 mmol) in AcOH (30 mL) were added TEA (0.6 mL, 4.51 mmol) and Br₂ (0.18 mL, 3.61 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 15 min and at room temperature for 15 hours. To a mixture was added saturated ammonium chloride and extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was carried on to the next step without purification.


20 [M+Na]⁺ 885.



2-(2-Bromo-6-chloro-5-(4-ethoxybenzyl)-3-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenoxy)ethanol (79)

To a solution of crude compound 78 (2.67 g, 3.1 mmol) in acetone (30 mL) were added 2-bromoethanol (0.33 mL, 4.63 mmol) and K_2CO_3 (640 mg, 4.63 mmol) at 0 °C. The mixture was stirred at 50 °C for 15 hours. The mixture was filtrated and concentrated *in vacuo*. The resultant was partitioned between EtOAc and water. The organic layer was washed with brine, dried over $MgSO_4$, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product 79 (2.68 g, 95%).


[M+Na]⁺ 929.



(2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(2-bromo-4-chloro-3-(2-chloroethoxy)-5-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran (80)

To a solution of alcohol 79 (2.68 g, 2.95 mmol) in acetonitrile (30 mL) were added CCl_4 (3.4 mL, 35.41 mmol) and PPh_3 (1.9 g, 7.38 mmol) at 0 °C. The mixture was stirred at 55 °C for 3 hours. The mixture was filtrated and concentrated *in vacuo*. The resultant was partitioned between EtOAc and water. The organic layer was washed with brine, dried over $MgSO_4$, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product 80 (2.59 g, 95%).


[M+Na]⁺ 947.



7-Chloro-6-(4-ethoxybenzyl)-4-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran (81)

To a solution of compound **80** (2.59 g, 2.79 mmol) in THF (28 mL) was added dropwise *n*-butyllithium (2.5 M in hexane, 2.2 mL, 5.59 mmol) at -78 °C under an atmosphere of nitrogen. The mixture was stirred for 18 hours at -78 °C to 10 °C. The mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **81** (2.0 g, 88%) as brown oil.


[M+Na]⁺ 833.



15 2-Chloro-3-(4-ethylbenzyl)-5-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-6-vinylphenol (82)

To a solution of compound **71** (1.16 g, 1.27 mmol) in THF (12.7 mL) was added dropwise *n*-butyllithium (2.5 M in hexane, 1.27 mL, 3.17 mmol) at -78 °C under an atmosphere of nitrogen. The mixture was stirred for 18 hours at -78 °C to 5 °C. The mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **82** (404 mg, 40%) as brown oil.


¹H NMR (400 MHz, CDCl₃) δ 7.32-7.28 (m, 16H), 7.22-7.16 (m, 4H), 7.10-7.01 (m, 4H), 6.88 (d, *J* = 8.0 Hz, 1H), 5.68-5.59 (m, 1H), 4.95-4.84 (m, 2H), 4.64-4.38 (m, 7H), 4.17-3.91 (m, 3H), 3.80-3.54 (m, 4H), 3.53-3.51 (m, 1H), 3.31-3.22 (m, 1H), 2.57 (q, *J* = 7.6 Hz, 2H), 1.18 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 817.



(3S,4R,5R,6R)-2-(3-(Allyloxy)-4-chloro-5-(4-ethylbenzyl)-2-vinylphenyl)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran (83)

5 A mixture of compound 82 (320 mg, 0.4 mmol) and allyl bromide (0.05 mL, 0.6 mmol) and K₂CO₃ (110 mg, 0.8 mmol) in acetone (2.0 mL) was stirred for 18 hours under reflux. The mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product 83
10 (130 mg, 37%) as colorless oil.

15 ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.28 (m, 16H), 7.20-7.15 (m, 5H), 7.06-6.99 (m, 4H), 6.86-6.84 (d, *J* = 8.0 Hz, 2H), 6.13-6.03 (m, 1H), 5.71 (d, *J* = 17.5 Hz, 1H), 5.54 (d, *J* = 10.8 Hz, 1H), 5.37 (d, *J* = 17.5 Hz, 1H), 5.22 (d, *J* = 10.8 Hz, 1H), 4.88-4.84 (m, 3H), 4.63-4.56 (m, 3H), 4.48 (d, *J* = 12.0 Hz, 1H), 4.39-4.33 (m, 3H), 4.06 (q, *J* = 18.1 Hz, 2H), 3.90 (d, *J* = 10.8 Hz, 1H), 3.76-3.64 (m, 4H), 3.532 (s, 1H), 2.55 (q, *J* = 7.6 Hz, 2H), 1.16 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 857.




20 8-Chloro-7-(4-ethylbenzyl)-5-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-2H-chromene (84)

A mixture of compound 83 (145 mg, 0.17 mmol) and Grubb's 2nd generation cat. (25 mg, 0.03 mmol) in CH₂Cl₂ (34 mL) was stirred at room temperature for 3 hours. The mixture was concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product 84 (120 mg, 82%) as colorless oil.
25

¹H NMR (400 MHz, CDCl₃) δ 7.31-7.29 (m, 12H), 7.23-7.15 (m, 6H), 7.06 (q, *J* = 8.4 Hz, 4H), 6.94-6.91 (m, 3H), 6.87 (s, 1H), 5.76-5.72 (m, 1H), 4.92-4.85 (m, 3H),

4.81-4.79 (m, 2H), 4.66-4.49 (m, 3H), 4.40-4.34 (m, 2H), 4.02 (q, $J = 16.4$ Hz, 2H), 3.93 (d, $J = 10.8$ Hz, 1H), 3.82-3.70 (m, 4H), 3.60-3.54 (m, 2H), 2.57 (q, $J = 7.6$ Hz, 2H), 1.19 (t, $J = 7.6$ Hz, 3H); [M+Na]⁺ 829.


5



2-(2-Bromo-3-chloro-4-(4-ethoxybenzyl)-6-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenoxy)ethanol (85)

¹H NMR (400 MHz, CDCl₃) δ 7.41-7.31 (m, 13H), 7.27-7.18 (m, 6H), 7.09 (d, $J = 8.7$ Hz, 2H), 6.87 (d, $J = 6.5$ Hz, 2H), 6.79 (d, $J = 8.7$ Hz, 2H), 4.95 (s, 2H), 4.93 (d, $J = 10.8$ Hz, 1H), 4.65 (d, $J = 10.9$ Hz, 1H), 4.60-4.49 (m, 4H), 4.18-4.12 (m, 3H), 4.07-4.00 (m, 5H), 3.93 (q, $J = 6.0$ Hz, 1H), 3.87-3.79 (m, 4H), 3.67-3.63 (m, 1H), 3.56 (t, $J = 5.5$ Hz, 1H), 2.83-2.77 (m, 1H), 1.38 (t, $J = 7.0$ Hz, 3H); [M+Na]⁺ 929.

15




5-Chloro-6-(4-ethoxybenzyl)-8-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzo[b][1,4]dioxine (86)

To a solution of alcohol **85** (1.02 g, 1.12 mmol) in toluene (20 mL) were added Pd(OAc)₂ (5 mg, 0.023 mmol), 2'-(*di-tert*-butylphosphino)-*N,N*-dimethylbiphenyl-2-amine (10 mg, 0.028 mmol) and Cs₂CO₃ (0.55 g, 1.68 mmol) at r.t. The mixture was evacuated and back-filled with nitrogen. The mixture was stirred at 100 °C for 20 hours. The mixture was cooled to r.t. and filtered off to remove inorganic salts. The filtrate was concentrated *in vacuo* and the residue was purified using normal phase column chromatography to provide the crude product **86** (509 mg, 55%).

¹H NMR (400 MHz, CDCl₃) δ 7.35-7.23 (m, 13H), 7.21-7.08 (m, 6H), 7.05-6.98 (m, 2H), 6.92-6.85 (m, 1H), 6.83-6.77 (m, 1H), 6.75-6.68 (m, 2H), 4.97-4.84 (m, 3H), 4.69-4.57 (m, 2H), 4.53-4.44 (m, 3H), 4.17-4.05 (m, 3H), 3.99-3.84 (m, 6H), 3.82-3.71

(m, 6H), 1.39-1.31 (m, 3H); [M+Na]⁺ 849.




5 **7-Bromo-4-chloro-2-methyl-2,3-dihydrobenzofuran-5-carbonitrile (87)**

The compound **38** (2.03 g, 7.45 mmol) in ethylene glycol (5 mL) was subjected to microwave conditions (Biotage[®]) at 250 °C for 90 min. The reaction mixture was cooled to r.t. and extracted with EtOAc/H₂O (50 mL/100 mL). The organic layer was dried over MgSO₄, filtered off, and evaporated *in vacuo*. The residue was purified using normal phase column chromatography to obtain the title product (1.05 g, 52%).

10 ¹H NMR (400 MHz, CDCl₃) δ 7.62 (s, 1H), 5.26-5.14 (m, 1H), 3.50 (dd, *J* = 16.6 Hz, 9.0 Hz, 1H), 2.97 (dd, *J* = 16.4 Hz, 7.6 Hz, 1H), 1.57 (d, *J* = 6.0 Hz, 3H); [M+H]⁺ 272.


15



7-Bromo-4-chloro-2-methyl-2,3-dihydrobenzofuran-5-carboxylic acid (88)

To a suspension of compound **87** (2.1 g, 7.71 mmol) in EtOH (40 mL) and H₂O (20 mL) was added NaOH (11 g, 270 mmol). The mixture was stirred at 100 °C for 15 hours. The mixture was cooled to r.t. and evaporated *in vacuo* to remove EtOH. The mixture was diluted with H₂O (100 mL) and cooled to 0 °C. To the mixture was added conc. HCl to acidify the reaction mixture with stirring. The product was precipitated, filtered and washed with H₂O (150 mL). The desired product was dried under high vacuum at 45 °C for 12 hours (2.4 g, 100%).


20 ¹H NMR (400 MHz, CDCl₃) δ 13.05 (br s, 1H), 8.13 (s, 1H), 5.25-5.13 (m, 1H), 3.52 (dd, *J* = 16.2 Hz, 9.0 Hz, 1H), 2.99 (dd, *J* = 16.2 Hz, 7.4 Hz, 1H), 1.57 (d, *J* = 6.4 Hz, 3H); [M+H]⁺ 291.



(7-Bromo-4-chloro-2-methyl-2,3-dihydrobenzofuran-5-yl)(4-ethoxyphenyl)methanone (89)

To a suspension of compound **88** (2.4 g, 8.23 mmol) in CH₂Cl₂ (50 mL) were added oxalyl chloride (0.87 mL, 9.88 mmol) and catalytic amounts of DMF at room temperature. The mixture was stirred at room temperature for 2 hours. The mixture was evaporated *in vacuo* and dried under high vacuum. The crude acid chloride was dissolved with CH₂Cl₂ (45 mL) and cooled to 0 °C. To the mixture was added phenetole (1.1 mL, 8.28 mmol) at 0 °C and stirred at 0 °C for 5 min. To the reaction mixture was added AlCl₃ (1.1 g, 8.28 mmol) portionwise at 0 °C. The mixture was stirred at 0 °C for 30 min, warmed up to room temperature and stirred at the temperature for 15 hours. The mixture was poured into ice-water and extracted with CH₂Cl₂ (50 mL x 2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product **89** was carried on to the next step without further purification (3.15 g).

¹H NMR (400 MHz, CDCl₃) δ 7.77 (d, *J* = 2.4 Hz, 2H), 6.95-6.85 (m, 3H), 5.11-5.01 (m, 1H), 4.11 (q, *J* = 7.0 Hz, 2H), 3.50 (dd, *J* = 16.1 Hz, 9.0 Hz, 1H), 2.99 (dd, *J* = 16.0 Hz, 7.6 Hz, 1H), 1.51 (d, *J* = 6.4 Hz, 3H), 1.42 (t, *J* = 7.0 Hz, 3H); [M+H]⁺ 395.




7-Bromo-4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran (90)

To a solution of crude methanone **89** (3.15 g, 7.96 mmol) in CH₂Cl₂/CH₃CN (25 mL/25 mL) were added triethylsilane (3.8 mL, 23.9 mmol) and boron trifluoride diethyl etherate (3.0 mL, 23.9 mmol) at 0 °C. The mixture was warmed up to room temperature slowly and stirred at room temperature for 15 hours. To the mixture was added aq. saturated K₂CO₃ solution (70 mL) slowly and extracted with EtOAc (50 mL x 2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by normal phase column chromatography to provide the desired product **90** (2.68 g, 85% (2-steps)).

¹H NMR (400 MHz, CDCl₃) δ 7.08 (s, 1H), 7.06 (d, *J* = 2.4 Hz, 2H), 6.82 (d, *J* = 6.2 Hz, 2H), 5.11-5.01 (m, 1H), 4.00 (q, *J* = 7.0 Hz, 2H), 3.90 (s, 2H), 3.42 (dd, *J* = 16.1 Hz, 8.9 Hz, 1H), 2.91 (dd, *J* = 16.1 Hz, 7.6 Hz, 1H), 1.51 (d, *J* = 6.3 Hz, 3H), 1.39 (t, *J* = 7.0 Hz, 3H); [M+H]⁺ 381.


5



3-Allyl-5-bromo-2-chloro-4-hydroxybenzonitrile (91)

4-(allyloxy)-5-bromo-2-chlorobenzonitrile **38** (2.5 g, 9.17 mmol) was dissolved in ethyleneglycol (10 mL). And the solution was irradiated under microwave for 15 min under control of internal temperature as 200 °C. After cooling down to room temperature, the resulting solution was purified by silica gel chromatography to afford title compound **91** (1.7 g, 68%) as a white solid.

¹H NMR (CDCl₃) δ 7.74 (s, 1H), 5.96-5.86 (m, 1H), 5.14-5.09 (m, 2H), 3.68 (dt, *J* = 1.6, 6.4 Hz, 2H); [M+H]⁺ 272.




O-2-Allyl-6-bromo-3-chloro-4-cyanophenyl dimethylcarbamothioate (92)

To a solution of 3-allyl-5-bromo-2-chloro-4-hydroxybenzonitrile **91** (1.7 g, 6.24 mmol), Et₃N (2.6 mL, 18.7 mmol) in CH₂Cl₂ (50 mL) was added dimethylthiocarbamoyl chloride (925 mg, 7.5 mmol). After adding DMAP (762 mg, 6.24 mmol) to reaction mixture, the resulting solution was stirred overnight at 50 °C. Water (50 mL) and EtOAc (50 mL) were poured into the flask, and normal work-up was performed. The organic phase was collected, and then purified by silica gel chromatography to give the desired product (1.7 g, 75.8%) as a white solid.

¹H NMR (CDCl₃) δ 7.84 (s, 1H), 5.92-5.82 (m, 1H), 5.16-5.05 (m, 2H), 3.68-3.63 (m, 1H), 3.51 (s, 3H), 3.50-3.44 (m, 1H), 3.43 (s, 3H); [M+H]⁺ 359.


30



S-2-Allyl-6-bromo-3-chloro-4-cyanophenyl dimethylcarbamothioate (93)

After dissolving O-2-allyl-6-bromo-3-chloro-4-cyanophenyl dimethylcarbamothioate 92 (1.7 g, 4.73 mmol) in diphenylether (20 mL), reaction mixture was heated to 180 °C overnight. The reaction progress was monitored by HPLC. After the reaction was completed, the resulting solution was purified by silica gel chromatography (at first, diphenylether was washed with n-hexane) to afford the title compound 93 (1.55 g, 91.2%) as a light yellow solid.

10 ^1H NMR (CDCl_3) δ 7.86 (s, 1H), 5.94-5.80 (m, 1H), 5.19-5.09 (m, 2H), 3.77-3.69 (m, 1H), 3.59 (s, 3H), 3.52-3.48 (m, 1H), 3.37 (s, 3H); $[\text{M}+\text{H}]^+$ 359.




3-Allyl-4-(allylthio)-5-bromo-2-chlorobenzonitrile (94)

To a solution of S-2-allyl-6-bromo-3-chloro-4-cyanophenyl dimethylcarbamothioate 93 (1.55 g, 4.31 mmol) in a mixture of THF (60 mL) and MeOH (30 mL) was added KOH (440 mg, 8.62 mmol) at 0 °C. The reaction solution was stirred for 4 hours at room temperature. After the reaction was completed, the volatile solvent was evaporated under reduced pressure. Normal work-up with EtOAc was preceded by acidification with 1 N HCl. The resulting solution was dried with MgSO_4 and then solvent was removed by evaporation. After further purification, the crude compound was used for the next step.

In a mixture of crude 3-allyl-5-bromo-2-chloro-4-mercaptopbenzonitrile and K_2CO_3 (1.79 g, 12.9 mmol) in CH_3CN (80 mL), allylbromide (1.12 mL, 12.9 mmol) was added dropwise. The reaction mixture was stirred overnight at room temperature, and then filtered off. The resulting solution was evaporated and purified by silica gel chromatography to give the desired product 94 (1.1 g, 77.7% overall yield) as a white solid.


10 ^1H NMR (CDCl_3) δ 7.81 (s, 1H), 5.92-5.82 (m, 1H), 5.79-5.71 (m, 1H), 5.56-5.49 (m, 2H), 5.28-5.09 (m, 2H), 4.79-4.70 (m, 2H), 3.51-3.48 (m, 2H); $[\text{M}+\text{H}]^+$ 328.



Methyl 5-bromo-2-chloro-3-(prop-1-enyl)-4-(prop-1-enylthio)benzoate(95)

To a solution of 3-allyl-4-(allylthio)-5-bromo-2-chlorobenzonitrile **94** (1.1 g, 3.35 mmol) in a mixture of EtOH (90 mL) and H₂O (10 mL) was added NaOH (545 mg, 13.4 mmol). The reaction mixture was warmed up to 100 °C, and stirred overnight. After reaction complete, the resulting solution was cooled down to room temperature. 1 N HCl solution was used for acidify reaction solution, and normal work-up with EtOAc was proceeded. Removal of volatile solvent was preceded by drying with MgSO₄. Without further purification, crude acid was used for next step. The crude acid was dissolved in MeOH (50 mL), treated with SOCl₂ (1 mL) provisionally. The reaction mixture was refluxed overnight and resulting solution was cooled down to room temperature and evaporated *in vacuo*. The residue was purified by silica gel chromatography to afford the desired product (710 mg, 63% overall yield) as a white solid.


[M+H]⁺ 362.



Methyl 7-bromo-4-chlorobenzo[b]thiophene-5-carboxylate (96)

To a solution of starting diene compound (710 mg, 1.96 mmol) in CH₂Cl₂ (40 mL) was added 2nd generation Grubb's catalyst (170 mg, 0.20 mmol) at room temperature. The resulting solution was stirred overnight at room temperature, filtered with Celite, and evaporated volatile solvent. The residue was purified by silica gel chromatography to afford the title compound (567 mg, 88%) as a light yellow solid.

¹H NMR (CDCl₃) δ 8.10 (s, 1H), 7.81-7.74 (m, 2H), 4.15 (s, 3H); [M+H]⁺ 305.




7-Bromo-4-chlorobenzo[b]thiophene-5-carboxylic acid (97)

To a solution of methyl 7-bromo-4-chlorobenzo[b]thiophene-5-carboxylate **96** (1.06 g, 3.3 mmol) in aqueous EtOH (40 mL) was added NaOH (400 mg, 10 mmol). The reaction mixture was stirred for 3 hours at room temperature. After the reaction was completed, the volatile solvent was removed under reduced pressure, acidification with 1 N HCl was accomplished. Drying with MgSO₄ was followed by normal work-up with EtOAc. After evaporating volatile solvent, the residue was used without further purification in ~88% yield.


[M+H]⁺ 292.

10

(7-Bromo-4-chlorobenzo[b]thiophen-5-yl)(4-ethoxyphenyl)methanone (98)

After dissolving crude 7-bromo-4-chlorobenzo[b]thiophene-5-carboxylic acid **97** (847 mg, 2.91 mmol) in CH₂Cl₂, (COCl)₂ (0.49 mL, 5.82 mmol) and catalytic amount DMF was added carefully at 0 °C. The resulting solution was stirred overnight at room temperature. The volatiles were evaporated under reduced pressure and dried *in vacuo*. The crude compound was used for the next step without further purification. To a solution of crude 7-bromo-4-chlorobenzo[b]thiophene-5-carbonyl chloride in CH₂Cl₂ (50 mL) was added ethoxybenzene (462 mg, 3.78 mmol) and AlCl₃ (464 mg, 3.49 mmol) at 0 °C. After warming the reaction mixture up to room temperature, it was stirred for 4 hours. The resulting compound was quenched with aq. NH₄Cl solution and the normal work-up with EtOAc was conducted. Purification by silica gel chromatography gave the title compound (917 mg, 79.8 %) as an off-white solid.

25 ¹H NMR (CDCl₃) δ 8.20 (s, 1H), 7.64-7.58 (m, 2H), 7.54-7.48 (m, 2H), 7.20-7.16 (m, 2H), 4.19 (q, *J* = 8.4 Hz, 2H), 1.34 (t, *J* = 8.4 Hz, 3H); [M+H]⁺ 395.


7-Bromo-4-chloro-5-(4-ethoxybenzyl)benzo[b]thiophene (99)

To a solution of (7-bromo-4-chlorobenzo[b]thiophen-5-yl)(4-


ethoxyphenyl)methanone **98** (917 mg, 2.32 mmol) in a mixture of CH₂Cl₂ (9 mL) and CH₃CN (30 mL) at 0 °C was added Et₃SiH (1.6 mL, 9.27 mmol) and BF₃·Et₂O (0.47 mL, 3.48 mmol). The reaction mixture was warmed to room temperature, and then stirred overnight. The resulting solution was quenched with aqueous sat. NH₄Cl solution (40 mL) and normal work-up with EtOAc was accomplished. After evaporating volatile solvents, the residue was purified by silica gel chromatography to afford the title compound (761 mg, 84%) as an off-white solid.

¹H NMR (CDCl₃) δ 8.19 (s, 1H), 7.65-7.58 (m, 2H), 7.52-7.47 (m, 2H), 7.22-7.18 (m, 2H), 4.18 (q, *J* = 8.4 Hz, 2H), 3.88 (s, 2H), 1.35 (t, *J* = 8.4 Hz, 3H); [M+H]⁺

10 381.




15 (2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)tetrahydro-2H-pyran (106)



Step 1) (2-Chloro-5-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenyl)methanol (**103**)

20 The title compound **103** was prepared from commercially available 5-bromo-2-chlorobenzoic acid according to the known procedure. (*Bioorg. Med. Chem.* **2010**, *18*, 2178–2194)




Step 2) 2-Chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl benzoate (**104**)

To a solution of alcohol **103** (9.9 g, 14.88 mmol) in pyridine (36 mL) was added benzoyl chloride (1.9 mL, 16.37 mmol) at room temperature. The mixture was stirred at

room temperature for 6 hours. The mixture was washed with *aq.* saturated NaHCO₃ solution. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the mixture of anomers of the title compound (10.5 g). The anomeric mixture of **104** was recrystallized 5 with IPA (150 mL). The precipitate was collected by filtration and washed with cold IPA (50 mL) and dried under high vacuum to obtain β -anomer of the title compound **104** (6.13 g, 54%).

¹H NMR (400 MHz, CDCl₃) δ 8.04 (dd, *J* = 1.2, 1.6 Hz, 2H), 7.56-7.52 (m, 2H), 7.42-7.37 (m, 4H), 7.33-7.27 (m, 13H), 7.20-7.11 (m, 5H), 6.90 (dd, *J* = 1.6, 2.0 Hz, 2H), 5.42 (s, 2H), 4.91 (q, *J* = 11.2 Hz, 2H), 4.86 (d, *J* = 10.8 Hz, 1H), 4.64-4.44 (m, 4H), 4.23 (d, *J* = 9.6 Hz, 1H), 3.90 (d, *J* = 10.4 Hz, 1H), 3.82-3.72 (m, 4H), 3.61-3.57 (m, 1H), 3.46 (t, *J* = 9.2 Hz, 1H); [M+Na]⁺ 791.

15



Step 3) (2-Chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenyl)methanol (**105**)


To a solution of benzoate **104** (6.13 g, 7.97 mmol) in THF/MeOH/H₂O (150 mL/5 mL/5 mL) was added LiOH monohydrate (1.0 g, 23.9 mmol) at room temperature.

20

The mixture was stirred at room temperature for 15 hours. The mixture was extracted with EtOAc/*aq.* saturated NH₄Cl solution (100 mL/100 mL). The organic layer was dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to yield the title compound **105** (5.33 g, 10%), which was carried on to the next step without further purification.

25

¹H NMR (400 MHz, CDCl₃) δ 7.50 (s, 1H), 7.38-7.17 (m, 20H), 6.94-6.92 (m, 2H), 4.96-4.46 (m, 9H), 4.23 (d, *J* = 9.2 Hz, 1H), 3.86 (d, *J* = 10.4 Hz, 1H), 3.81-3.67 (m, 4H), 3.61-3.59 (m, 1H), 3.44 (t, *J* = 9.2 Hz, 1H); [M+Na]⁺ 687.




30

Step 4) (2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-

(bromomethyl)-4-chlorophenyl)tetrahydro-2H-pyran (**106**)

To a solution of alcohol **105** (5.33 g, 8.01 mmol) in ether (50 mL) were added phosphorus tribromide (0.26 mL, 2.80 mmol) and catalytic amount of pyridine at 0 °C. The mixture was allowed to warm to room temperature and stirred at room temperature for 15 hours. The mixture was extracted with EtOAc/H₂O (100 mL/150 mL). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the title bromide **106** (4.15 g, 71%).


¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, *J* = 1.6 Hz, 1H), 7.34-7.25 (m, 15H), 7.22-7.11 (m, 5H), 6.94-6.92 (m, 2H), 4.96-4.85 (m, 3H), 4.69-4.46 (6H), 4.19 (d, *J* = 9.2 Hz, 1H), 3.91 (d, *J* = 10.8 Hz, 1H), 3.82-3.71 (m, 4H), 3.59-3.56 (m, 1H), 3.45 (t, *J* = 9.2 Hz, 1H); [M+Na]⁺ 749.



(2-Methyl-5-((3S,4R,5R,6R)-3,4,5-tris(benzylxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenyl)methanol (**110**)

The title compound **110** was prepared from commercially available 5-bromo-2-methylbenzoic acid according to the known procedure. (*ACS Med. Chem. Lett.* **2011**, 2,

20 182-187)



2-(2,3-Dihydrobenzo[b]thiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(**114**)

Step 1) 2,3-Dihydrobenzo[b]thiophene (**112**)

Trifluoroacetic acid(5.2mL) was slowly added to the mixture of benzothiophene (1 g, 7.45 mmol) and triethylsilane (3.6 mL, 22.35 mmol) with heating under reflux at 50 °C for 125 hours. After cooling to 0 °C, the reaction was quenched by addition of *aq.* 30 saturated NH₄Cl solution. The mixture was diluted with water and extracted with

EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and evaporated *in vacuo*. The residue was purified by silica gel column chromatography to provide the intermediate **112** (415 mg, 41%).

5 ¹H NMR (400 MHz, CDCl₃) δ 7.22-7.16 (m, 2H), 7.12-7.08 (m, 1H), 7.00 (td, *J* = 7.4, 1.2 Hz, 1H), 3.36-3.32 (m, 2H), 3.29-3.25 (m, 2H).

Step 2) 5-Bromo-2,3-dihydrobenzo[b]thiophene (**113**)

Iron powder (10.4 mg, 1.47 mmol) was added to a solution of 2,3-dihydrobenzo[b]thiophene **112** (400 mg, 2.94 mmol) in dichloromethane (5.9 mL). Bromine (0.15 mL, 2.94 mmol) was added dropwise to the mixture with stirring under ice-cooling. This mixture was stirred at the same temperature for 30 minutes. Saturated aqueous sodium hydrogen carbonate solution was added to the mixture and this was extracted with dichloromethane. The organic layer was washed with water, dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to provide the desired product **113** (396 mg, 63%).

15 ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.29 (m, 1H), 7.23-7.20 (m, 1H), 7.05 (d, *J* = 8.0 Hz, 1H), 3.38-3.34 (m, 2H), 3.28-3.24 (m, 2H); [M+H]⁺ 215.

Step 3) 2-(2,3-Dihydrobenzo[b]thiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**114**)

20 To a solution of 5-bromo-2,3-dihydrobenzo[b]thiophene (**113**) (390 mg, 1.81 mmol) in DMF (7.5 mL) were added bis(pinacolato)diboron (1.38 g, 5.44 mmol), Pd(dppf)₂Cl₂ (30 mg, 0.036 mmol) and CH₃CO₂K (890 mg, 9.07 mmol) at room temperature. The mixture was stirred at 100 °C for 15 hours. The reaction mixture was cooled to room temperature and filtered off through Celite. The filtrate was 25 concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the title compound **114** (260 mg, 55%).

30 ¹H NMR (400 MHz, CDCl₃) δ 7.61 (s, 1H), 7.55 (dd, *J* = 8.4, 0.8 Hz, 1H), 7.22 (d, *J* = 7.6 Hz, 1H), 3.37-3.32 (m, 2H), 3.29-3.25 (m, 2H), 1.33 (s, 12H); [M+H]⁺ 263.


5-Bromo-1-isopropyl-1H-indazole (**115**) and 5-bromo-2-isopropyl-2H-indazole (**116**)

To a solution of 5-bromo-1H-indazole (1 g, 5.07 mmol) in DMF (17 mL) were



added 2-bromopropane (0.7 mL, 7.61 mmol) and sodium hydride (60% oil) (223 mg, 5.58 mmol) at 0 °C. The mixture was stirred at room temperature for 12 hours. The mixture was poured into water and extracted with EtOAc (50 mL x 2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue 5 was purified by silica gel column chromatography to provide the title compounds **115** (680 mg, 47%) and **116** (500 mg, 35%).

¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.86 (dd, *J* = 1.8, 0.8 Hz, 1H), 7.43 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.33 (d, *J* = 9.2 Hz, 1H), 4.86-4.76 (m, 1H), 1.59 (s, 3H), 1.57 (s, 3H); δ 7.90 (d, *J* = 0.8 Hz, 1H), 7.80 (dd, *J* = 1.8, 0.8 Hz, 1H), 7.43 (dt, *J* = 9.2, 0.8 Hz, 1H), 7.32 (dd, *J* = 9.0, 2.0 Hz, 1H), 4.83-4.73 (m, 1H), 1.66 (s, 3H), 1.64 (s, 3H); [M+H]⁺ 239.




15 5-(2-Chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-
(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)-1-isopropyl-1H-indazole (117)

To a solution of benzyl bromide (1.1 g, 1.52 mmol) in toluene/EtOH (1.35 mL/1.5 mL) were added a pinacol ester of the compound **115** (870 mg, 3.04 mmol), Pd(PPh₃)₄ (90 mg, 0.076 mmol) and Cs₂CO₃ (990 mg, 3.04 mmol) at 0 °C. The mixture 20 was stirred at 100°C for 15 hours. The reaction mixture was cooled to room temperature and filtered off through celite. The filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the title compound **117** (780 mg, 63%).



[M+Na]⁺ 829.

25



6-(2-Chloro-5-(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-
tetrahydro-2H-pyran-2-yl)benzyl-2,3-dihydrobenzo[b][1,4]dioxine (119)


To a solution of (*2R,3R,4R,5S,6S*)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)-tetrahydro-2*H*-pyran (**106**) (500 mg, 0.687 mmole) in acetone (6 mL) and water (2 mL) was added 2,3-dihydrobenzo[*b*][1,4]dioxin-6-ylboronic acid (247 mg, 1.37 mmole) and K₂CO₃ (380 mg, 2.75 mmole). The reaction mixture was cooled in an ice-bath, and then bis(triphenylphosphine) palladium(II) dichloride (24.1 mg, 0.0344 mmole) was added. The reaction mixture was stirred at ambient temperature overnight. Then brine was added and the resulting mixture was extracted with ethyl acetate. The organic layer was dried over MgSO₄, and the solvent was concentrated *in vacuo*. The residue was purified by silica gel chromatography to yield the title compound (501 mg, 0.640 mmole, 93 %) as a colorless gum.



15 5-Bromo-2,3-dihydro-1*H*-indene (120**)**

5-Aminoindane was treated with concentrated hydrobromic acid. The suspension was cooled to -5 °C, and 5 M sodium nitrite solution was added at a temperature between 0 °C to 5 °C in period of 30 minutes through an addition funnel. Stirring was continued for 20 minutes at 0 °C to 5 °C. The reaction mixture was now very dark fluid slurry. In a second reaction vessel, a solution of copper (I) bromide in concentrated hydrobromic acid had been prepared and preheated to 40 °C. When the diazonium salt slurry was added in portions, a very slow gas evolution was observed which became vehement when heating to 60 °C. After stirring at 60 °C for 40 min, the gas evolution ceased. The mixture was poured onto water. The product was extracted twice with ethyl acetate. Some of the precipitated copper bromide was removed by filtration to facilitate phase separation. The organic extracts were washed twice with water and one time with brine. The combined organic extracts were dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. After flash chromatography, the title compound was obtained as pale yellow oil.

30 ¹H NMR (400MHz, CDCl₃) δ 7.29 (s, 1H), 7.18-7.20 (m, 1H), 7.02 (d, *J* = 8.0 Hz, 1H), 2.78-2.86 (m, 4H), 1.99-2.06 (m, 2H).




2-(2,3-Dihydro-1*H*-inden-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (121)

To a stirred solution of 5-bromo-2,3-dihydro-1*H*-indene (**120**) (800 mg, 4.1 mmol) in *N,N*-dimethylformamide (10 mL), bis(pinacolato)diboron (2.1 g, 8.2 mmol) was added and deoxygenated twice. Potassium acetate (2.0 g, 20.5 mmol) and Pd(PPh₃)₂Cl₂ (84 mg, 0.12 mmol) were added thereto and again deoxygenated. The reaction mixture was heated to 100 °C for 12 h. The reaction mixture was filtered through Celite bed and evaporated to dryness. The crude compound was purified through column chromatography on silica gel to afford the title compound (820 mg, 83%).

¹H NMR (400MHz, CDCl₃) δ 7.69 (s, 1H), 7.57 (d, *J* = 7.6 Hz, 1H), 7.24-7.26 (m, 1H), 2.91 (q, *J* = 7.2, 6.0 Hz, 4H), 2.05 (m, 2H), 1.34 (s, 12H).

[M+H]⁺ 245.


15



(2*R*,3*R*,4*R*,5*S*,6*S*)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-(4-chloro-3-((2,3-dihydro-1*H*-inden-5-yl)methyl)phenyl)-tetrahydro-2*H*-pyran (122)

To a solution of (2*R*,3*R*,4*R*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)-tetrahydro-2*H*-pyran (**106**) (580 mg, 0.8 mmole) in toluene/EtOH (9 mL/8 mL) were added 2-(2,3-dihydro-1*H*-inden-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**121**) (400 mg, 1.6 mmol), tetrakis(triphenylphosphine)palladium (180 mg, 0.16 mmol), and Cs₂CO₃ (2.1 g, 2.32 mmol) at room temperature. The mixture was stirred at 100 °C. The mixture was cooled to room temperature and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the title compound (425 mg, 70%).

[M+Na]⁺ 787.



6-(2-Chloro-5-((2S,3R,4R,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-thiopyran-2-yl)benzyl)-2,3-dihydrobenzo[b][1,4]dioxine (126)


To a solution of 6-(5-bromo-2-chlorobenzyl)-2,3-dihydrobenzo[b][1,4]dioxine (124, 384 mg, 1.1 mmol) in tetrahydrofuran (5 mL) at -78 °C under an atmosphere of nitrogen was added dropwise *n*-butyllithium (2.5 M in hexane, 0.45 mL, 1.1 mmol), and the mixture was stirred for 0.5 h at the same temperature. Then a solution of (3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-thiopyran-2-one (123, 300 mg, 0.54 mmol, This compound was synthesized by reference to H. Driguez and B. Henrissat, *Tetrahedron Lett.* **1981**, 22, 5061-5062, Kakinuma, H., et al., *J. Med. Chem.* **2010**, 53, 3247-3261) in tetrahydrofuran (5 mL) was added dropwise, and the mixture was stirred for 15 min at the same temperature. The reaction mixture was quenched by addition of saturated ammonium chloride solution. After complete addition, the solution was gradually raised to room temperature. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (silica gel, 3 to 30% tetrahydrofuran in hexane) to yield (3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-2-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)tetrahydro-2H-thiopyran-2-ol (125, 416 mg, 0.51 mmol, 95%) as a white solid.

To a stirred -15 °C solution of lactol (125, 410mg, 0.50 mmol) in dichloromethane/acetonitrile (4 mL/4 mL) was added triethylsilane (0.49 mL, 3.02 mmol) followed by boron trifluoride diethyl etherate (0.26 mL, 2.01 mmol) at a rate such that the reaction temperature was maintained between -15 and 0 °C. The solution was allowed to warm to 0 °C over 0.5 h prior to quenching with saturated sodium bicarbonate solution. After removal of organic volatiles under a reduced pressure, the residue was partitioned between ethyl acetate and water. Following extraction of the aqueous layer with ethyl acetate, the combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (silica gel, 3 to 25% ethyl acetate in hexane) to yield the title compound (126, 215 mg, 0.27 mmol, 53%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 4.4 Hz, 1H), 7.36-7.25 (m, 15H),

7.21-7.14 (m, 5H), 6.76-6.72 (m, 4H), 6.64 (dd, $J = 2.0, 8.4$ Hz, 1H), 4.93 (d, $J = 10.8$ Hz, 1H), 4.90 (s, 2H), 4.63 (d, $J = 10.4$ Hz, 1H), 4.55-4.53 (m, 3H), 4.22 (s, 4H), 4.06 (d, $J = 15.2$ Hz, 3H), 3.96-3.88 (m, 4H), 3.85-3.81 (m, 2H), 3.73 (dd, $J = 2.8, 9.6$ Hz, 1H), 3.55 (t, $J = 8.8$ Hz, 1H), 3.15-3.10 (m, 1H); $[M+Na]^+$ 821.


5



6-(5-Bromo-2-chlorobenzyl)-2,3-dihydrobenzo[b][1,4]dioxine (130)

10 To a stirred suspension of 5-bromo-4-methoxy-2-chlorobenzoic acid (**128**, 4 g, 15.2 mmol) in dichloromethane (100 mL) was added oxalyl chloride (1.6 mL, 18.3 mmol) and DMF (2 drops) at 0 °C and stirred for 2 h. The mixture was concentrated, and the residual colorless solid was dissolved in dichloromethane (100 mL). To this solution were added 1,4-benzodioxane (2 mL, 16.7 mmol) and then AlCl₃ (2.23 g, 16.7 mmol) portionwise. After being stirred at room temperature overnight, the mixture was poured into ice water and extracted with dichloromethane two times. The combined organic layers were washed with 1 M HCl, water, and brine, then dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude residue was diluted with dichloromethane/ acetonitrile (35 mL/35 mL) and added triethylsilane (7.4 mL, 45.6 mmol) followed by boron trifluoride diethyl etherate (5.8 mL, 45.6 mmol) at -10 °C. The solution was allowed to warm to room temperature over 5 h prior to quenching with saturated sodium bicarbonate solution. After removal of organic volatiles under a reduced pressure, the crude residue was purified by silica gel chromatography (3 to 10% tetrahydrofuran in hexane) to yield the title compound (**130**, 3.6 g, 9.74 mmol, 64%; 3 steps) as a white solid.


25 ¹H NMR (400 MHz, CDCl₃) δ 7.35 (s, 1H), 6.94 (s, 1H), 6.83 (dd, $J = 1.6, 6.8$ Hz, 1H), 6.69 (s, 1H), 6.69-6.67 (m, 1H), 4.27 (s, 4H), 3.93 (s, 2H), 3.90 (s, 3H).



(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(5-(4-ethylbenzyl)-4'-methoxy-6-methylbiphenyl-3-yl)-tetrahydro-2H-pyran-3,4,5-triyl triacetate (132)

To a solution of (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-bromo-5-(4-ethylbenzyl)-4-methylphenyl)-tetrahydro-2H-pyran-3,4,5-triyl triacetate (131) (WO2008/101939, Example V) (500 mg, 0.807 mmole) in toluene (6 mL) and water (3 mL) were added 4-methoxyphenylboronic acid (147 mg, 0.969 mmole), Pd(OAc)₂ (18.1 mg, 0.0807 mmole), tricyclohexylphosphonium tetrafluoroborate (59.4 mg, 0.161 mmole), and K₃PO₄ (685 mg, 3.23 mmole). The mixture was stirred at 100 °C overnight. After cooling to ambient temperature, the mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography to yield the title compound (484 mg, 0.748 mmole, 93%) as a yellow solid.

[M+Na]⁺ 669.



(3aS,5R,6S,6aS)-6-Hydroxy-2,2-dimethyltetrahydrofuro[3,2-d][1,3]dioxol-5-yl)(morpholino)methanone (134)

Step 1) (3aS,5S,6R,6aS)-5-(Hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,2-d][1,3]dioxol-6-ol

To a suspension of L-(-)-xylose (133, 19.15 g, 127.5 mmol) and MgSO₄ (30.72 g, 255.0 mmol) in acetone (190 mL) was added conc. H₂SO₄ (1.9 mL) at room temperature. After 12 h, the reaction mixture (all L-(-)-xylose had been consumed) was filtered and the collected solids were washed with acetone (twice, 20 mL per wash). The stirring yellow filtrate was neutralized with NH₄OH solution to pH ≈ 9. The suspended

solids were removed by filtration. The filtrate was concentrated to afford crude bis-acetonide intermediate as yellow oil. The yellow oil was suspended in water (5 mL), and then the pH was adjusted from 9 to 2 with 1 N HCl in water solution. The reaction mixture was stirred for 12 h at room temperature. The resulting mixture was neutralized 5 by the addition of 25% (w/w) K₃PO₄ in water until pH ≈ 7. The mixture was extracted with EtOAc. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography to provide the title compound (12.63 g, 52%) as yellow oil.

10 ¹H NMR (400 MHz, CD₃OD) δ 5.88 (d, *J* = 4.0 Hz, 1H), 4.47 (d, *J* = 4.0 Hz, 1H), 4.18-4.14 (m, 1H), 4.11 (d, *J* = 2.8 Hz, 1H), 3.83-3.71 (m, 2H), 1.45 (s, 3H), 1.29 (s, 3H).

Step 2) (3aS,5R,6S,6aS)-6-Hydroxy-2,2-dimethyltetrahydrofuro[3,2-*d*][1,3]dioxole-5-carboxylic acid

15 To a solution of (3aS,5S,6R,6aS)-5-(Hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,2-*d*][1,3]dioxol-6-ol (14.6 g, 76.7 mmol), NaHCO₃ (19.3 g, 230.3 mmol) and NaBr (1.6 g, 15.4 mmol) in acetone/water (120/40 mL) was added TEMPO (2,2,6,6-Tetramethyl-1-piperidinyloxy free radical) (0.24 g, 1.5 mmol) at room temperature. The mixture was cooled to 0 °C, and trichloroisocyanuric acid (17.8 g, 76.7 mmol) was then added in portions. The suspension was stirred for 12 h at room 20 temperature. Methanol (2.0 mL) was added and the mixture was stirred for 2 h at room temperature. The mixture was filtered, washed with acetone (twice, 20 mL per wash). The organic solvent was removed under vacuum and the aqueous layer was extracted with EtOAc and the organic layer was concentrated *in vacuo*. Acetone was added and the mixture was filtered. The filtrate was concentrated to afford the desired acid (9.0 g, 25 58%) as a pale yellow solid.


1H NMR (400 MHz, CD₃OD) δ 5.98 (d, *J* = 3.6 Hz, 1H), 4.71 (d, *J* = 3.2 Hz, 1H), 4.51 (d, *J* = 3.6 Hz, 1H), 4.36 (d, *J* = 3.6 Hz, 1H), 1.45 (s, 3H), 1.31 (s, 3H).

Step 3) ((3aS,5R,6S,6aS)-6-Hydroxy-2,2-dimethyltetrahydrofuro[3,2-*d*][1,3]dioxol-5-yl)(morpholino)methanone (**134**)

30 To a suspension of (3aS,5R,6S,6aS)-6-Hydroxy-2,2-dimethyltetrahydrofuro[3,2-*d*][1,3]dioxole-5-carboxylic acid (9.0 g, 44.2 mmol) and HBTU (25.1 g, 66.3 mmol, *N,N,N',N'*-tetramethyl-*O*-(1*H*-benzotriazol-1-yl)uronium hexafluorophosphate) in tetrahydrofuran was added 4-methylmorpholine (7.3 mL, 66.3 mmol) at room temperature. After 1 h, morpholine (5.8 mL, 66.3 mmol) was added to the mixture at 35 room temperature. After 12 h, the resulting mixture was filtered and the filter cake was washed with tetrahydrofuran. The filtrate was concentrated *in vacuo*, and the crude was

purified by silica gel column chromatography to provide the title compound (5.8 g, 48%) as a yellow solid.


¹H NMR (400 MHz, CD₃OD) δ 6.01 (d, *J* = 3.6 Hz, 1H), 5.10 (s, 1H), 4.59 (d, *J* = 2.4 Hz, 1H), 4.57 (d, *J* = 3.6 Hz, 1H), 4.47 (d, *J* = 2.4 Hz, 1H), 3.85-3.62 (m, 6H), 5 3.53-3.49 (m, 2H), 1.49 (s, 3H), 1.33 (s, 3H); [M+H]⁺ 274.



10 (4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)methyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[3,2-
d][1,3]dioxol-5-yl)methanone (135)

To a solution of bromide (2.5 g, 7.4 mmol) in toluene/tetrahydrofuran (10/5mL) was added n-BuLi (2.5 M solution in hexane) at -78 °C. After 1 h, **134** (0.67 g, 2.5 mmol) in toluene (5 mL) was added to the mixture (using cannula) at -78 °C. After 1 h, the resulting mixture was quenched with CH₃OH, diluted with EtOAc and washed with saturated NaCl solution. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography to provide the title compound (0.77 g, 70%) as a white solid.

20 ¹H NMR (400 MHz, CDCl₃) δ 7.87 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.81 (d, *J* = 2.0 Hz, 1H), 7.48 (d, *J* = 8.4 Hz, 1H), 6.80 (dd, *J* = 7.2, 1.6 Hz, 1H), 6.68-6.65 (m, 2H), 6.06 (d, *J* = 3.6 Hz, 1H), 5.21 (d, *J* = 2.4 Hz, 1H), 4.57 (d, *J* = 4.0 Hz, 1H), 4.55 (br s, 1H), 4.23 (s, 4H), 4.04-4.02 (m, 2H), 1.54 (s, 3H), 1.35 (s, 3H); [M+H]⁺ 447.




25

(3aS,5S,6R,6aS)-5-((S)-(4-Chloro-3-((2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)methyl)phenyl)(hydroxy)methyl)-2,2-dimethyltetrahydrofuro[3,2-*d*][1,3]dioxol-6-ol (136)

To a solution of compound **135** (0.77 g, 1.7 mmol) in CH₃OH was added CeCl₃·7H₂O and the mixture was stirred at room temperature until all solids were dissolved. The mixture was then cooled to -78 °C and NaBH₄ was added in portions. The mixture was stirred for 1 h at -78 °C, slowly warmed to 0 °C and quenched with saturated NH₄Cl solution. The mixture was concentrated under reduced pressure to remove CH₃OH and then extracted with EtOAc and washed with saturated NaCl solution. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to afford the desired alcohol (0.67 g, 87%) as a white solid. The obtained product was used for the next step without purification.

¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 8.4 Hz, 1H), 7.28 (d, *J* = 2.0 Hz, 1H), 7.21 (d, *J* = 2.4 Hz, 1H), 6.78 (d, *J* = 8.4 Hz, 1H), 6.68 (d, *J* = 1.6 Hz, 1H), 6.66 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.02 (d, *J* = 3.6 Hz, 1H), 5.18 (t, *J* = 2.8 Hz, 1H), 4.50 (d, *J* = 4.0 Hz, 1H), 4.23 (s, 4H), 4.13-4.12 (m, 2H), 4.01-3.99 (m, 2H), 3.81 (d, *J* = 2.8 Hz, 1H), 1.55 (s, 3H), 1.30 (s, 3H); [M+Na]⁺ 471.

20




(3*S*,4*R*,5*S*,6*S*)-6-(4-Chloro-3-((2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)methyl)phenyl)tetrahydro-2*H*-pyran-2,3,4,5-tetrayl tetraacetate (137)

A solution of compound **136** (0.67 g, 1.5 mmol) in AcOH/water (4.0/2.5 mL) was stirred for 12h at 100 °C. The resulting mixture was cooled to room temperature and concentrated under reduced pressure. The crude oil was treated with acetic anhydride (1.2 mL, 12.0 mmol) in pyridine (4.0 mL) at 0 °C. The mixture was stirred for 8 h at room temperature. The resulting mixture was quenched with water, extracted with EtOAc and washed with brine. The organic layer was dried over dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the title compound (0.65 g, 75%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.35 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.19 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.09-7.07 (m, 1H), 6.78 (d, *J* = 7.6 Hz, 1H), 6.64-6.60 (m, 2H), 6.44 (d, *J* =

3.6 Hz, 1H α), 5.84 (d, J = 8.4 Hz, 1H β), 5.56 (t, J = 10.0 Hz, 1H α), 5.34 (t, J = 9.2 Hz, 1H β), 5.27-5.19 (m, 1H), 5.12-5.06 (m, 1H β), 5.06-5.01 (m, 1H α), 4.79 (d, J = 10.4 Hz, 1H α), 4.47 (d, J = 9.6 Hz, 1H β), 4.23 (s, 4H), 4.04-3.88 (m, 2H), 2.19 (s, 3H α), 2.10 (s, 3H β), 2.06 (s, 3H β), 2.04 (s, 3H α), 2.01 (s, 3H α), 2.00 (s, 3H β), 1.76 (s, 3H α), 1.74 (s, 3H β); [M+Na]⁺ 599.




10 (2S,3S,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate (138)

To a solution of compound 137 (200 mg, 0.35 mmol) and thiourea (53 mg, 0.70 mmol) in 1,4-dioxane (5.0 mL) was added TMSOTf (96 μ L, 0.53 mmol) and the reaction mixture was heated to 80 °C for 3 h. The mixture was cooled to room temperature, and MeI (55 μ L, 0.87 mmol) and DIPEA (0.30 mL, 1.75 mmol) were added thereto and the mixture was stirred for 3 h. The resulting mixture was diluted with EtOAc and washed with water. The organic layer was dried over dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude was purified by preparative HPLC (reverse phase) to provide the title compound (60 mg, 30%) as a white solid.

15 ¹H NMR (400 MHz, CDCl₃) δ 7.35 (d, J = 8.0 Hz, 1H), 7.19 (dd, J = 8.4, 2.0 Hz, 1H), 7.05 (d, J = 2.4 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 6.65-6.61 (m, 2H), 5.31 (d, J = 9.2 Hz, 1H), 5.19 (d, J = 9.6 Hz, 1H), 5.04 (d, J = 9.6 Hz, 1H), 4.50 (d, J = 10.0 Hz, 1H), 4.37 (d, J = 10.0 Hz, 1H), 4.23 (s, 4H), 4.03-3.89 (m, 2H), 2.17 (s, 3H), 2.09 (s, 3H), 2.00 (s, 3H), 1.74 (s, 3H); [M+Na]⁺ 587.


25



(2S,3S,4R,5S,6S)-2-Bromo-6-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (139)

Compound **137** (100 mg, 0.17 mmol) was treated with 33% HBr in AcOH (350 μ L) for 30 min at room temperature. The reaction mixture was diluted with CH₂Cl₂ (1 mL), stirred for 30 min, diluted with more CH₂Cl₂ (50 mL), and washed with cold water (10 mL x 2), and saturated NaHCO₃ solution (40 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to provide the title compound (100 mg, 99%) as an off-white solid. The obtained product was used for the next step without purification.


¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, *J* = 8.4 Hz, 1H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.12 (d, *J* = 1.6 Hz, 1H), 6.78 (d, *J* = 8.0 Hz, 1H), 6.71 (d, *J* = 4.0 Hz, 1H), 6.64-6.61 (m, 2H), 5.64 (t, *J* = 9.6 Hz, 1H), 5.11 (t, *J* = 10.0 Hz, 1H), 4.95 (dd, *J* = 10.0, 2.8 Hz, 2H), 4.23 (s, 4H), 4.05-3.88 (m, 2H), 2.12 (s, 3H), 2.02 (s, 3H), 1.77 (s, 3H); [M+Na]⁺ 619.



(2*S*,3*S*,4*R*,5*S*,6*S*)-2-(4-Chloro-3-((2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxytetrahydro-2*H*-pyran-3,4,5-triyl triacetate (**140**)

A mixture of compound **139** (100 mg, 0.17 mmol) and ZnO (14 mg, 0.17 mmol) in CH₃OH (2.0 mL) was stirred for 1 h at 70 °C. The resulting mixture was filtered through Celite® with EtOAc, and concentrated *in vacuo*. The crude was purified by preparative HPLC (reverse phase) to provide the title compound (40 mg, 43%) as a white solid.


¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, *J* = 8.4 Hz, 1H), 7.23 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.09 (d, *J* = 2.0 Hz, 1H), 6.78 (d, *J* = 8.0 Hz, 1H), 6.65-6.61 (m, 2H), 5.28 (t, *J* = 9.6 Hz, 1H), 5.10 (dd, *J* = 9.6, 8.0 Hz, 1H), 5.02 (t, *J* = 9.6 Hz, 1H), 4.54 (d, *J* = 8.0 Hz, 1H), 4.34 (d, *J* = 10.0 Hz, 1H), 4.23 (s, 4H), 4.04-3.90 (m, 2H), 3.48 (s, 3H), 2.07 (s, 3H), 1.99 (s, 3H), 1.74 (s, 3H); [M+Na]⁺ 571.



(2S,3S,4R,5S)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate (142)

To a suspension of E093 (210 mg, 0.5 mmol) in CH₂Cl₂ (5.0 mL) was added 5 pyridine (350 µL, 4.4 mmol), Ac₂O (410 µL, 4.4 mmol) and DMAP (3.0 mg, 0.03 mmol) at room temperature. After 12 h, the resulting mixture was diluted with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the title compound (240 mg, 87%) as a white solid.


10 ¹H NMR (400 MHz, CDCl₃) δ 7.36 (dd, *J* = 8.0, 2.4 Hz, 1H), 7.24-7.21 (m, 1H), 7.13-7.08 (m, 1H), 5.56 (t, *J* = 9.6 Hz, 1H α), 5.28 (t, *J* = 9.6 Hz, 1H β), 5.10 (dd, *J* = 9.6, 8.0 Hz, 1H β), 5.04-4.99 (m, 4H), 4.64 (d, *J* = 10.0 Hz, 1H α), 4.54 (d, *J* = 8.4 Hz, 1H β), 4.34 (d, *J* = 10.0 Hz, 1H β), 4.23 (s, 4H), 4.01-3.92 (m, 2H), 3.48 (s, 3H β), 3.41 (s, 3H α), 2.10 (s, 3H α), 2.07 (s, 3H β), 1.99 (s, 3H α), 1.98 (s, 3H β), 1.74 (s, 3H α), 15 1.73 (s, 3H β); [M+Na]⁺ 571.



(2S,3S,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate (143)

A sample of anomeric mixture 142 was separated into the two isomers by preparative HPLC (reverse phase). The first isomer was identified as the β-isomer (140, 30 mg, white solid) and the second isomer was identified as the α-isomer (143, 40 mg, white solid).

25 α isomer : ¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, *J* = 8.0 Hz, 1H), 7.24-7.20 (m, 1H), 7.13 (d, *J* = 2.0 Hz, 1H), 6.79-6.76 (m, 1H), 6.66-6.62 (m, 2H), 5.56 (t, *J* = 9.6 Hz, 1H), 5.04-4.98 (m, 3H), 4.64 (d, *J* = 10.0 Hz, 1H), 4.23 (s, 4H), 4.05-3.89 (m, 2H), 3.41 (s, 3H), 2.10 (s, 3H), 1.99 (s, 3H), 1.74 (s, 3H); [M+Na]⁺ 571.



(4-Bromo-2-((4-

5 ethylphenyl)(triisopropylsilyloxy)methyl)benzyloxy)triisopropyl silane (147)

Step 1) To a solution of 6-bromophthalide (**144**, 550 mg, 2.58 mmol) in dichloromethane (20.0 mL) was slowly added DIBAL-H (2.7 mL, 1.0 M solution in hexane) at -78 °C, and the reaction mixture was stirred for 1.5 h at -78 °C. The resulting mixture was quenched with sat. Na₂SO₄ and allowed to warm to room temperature. To 10 the mixture was added anhydrous Na₂SO₄, and the mixture was stirred for 12h, then filtered and concentrated *in vacuo*. The crude was purified by silica gel column chromatography to provide 6-bromo-1,3-dihydroisobenzofuran-1-ol (**145**, 530 mg, 96%) as yellow oil.


Step 2) To a solution of compound **145** (2.1 g, 9.77 mmol) in tetrahydrofuran (40.0 mL) was slowly added 4-ethylphenylmagnesium bromide (39 mL, 0.5 M solution in THF) at 0 °C, and the reaction mixture was stirred for 12 h at room temperature. The resulting mixture was quenched with sat. NH₄Cl, diluted with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude was purified by silica gel column chromatography to provide (5-bromo-2-(hydroxymethyl)phenyl)(4-ethylphenyl)methanol (**146**, 1.53 g, 49%) as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.50 (d, *J* = 2.0 Hz, 1H), 7.42 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.26-7.17 (m, 5H), 5.97 (s, 1H), 4.58 (d, *J* = 12.8 Hz, 1H), 4.43 (d, *J* = 12.4 Hz, 1H), 2.65 (q, *J* = 7.6 Hz, 2H), 1.23 (t, *J* = 7.6 Hz, 3H).

Step 3) To a solution of compound **146** (1.53 g, 4.76 mmol), imidazole (1.1 g, 16.66 mmol) and DMAP (57 mg, 0.47 mmol) in DMF (20.0 mL) was slowly added TIPSCl (2.0 mL, 9.52 mmol) at 0 °C, and the reaction mixture was stirred for 8 h at room temperature. The resulting mixture was diluted with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to afford the desired title compound as yellow oil. The obtained product was used for the next step without purification.

Step 4) To a solution of (5-bromo-2-((triisopropylsilyloxy)methyl)phenyl)(4-

ethylphenyl)methanol (4.76 mmol) and 2,6-lutidine (1.6 mL, 13.51 mmol) in dichloromethane (30.0 mL) was slowly added TIPSOTf (1.8 mL, 6.75 mmol) at 0 °C, and the reaction mixture was stirred for 12 h at room temperature. The resulting mixture was quenched with CH₃OH, diluted with EtOAc and washed with brine. The organic 5 layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude was purified by silica gel column chromatography to provide the title compound (2.94 g, 97% 2-step) as yellow oil.

10 ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 2.4 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.39 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.21 (d, *J* = 8.4 Hz, 2H), 7.08 (d, *J* = 8.0 Hz, 2H), 5.81 (s, 1H), 4.63-4.61 (m, 2H), 2.59 (q, *J* = 7.6 Hz, 2H), 1.18 (t, *J* = 7.6 Hz, 3H), 1.11-0.94 (m, 42H).



15 (2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(3-(4-ethylphenyl)-1,3-dihydroisobenzofuran-5-yl)tetrahydro-2H-pyran-3,4,5-triacetate(151)

Step 1) To a solution of bromide (**147**, 2.94 g, 4.64 mmol) in tetrahydrofuran/toluene (5.0/10.0 mL) was slowly added *n*-butyllithium solution (2.0 mL, 2.5 M in hexane) at -78 °C and the reaction mixture was stirred for 1h. Then a 20 solution of TMS-protected gluconolactone **12** (2.4 g, 5.10 mmol) in toluene (5 mL) was added dropwise, and the mixture was stirred for 1 hour at -78 °C. After 1 h, the resulting mixture was quenched with sat. NH₄Cl solution, and then the solution was gradually raised to room temperature. The mixture was diluted with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to afford 25 the desired (3*R*,4*S*,5*R*,6*R*)-2-(3-((4-ethylphenyl)(triisopropylsilyloxy)methyl)-4-((triisopropylsilyl oxy)methyl)phenyl)-3,4,5-tris(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)-tetrahydro-2*H*-pyran-2-ol **148** as a yellow oil. The obtained product was used for the next step without purification.

Step 2) To a solution of compound **148** (4.88 g, 4.77 mmol) in 30 dichloromethane/acetonitrile (15.0/15.0 mL) was slowly added triethylsilane (1.5 mL, 9.54 mmol) and boron trifluoride diethyl etherate (0.9 mL, 7.15 mmol) at -30 °C and the reaction mixture was stirred for 0.5 h. The mixture was quenched with CH₃OH, diluted

with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*.

Step 3) To a solution of (2S,3R,4R,5S,6R)-2-(3-((4-ethylphenyl)(triisopropylsilyloxy)methyl)-4-((triisopropylsilyloxy)methyl) phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol in dichloromethane (30.0 mL) was added Ac₂O (3.9 mL, 41.5 mmol), DMAP (30 mg, 0.24 mmol) and pyridine (3.3 mL, 41.5 mL) at room temperature and the mixture was stirred for 12 h. The resulting mixture was diluted with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude was purified by silica gel column chromatography to provide (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-((4-ethylphenyl)(triisopropylsilyloxy)methyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (**149**, 870 mg, 20%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.70-7.69 (m, 2H), 7.25-7.15 (m, 3H), 7.07-7.04 (m, 2H), 5.89-5.84 (m, 1H), 5.38-5.15 (m, 3H), 4.76-4.60 (m, 2H), 4.45-4.41 (m, 1H), 4.33-4.28 (m, 1H), 4.20-4.13 (m, 1H), 3.89-3.83 (m, 1H), 2.60-2.54 (m, 2H), 2.09-2.08 (m, 3H), 2.06 (s, 3H), 2.02-2.00 (m, 3H), 1.78 (s, 3H), 1.19-1.10 (m, 3H), 1.09-0.95 (m, 42H).


Step 4) To a solution of compound **149** (870 mg, 0.98 mmol) in tetrahydrofuran (10.0 mL) was slowly added tetrabutylammonium fluoride solution (5.0 mL, 1.0 M in tetrahydrofuran) at 0 °C and the reaction mixture was stirred for 2 h. The resulting mixture was quenched with sat. NH₄Cl solution, diluted with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude was purified by silica gel column chromatography to provide (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-((4-ethylphenyl)(hydroxy)methyl)-4-(hydroxymethyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (**150**, 500 mg, 89%) as a pale yellow solid.

¹H NMR (400 MHz, CDCl₃) δ 7.35-7.32 (m, 2H), 7.26-7.21 (m, 3H), 7.19-6.98 (m, 2H), 6.06-6.04 (m, 1H), 5.33-5.28 (m, 1H), 5.25-5.19 (m, 1H), 5.13-5.02 (m, 1H), 4.66-4.63 (m, 1H), 4.52-4.48 (m, 1H), 4.40-4.37 (m, 1H), 4.30-4.25 (m, 1H), 4.18-4.13 (m, 1H), 3.84-3.80 (m, 1H), 2.68-2.61 (m, 2H), 2.08 (s, 3H), 2.05 (s, 3H), 2.00-1.99 (m, 3H), 1.84-1.83 (m, 3H), 1.25-1.20 (m, 3H).


Step 5) To a solution of compound **150** (500 mg, 0.87 mmol) in toluene (10.0 mL) was added *p*-TsCl (183 mg, 0.96 mmol) and the reaction mixture was heated to 90 °C for 12 h. The resulting mixture was diluted with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude was purified by silica gel column chromatography to provide (2R,3R,4R,5S,6S)-2-

(Acetoxymethyl)-6-(3-(4-ethylphenyl)-1,3-dihydroisobenzofuran-5-yl)tetrahydro-2*H*-pyran-3,4,5-triyl triacetate (**151**, 380 mg, 79%) as a yellow solid.

¹H NMR (400 MHz, CDCl₃) δ 7.38-7.25 (m, 3H), 7.22-6.87 (m, 4H), 6.11-6.10 (m, 1H), 5.34-5.07 (m, 5H), 4.35-4.32 (m, 1H), 4.28-4.22 (m, 1H), 4.17-4.10 (m, 1H), 3.81-3.74 (m, 1H), 2.68-2.57 (m, 2H), 2.07-2.06 (m, 3H), 2.04 (s, 3H), 1.99-1.97 (m, 3H), 1.81 (s, 3H), 1.25-1.16 (m, 3H).



10



4-Hydroxy-3-methoxy-2-nitrobenzaldehyde (153)

Step 1) To the fuming HNO₃ (230 mL), acetate **152** (56 g, 288 mmol) was added portionwise while the temperature should be maintained from -20°C to 0°C. The mixture was stirred at 0°C for 30 min after the completion of addition. The mixture was poured into water (1.3 L) with stirring. The mixture was stirred at r.t. for 1 hr and the crude product was precipitated. The crude product was filtered and washed with H₂O (1 L) and dried under high vacuum.

Step 2) To the mixture of crude nitro compound in THF/MeOH/H₂O (450mL/150 mL/150 mL) was added LiOH monohydrate (25 g, 576 mmol). The mixture was stirred at r.t for 15 hours. The mixture was acidified with aq. 10% HCl solution (pH ~ 5). The mixture was extracted with EtOAc (500 mL×2). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **153** (38 g, 67% (2-steps)).

¹H NMR (400 MHz, DMSO-d₆) δ 11.83 (s, 1H), 9.75 (s, 1H), 7.65 (d, *J* = 8.57 Hz, 1H), 7.21 (d, *J* = 8.5 Hz, 1H), 3.85 (s, 3H).


10



5-Bromo-4-hydroxy-3-methoxy-2-nitrobenzaldehyde (154)

To the mixture of aldehyde **153** (28.0 g, 142 mmol) and I₂ (1.5 g) in AcOH (160 mL) was added Br₂ (8.0 mL, 157 mmol) at 0°C. The mixture was warmed up to r.t. and stirred at r.t. for 15 hours. The mixture was poured into water (2.0 L) with stirring. The mixture was stirred at r.t. for 30 min. The mixture was extracted with EtOAc (1 L×2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to provide the compound **154** (38 g, 98%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.53 (s, 1H), 10.12 (s, 1H), 7.80 (s, 1H), 3.81 (s, 3H).



25 2-Amino-5-bromo-4-hydroxy-3-methoxybenzaldehyde (155)

To the mixture of phenol **154** (25.4 g, 92 mmol) in EtOH/H₂O (350 mL/100 mL) were added FeSO₄·7H₂O (4.7 g) and Fe powder (47 g). The mixture was stirred at 100°C for 1 hr. The mixture was cooled down to 50°C and filtered to remove inorganic materials through celite. The filtrate was concentrated *in vacuo* to provide the title compound **155** (19.0 g, 84%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.57 (s, 1H), 9.63 (s, 1H), 7.56 (s, 1H), 6.94 (br s, 2H), 3.65 (s, 3H).

5



5-Bromo-2-chloro-4-hydroxy-3-methoxybenzaldehyde (156)

A mixture of phenol **155** (13.0 g, 52.8 mmol) in c-HCl (40 mL) was added H₂O (20 mL). The mixture was cooled to 0°C. NaNO₂ (5 g) was added portionwise slowly to the mixture at 0°C, and CuCl (8.0 g, dissolved in c-HCl (80 mL) was added thereto very slowly at 0°C. The mixture was stirred at 100°C for 1 hr and cooled to r.t. The product was precipitated, filtered, washed with H₂O (500mL) and dried under high vaccum to provide the title compound **156** (12.9 g, 92%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.51 (s, 1H), 10.11 (s, 1H), 7.80 (s, 1H), 3.12 (s, 3H).

15



5-Bromo-2-chloro-3,4-dimethoxybenzaldehyde (157)

To the mixture of aldehyde **156** (15.0 g, 56.5 mmol) in THF (300 mL) were added dimethylsulfate (7.0 mL, 73.5 mmol) and LiOH monohydrate (3.1 g, 73.5 mmol). The mixture was stirred for 3 hours at 65°C. The mixture was cooled to r.t. and filtered to remove insoluble materials through celite. The filtrate was extracted with EtOAc/aq. 50% NaCl solution (200 mL/500 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **157** (11.1 g, 70%).


¹H NMR (400 MHz, CDCl₃) δ 10.37 (s, 1H), 7.96 (s, 1H), 3.97(s, 3H), 3.94 (s, 3H).




5-Bromo-2-chloro-3,4-dimethoxybenzoic acid (158)

To the mixture of aldehyde **157** (11.1 g, 39.4 mmol), 2-methyl-2-butene (105 mL, 985 mmol) in t-BuOH (300 mL) was added KH₂PO₄ (38 g, 276 mmol). NaClO₂ (32 g, 355 mmol, dissolved in H₂O (160 mL)) was added to the reaction mixture. The mixture was stirred at r.t. for 15 hours. The mixture was evaporated in vacuo to remove the solvent. The residue was extracted with EtOAc/aq. 5% HCl solution (500 mL/300 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to provide the title compound **158** (11.6 g, 99%).

10 ¹H NMR (400 MHz, DMSO-d₆) δ 13.51 (s, 1H), 7.80 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H).






(5-Bromo-2-chloro-3,4-dimethoxyphenyl)(4-ethoxyphenyl)methanone (159)

Similar procedure with preparation of **73** proceeded except for using compound
 5 **158** to obtain the compound **159**.

¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 8.6 Hz, 2H), 7.29 (s, 1H), 6.96 (d, *J* = 8.6 Hz, 2H); 4.05 (q, *J* = 6.99 Hz, 2H), 4.00 (s, 3H), 3.98 (s, 3H), 1.48 (t, *J* = 7.0 Hz, 3H).

10




1-Bromo-4-chloro-5-(4-ethoxybenzyl)-2,3-dimethoxybenzene (160)

Similar procedure with preparation of **74** proceeded except for using compound
 15 **159** to obtain the compound **160**.

¹H NMR (400 MHz, CDCl₃) δ 7.121 (d, *J* = 8.6 Hz, 2H), 7.09 (s, 1H), 6.87 (d, *J* = 8.6 Hz, 2H), 4.05 (q, *J* = 6.99 Hz, 2H), 3.99 (s, 2H), 3.94 (s, 3H), 1.44 (t, *J* = 7.0 Hz, 3H).

20




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2,3-dimethoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E151)


Similar procedure with preparation of **75** proceeded except for using compound
 25 **160** to obtain the compound **E151**.

¹H NMR (400 MHz, CD₃OD) δ 7.14 (s, 1H), 7.12 (d, *J* = 8.8 Hz, 2H), 7.82 (d, *J* = 8.7 Hz, 2H), 4.87 (s, 4H), 4.56 (d, *J* = 9.2 Hz, 1H), 4.13-3.94 (m, 4H), 3.93-3.84 (m, 7H), 3.67 (dd, *J* = 11.9 Hz, 5.7 Hz, 1H), 3.59-3.45 (m, 2H), 3.42-3.34 (m, 2H), 1.38 (t, *J*

= 7.0 Hz, 3H); [M+Na]⁺ 491.




5



(2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-5-(4-ethoxybenzyl)-2,3-dimethoxyphenyl)tetrahydro-2H-pyran (162)

Similar procedure with preparation of 76 proceeded except for using compound 10 E151 to obtain the compound 162.

[M+Na]⁺ 851.




15 2-Chloro-3-(4-ethoxybenzyl)-6-methoxy-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)phenol (163)

Similar procedure with preparation of **77** proceeded except for using compound **162** to obtain the compound **163**.

$[M+Na]^+$ 837.

5




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-3-hydroxy-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E152)

Similar procedure with preparation of **E005** proceeded except for using
10 compound **163** to obtain the compound **E152**.

¹H NMR (400 MHz, CD₃OD) δ 7.11 (d, *J* = 8.6 Hz, 2H), 6.86 (s, 1H), 6.82 (d, *J* = 8.7 Hz, 2H), 4.87 (s, 4H), 4.52 (d, *J* = 9.6 Hz, 1H), 4.06-3.97 (m, 4H), 3.91-3.83 (m, 4H), 3.66 (dd, *J* = 12.0 Hz, 5.6 Hz, 1H), 3.59 (t, *J* = 9.2 Hz, 1H), 3.50 (t, *J* = 8.4 Hz, 1H), 3.46-3.34 (m, 2H), 1.38 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 477.

15




5

2-Chloro-3-(4-ethylbenzyl)-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)phenol (161)

Similar procedure with preparation of 27 proceeded to obtain the compound **161**.
 $[M+Na]^+$ 791.

10




2-Bromo-6-chloro-5-(4-ethylbenzyl)-3-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)phenol (162)

Similar procedure with preparation of **28** proceeded to obtain the compound **162**.

[M+Na]⁺ 869.

5




(2S,3S,4R,5R,6R)-2-(3-(Allyloxy)-2-bromo-4-chloro-5-(4-ethylbenzyl)phenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran (163)

10 Similar procedure with preparation of **29** proceeded except for using allyl bromide and Cs₂CO₃ to obtain the compound **163**.

[M+Na]⁺ 909.


15



7-Chloro-6-(4-ethylbenzyl)-3-methyl-4-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran (164)

20 To a solution of the **163** (1.52 g, 1.71 mmol) were added Bu₃SnH (3.7 ml, 13.7 mmol) and AIBN (112 mg, 0.68 mmol). After stirring for 20 h at 120 °C, aq. 10% KF solution was added to quench the reaction. The residue was dissolved in EtOAc (100 mL), washed with saturated NaHCO₃ solution, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **164** (538 mg, 40%).

25 [M+Na]⁺ 831.



(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethylbenzyl)-3-methyl-2,3-


dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E153)



Similar procedure with preparation of 73 proceeded to obtain the compound

5 **E152.**

¹H NMR (400 MHz, CD₃OD) δ 7.13-7.07 (m, 4H), 6.98 (s, 0.7H), 6.92 (s, 0.3H), 4.87 (s, 4H), 4.68-4.55 (m, 1H), 4.33-4.24 (m, 2H), 4.08-3.98 (m, 2H), 3.90 (dd, *J* = 12.7 Hz, 0.9 Hz, 1H), 3.81-3.60 (m, 2H), 3.51-3.33 (m, 4H), 2.61 (q, *J* = 7.6 Hz, 2H), 1.39 (d, *J* = 6.9 Hz, 0.9H), 1.33 (d, *J* = 7.0 Hz, 2.1H), 1.22 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺

10 471.





5

(5-Bromo-2-chloro-3-hydroxyphenyl)(phenyl)methanone (166)

To a suspension of compound **56** (6.0 g, 22.6 mmol) in CH_2Cl_2 (100 mL) were added oxalyl chloride (2.4 mL, 27.1 mmol) and catalytic amounts of DMF at room temperature. The mixture was stirred at room temperature for 2 hours. The mixture was evaporated *in vacuo* and dried under high vacuum. The crude acid chloride was dissolved with benzene (100 mL) and cooled to 0 °C. To the reaction mixture was added


10

AlCl₃ (6.9 g, 52.0 mmol) portionwise at 0 °C. The mixture was stirred at 90°C for 15 hours. The mixture was cooled to rt and evaporated *in vacuo*. The residue was cooled to 0°C and aq. 1N HCl solution was added. The mixture was extracted with EtOAc (150 mL x 1). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*.

- 5 The residue was purified by silica gel column chromatography to provide the compound **166** (7.33 g, quantitative yield).

¹H NMR (400 MHz, CDCl₃) δ 7.85-7.82 (m, 2H), 7.70-7.64 (m, 1H), 7.55-7.49 (m, 2H), 7.37 (d, *J* = 2.2 Hz, 1H), 7.13 (d, *J* = 2.2 Hz, 1H), 5.94 (s, 1H).


10



(3-(Allyloxy)-5-bromo-2-chlorophenyl)(phenyl)methanone (167)

Similar procedure with preparation of **163** proceeded to obtain the compound **167**.


15 [M+H]⁺ 351.



1-(Allyloxy)-3-benzyl-5-bromo-2-chlorobenzene (168)


- 20 To a solution of methanone **167** (7.9 g, 22.6 mmol) in TFA (90 mL) were added triethylsilane (18.5 mL, 113 mmol) and catalytic triflic acid at 0 °C. The mixture was warmed up to room temperature slowly and stirred at room temperature for 15 hours. The mixture was evaporated *in vacuo*. The residue was diluted with EtOAc (150 mL) and neutralized with aq. Saturated NaHCO₃ solution. The mixture was extracted with 25 EtOAc (150 mL x 1). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **168** (6.1 g, 80.1%).

¹H NMR (400 MHz, CDCl₃) δ 7.34-7.19 (m, 5H), 6.96 (dd, *J* = 9.4 Hz, 2.1 Hz, 2H), 6.13-6.03 (m, 1H), 5.51 (dd, *J* = 17.2 Hz, 1.4 Hz, 1H), 5.37 (dd, *J* = 10.5 Hz, 1.2 Hz, 1H), 4.62 (dd, *J* = 3.6 Hz, 1.4 Hz, 1H), 4.11 (s, 2H).



(2S,3S,4R,5R,6R)-2-(3-(Allyloxy)-5-benzyl-4-chlorophenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran (169)


5 Similar procedure with preparation of 76 proceeded except for using compound 168 to obtain the compound 169.
 $[M+Na]^+$ 803.



3-Benzyl-2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)phenol (170)

Similar procedure with preparation of 27 proceeded except for using compound 169 to obtain the compound 170.


15 $[M+Na]^+$ 763.



3-Benzyl-6-bromo-2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)phenol (171)


Similar procedure with preparation of 28 proceeded except for using compound 170 to obtain the compound 171.

$[M+Na]^+$ 841.



3-(3-Benzyl-6-bromo-2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)phenoxy)propan-1-ol (172)


5 Similar procedure with preparation of **29** proceeded except for using compound **171** to obtain the compound **172**.
 $[M+Na]^+$ 899.



(2S,3S,4R,5R,6R)-2-(5-Benzyl-2-bromo-4-chloro-3-(3-chloropropoxy)phenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran (173)

Similar procedure with preparation of **29-1** proceeded except for using compound **172** to obtain the compound **173**.


15 $[M+Na]^+$ 917.



7-Benzyl-8-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)chroman (174)

Similar procedure with preparation of **30** proceeded except for using compound **173** to obtain the compound **174**.


$[M+Na]^+$ 803.



(2S,3R,4R,5S,6R)-2-(7-Benzyl-8-chlorochroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (175)

5 Similar procedure with preparation of E005 proceeded except for using compound 174 to obtain the compound 175.


[M+Na]⁺ 443.



(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(7-benzyl-8-chlorochroman-5-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (176)

Similar procedure with preparation of 25 proceeded except for using compound 175 to obtain the compound 176.


15 [M+Na]⁺ 611.




(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(7-(4-acetylbenzyl)-8-chlorochroman-5-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (177)

To a solution of the acetate 176 (500 mg, 0.85 mmol) in CH₂Cl₂ (20 mL) were added AlCl₃ (691 mg, 5.18 mmol) and acetyl chloride (0.37 mL, 5.18 mmol) at 0 °C. The mixture was warmed up to rt slowly and left at rt for 3 hours. The mixture was cooled to 0°C and added aq. 1N HCl solution to quench the reaction. The mixture was

extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **177** (540 mg, quantitative yield).



5




(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(7-(4-acetylbenzyl)-8-chlorochroman-5-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (178)

10 To a solution of the acetate **177** (540 mg, 0.86 mmol) in THF (20 mL) were added NaBH₄ (65 mg, 1.71 mmol) and MeOH (0.23 mL, 5.56 mmol) at -20°C. The mixture was warmed up to rt slowly and at room temperature for 3 hours. To the mixture, aq. saturated NaHCO₃ solution was added to quench the reaction. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **178** (480 mg, 89%).





15



(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(8-chloro-7-(4-vinylbenzyl)chroman-5-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (179)

20 To a solution of acetate **178** (480 mg, 0.76 mmol) in Toluene (10 mL) was added p-TsOH monohydrate. The mixture was stirred for 90 min at 120°C. The mixture was cooled to rt and evaporated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **179** (270 mg, 58%).






(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(8-chloro-7-(4-cyclopropylbenzyl)chroman-5-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (180)

5 The mixture of Et₂Zn (1.1 M in toluene, 4 mL, 4.39 mmol) and CH₂Cl₂ (8 mL) was cooled to 0°C. TFA ((0.34 mL, 4.39 mmol) in CH₂Cl₂ (4 mL)) was added to the mixture at 0°C. The mixture was stirred at 0°C for 1 hr. CH₂I₂ ((0.36 mL, 4.39 mmol) in CH₂Cl₂ (4 mL)) was added to the mixture at 0°C. The mixture was stirred at 0°C for 1 hr. The acetate **179** ((270 mg, 0.44 mmol) in CH₂Cl₂ (4 mL)) was added to the mixture at 10 0°C. The mixture was warmed up to rt slowly and stirred at room temperature for 15 hours. The mixture was extracted with EtOAc/aq. sat'd NH₄Cl (50 mL/50 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified using normal phase column chromatography to provide the title product **180** (152 mg, 55%).

15 [M+Na]⁺ 651.





20 (2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-cyclopropylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E155)

To a suspension of acetate **180** (152 mg, 0.24 mmol) in MeOH (5 mL) was added NaOMe (25 wt % in MeOH, 0.05 mL) at room temperature. The mixture was stirred at room temperature for 1 hour. Glacial AcOH was added to the mixture to acidify the mixture. The mixture was concentrated under reduced pressure. The residue was purified by prep HPLC (reverse phase) to provide the compound **E155** (37 mg, 34%).

¹H NMR (400 MHz, CD₃OD) δ 7.08 (d, *J* = 8.2 Hz, 2H), 7.00 (s, 1H), 6.97 (d, *J* = 8.2 Hz, 2H), 4.90 (s, 4H), 4.43-4.37 (m, 1H), 4.38-4.16 (m, 2H), 4.03 (ABq, Δ*v*_{AB} =

10.0 Hz, J_{AB} = 15.0 Hz, 2H), 3.92-3.85 (m, 1H), 3.71-3.64 (m, 1H), 3.55-3.44 (m, 2H), 3.37-3.32 (m, 2H), 3.05-2.92 (m, 1H), 2.91-2.83 (m, 1H), 2.07-1.99 (m, 2H), 1.91-1.82 (m, 1H), 0.97-0.90 (m, 2H), 0.66-0.61 (m, 2H); [M+Na]⁺ 483.




3-(Allyloxy)-5-bromo-2-chloro-N-methoxy-N-methylbenzamide (182)

10

Similar procedure with preparation of 22 proceeded to obtain the compound 182.


[M+H]⁺ 334.



(3-(Allyloxy)-5-bromo-2-chlorophenyl)(4-methoxyphenyl)methanone (183)

5 Similar procedure with preparation of **31** proceeded except for using compound **182** to obtain the compound **183**.

[M+H]⁺ 381.



1-(Allyloxy)-5-bromo-2-chloro-3-(4-methoxybenzyl)benzene (184)

Similar procedure with preparation of **74** proceeded except for using compound **183** to obtain the compound **184**.


15 ¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, *J* = 8.7 Hz, 2H), 6.94 (dd, *J* = 14.3 Hz, 2.1 Hz, 2H), 6.88 (d, *J* = 8.7 Hz, 2H), 6.14-6.03 (m, 1H), 5.51 (qd, *J* = 8.6 Hz, 0.76 Hz, 1H), 5.51 (qd, *J* = 5.3 Hz, 0.66 Hz, 1H), 4.63-4.59 (m, 2H), 4.04 (s, 2H), 3.82 (s, 3H).



2-Allyl-3-bromo-6-chloro-5-(4-methoxybenzyl)phenol (185)

The mixture of bromide **184** (2.52 g, 6.85 mmol) in N,N-diethylaniline (8 mL) was stirred at 200°C for 45 hours. The mixture was cooled to rt and extracted with EtOAc/aq. 1N HCl solution (100 mL/100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the desired product **185** (2.3 g, 91%).

25 ¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, *J* = 8.7 Hz, 2H), 6.99 (s, 1H), 6.87 (d, *J* = 8.7 Hz, 2H), 6.00-5.95 (m, 1H), 5.87 (s, 1H), 5.15-5.05 (m, 2H), 3.98 (s, 2H), 3.82 (s, 3H), 3.62 (dt, *J* = 5.4 Hz, 1.5 Hz, 2H).




(2-Allyl-3-bromo-6-chloro-5-(4-methoxybenzyl)phenoxy)(tert-butyl)dimethylsilane (186)

5 To a solution of phenol **185** (2.29 g, 6.23 mmol) in DMF (30 mL) were added *tert*-butyldimethylsilyl chloride (1M in THF, 9.35 mL, 9.35 mmol), imidazole (1.3 g, 18.7 mmol) and catalytic DMAP. The mixture was stirred at 50 °C for 15 hours. The mixture was extracted with EtOAc/aq. 50% NaCl solution (100 mL/500 mL). The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **186** (2.57 g, 86%).

10 ¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, *J* = 8.7 Hz, 2H), 7.01 (s, 1H), 6.87 (d, *J* = 8.7 Hz, 2H), 5.93-5.81 (m, 1H), 5.08-4.96 (m, 2H), 3.99 (s, 2H), 3.83 (s, 3H), 3.58 (dt, *J* = 5.1 Hz, 1.6 Hz, 2H), 1.05 (s, 9H), 0.30 (s, 6H).


15



3-(6-Bromo-2-((tert-butyldimethylsilyl)oxy)-3-chloro-4-(4-methoxybenzyl)phenyl)propan-1-ol (187)

20 To a solution of bromide **186** (2.57 g, 5.33 mmol) in THF (35 mL) was added borane dimethylsulfide complex (10M in THF, 0.18 mL, 1.76 mmol) at 0°C. The mixture was stirred at rt for 1 hr. The mixture was cooled to 0°C and H₂O (0.5 mL), aq. 3N NaOH solution (1.1 mL), 35% H₂O₂ (0.65 mL) were added to the mixture.) The mixture was stirred at 50 °C for 30 min and cooled to rt. The mixture was extracted with EtOAc/aq. 50% NaCl solution (100 mL/100 mL). The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **187** (1.73 g, 65%).

25 ¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, *J* = 8.7 Hz, 2H), 7.01 (s, 1H), 6.87 (d, *J* = 8.7 Hz, 2H), 3.99 (s, 2H), 3.83 (s, 3H), 3.63 (q, *J* = 5.9 Hz, 2H), 2.91 (t, *J* = 7.5 Hz, 2H), 30 1.86-1.77 (m, 2H), 1.47-1.44 (m, 1H), 1.05 (s, 9H), 0.30 (s, 3H).




3-Bromo-6-chloro-2-(3-hydroxypropyl)-5-(4-methoxybenzyl)phenol (188)

To a solution of alcohol **187** (1.73 g, 3.46 mmol) in THF (28 mL) was added TBAF (1 M in THF, 7.0 mL, 6.92 mmol) at 0°C. The mixture was stirred for 1 hr at rt.

5 The mixture was extracted with EtOAc/aq. sat'd NH₄Cl solution (500 mL/50 mL). The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **188** (1.19 g, 89%).

10 ¹H NMR (400 MHz, CDCl₃) δ 7.14 (d, *J* = 8.7 Hz, 2H), 6.98 (s, 1H), 6.88 (d, *J* = 8.7 Hz, 2H), 6.79 (br s, 1H), 3.99 (s, 2H), 3.83 (s, 3H), 3.68 (t, *J* = 6.0 Hz, 2H), 2.98 (t, *J* = 7.0 Hz, 2H), 1.97-1.87 (m, 3H).




15 **5-Bromo-8-chloro-7-(4-methoxybenzyl)chroman (189)**

(step 1) To a solution of alcohol **188** (1.19 g, 3.09 mmol) in benzene (30 mL) were added PPh₃ (1.21 g, 4.63 mmol) and imidazole (1.18 g, 4.63 mmol) at rt. I₂ (in benzene (3 mL), 0.42 g, 6.18 mmol) was added to the reaction mixture. The mixture was stirred at room temperature for 15 hours. The mixture was extracted with ether/aq.

20 sat'd NaHCO₃ solution (100 mL/100 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude iodide was carried on to the next step without further purification.

(step 2) To a solution of crude iodide (1.60 g) in acetone (35 mL) was added K₂CO₃ (0.64 g, 4.64 mmol). The mixture was stirred at 50°C for 15 hours. The mixture was cooled to r.t. and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the desired product **189** (0.97 g, 85% (2-steps)).

25 ¹H NMR (400 MHz, CDCl₃) δ 7.14 (d, *J* = 8.7 Hz, 2H), 6.96 (s, 1H), 6.86 (d, *J* = 8.7 Hz, 2H), 4.28 (t, *J* = 5.2 Hz, 2H), 4.01 (s, 2H), 3.82 (s, 3H), 2.77 (t, *J* = 6.6 Hz, 2H), 2.10-2.02 (m, 2H).





(2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-methoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E156)

Similar procedure with preparation of E011 proceeded except for using compound 189 to obtain the compound E156.

¹H NMR (400 MHz, CD₃OD) δ 7.12 (d, *J* = 8.7 Hz, 2H), 7.00 (s, 1H), 6.81 (d, *J* = 8.7 Hz, 2H), 4.91 (s, 4H), 4.42-4.36 (m, 1H), 4.25-4.19 (m, 2H), 4.01 (ABq, Δ*v*_{AB} = 10.0 Hz, *J*_{AB} = 15.1 Hz, 2H), 3.91-3.85 (m, 1H), 3.77 (s, 3H), 3.71-3.63 (m, 1H), 3.55-3.33 (m, 4H), 3.05-2.97 (m, 1H), 2.93-2.84 (m, 1H), 2.05-1.99 (m, 2H); [M+Na]⁺ 473.

10






(5-Bromo-2-chloro-3,4-dimethoxyphenyl)(4-cyclopropylphenyl)methanone

(190)

5 Similar procedure with preparation of **159** proceeded to obtain the compound
190.

[M+H]⁺ 395.




1-Bromo-4-chloro-5-(4-cyclopropylbenzyl)-2,3-dimethoxybenzene (191)

10 Similar procedure with preparation of **160** proceeded to obtain the compound
191.

¹H NMR (400 MHz, CDCl₃) δ 7.13-7.09 (m, 3H), 7.05 (d, *J* = 8.2 Hz, 2H), 4.01

15 (s, 2H), 3.94 (s, 3H), 3.92 (s, 3H), 1.95-1.85 (m, 1H), 1.01-0.94 (m, 2H), 0.75-0.67 (m, 2H).




6-Bromo-3-chloro-4-(4-cyclopropylbenzyl)benzene-1,2-diol (192)

Similar procedure with preparation of **77** proceeded to obtain the compound **192.**

¹H NMR (400 MHz, CDCl₃) δ 7.09 (d, *J* = 8.2 Hz, 2H), 7.03 (d, *J* = 8.2 Hz, 2H), 6.90 (s, 1H), 5.74 (s, 1H), 5.59 (s, 1H), 3.98 (s, 2H), 1.95-1.84 (m, 1H), 1.00-0.94 (m, 2H), 0.73-0.67 (m, 2H).


25



7-Bromo-4-chloro-5-(4-cyclopropylbenzyl)benzo[d][1,3]dioxole (193)

To a solution of phenol **192** (1.75 g, 4.95 mmol) in DMF (25 mL) were added dibromomethane (0.42 mL, 5.94 mmol) and Cs₂CO₃ (5.7 g, 17.3 mmol) at r.t. The mixture was stirred at 90°C for 12 hours. The mixture was cooled to r.t. and filtered off
5 to remove inorganic salts. The filtrate was extracted with EtOAc/aq. 50% NaCl solution (100 mL/500 mL). The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **193** (1.17 g, 65%).



¹H NMR (400 MHz, CDCl₃) δ 7.05 (d, *J* = 8.2 Hz, 2H), 7.00 (d, *J* = 8.2 Hz, 2H),
10 6.77 (s, 1H), 6.10 (s, 2H), 3.93 (s, 2H), 1.91-1.83 (m, 1H), 0.99-0.90 (m, 2H), 0.69-0.63 (m, 2H).



15 **(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E158)**

Similar procedure with preparation of **E011** proceeded except for using compound **193** to obtain the compound **E158**.

¹H NMR (400 MHz, CD₃OD) δ 7.07 (d, *J* = 8.2 Hz, 2H), 6.98 (d, *J* = 8.2 Hz, 2H), 6.88 (s, 1H), 6.06 (dd, *J* = 7.0 Hz, 1.0 Hz, 2H), 4.85 (s, 4H), 4.28 (d, *J* = 9.6 Hz, 1H), 3.98 (ABq, Δv_{AB} = 10.9 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88 (d, *J* = 10.5 Hz, 1H), 3.72-3.63 (m, 1H), 3.60 (t, *J* = 9.2 Hz, 1H), 3.49-3.33 (m, 3H), 1.93-1.81 (m, 1H), 0.97-0.89 (m, 2H), 0.68-0.60 (m, 2H); [M+Na]⁺ 471.




5-Bromo-2-chloro-N,3,4-trimethoxy-N-methylbenzamide (195)

5 Similar procedure with preparation of 182 proceeded except for using compound 158 to obtain the compound 195.

10 ¹H NMR (400 MHz, CDCl₃) δ 7.33 (s, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.55 (br s, 3H), 3.39 (br s, 3H).

15




(5-Bromo-2-chloro-3,4-dimethoxyphenyl)(4-isopropylphenyl)methanone (196)

Similar procedure with preparation of 183 proceeded except for using compound 195 to obtain the compound 196.

15



¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.4 Hz, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.30 (s, 1H), 4.01 (s, 3H), 3.99 (s, 3H), 3.08-2.95 (m, 1H), 1.31 (d, *J* = 6.9 Hz, 6H).



7-Bromo-4-chloro-5-(4-isopropylbenzyl)benzo[d][1,3]dioxole (197)

5 Similar procedure with preparation of **193** proceeded to obtain the compound
197.



10 ¹H NMR (400 MHz, CDCl₃) δ 7.19 (d, *J* = 8.1 Hz, 2H), 7.13 (d, *J* = 8.2 Hz, 2H),
6.84 (s, 1H), 6.13 (s, 2H), 3.99 (s, 2H), 2.98-2.85 (m, 1H), 1.27 (d, *J* = 6.9 Hz, 6H).



8-Bromo-5-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxine

15 **(200)** Similar procedure with preparation of **193** proceeded except for using 1,2-dibromoethane to obtain the compound **200**.

20 ¹H NMR (400 MHz, CDCl₃) δ 7.09 (d, *J* = 8.2 Hz, 2H), 7.03 (d, *J* = 8.2 Hz, 2H),
6.96 (s, 1H), 4.41-4.36 (m, 4H), 3.99 (s, 2H), 2.09-1.83 (m, 1H), 0.99-0.91 (m, 2H),
0.71-0.66 (m, 2H).




5

6-Bromo-3-chloro-4-(4-ethoxybenzyl)benzene-1,2-diol (201)

Similar procedure with preparation of **77** proceeded except for using compound **160** to obtain the compound **201**.


10 $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.10 (d, $J = 8.2$ Hz, 2H), 6.88 (d, $J = 8.2$ Hz, 2H), 6.85 (s, 1H), 5.80 (br s, 1H), 5.68 (br s, 1H), 4.04 (d, $J = 7.0$ Hz, 2H), 3.96 (s, 2H), 1.44 (t, $J = 7.0$ Hz, 3H).



2,3-Bis(allyloxy)-1-bromo-4-chloro-5-(4-ethoxybenzyl)benzene (202)

1 ^1H NMR (400 MHz, CDCl_3) δ 7.12 (s, 1H), 7.10 (d, $J = 8.2$ Hz, 2H), 6.87 (d, $J = 8.2$ Hz, 2H), 6.21-6.08 (m, 2H), 5.46-5.39 (m, 2H), 5.31-5.25 (m, 2H), 4.63-4.54 (m, 4H), 4.04 (d, $J = 7.0$ Hz, 2H), 4.00 (s, 2H), 1.44 (t, $J = 7.0$ Hz, 3H).

5




(2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-((benzyloxy)methyl)-6-(2,3-

10 bis(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran (203)

Similar procedure with preparation of **162** proceeded except for using compound **202** to obtain the compound **203**.

[M+Na]⁺ 903.

15




3-Chloro-4-(4-ethoxybenzyl)-6-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-

((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)benzene-1,2-diol (204)

To a solution of compound **203** (2.82 g, 2.06 mmol) in THF (20 mL) were added **20** NaBH_4 (0.23 g, 6.00 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (0.23 g, 0.20 mmol) at 0 °C. The mixture was warmed up to r.t. slowly and stirred at r.t. for 12 h. The mixture was cooled to 0 °C and aq. sat'd NH_4Cl solution (50 mL) was added to the mixture slowly. The mixture was extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the product **204** (1.42 g, 86%).

25

[M+Na]⁺ 823.




5 6-Chloro-7-(4-ethoxybenzyl)-9-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)-3,4-dihydro-2H-benzo[b][1,4]dioxepine (205)

Similar procedure with preparation of **200** proceeded except for using 1,3-dibromopropane to obtain the compound **205**.

[M+Na]⁺ 863.


10



(2S,3R,4R,5S,6R)-2-(9-Chloro-8-(4-ethoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E164)

15 Similar procedure with preparation of **E005** proceeded except for using compound **205** to obtain the compound **E164**.

¹H NMR (400 MHz, CD₃OD) δ 7.11 (d, *J* = 8.8 Hz, 2H), 7.07 (s, 1H), 6.82 (d, *J* = 8.7 Hz, 2H), 4.85 (s, 4H), 4.63-4.55 (m, 1H), 4.31-4.17 (m, 2H), 4.17-4.07 (m, 2H), 4.05-3.93 (m, 4H), 3.88 (dd, *J* = 11.9 Hz, 1.6 Hz, 1H), 3.71-3.64 (m, 1H), 3.49-3.43 (m, 2H), 3.41-3.34 (m, 2H), 2.29-2.10 (m, 2H), 1.38 (t, *J* = 7.0 Hz, 1H); [M+Na]⁺ 503.




1-(Allyloxy)-3-benzyl-5-bromo-2-chlorobenzene (206)

25 ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.28 (m, 2H), 7.24-7.22 (m, 1H), 7.21-7.18 (m, 2H), 6.93 (d, *J* = 2.4 Hz, 1H), 6.91 (d, *J* = 2.0 Hz, 1H), 6.10-6.00 (m, 1H), 5.46 (dq,

J = 17.2, 1.6 Hz, 1H), 5.33 (dq, *J* = 10.8, 1.6 Hz, 1H), 4.58 (dt, *J* = 5.2, 1.6 Hz, 2H), 4.08 (s, 2H); [M+H]⁺ 337.


5



Methyl 4-bromo-7-chloro-2,3-dihydrobenzofuran-6-carboxylate (207)

¹H NMR (400 MHz, DMSO) δ 7.47 (s, 1H), 4.75 (t, *J* = 8.8 Hz, 2H), 3.84 (s, 3H), 3.34 (s, 3H), 3.33 (t, *J* = 9.2 Hz, 2H); [M+H]⁺ 291, 293.


10



4-Bromo-7-chloro-2,3-dihydrobenzofuran-6-carbaldehyde (208)


¹H NMR (400 MHz, CDCl₃) δ 10.31 (s, 1H), 7.57 (s, 1H), 4.79 (t, *J* = 9.2 Hz, 2H), 3.34 (t, *J* = 9.2 Hz, 2H); [M+H]⁺ 261.

15



4-Bromo-7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran (209)

¹H NMR (400 MHz, CDCl₃) δ 7.06 (d, *J* = 8.0 Hz, 2H), 6.98 (d, *J* = 8.4 Hz, 2H), 6.79 (s, 1H), 4.67 (t, *J* = 8.8 Hz, 2H), 3.95 (s, 2H), 3.22 (t, *J* = 8.8 Hz, 2H), 1.88-1.81 (m, 1H), 0.94-0.89 (m, 2H), 0.67-0.63 (m, 2H); [M+H]⁺ 363.




25

4-Bromo-7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzofuran (210)

¹H NMR (400 MHz, CDCl₃) δ 7.10 (d, *J* = 8.4 Hz, 2H), 6.83 (d, *J* = 8.8 Hz, 2H),

6.79 (s, 1H), 4.71 (t, $J = 8.8$ Hz, 2H), 3.96 (s, 2H), 3.79 (s, 3H), 3.26 (t, $J = 8.8$ Hz, 2H); $[M+H]^+$ 353.


5



4-Bromo-7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran (211)

^1H NMR (400 MHz, CDCl_3) δ 7.09 (d, $J = 8.8$ Hz, 2H), 6.81 (d, $J = 8.8$ Hz, 2H), 6.78 (s, 1H), 4.70 (t, $J = 8.8$ Hz, 2H), 4.00 (q, $J = 7.2$ Hz, 2H), 3.94 (s, 2H), 3.25 (t, $J = 8.8$ Hz, 2H), 1.40 (t, $J = 7.2$ Hz, 3H); $[M+H]^+$ 366.


10



(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(3-(allyloxy)-5-benzyl-4-chlorophenyl)tetrahydro-2H-pyran-3,4,5-triacetate (212)

^1H NMR (400 MHz, DMSO) δ 7.31-7.27 (m, 2H), 7.22-7.21 (m, 1H), 7.19-7.16 (m, 2H), 7.09 (d, $J = 1.6$ Hz, 1H), 6.88 (d, $J = 1.6$ Hz, 1H), 6.12-6.03 (m, 1H), 5.47 (dq, $J = 17.6, 2.0$ Hz, 1H), 5.35 (t, $J = 9.6$ Hz, 1H), 5.30 (dq, $J = 10.4, 1.6$ Hz, 1H), 5.12 (t, $J = 9.6$ Hz, 1H), 5.06 (t, $J = 9.6$ Hz, 1H), 4.66-4.62 (m, 3H), 4.13-4.03 (m, 5H), 2.04 (s, 3H), 2.03 (s, 3H), 1.95 (s, 3H), 1.70 (s, 3H); $[M+\text{Na}]^+$ 611.

20




(2S,3S,4R,5R,6R)-2-(3-(Allyloxy)-5-benzyl-4-chlorophenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran (213)

^1H NMR (400 MHz, CDCl_3) δ 7.36-7.31 (m, 13H), 7.26-7.19 (m, 10H), 6.94 (d, $J = 1.6$ Hz, 2H), 6.91 (dd, $J = 14.8, 2.0$ Hz, 2H), 6.10-6.00 (m, 1H), 5.46 (dq, $J =$


17.2, 1.6 Hz, 1H), 5.31 (dq, $J = 10.8, 1.6$ Hz, 1H), 4.94 (ABq, $J_{AB} = 15.2$ Hz, 2H), 4.90 (d, $J = 10.8$ Hz, 1H), 4.70-4.64 (m, 2H), 4.57 (d, $J = 12.4$ Hz, 1H), 4.52-4.49 (m, 2H), 4.46 (d, $J = 10.8$ Hz, 1H), 4.23-4.16 (m, 2H), 4.08 (d, $J = 15.2$ Hz, 1H), 3.89 (d, $J = 10.8$ Hz, 1H), 3.84-3.75 (m, 4H), 3.61-3.57 (m, 1H), 3.48-3.44 (m, 1H); [M+Na]⁺ 803.

5




3-Benzyl-2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)phenol (214)

10 ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.31 (m, 13H), 7.27-7.21 (m, 8H), 7.18-7.16 (m, 2H), 7.08 (d, $J = 2.0$ Hz, 1H), 6.98 (dd, $J = 7.6, 2.0$ Hz, 2H), 6.89 (d, $J = 2.0$ Hz, 1H), 4.93 (ABq, $J_{AB} = 16.0$ Hz, 2H), 4.89 (d, $J = 10.8$ Hz, 1H), 4.67 (d, $J = 4.8$ Hz, 1H), 4.64 (d, $J = 6.0$ Hz, 1H), 4.57 (d, $J = 12.4$ Hz, 1H), 4.46 (d, $J = 10.4$ Hz, 1H), 4.19-4.12 (m, 2H), 4.03 (d, $J = 15.2$ Hz, 1H), 3.95 (d, $J = 10.4$ Hz, 1H), 3.82-3.75 (m, 4H), 3.61-3.57 (m, 1H), 3.49-3.45 (m, 1H); [M+Na]⁺ 763.



20 (2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(6-benzyl-7-chloro-2,3-dihydrobenzofuran-4-yl)tetrahydro-2H-pyran-3,4,5-triacetate (215)

25 ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.28 (m, 2H), 7.25-7.18 (m, 3H), 6.59 (s, 1H), 5.30 (t, $J = 9.2$ Hz, 2H), 5.19 (t, $J = 9.6$ Hz, 1H), 4.77-4.68 (m, 2H), 4.35-4.32 (m, 1H), 4.31-4.26 (m, 1H), 4.21-4.14 (m, 1H), 4.11 (m, 1H), 4.02 (d, $J = 15.6$ Hz, 1H), 3.83-3.79 (m, 1H), 3.42 (td, $J = 8.8, 1.6$ Hz, 2H), 2.10 (s, 3H), 2.09 (s, 3H), 2.03 (s, 3H), 1.70 (s, 3H); [M+Na]⁺ 597.



2-Allyl-3-bromo-6-chloro-5-(4-methoxybenzyl)phenol (216)

A solution of 1-(allyloxy)-5-bromo-2-chloro-3-(4-methoxybenzyl)benzene (1.20 g, 3.26 mmol) in diethylaniline (3 mL) was heated in a sealed tube at 200 °C for 24 h under nitrogen atmosphere. The mixture was cooled to room temperature and quenched by slow addition of 1 M HCl (50~100 mL). The mixture was extracted with ethyl acetate (100~150 mL). The organic layer was dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **216** (1.10 g, 2.99 mmol, 92%).


10 ¹H NMR (400 MHz, CDCl₃) δ 7.10 (d, *J* = 8.8 Hz, 2H), 6.95 (s, 1H), 6.84 (d, *J* = 8.8 Hz, 2H), 5.97-5.87 (m, 1H), 5.10-5.06 (m, 1H), 5.05-5.03 (m, 1H), 3.95 (s, 2H), 3.79 (s, 3H), 3.58 (d, *J* = 6.4 Hz, 2H); [M+H]⁺ 369.



15 O-2-Allyl-3-bromo-6-chloro-5-(4-methoxybenzyl)phenyl dimethylcarbamothioate (217)

To a solution of compound **216** (1.62 g, 4.41 mmol) and *N,N'*-dimethylcarbamoyl chloride (1.09 g, 8.81 mmol) in CH₂Cl₂ (15 mL) were added 20 DMAP (0.93 g, 7.64 mmol) and TEA (2.45 mL, 17.6 mmol) at rt. After stirring at 35 °C overnight, the reaction mixture was cooled to rt and quenched with 1 M HCl (50 mL). The mixture was extracted with DCM (100 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **217** (1.82 g, 4.00 mmol, 91%) as a white solid.


25 ¹H NMR (400 MHz, CDCl₃) δ 7.23 (s, 1H), 7.10 (d, *J* = 8.8 Hz, 2H), 6.85 (d, *J* = 8.8 Hz, 2H), 5.92-5.82 (m, 1H), 5.07-5.05 (m, 1H), 5.04-5.00 (m, 1H), 3.98 (ABq, Δv_{AB} = 20.8 Hz, *J*_{AB} = 15.6 Hz, 2H), 3.79 (s, 3H), 3.56-3.51 (m, 1H), 3.48 (s, 3H), 3.42-3.38 (m, 1H), 3.37 (s, 3H); [M+H]⁺ 456.



S-2-Allyl-3-bromo-6-chloro-5-(4-methoxybenzyl)phenyl dimethylcarbamothioate (218)

A solution of compound 217 (1.70 g, 3.74 mmol) in phenylether (8 mL) was stirred at 240 °C for 24 h under nitrogen atmosphere. The reaction mixture was purified by silica gel column chromatography to provide the compound 218 (1.48 g, 3.25 mmol, 87%).


10 ^1H NMR (400 MHz, CDCl_3) δ 7.33 (s, 1H), 7.10 (d, $J = 8.8$ Hz, 2H), 6.86 (d, $J = 8.8$ Hz, 2H), 5.91-5.82 (m, 1H), 5.05 (dd, $J = 10.4, 1.6$ Hz, 1H), 5.05 (dd, $J = 10.4, 1.6$ Hz, 1H), 4.96 (dd, $J = 17.0, 1.8$ Hz, 1H), 4.04 (s, 2H), 3.83 (d, $J = 6.0$ Hz, 2H), 3.80 (s, 3H), 3.17 (br s, 3H), 3.03 (br s, 3H); $[\text{M}+\text{H}]^+$ 456.



15 S-3-Bromo-6-chloro-5-(4-methoxybenzyl)-2-(2-oxoethyl)phenyl dimethylcarbamothioate (219)

To a solution of 218 (1.48 g, 3.25 mmol) in THF/water (15 mL/15 mL) were added NaIO_4 (2.78 g, 13.02 mmol) and OsO_4 (0.4 mL, 2.5% in isopropanol). After stirring at rt overnight, the reaction was quenched with saturated Na_2SO_3 solution (20 mL), and the mixture was extracted with ethyl acetate (50 mL x 2). The organic layer was washed with brine, dried over anhydrous MgSO_4 , filtered and concentrated *in vacuo*. The crude product 219 was dried under high vacuum and used without further purification (1.57 g, 3.44 mmol, 106%).

20 ^1H NMR (400 MHz, CDCl_3) δ 9.63 (s, 1H), 7.38 (s, 1H), 7.11 (d, $J = 8.8$ Hz, 2H), 6.87 (d, $J = 8.8$ Hz, 2H), 4.19 (d, $J = 1.2$ Hz, 2H), 4.05 (s, 2H), 3.81 (s, 3H), 3.14 (br s, 3H), 3.01 (br s, 3H); $[\text{M}+\text{Na}]^+$ 480.




S-3-Bromo-6-chloro-2-(2-hydroxyethyl)-5-(4-methoxybenzyl)phenyl dimethylcarbamothioate (220)

To a solution of compound **219** (1.46 g, 3.18 mmol) in THF/MeOH (70 mL/7 mL) were added NaBH₄ (132 mg, 3.50 mmol) at 0 °C under nitrogen atmosphere. After stirring at 0 °C for 2 hrs, the reaction mixture was quenched with saturated NaHCO₄ (50 mL) and extracted with ethyl acetate (100 mL x 2). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **220** (1.02 g, 2.22 mmol, 70%).

¹H NMR (400 MHz, CDCl₃) δ 7.35 (s, 1H), 7.10 (d, *J* = 8.4 Hz, 2H), 6.86 (d, *J* = 8.8 Hz, 2H), 4.03 (s, 2H), 3.84 (t, *J* = 6.6 Hz, 2H), 3.80 (s, 3H), 3.40 (t, *J* = 6.6 Hz, 2H), 3.19 (br s, 3H), 3.04 (br s, 3H); [M+H]⁺ 460.


15



4-Bromo-7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzo[b]thiophene (221)

A mixture of compound **220** (0.96, 2.09 mmol) and KOH (0.70 g, 12.6 mmol) in THF/MeOH (9.6 mL/9.6 mL) was heated in a sealed tube at 60 °C for 4 hrs. After cooling to rt, the reaction mixture was quenched with 1 M HCl (40 mL) and extracted with ethyl acetate (50 mL x 2). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the compound **221** (0.65 g, 1.76 mmol, 84%).


25 ¹H NMR (400 MHz, CDCl₃) δ 7.09 (d, *J* = 8.8 Hz, 2H), 6.93 (s, 1H), 6.84 (d, *J* = 8.8 Hz, 2H), 3.93 (s, 2H), 3.79 (s, 3H), 3.46-3.36 (m, 4H); [M+H]⁺ 371.



5-Bromo-8-chloro-7-(4-methoxybenzyl)thiochroman (222)


¹H NMR (400 MHz, CDCl₃) δ 7.10 (d, *J* = 8.8 Hz, 2H), 7.08 (s, 1H), 6.84 (d, *J* = 8.4 Hz, 2H), 3.96 (s, 2H), 3.79 (s, 3H), 3.01-2.98 (m, 2H), 2.84 (t, *J* = 6.2 Hz, 2H), 2.15-2.09 (m, 2H); [M+H]⁺ 385.

5

1-(5,6,7,8-Tetrahydronaphthalen-2-yl)ethanone (223)

¹H NMR (400 MHz, CDCl₃) δ 7.68-7.65 (m, 2H), 7.14 (d, *J* = 8.4 Hz, 1H), 2.84-

10 2.78 (m, 4H), 2.57 (s, 3H), 1.84-1.79 (m, 4H); [M+H]⁺ 175.

5,6,7,8-Tetrahydronaphthalene-2-carboxylic acid (224)

¹H NMR (400 MHz, CDCl₃) δ 7.82-7.78 (m, 2H), 7.15 (d, *J* = 7.6 Hz, 1H), 2.86-

15 2.78 (m, 4H), 1.84-1.79 (m, 4H); [M+H]⁺ 177.


1,4-Dibromo-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (225)

¹H NMR (400 MHz, CDCl₃) δ 7.92 (s, 1H), 2.86-2.78 (m, 4H), 1.85-1.79 (m, 4H); [M+H]⁺ 335.

Preparation of final derivatives:

25

EXAMPLE 001




(2S,3R,4R,5S,6R)-2-(7-Bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E001)

To a solution of compound **15** (0.94 g, 1.85 mmol) in CH₂Cl₂/CH₃CN (8.9 mL/8.9 mL) were added triethylsilane (0.59 mL, 3.7 mmol) and boron trifluoride diethyl etherate (0.46 mL, 3.7 mmol) at -60 °C under nitrogen atmosphere. The mixture was warmed up to -30 °C for 2 h. The reaction mixture was quenched with saturated NaHCO₃ solution (15 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by prep HPLC (reverse phase) to provide the compound **E001** (0.15 g, 0.306 mmol, 17%).

¹H NMR (400 MHz, CD₃OD) δ 7.12 (s, 1H), 7.07 (d, *J* = 8.4 Hz, 2H), 6.77 (d, *J* = 8.8 Hz, 2H), 4.19 (d, *J* = 9.2 Hz, 1H), 3.98 (ABq, Δ*v*_{AB} = 15.3 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.84 (d, *J* = 10.8 Hz, 1H), 3.72 (s, 3H), 3.66-3.62 (m, 1H), 3.44-3.40 (m, 2H), 3.38-3.32 (m, 2H), 3.22-3.14 (m, 1H), 3.08-3.01 (m, 1H), 2.92 (t, *J* = 7.6 Hz, 2H), 2.06 (m, 2H); [M-OH]⁺ 461.


EXAMPLE 002

20



(2S,3R,4R,5S,6R)-2-(6-(4-Ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E002)

¹H NMR (400 MHz, CD₃OD) δ 7.08-7.03 (m, 3H), 6.93 (s, 1H), 6.76 (d, *J* = 8.4 Hz, 2H), 4.22 (d, *J* = 9.2 Hz, 1H), 3.96 (q, *J* = 6.8 Hz, 2H), 3.86-3.82 (m, 3H), 3.67-3.62 (m, 1H), 3.50 (t, *J* = 8.8 Hz, 1H), 3.46-3.42 (m, 1H), 3.37-3.35 (m, 2H), 3.06-2.97 (m, 1H), 2.94-2.85 (m, 1H), 2.81 (t, *J* = 7.2 Hz, 2H), 2.00 (m, 2H), 1.33 (t, *J* = 6.8 Hz, 3H); [M-OH]⁺ 397.


EXAMPLE 003

5

(2S,3R,4R,5S,6R)-2-(7-Bromo-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E003)

¹H NMR (400 MHz, CD₃OD) δ 7.12 (s, 1H), 7.06 (d, *J* = 8.4 Hz, 2H), 6.75 (d, *J* = 8.8 Hz, 2H), 4.19 (d, *J* = 9.6 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 15.3 Hz, *J*_{AB} = 15.2 Hz, 2H), 10 3.96 (q, *J* = 6.8 Hz, 2H), 3.84 (d, *J* = 11.2 Hz, 1H), 3.66-3.62 (m, 1H), 3.44-3.40 (m, 2H), 3.38-3.33 (m, 2H), 3.22-3.13 (m, 1H), 3.08-3.01 (m, 1H), 2.92 (t, *J* = 7.6 Hz, 2H), 2.06 (m, 2H), 1.33 (t, *J* = 6.8 Hz, 3H); [M-OH]⁺ 475.

15


EXAMPLE 004

(2S,3R,4R,5S,6R)-2-(7-Bromo-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E004)

¹H NMR (400 MHz, CD₃OD) δ 7.20 (s, 1H), 7.12 (ABq, Δ*v*_{AB} = 7.4 Hz, *J*_{AB} = 8.4 Hz, 4H), 4.26 (d, *J* = 9.2 Hz, 1H), 4.11 (ABq, Δ*v*_{AB} = 14.8 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.91 (d, *J* = 11.6 Hz, 1H), 3.73-3.68 (m, 1H), 3.52-3.47 (m, 2H), 3.44-3.40 (m, 2H), 3.29-3.21 (m, 1H), 3.16-3.07 (m, 1H), 3.00 (t, *J* = 7.6 Hz, 2H), 2.63 (t, *J* = 7.6 Hz, 2H), 2.13 (m, 2H), 1.24 (t, *J* = 7.6 Hz, 3H); [M-OH]⁺ 459.

25

EXAMPLE 005




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E005)

To a solution of compound **18** (0.87 g, 1.09 mmol) in THF/MeOH (8.9 mL/8.9 mL) were added Pd/C (10% Pd, 122 mg). The mixture was stirred at rt under hydrogen atmosphere for 15 h. The catalyst removed by filtration, and then the filtrate was concentrated *in vacuo*. The residue was purified by prep HPLC (reverse phase) to provide the compound **E005** (0.11 g, 0.25 mmol, 23%).

10 ¹H NMR (400 MHz, CD₃OD) δ 7.16 (s, 1H), 7.09 (d, *J* = 8.8 Hz, 2H), 6.79 (d, *J* = 8.8 Hz, 2H), 4.22 (d, *J* = 6.4 Hz, 1H), 3.99 (ABq, Δ*v*_{AB} = 16.5 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.86 (d, *J* = 8.0 Hz, 1H), 3.74 (s, 3H), 3.68-3.63 (m, 1H), 3.48-3.44 (m, 2H), 3.38-3.34 (m, 2H), 3.19-3.11 (m, 1H), 3.06-2.98 (m, 1H), 2.94 (t, *J* = 7.6 Hz, 2H), 2.081 (m, 2H); [M+Na]⁺ 457.

15

EXAMPLE 006




20 (2S,3R,4R,5S,6R)-2-(7-Fluoro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E006)

¹H NMR (400 MHz, CD₃OD) δ 7.20-7.08 (m 3H), 6.79 (dt, *J* = 8.0, 2.5 Hz, 2H), 4.20 (d, *J* = 9.2 Hz, 1H), 3.91-3.83 (m, 3H), 3.74 (s, 3H), 3.69-3.63 (m, 1H), 3.48-3.44 (m, 2H), 3.38-3.35 (m, 2H), 3.11-3.04 (m, 1H), 2.99-2.93 (m, 1H), 2.89 (t, *J* = 7.6 Hz, 2H), 2.09 (m, 2H); [M+Na]⁺ 441.

25

EXAMPLE 007




(2R,3S,4R,5R,6S)-2-(Hydroxymethyl)-6-(6-(4-methoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran-3,4,5-triol (E007)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.05 (s, 1H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.76 (d, *J* = 8.8 Hz, 2H), 4.23 (d, *J* = 9.6 Hz, 1H), 3.90 (s, 2H), 3.86 (d, *J* = 12.0 Hz, 1H), 3.72 (s, 1H), 3.68-3.64 (m, 1H), 3.54 (t, *J* = 8.8 Hz, 1H), 3.49-3.44 (m, 1H), 3.39-3.35 (m, 2H), 3.11-3.03 (m, 1H), 3.00-2.92 (m, 1H), 2.82 (t, *J* = 7.6 Hz, 2H), 2.08-2.00 (m, 5H); [M+Na]⁺ 437.

10

EXAMPLE 008




15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E008)

1 ¹H NMR (400 MHz, CD₃OD) δ 7.16 (s, 1H), 7.08 (d, *J* = 8.8 Hz, 2H), 6.77 (d, *J* = 8.8 Hz, 2H), 4.21 (d, *J* = 9.6 Hz, 1H), 4.04-3.94 (m, 4H), 3.87 (d, *J* = 11.2 Hz, 1H), 3.69-3.63 (m, 1H), 3.48-3.43 (m, 2H), 3.38-3.34 (m, 2H), 3.19-3.11 (m, 1H), 3.06-2.98 (m, 1H), 2.94 (t, *J* = 7.2 Hz, 2H), 2.082 (m, 2H), 1.35 (t, *J* = 6.8 Hz, 3H); [M+Na]⁺ 471.

20

EXAMPLE 009




(2S,3R,4R,5S,6R)-2-(6-(4-Ethoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E009)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.06 (s, 1H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.76 (d, *J* = 8.8 Hz, 2H), 4.24 (d, *J* = 9.2 Hz, 1H), 3.97 (q, *J* = 6.8 Hz, 2H), 3.91 (s, 2H), 3.88 (d, *J* = 12.4 Hz, 1H), 3.69-3.64 (m, 1H), 3.55 (t, *J* = 8.8 Hz, 1H), 3.50-3.45 (m, 1H), 3.40-3.36 (m, 2H), 3.13-3.04 (m, 1H), 3.01-2.93 (m, 1H), 2.83 (t, *J* = 7.2 Hz, 2H), 2.09-2.02 (m, 5H), 1.35 (t, *J* = 7.2 Hz, 3H); [M+H]⁺ 451.

10

EXAMPLE 010




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E010)

15 To a solution of compound **35** (1.03 g, 1.30 mmol) in THF/MeOH (30 mL/30 mL) was added Pd/C (10% Pd, 154 mg). The mixture was stirred at rt under hydrogen atmosphere for 15 h. The catalyst removed by filtration, and then the filtrate was concentrated *in vacuo*. The residue was purified by prep HPLC (reverse phase) to provide the compound **E010** (0.28 g, 0.64 mmol, 49%).

20 ¹H NMR (400 MHz, CD₃OD) δ 7.12 (s, 1H), 7.07 (s, 4H), 4.61 (sext, *J* = 8.8 Hz, 2H), 4.30 (d, *J* = 9.6 Hz, 1H), 3.97 (ABq, Δν_{AB} = 9.6 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.84 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.67-3.62 (m, 1H), 3.59 (t, *J* = 14.8 Hz, 1H), 3.45-3.39 (m, 1H), 3.37-3.40 (m, 2H), 3.23 (t, *J* = 8.4 Hz, 2H), 2.58 (q, *J* = 7.6 Hz, 2H), 1.19 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 457.

25

EXAMPLE 011



(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E011)


To a solution of bromide **90** (2.38 g, 6.24 mmol) in toluene / THF (30 mL / 15 mL) at -78 °C under an atmosphere of nitrogen was added dropwise *n*-butyllithium (2.5 M in hexanes, 2.5 mL, 6.24 mmol), and the mixture was stirred for 40 min at the same temperature. Then a solution of TMS-protected gluconolactone (2.30 g, 4.80 mmol) in toluene (15 mL) was added dropwise, and the mixture was stirred for 2 hours at -78 °C. The reaction mixture was quenched by addition of aqueous saturated ammonium chloride (50 mL). After complete addition, the solution was gradually raised to room temperature. The reaction mixture was stirred at r.t. for 1 hour. The organic layer was separated and the aqueous layer was extracted with EtOAc (50 mL). The combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to yield the compound (3*R*,4*S*,5*R*,6*R*)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-3,4,5-tris(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)tetrahydro-2H-pyran-2-ol, which was carried on to the next step without further purification (4.46 g).

To a solution of the crude alcohol (4.46 g, 5.79 mmol) in THF (50 mL) were added CH₃SO₃H (0.6 N in MeOH, 18 mL, 10.4 mmol) at -78 °C. The mixture was allowed to slowly warm to -30 °C. To a mixture was added *aq.* saturated NaHCO₃ solution (50 mL) to quench the reaction. After dilution with water, the mixture was stirred at room temperature for 30 min and extracted with EtOAc (100 mL x 2). The organic layer was dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The crude (3*R*,4*S*,5*S*,6*R*)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol (2.52 g) was carried on to the next step without further purification. To a solution of the triol compound (2.52 g) in CH₂Cl₂ / CH₃CN (25 mL / 25 mL) were added triethylsilane (1.7 mL, 10.2 mmol) and boron trifluoride diethyl etherate (1.3 mL, 10.2 mmol) at -60 °C. The mixture was allowed to slowly warm to -10 °C. To a mixture was added *aq.* saturated NaHCO₃ solution (20 mL) to quench the reaction. The reaction mixture was stirred at r.t. and evaporated *in vacuo* to remove CH₂Cl₂ and CH₃CN. The mixture was extracted

with EtOAc (100 mL x 2). The combined organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified using reverse phase preparative HPLC to provide the title compound **E011** (81 mg, 2.8% (3-steps)).

¹H NMR (400 MHz, CD₃OD) δ 7.11 (d, *J* = 3.5 Hz, 1H), 7.07 (d, *J* = 8.6 Hz, 2H), 6.77 (d, *J* = 8.6 Hz, 2H), 5.04-4.95 (m, 1H), 4.83 (s, 4H), 4.31 (t, *J* = 8.6 Hz, 1H), 3.98 (q, *J* = 7.0 Hz, 2H), 3.96-3.81 (m, 3H), 3.69-3.62 (m, 1H), 3.59-3.53 (m, 1H), 3.49-3.25 (m, 4H), 2.81 (dd, *J* = 16.0 Hz, 7.4 Hz, 2H), 1.45 (t, *J* = 6.2 Hz, 3H), 1.35 (t, *J* = 7.0 Hz, 3H); [M+NH₄]⁺ 482

10


EXAMPLE 012

(2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-ethoxybenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E012)

To a solution of compound **30** (255 mg, 0.309 mmol) in THF / MeOH (15 mL / 15 mL) was added 10% Pd/C (71 mg) at rt. The reaction mixture was stirred at r.t. for 15 hours under hydrogen and filtered off. The filtrate was concentrated *in vacuo* and the residue was purified using reverse phase preparative HPLC to provide the title compound **E012** (51 mg, 36%).

¹H NMR (400 MHz, CD₃OD) δ 7.19 (s, 1H), 7.06 (d, *J* = 8.8 Hz, 2H), 6.77 (d, *J* = 8.7 Hz, 2H), 4.90 (s, 4H), 4.66-4.55 (m, 1H), 4.19-4.06 (m, 2H), 3.98 (q, *J* = 7.0 Hz, 2H), 3.93 (ABq, Δν_{AB} = 10.4 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.84 (d, *J* = 10.6 Hz, 1H), 3.69-3.61 (m, 1H), 3.50-3.43 (m, 2H), 3.41-3.32 (m, 2H), 2.79 (t, *J* = 6.6 Hz, 2H), 2.05-1.96 (m, 2H), 1.35 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 487.

EXAMPLE 013




(2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-ethoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
(E013)

To a solution of compound **86** (509 mg, 0.615 mmol) in THF / MeOH (10 mL / 10 mL) was added 10% Pd/C (77 mg) at r.t. The reaction mixture was stirred at r.t. for 15 hours under hydrogen and filtered off. The filtrate was concentrated *in vacuo* and the residue was purified using reverse phase preparative HPLC to provide the title compound **E013** (75 mg, 10%).

¹H NMR (400 MHz, CD₃OD) δ 7.09 (d, *J* = 8.8 Hz, 2H), 6.95 (s, 1H), 6.80 (d, *J* = 8.7 Hz, 2H), 4.88 (s, 4H), 4.63-4.55 (m, 1H), 4.37-4.33 (m, 2H), 4.31-4.25 (m, 2H), 4.00 (q, *J* = 7.0 Hz, 2H), 3.96 (ABq, Δ*v*_{AB} = 13.3 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.87 (d, *J* = 11.0 Hz, 1H), 3.73-3.63 (m, 1H), 3.53-3.44 (m, 2H), 3.41-3.36 (m, 2H), 1.38 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 489.

EXAMPLE 014




20

(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E014)


¹H NMR (400 MHz, CD₃OD) δ 7.11 (d, *J* = 3.5 Hz, 1H), 7.07 (d, *J* = 8.6 Hz, 2H), 6.77 (d, *J* = 8.6 Hz, 2H), 5.04-4.95 (m, 1H), 4.83 (s, 4H), 4.31 (t, *J* = 8.6 Hz, 1H), 3.98 (q, *J* = 7.0 Hz, 2H), 3.96-3.81 (m, 3H), 3.69-3.62 (m, 1H), 3.59-3.53 (m, 1H), 3.49-

3.25 (m, 4H), 2.81 (dd, $J = 16.0$ Hz, 7.4 Hz, 2H), 1.45 (t, $J = 6.2$ Hz, 3H), 1.35 (t, $J = 7.0$ Hz, 3H); $[M+NH_4]^+$ 482.

5

EXAMPLE 015

- 10 (2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-ethoxybenzyl)chroman-8-yl)-6-
hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E015)
- 15 1H NMR (400 MHz, CD_3OD) δ 7.19 (s, 1H), 7.06 (d, $J = 8.8$ Hz, 2H), 6.77 (d, $J = 8.7$ Hz, 2H), 4.90 (s, 4H), 4.66-4.55 (m, 1H), 4.19-4.06 (m, 2H), 3.98 (q, $J = 7.0$ Hz, 2H), 3.93 (ABq, $\Delta\nu_{AB} = 13.3$ Hz, $J_{AB} = 15.2$ Hz, 2H), 3.84 (d, $J = 10.6$ Hz, 1H), 3.69-3.61 (m, 1H), 3.50-3.43 (m, 2H), 3.41-3.32 (m, 2H), 2.79 (t, $J = 6.6$ Hz, 2H), 2.05-1.96 (m, 2H), 1.35 (t, $J = 7.0$ Hz, 3H); $[M+Na]^+$ 487.


EXAMPLE 016

- 20 (2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-methoxybenzyl)chroman-8-yl)-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E016)
- 25 1H NMR (400 MHz, CD_3OD) δ 7.19 (s, 1H), 7.08 (d, $J = 8.8$ Hz, 2H), 6.79 (d, $J = 8.7$ Hz, 2H), 4.87 (s, 4H), 4.64-4.57 (m, 1H), 4.21-4.07 (m, 2H), 3.96 (ABq, $\Delta\nu_{AB} = 13.3$ Hz, $J_{AB} = 15.2$ Hz, 2H), 3.84 (d, $J = 10.4$ Hz, 1H), 3.75 (s, 3H), 3.71-3.60 (m, 1H), 3.49-3.42 (m, 2H), 3.38-3.33 (m, 2H), 2.79 (t, $J = 6.6$ Hz, 2H), 2.04-1.96 (m, 2H);

[M+Na]⁺ 473.

EXAMPLE 017

5




(2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-ethylbenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E017)

¹H NMR (400 MHz, CD₃OD) δ 7.23 (s, 1H), 7.09 (s, 4H), 4.92 (s, 4H), 4.68-

10 4.61 (m, 1H), 4.24-4.11 (m, 2H), 4.02 (ABq, Δv_{AB} = 11.8 Hz, J_{AB} = 15.1 Hz, 2H), 3.87 (d, J = 10.6 Hz, 1H), 3.73-3.62 (m, 1H), 3.53-3.47 (m, 2H), 3.43-3.31 (m, 2H), 2.82 (t, J = 6.6 Hz, 2H), 2.60 (q, J = 7.6 Hz, 2H), 2.07-2.01 (m, 2H), 1.22 (t, J = 7.6 Hz, 3H); [M+Na]⁺ 471.

15

EXAMPLE 019



(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzofuran-4-


20 yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E019)

A suspension of compound **68** (340 mg, 0.48 mmol) and Pd/C (10% wt., 45 mg) in THF (4.0 mL) and MeOH (2.0 mL) was stirred at room temperature under an atmosphere of H₂ for 24 hours. The mixture was filtered through a Celite pad and concentrated *in vacuo*. The residue was purified by prep HPLC (C18) to afford the product **E019** (15 mg, 7%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.11-7.09 (m, 2H), 6.84 (s, 1H), 6.81-6.79 (m, 2H), 4.62 (t, J = 8.6 Hz, 2H), 4.14 (d, J = 9.2 Hz, 1H), 3.97 (ABq, Δv_{AB} = 17.9 Hz, J_{AB}

= 14.8 Hz, 2H), 3.88 (dd, J = 11.8, 1.4 Hz, 1H), 3.75 (s, 3H), 3.70-3.65 (m, 1H), 3.49-3.35 (m, 5H); [M+Na]⁺ 459.

5


EXAMPLE 020

(2S,3R,4R,5S,6R)-2-(6-(4-Ethylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E020)

10 A suspension of compound **72** (490 mg, 0.61 mmol) and Pd/C (10% wt., 74 mg) in THF (4 mL) and MeOH (2 mL) was stirred at room temperature under an atmosphere of H₂ for 14 hours. The mixture was filtered through a Celite pad and concentrated *in vacuo*. The residue was purified by prep HPLC (C18) to afford the product **E020** (25 mg, 8%) as a brown solid.

15 ¹H NMR (400 MHz, CDCl₃) δ 7.07 (dd, J = 10.2, 8.6 Hz, 4H), 6.85 (s, 1H), 4.61 (t, J = 8.8 Hz, 2H), 4.14 (d, J = 9.2 Hz, 1H), 4.00 (ABq, $\Delta\nu_{AB}$ = 18.5 Hz, J_{AB} = 15.0 Hz, 2H), 3.87 (dd, J = 12.0, 1.2 Hz, 1H), 3.69-3.65 (m, 1H) 3.49-3.35 (m, 5H), 2.58 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H); [M+Na]⁺ 457.

20

EXAMPLE 021

(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-methoxybenzyl)-2,3-dihydrobenzofuran-7-


25 yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E021)

A suspension of compound **50** (407 mg, 0.51 mmol) and Pd/C (10% wt., 50 mg) in THF (5.0 mL) and MeOH (2.5 mL) was stirred at room temperature under an

atmosphere of H₂ for 24 hours. The mixture was filtered through a Celite pad and concentrated *in vacuo*. The residue was purified by prep HPLC (C18) to afford the product **E021** (65 mg, 27%) as a white solid.

5 ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.12 (s, 1H), 7.04 (dt, *J* = 8.2, 2.4 Hz, 2H), 6.79 (dt, *J* = 8.2, 2.4 Hz, 2H), 4.65-4.54 (m, 2H), 4.31 (d, *J* = 9.6 Hz, 1H), 3.94 (ABq, Δ*v*_{AB} = 10.4 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.85 (dd, *J* = 11.8, 1.8 Hz, 1H), 3.76 (s, 3H), 3.68-3.57 (m, 2H), 3.46-3.35 (m, 3H), 3.21 (t, *J* = 8.6 Hz, 2H); [M+Na]⁺ 459.

10


EXAMPLE 022

(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E022)

15

15 ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.12 (s, 1H), 7.08 (d, *J* = 8.8 Hz, 2H), 6.79 (d, *J* = 8.8 Hz, 2H), 4.66-4.55 (m, 2H), 4.31 (d, *J* = 9.6 Hz, 1H), 4.01-3.94 (m, 4H), 3.87-3.84 (m, 1H), 3.68-3.58 (m, 2H), 3.45-3.37 (m, 3H), 3.2 (t, *J* = 8.6 Hz, 2H), 1.36 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 473.

20

EXAMPLE 023

(2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-ethylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E023)


A suspension of **84** (170 mg, 0.21 mmol) and Pd/C (10 wt. %, 25.5 mg) in THF (2.0 mL) and MeOH (1.0 mL) was stirred at room temperature for 6 hours under

atmosphere of H₂. The mixture was filtered through a Celite pad and concentrated *in vacuo*. The residue was purified by a prep HPLC to provide the product **E023** (28 mg, 28%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.07 (ABq, Δν_{AB} = 7.4 Hz, J_{AB} = 8.4 Hz, 2H), 6.98 (s, 1H), 4.38-4.36 (m, 1H), 4.22-4.18 (m, 2H), 4.02 (ABq, Δν_{AB} = 7.2 Hz, J_{AB} = 15.4 Hz, 2H), 3.86 (d, J = 12.2 Hz, 1H), 3.65 (dd, J = 12.2, 5.2 Hz, 1H), 3.52-3.45 (m, 2H), 3.41-3.34 (m, 2H), 3.03-2.82 (m, 2H), 2.58 (q, J = 7.6 Hz, 2H), 2.00-1.98 (m, 2H), 1.19 (t, J = 7.6 Hz, 3H); [M+Na]⁺ 471.

10

EXAMPLE 024




15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E024)

A suspension of compound **81** (2.0 g, 2.46 mmol) and Pd/C (10% wt., 200 mg) in THF (12 mL) and MeOH (12 mL) was stirred at room temperature under an atmosphere of H₂ for 16 hours. The mixture was filtered through a Celite pad and concentrated *in vacuo*. The residue was purified by prep HPLC (C18) to afford the product **E024** (514 mg, 46%).

20 ¹H NMR (400 MHz, CD₃OD) δ 7.06 (dd, J = 6.8, 2.0 Hz, 2H), 6.82 (s, 1H), 6.76 (dd, J = 6.8, 2.0 Hz, 2H), 4.59(t, J = 8.8, Hz, 2H), 4.11(d, J = 9.2, Hz, 1H), 3.99-3.93 (m, 4H), 3.89-3.83 (m, 1H), 3.67-3.62 (m, 1H), 3.47-3.37 (m, 4H), 3.37-3.33 (m, 2H), 1.33 (t, J = 7.2 Hz, 3H); [M+Na]⁺ 473.

EXAMPLE 025




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(quinolin-6-ylmethyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E025)

¹H NMR (400 MHz, CD₃OD) δ 8.77 (dd, *J* = 4.4, 1.6 Hz, 1H), 8.27 (t, *J* = 8.4 Hz, 1H), 7.94 (t, *J* = 8.4 Hz, 1H), 7.72-7.66 (m, 2H), 7.52-7.32 (m, 4H), 4.33 (ABq, Δ*v*_{AB} = 10.5 Hz, *J*_{AB} = 15.6 Hz, 2H), 4.12 (d, *J* = 9.2 Hz, 1H), 3.87 (d, *J* = 10.4 Hz, 1H), 3.73-3.67 (m, 1H), 3.48-3.38 (m, 4H); [M+H]⁺ 416.

10

EXAMPLE 026




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(quinoxalin-6-ylmethyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E026)

¹H NMR (400 MHz, CD₃OD) δ 8.82 (s, 2H), 8.0 (dd, *J* = 4.0, 3.2 Hz, 1H), 7.82-7.72 (m, 2H), 7.51 (dd, *J* = 2.8, 2.0 Hz, 1H), 7.45-7.34 (m, 2H), 4.33 (ABq, Δ*v*_{AB} = 9.8 Hz, *J*_{AB} = 15.6 Hz, 2H), 4.14 (d, *J* = 9.6 Hz, 1H), 3.89-3.85 (m, 1H), 3.73-3.67 (m, 1H), 3.48-3.39 (m, 4H); [M+H]⁺ 417.

20


EXAMPLE 029



(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-

(2S,3R,4R,5S,6R)-2-(3-((3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E029)


¹H NMR (400 MHz, CD₃OD) δ 7.38-7.36 (m, 2H), 7.31 (dd, *J* = 8.0, 3.0 Hz, 1H), 6.87-6.85 (m, 1H), 6.80-6.78 (m, 2H), 4.14-4.11 (m, 5H), 4.02 (ABq, Δ*v*_{AB} = 18.0 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.92-3.88 (m, 1H), 3.74-3.67 (m, 1H), 3.50-3.41 (m, 4H), 5 2.14 (quint, *J* = 5.6 Hz, 2H); [M+NH₄]⁺ 454.

EXAMPLE 030

10

(2S,3R,4R,5S,6R)-2-(3-((3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E030)


¹H NMR (400 MHz, CD₃OD) δ 7.24-7.22 (m, 2H), 7.16-7.14 (m, 1H), 6.85 (d, *J* = 8.0 Hz, 1H), 6.74-6.70 (m, 2H), 4.13-4.10 (m, 5H), 3.92-3.89 (m, 3H), 3.74-3.67 (m, 1H), 3.52-3.42 (m, 4H), 2.21 (s, 3H), 2.14 (quint, *J* = 5.2 Hz, 2H); [M+Na]⁺ 439.

EXAMPLE 031

20

(2S,3R,4R,5S,6R)-2-(3-(Benzo[b]thiophen-5-ylmethyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E031)


¹H NMR (400 MHz, CD₃OD) δ 7.81 (d, *J* = 8.0 Hz, 1H), 7.66 (s, 1H), 7.53 (d, *J* = 5.6 Hz, 1H), 7.41-7.39 (m, 2H), 7.34-7.29 (m, 2H), 7.26-7.23 (m, 1H), 4.26 (ABq, Δ*v*_{AB} = 17.4 Hz, *J*_{AB} = 15.0 Hz, 2H), 4.12 (d, *J* = 9.2 Hz, 1H), 3.91-3.88 (m, 1H), 3.73-3.68 (m, 1H), 3.49-3.40 (m, 4H); [M+NH₄]⁺ 438.

EXAMPLE 032

5 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b]thiophen-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E032)

¹H NMR (400 MHz, CD₃OD) δ 7.33-7.30 (m, 2H), 7.27-7.24 (m, 1H), 7.03-7.01 (m, 2H), 6.93-6.89 (m, 2H), 4.08-4.03 (m, 2H), 4.01-3.95 (m, 3H), 3.87-3.83 (m, 1H), 3.70-3.64 (m, 1H), 3.45-3.35 (m, 4H), 3.18-3.14 (m, 2H); [M+Na]⁺ 445.

10


EXAMPLE 033

15 (2S,3R,4R,5S,6R)-2-(3-((1-Benzyl-1H-indazol-5-yl)methyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E033)

¹H NMR (400 MHz, CD₃OD) δ 7.98-7.97 (m, 1H), 7.56-7.55 (m, 1H), 7.46-7.36 (m, 3H), 7.32-7.27 (m, 5H), 7.19-7.14 (m, 2H), 5.61 (s, 2H), 4.26-4.16 (m, 2H), 4.10 (d, J = 9.2 Hz, 1H), 3.91-3.80 (m, 1H), 3.74-3.65 (m, 1H), 3.49-3.39 (m, 4H); [M+H]⁺ 495.

20

EXAMPLE 034




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((1-methyl-1H-indol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E034)

15 ^1H NMR (400 MHz, CD₃OD) δ 7.38-7.33 (m, 3H), 7.30-7.26 (m, 2H), 7.11 (d, *J* = 2.8 Hz, 1H), 7.06 (dd, *J* = 8.4, 1.6 Hz, 1H), 6.35 (dd, *J* = 3.2, 0.8 Hz, 1H), 4.20 (ABq, $\Delta\nu_{AB}$ = 24.0 Hz, *J*_{AB} = 15.2 Hz, 2H), 4.08 (d, *J* = 9.6 Hz, 2H), 3.89-3.86 (m, 1H), 3.78 (s, 3H), 3.71-3.67 (m, 1H), 3.48-3.37 (m, 4H); [M+Na]⁺ 440.

10

EXAMPLE 035




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((1-methyl-1H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E035)

15 ^1H NMR (400 MHz, CD₃OD) δ 7.90-7.89 (m, 1H), 7.53-7.51 (m, 1H), 7.46-7.42 (m, 1H), 7.39-7.31 (m, 4H), 4.21 (ABq, $\Delta\nu_{AB}$ = 17.4 Hz, *J*_{AB} = 15.0 Hz, 2H), 4.09 (d, *J* = 9.2 Hz, 1H), 4.03 (s, 3H), 3.88-3.85 (m, 1H), 3.71-3.66 (m, 1H), 3.45-3.37 (m, 4H); [M+H]⁺ 419.

20


EXAMPLE 036



(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2-methyl-2H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E036)

¹H NMR (400 MHz, CD₃OD) δ 8.04 (s, 1H), 7.48 (d, *J* = 8.8 Hz, 1H), 7.40 (d, *J* = 0.4 Hz, 1H), 7.37-7.35 (m, 1H), 7.30 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.20 (dd, *J* = 8.8, 1.6 Hz, 1H), 4.21-4.15 (m, 5H), 4.09 (d, *J* = 9.6 Hz, 1H), 3.88-3.85 (m, 1H), 3.70-3.65 (m, 1H), 3.46-3.35 (m, 4H); [M+H]⁺ 419.

EXAMPLE 037


10

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((1-ethyl-1H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E037)

¹H NMR (400 MHz, CD₃OD) δ 7.87 (d, *J* = 0.8 Hz, 1H), 7.48 (t, *J* = 0.8 Hz, 1H), 7.44 (d, *J* = 8.4 Hz, 1H), 7.35-7.33 (m, 2H), 7.30-7.26 (m, 2H), 4.40 (q, *J* = 7.2 Hz, 2H), 4.18 (ABq, Δ*v*_{AB} = 17.4 Hz, *J*_{AB} = 15.0 Hz, 2H), 4.06 (d, *J* = 9.6 Hz, 1H), 3.85-3.82 (m, 1H), 3.67-3.63 (m, 1H), 3.43-3.32 (m, 4H), 1.41 (t, *J* = 7.2 Hz, 3H); [M+H]⁺ 433.

EXAMPLE 038


20

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2-ethyl-2H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E038)

¹H NMR (400 MHz, CD₃OD) δ 8.08 (d, *J* = 0.4 Hz, 1H), 7.47 (d, *J* = 9.2 Hz, 1H), 7.39 (d, *J* = 0.8 Hz, 1H), 7.35-7.33 (m, 2H), 7.27 (dd, *J* = 8.2, 1.6 Hz, 1H), 7.18 (dd, *J* = 8.8, 1.6 Hz, 1H), 4.42 (q, *J* = 7.2 Hz, 2H), 4.14 (ABq, Δ*v*_{AB} = 18.6 Hz, *J*_{AB} = 15.2 Hz, 2H), 4.06 (d, *J* = 9.6 Hz, 1H), 3.85-3.82 (m, 1H), 3.67-3.63 (m, 1H), 3.43-3.32

(m, 4H), 1.54 (t, $J = 7.2$ Hz, 3H); $[M+H]^+$ 433.

EXAMPLE 039




5

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((1-isopropyl-1H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E039)

^1H NMR (400 MHz, CD₃OD) δ 7.91 (s, 1H), 7.51-7.47 (m, 2H), 7.38-7.36 (m, 2H), 7.30 (dd, $J = 8.8, 1.6$ Hz, 2H), 4.94-4.88 (m, 1H), 4.20 (ABq, $\Delta\nu_{AB} = 17.4$ Hz, $J_{AB} = 15.0$ Hz, 2H), 4.09 (d, $J = 9.6$ Hz, 1H), 3.88-3.85 (m, 1H), 3.70-3.66 (m, 1H), 3.46-3.38 (m, 4H), 1.54 (s, 3H), 1.52 (s, 3H); $[M+H]^+$ 447.

EXAMPLE 040

15




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2-isopropyl-2H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E040)

^1H NMR (400 MHz, CD₃OD) δ 8.13 (d, $J = 0.8$ Hz, 1H), 7.51 (d, $J = 8.8$ Hz, 1H), 7.43-7.42 (m, 1H), 7.38-7.36 (m, 2H), 7.30 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.20 (dd, $J = 9.2, 1.6$ Hz, 1H), 4.82-4.76 (m, 1H), 4.17 (ABq, $\Delta\nu_{AB} = 18.7$ Hz, $J_{AB} = 15.4$ Hz, 2H), 4.09 (d, $J = 9.6$ Hz, 1H), 3.89-3.85 (m, 1H), 3.71-3.66 (m, 1H), 3.47-3.38 (m, 4H), 1.63 (s, 3H), 1.61 (s, 3H); $[M+H]^+$ 447.

25

EXAMPLE 041




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E041)

10 ¹H NMR (400 MHz, CD₃OD) δ 7.09-7.07 (m, 2H), 7.01 (d, *J* = 1.6 Hz, 1H),
 5 6.92 (d, *J* = 1.6 Hz, 1H), 6.79-6.77 (m, 2H), 4.08-4.03 (m, 2H), 4.00-3.95 (m, 3H), 3.88
 (s, 3H), 3.86 (d, *J* = 2.0 Hz, 1H), 3.74-3.68 (m, 1H), 3.47-3.33 (m, 4H), 1.35 (t, *J* = 7.2
 Hz, 3H); [M+NH₄]⁺ 456.

10

EXAMPLE 042




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)-5-hydroxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E042)

15 ¹H NMR (400 MHz, CD₃OD) δ 7.11-7.08 (m, 2H), 6.89 (d, *J* = 2.0 Hz, 1H),
 6.82 (d, *J* = 1.6 Hz, 1H), 6.81-6.78 (m, 2H), 4.05-3.95 (m, 5H), 3.89-3.86 (m, 1H), 3.71-
 3.67 (m, 1H), 3.47-3.36 (m, 4H), 1.36 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 447.

20

EXAMPLE 043




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-5-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E043)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.02 (d, *J* = 1.6 Hz, 1H), 6.93 (d, *J* = 1.6 Hz, 1H), 6.70 (dd, *J* = 8.0, 0.8 Hz, 1H), 6.65-6.62 (m, 2H), 4.18 (s, 4H), 4.09 (d, *J* = 9.6, Hz, 1H), 3.97 (ABq, Δ*v*_{AB} = 22.4 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.92-3.86 (m, 4H), 3.71 (dd, *J* = 12.0, 5.2 Hz, 1H), 3.48-3.35 (m, 4H); [M+Na]⁺ 475.

10

EXAMPLE 044




15 (2S,3R,4R,5S,6R)-2-(5-Chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E044)

1H NMR (400 MHz, CD₃OD) δ 7.18 (s, 1H), 6.68 (d, *J* = 8.0 Hz, 1H), 6.63 (d, *J* = 2.4 Hz, 1H), 6.61-6.59 (m, 1H), 4.62-4.60 (m, 1H), 4.18 (s, 4H), 4.15-4.11 (m, 2H), 3.91 (d, *J* = 3.6, Hz, 2H), 3.86-3.83 (m, 1H), 3.68-3.63 (m, 1H), 3.47-3.45 (m, 2H), 3.38-3.36 (m, 2H), 2.77 (t, *J* = 6.8 Hz, 2H), 2.04-1.98 (m, 2H); [M+NH₄]⁺ 496.

20

EXAMPLE 045




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E045)

5 ¹H NMR (400 MHz, CD₃OD) δ 6.83 (s, 1H), 6.79-6.67 (m, 1H), 6.64-6.61 (m, 2H), 4.61(t, *J* = 8.6, Hz, 2H), 4.17 (s, 4H), 4.14(d, *J* = 9.2, Hz, 1H), 3.96-3.86 (m, 3H), 3.69-3.64 (m, 1H), 3.48-3.36 (m, 6H); [M+Na]⁺ 487.

10

EXAMPLE 046



(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)benzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E046)

15 To a solution of 7-bromo-4-chloro-5-(4-ethoxybenzyl)benzo[b]thiophene **99** (906 mg, 2.37 mmol) in THF (30 mL) at -78 °C was added *n*-BuLi (2.5 M in hexane, 1.04 mmol, 2.61 mmol) not to exceed -70 °C of internal temperature. After stirring for 30 min at -78 °C, per-silylated glucolactone **12** (1.11 g, 2.38 mmol) in THF (20 mL) was added to the reaction mixture dropwise. It was stirred for 10 min at -78 °C, and then 20 stirred for 4 hours with slowly warming up to room temperature. The resulting solution was quenched with aqueous sat. NH₄Cl solution (20 mL). Drying with MgSO₄ was preceded by collection of organic phase with EtOAc. After removal of volatile solvents and drying *in vacuo*, the crude product was used without further purification.


25 To a crude intermediate solution with MeOH (50 mL) was added methanesulfonic acid (3 mL), and reaction temperature was raised up to 90 °C overnight. After evaporation and drying *in vacuo*, the crude compound was used without further purification.

The crude intermediate was dissolved in a mixture of CH₂Cl₂ (30 mL) and

CH₃CN (30 mL). After cooling down to -10 °C, Et₃SiH (0.77 mL) and BF₃·Et₂O (0.39 mL) was added dropwise, maintaining internal temperature between -20 ~ -10 °C. After stirring for -10 °C for 30 min, the reaction mixture was warmed up to 0 °C and stirred for 5 hours. The resulting solution was quenched with sat NaHCO₃ solution, and normal work-up with EtOAc was accomplished. Prep HPLC was used for purification of the title compound (65 mg, 6% overall yield) as an off-white solid.

¹H NMR (CDCl₃) δ 8.20 (s, 1H), 7.71-7.64 (m, 2H), 7.49-7.41 (m, 2H), 7.24-7.18 (m, 2H), 4.96-4.60 (m, 2H), 4.19 (q, J = 8.4 Hz, 2H), 4.12-3.88 (m, 2H), 3.77 (s, 2H), 3.82-3.60 (m, 3H), 3.57-3.49 (m, 1H), 2.65-2.63 (m, 2H), 2.41-2.35 (m, 2H), 1.35 (t, J = 8.4 Hz, 3H); [M+Na]⁺ 488.


EXAMPLE 047



¹H NMR (400 MHz, CD₃OD) δ 7.33 (d, J = 8.0 Hz, 1H), 7.22-7.19 (m, 2H), 6.73-6.70 (m, 1H), 6.65-6.63 (m, 2H), 4.19 (s, 4H), 3.95 (s, 2H), 3.93 (d, J = 3.6 Hz, 1H), 3.77-3.70 (m, 3H), 3.59 (dd, J = 8.8, 10.0 Hz, 1H), 3.24 (t, J = 8.4 Hz, 1H), 3.02-2.97 (m, 1H); [M+Na]⁺ 461.

30

EXAMPLE 048




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol (E048)

5 Compound **E048** (17 mg, 3.4% yield; 3 steps) was prepared according to the method described for the synthesis of **E047** using compounds **123** (600 mg, 1.08 mmol) and **130** (880 mg, 2.38 mmol) as a white solid.

10 ¹H NMR (400 MHz, CD₃OD) δ 7.22 (s, 1H), 6.98 (s, 1H), 6.70 (d, *J* = 8.8 Hz, 1H), 6.61 (dd, *J* = 2.0, 5.6 Hz, 2H), 4.18 (s, 4H), 3.92 (dd, *J* = 4.0, 11.2 Hz, 1H), 4.88 (d, *J* = 4.8 Hz, 2H), 3.82 (s, 3H), 3.73 (dd, *J* = 6.4, 11.2 Hz, 1H), 3.59 (dd, *J* = 9.2, 10.0 Hz, 1H), 3.24 (t, *J* = 8.8 Hz, 1H), 3.00-2.95 (m, 1H); [M+Na]⁺ 491 .

EXAMPLE 049

15




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E049)

20 To a solution of 6-(2-chloro-5-(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)benzyl-2,3-dihydrobenzo[b][1,4]dioxine (119) (501 mg, 0.640 mmole) was added BCl₃ (1M in DCM, 5.1 mL, 5.12 mmole) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min followed by quenching with MeOH and concentrated *in vacuo*. The resulting crude residue was purified by reverse phase preparative HPLC to yield the title compound (89.4 mg, 0.211 mmole, 33%) as a white solid.

25 ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.37 (d, *J* = 8.0 Hz, 1H), 7.33 (d, *J* = 2.0 Hz, 1H), 7.23 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.76-6.74 (m, 1H), 6.65-6.63 (m, 2H), 4.94 (dd, *J* =

4.8, 2.0 Hz, 1H), 4.82 (d, J = 5.6 Hz, 1H), 4.43 (t, J = 5.6 Hz, 1H), 4.18 (s, 4H), 3.99 (d, J = 9.6 Hz, 1H), 3.93 (ABq, $\Delta\nu_{AB}$ = 16.4 Hz, J_{AB} = 15.2 Hz, 2H), 3.72-3.67 (m, 1H), 3.47-3.41 (m, 1H), 3.23-3.08 (m, 5H); [M+Na]⁺ 445.

5


EXAMPLE 050

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-dimethylamino)benzyl)phenyl)-6-

10 (hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E050)

¹H NMR (400 MHz, MeOD) δ 7.34 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 2.0 Hz, 1H), 7.26 (dd, J = 8.4, 2.0 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.77 (d, J = 8.4 Hz, 2H), 4.08 (d, J = 9.6 Hz, 1H), 4.00 (ABq, $\Delta\nu_{AB}$ = 20.0 Hz, J_{AB} = 15.2 Hz, 2H), 3.87 (dd, J = 12.0, 1.6 Hz, 1H), 3.73-3.66 (m, 1H), 3.45-3.33 (m, 4H), 2.90 (s, 6H); [M+Na]⁺ 430.


15

EXAMPLE 051

20 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(3,4-dimethoxybenzyl)phenyl)-6-
(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E051)

¹H NMR (400 MHz, MeOD) δ 7.35 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.28 (dd, J = 8.0, 2.0 Hz, 1H), 6.85-6.82 (m, 2H), 6.73 (dd, J = 8.0, 2.0 Hz, 1H), 4.09 (d, J = 9.2 Hz, 1H), 4.04 (ABq, $\Delta\nu_{AB}$ = 11.6 Hz, J_{AB} = 15.2 Hz, 2H), 3.87 (dd, J = 12.0, 2.0 Hz, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 3.71-3.67 (m, 1H), 3.45-3.26 (m, 4H); [M+Na]⁺ 447.

EXAMPLE 052




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-hydroxyphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E052)

5 ¹H NMR (400 MHz, MeOD) δ 7.25 (s, 1H), 6.87 (s, 1H), 6.71 (dd, *J* = 7.6, 0.8 Hz, 1H), 6.65-6.63 (m, 2H), 4.54 (d, *J* = 9.2 Hz, 1H), 4.20 (s, 4H), 3.94-3.85 (m, 3H), 3.74-3.70 (m, 1H), 3.52-3.41 (m, 4H); [M+Na]⁺ 461.

10

EXAMPLE 053




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E053)

15 ¹H NMR (400 MHz, MeOD) δ 7.39 (d, *J* = 26.4 Hz, 1H), 6.95 (s, 1H), 6.72-6.70 (m, 1H), 6.65-6.61 (m, 2H), 4.35-4.30 (m, 1H), 4.21-4.20 (m, 4H), 4.16 (dd, *J* = 3.2, 1.2 Hz, 1H), 4.11-4.03 (m, 2H), 3.93-3.89 (m, 2H), 3.86 (s, 3H), 3.84-3.82 (m, 1H), 3.70-3.65 (m, 2H); [M+Na]⁺ 475.

20

EXAMPLE 054




(2S,3R,4R,5S,6R)-2-(3-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-

(methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E054)

¹H NMR (400 MHz, MeOD) δ 7.20-7.19 (m, 2H), 7.12 (d, *J* = 8.0 Hz, 1H), 6.69 (d, *J* = 8.4 Hz, 1H), 6.59-6.54 (m, 2H), 4.17 (s, 4H), 4.08 (d, *J* = 9.2 Hz, 1H), 3.90-3.87 (m, 3H), 3.71-3.67 (m, 1H), 3.47-3.35 (m, 4H), 2.18 (s, 3H); [M+Na]⁺ 425.

5


EXAMPLE 055

10 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(3,4-dihydroxybenzyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E055)

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.74 (br s, 2H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.27 (d, *J* = 2.0 Hz, 1H), 7.22 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.62 (d, *J* = 7.6 Hz, 1H), 6.55 (d, *J* = 2.0 Hz, 1H), 7.45 (dd, *J* = 8.0, 2.0 Hz, 1H), 4.63 (br s, 4H), 3.98 (d, *J* = 9.2 Hz, 1H), 15 3.87 (ABq, Δ*v*_{AB} = 20.8 Hz, *J*_{AB} = 14.8 Hz, 2H), 3.69 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.44 (dd, *J* = 11.6, 5.6 Hz, 1H), 3.28-3.09 (m, 5H); [M+Na]⁺ 419.

EXAMPLE 056

20




(2S,3R,4R,5S,6R)-2-(3-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E056)

To a solution of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(3,4-dihydroxybenzyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E055) (30 mg, 0.0756 mmole) in DMF (4 mL) were added K₂CO₃ and CH₂I₂ (7.3 μL). The reaction mixture was stirred at 100 °C overnight and filtered. The resulting crude solution was purified by reverse phase preparative HPLC to yield the title compound (16 mg, 0.0401 mmole, 53%) as a

brown gum.

¹H NMR (400 MHz, MeOD) δ 7.34 (d, *J* = 8.4 Hz, 1H), 7.32 (d, *J* = 2.0 Hz, 1H), 7.27 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.71-6.65 (m, 3H), 5.87 (s, 2H), 4.09 (d, *J* = 9.6 Hz, 1H), 4.01 (ABq, Δ*v_{AB}* = 17.2 Hz, *J_{AB}* = 15.2 Hz, 2H), 3.87 (dd, *J* = 12.0, 2.0 Hz, 1H), 3.69 (dd, *J* = 12.0, 5.2 Hz, 1H), 3.48-3.38 (m, 4H); [M+Na]⁺ 431.

EXAMPLE 057



10


(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydro-1H-inden-5-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E057)

To a solution of (2R,3R,4R,5S,6S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(4-chloro-3-((2,3-dihydro-1H-inden-5-yl)methyl)phenyl)-tetrahydro-2H-pyran (122) (425 mg, 0.56 mmol) in THF:MeOH(v/v=1:1)(8 mL) at room temperature was added Pd/C. The mixture was stirred under H₂ for 2 h, Pd/C was removed by filtration and the solvent was removed under reduced pressure. The crude product was purified by preparative HPLC to furnish the title compound (42 mg, 0.10 mmol, 18%).

¹H NMR (400MHz, CD₃OD) δ 7.30-7.40 (m, 3H), 6.97-7.13 (m, 3H), 4.07-4.14 (m, 3H), 3.90-3.93 (m, 1H), 3.71-3.75 (dd, *J* = 12.0, 5.2 Hz, 1H), 3.39-3.52 (m, 3H), 3.31-3.33 (m, 1H), 2.82-2.89 (m, 4H), 2.07 (q, *J* = 29.6 Hz, 2H); [M+Na]⁺ 427.

EXAMPLE 058

25




6-(2-Chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)benzyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (E058)

5 ¹H NMR (400MHz, CD₃OD) δ 7.43 (d, *J* = 8.4 Hz, 1H), 7.37 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.11 (d, *J* = 2.0 Hz, 1H), 6.96-7.02(m, 2H), 6.89-6.93 (m, 1H), 6.01-6.83 (m, 1H), 5.28 (d, *J* = 17.2 Hz, 1H), 5.17 (d, *J* = 16.8 Hz, 1H), 4.75-4.76 (m, 2H), 4.00-4.02 (m, 1H), 3.79-3.83 (m, 1H), 3.60-3.64 (m, 1H), 3.32-3.40 (m, 3H), 3.15 (t, *J* = 18.0 Hz, 1H); [M+Na]⁺ 458.

10

EXAMPLE 059




6-(2-Chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)benzyl)-4-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one (E059)

15 ¹H NMR (400MHz, CD₃OD) δ 7.29-7.37 (m, 3H), 7.02 (d, *J* = 8.4 Hz, 1H), 6.91-6.93 (m, 1H), 6.80 (d, *J* = 1.6 Hz, 1H), 4.54 (s, 2H), 4.11 (d, *J* = 9.5 Hz, 1H), 4.05 (ABq, Δ*v*_{AB} = 16.0 Hz, *J*_{AB} = 15.3 Hz, 2H), 3.86-3.90 (m, 1H), 3.68-3.73 (m, 1H), 3.39-3.49 (m, 3H), 3.35 (s, 1H), 3.31 (s, 3H); [M+Na]⁺ 472.

20

EXAMPLE 060




25 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-((5,6,7,8-tetrahydronaphthalen-2-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E060)

1H NMR (400MHz, CD₃OD) δ 7.26-7.35 (m, 3H), 6.85-6.92 (m, 3H), 4.08 (d, *J* = 9.6 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 20.0 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.86-3.89 (m, 1H), 3.69

(dd, $J = 11.6, 5.2$ Hz, 1H), 3.38-3.45 (m, 3H), 3.27-3.29 (m, 1H), 2.69 (d, $J = 5.2$ Hz, 4H), 1.75-1.78 (m, 4H); $[M+Na]^+$ 441.

5


EXAMPLE 061

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(thiochroman-6-ylmethyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E061)

10

^1H NMR (400MHz, CD₃OD) δ 7.27-7.35 (m, 3H), 6.85-6.91 (m, 3H), 4.09 (d, $J = 9.6$ Hz, 1H), 3.98 (ABq, $\Delta\nu_{AB} = 17.2$ Hz, $J_{AB} = 15.2$ Hz, 2H), 3.87 (dd, $J = 12.2, 1.6$ Hz, 1H), 3.69 (dd, $J = 12.0, 5.2$ Hz, 1H), 3.38-3.48(m, 3H), 3.27-3.29 (m, 1H), 2.95-2.98 (m, 2H), 2.71 (t, $J = 6.0$ Hz, 2H), 2.01-2.07 (m, 2H); $[M+Na]^+$ 459.

15

EXAMPLE 063


(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E063)

20

^1H NMR (400 MHz, MeOD) δ 7.42-7.35 (m, 3H), 6.73-6.67 (m, 2H), 6.58-6.53 (m, 2H), 4.50 (dd, $J = 30.0, 16.8$ Hz, 2H), 4.28-4.25 (m, 2H), 4.08 (d, $J = 9.6$ Hz, 1H), 3.85 (dd, $J = 12.0, 1.6$ Hz, 1H), 3.68-3.64 (m, 1H), 3.43-3.35 (m, 5H), 3.24 (t, $J = 8.8$ Hz, 1H). $M\text{Na}^+$ 444.

25

EXAMPLE 064




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,2-dimethyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E064)

5 ¹H NMR (400 MHz, MeOD) δ 7.36-7.33 (m, 2H), 7.27 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.74-6.58 (m, 3H), 4.10 (d, *J* = 9.6 Hz, 1H), 4.03-3.93 (m, 2H), 3.89-3.84 (m, 3H), 3.71-3.67 (m, 1H), 3.48-3.27 (m, 4H), 1.29 (s, 6H); [M+Na]⁺ 473.

10

EXAMPLE 065




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2-methyl-2,3-dihydrobenzofuran-5-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E065)

15 ¹H NMR (400 MHz, MeOD) δ 7.34 (d, *J* = 8.4 Hz, 1H), 7.29 (d, *J* = 1.6 Hz, 1H), 7.26 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.95 (d, *J* = 1.6 Hz, 1H), 6.88 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.66 (d, *J* = 8.4 Hz, 1H), 4.07 (d, *J* = 9.2 Hz, 1H), 3.98 (ABq, Δ*v*_{AB} = 20.8 Hz, *J*_{AB} = 16.0 Hz, 2H), 3.87 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.70-3.66 (m, 1H), 3.47-3.27 (m, 4H), 3.04-2.98 (m, 1H), 2.92-2.86 (m, 1H); [M+H]⁺ 421.

20

EXAMPLE 066




(2S,3R,4R,5S,6R)-2-(3-(Benzo[d][1,3]oxathiol-5-ylmethyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E066)

10 ¹H NMR (400 MHz, MeOD) δ 7.36-7.34 (m, 2H), 7.29 (dd, *J* = 8.0, 2.0 Hz, 1H),
 7.00 (d, *J* = 1.6 Hz, 1H), 6.84 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.70 (d, *J* = 8.0 Hz, 1H), 5.64 (s,
 5 2H), 4.10 (d, *J* = 9.6 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 16.8 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88 (dd,
 J = 12.4, 2.0 Hz, 1H), 3.72-3.68 (m, 1H), 3.48-3.28 (m, 4H); [M+Na]⁺ 447.

EXAMPLE 067

10




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((4,4-dimethylchroman-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E067)

15 ¹H NMR (400 MHz, MeOD) δ 7.34 (d, *J* = 8.0 Hz, 1H), 7.31 (d, *J* = 2.0 Hz, 1H),
 7.26 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.18 (d, *J* = 2.0 Hz, 1H), 6.84-6.47 (m, 2H), 4.12-4.06 (m,
 3H), 4.00 (ABq, Δ*v*_{AB} = 15.2 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.87 (dd, *J* = 12.0, 1.6 Hz, 1H),
 3.70-3.66 (m, 1H), 3.47-3.25 (m, 4H), 1.81-1.77 (m, 2H), 1.29 (s, 6H); [M+Na]⁺ 471.

20

EXAMPLE 068




(2S,3R,4R,5S,6R)-2-(3-((4H-Benzo[d][1,3]dioxin-6-yl)methyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E068)

25 ¹H NMR (400 MHz, MeOD) δ 7.34 (d, *J* = 8.0 Hz, 1H), 7.32 (d, *J* = 1.6 Hz, 1H),
 7.28 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.99 (dd, *J* = 8.4, 2.0 Hz, 1H), 6.83 (s, 1H), 6.72 (d, *J* =
 8.4 Hz, 1H), 5.19 (s, 2H), 4.82 (s, 2H), 4.08 (d, *J* = 9.6 Hz, 1H), 4.02 (ABq, Δ*v*_{AB} = 14.0
 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.87 (dd, *J* = 12.4, 2.0 Hz, 1H), 3.71-3.67 (m, 1H), 3.48-3.26

(m, 4H); [M+Na]⁺ 445.

EXAMPLE 069

5




(2S,3R,4R,5S,6R)-2-(3-(Benzo[b][1,4]dioxin-6-yl)methyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E069)

¹H NMR (400 MHz, MeOD) δ 7.35 (d, *J* = 8.4 Hz, 1H), 7.33 (d, *J* = 2.0 Hz, 1H),
 10 7.29 (dd, *J* = 8.4, 2.0 Hz, 1H), 6.66 (dd, *J* = 8.4, 2.0 Hz, 1H), 6.51 (d, *J* = 8.0 Hz, 1H),
 6.44 (d, *J* = 2.0 Hz, 1H), 5.93 (ABq, Δ*v*_{AB} = 4.4 Hz, *J*_{AB} = 3.6 Hz, 2H), 4.11 (d, *J* = 9.6
 Hz, 1H), 3.93 (ABq, Δ*v*_{AB} = 16.8 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88 (dd, *J* = 12.4, 2.0 Hz,
 1H), 3.72-3.68 (m, 1H), 3.49-3.27 (m, 4H); [M+Na]⁺ 443.

15


EXAMPLE 072



(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]oxathiin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E072)

¹H NMR (400 MHz, MeOD) δ 7.35 (d, *J* = 8.4 Hz, 1H), 7.32 (d, *J* = 2.4 Hz, 1H),
 20 7.28 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.81-6.78 (m, 2H), 6.67 (dd, *J* = 7.2, 1.6 Hz, 1H), 4.34-
 4.32 (m, 2H), 4.10 (d, *J* = 9.6 Hz, 1H), 3.96 (ABq, Δ*v*_{AB} = 19.2 Hz, *J*_{AB} = 15.2 Hz, 2H),
 3.88 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.72-3.67 (m, 1H), 3.48-3.27 (m, 4H), 3.12-3.09 (m,
 25 2H); [M+Na]⁺ 461.

EXAMPLE 073



(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((1,1-dioxo-2,3-dihydrobenzo[b][1,4]oxathiin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E073)


5 To a solution of (2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]oxathiin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E072) (50 mg, 0.114 mmole) in CH₂Cl₂ was added mCPBA (76.6 mg, 0.342 mmole). The reaction mixture was stirred at ambient temperature overnight and concentrated *in vacuo*. The resulting crude residue was purified by reverse phase preparative HPLC to yield the title compound (18.4 mg, 0.0391 mmole, 34%) as an off-white solid.

10

15 ¹H NMR (400 MHz, MeOD) δ 7.64-7.56 (m, 1H), 7.40-7.31 (m, 4H), 7.03-6.82 (m, 1H), 4.78-4.75 (m, 2H), 4.14-4.10 (m, 3H), 3.88 (dd, *J* = 12.4, 2.4 Hz, 1H), 3.70 (dd, *J* = 16.8, 5.2 Hz, 1H), 3.62-3.59 (m, 2H), 3.47-3.27 (m, 4H); [M+Na]⁺ 493.

15

EXAMPLE 074




20 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-((1-oxo-2,3-dihydrobenzo[b][1,4]oxathiin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E074)

To a solution of (2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]oxathiin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E072) (50 mg, 0.114 mmole) in DCM was added mCPBA (25.5 mg, 0.114 mmole) at 0 °C. The reaction mixture was stirred at ambient temperature overnight and concentrated *in vacuo*. The resulting crude residue was purified by reverse phase preparative HPLC to yield the title compound (21.4 mg, 0.0470 mmole, 31 %) as a white solid.

¹H NMR (400 MHz, MeOD) δ 7.43-7.31 (m, 5H), 6.98 (d, *J* = 8.4 Hz, 1H), 4.60-4.57 (m, 2H), 4.13-4.11 (m, 3H), 3.88 (dd, *J* = 12.0, 2.0 Hz, 1H), 3.70 (dd, *J* = 22.4, 5.2 Hz, 1H), 3.49-3.24 (m, 4H), 3.21-3.16 (m, 2H); [M+Na]⁺ 477.

5


EXAMPLE 075



10 (2S,3R,4R,5S,6R)-2-(5-(4-(Ethylbenzyl)-4'-methoxy-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E075)

To a solution of (2*R*,3*R*,4*R*,5*S*,6*S*)-2-(acetoxymethyl)-6-(5-(4-ethylbenzyl)-4'-methoxy-6-methylbiphenyl-3-yl)-tetrahydro-2*H*-pyran-3,4,5-triyl triacetate (450 mg, 0.696 mmole) in MeOH (10 mL) was added NaOMe (25 wt % in MeOH, 2.1 mL, 9.05 mmole). The reaction mixture was stirred at ambient temperature for 2h before AcOH (3 mL) was added. Purification by reverse phase preparative HPLC provided the title compound (207 mg, 0.433 mmole, 62%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 7.26 (d, *J* = 1.6 Hz, 1H), 7.21-7.18 (m, 3H), 7.10 (d, *J* = 3.2 Hz, 4H), 6.97 (d, *J* = 8.8 Hz, 2H), 4.14 (d, *J* = 9.2 Hz, 1H), 4.05 (s, 1H), 3.91 (dd, *J* = 11.6, 1.2 Hz, 1H), 3.85 (s, 3H), 3.74-3.70 (m, 1H), 3.50-3.42 (m, 4H), 3.62 (q, *J* = 7.6 Hz, 2H), 2.09 (s, 3H), 1.23 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 501.

EXAMPLE 076




(2S,3R,4R,5S,6R)-2-(5-(4-(Ethylbenzyl)-6-methylbiphenyl-3-yl)-6-hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E076)

5 ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.42 (t, *J* = 7.2 Hz, 2H), 7.36-7.32 (m, 1H),
 7.26 (d, *J* = 6.8 Hz, 2H), 7.18 (s, 1H), 7.10 (q, *J* = 7.6 Hz, 4H), 7.05 (d, *J* = 1.2 Hz, 1H),
 4.91 (d, *J* = 5.2 Hz, 2H), 4.77 (d, *J* = 5.6 Hz, 1H), 4.42 (t, *J* = 5.6 Hz, 1H), 4.08 (q, *J* =
 5.2 Hz, 1H), 4.03-3.94 (m, 3H), 3.68 (dd, *J* = 10.4, 5.6 Hz, 1H), 3.29-3.12 (m, 4H), 2.56
 (q, *J* = 7.6 Hz, 2H), 2.05 (s, 3H), 1.15 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 471.

10


EXAMPLE 077



15 (2S,3R,4R,5S,6R)-2-(5-(4-(Ethoxybenzyl)-6-methylbiphenyl-3-yl)-6-hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E077)

1 ¹H NMR (400 MHz, DMSO-*d*₆MeOD) δ 7.42 (t, *J* = 7.2 Hz, 2H), 7.36-7.32 (m,
 1H), 7.26 (d, *J* = 7.2 Hz, 2H), 7.16 (s, 1H), 7.09-7.04 (m, 3H), 6.84 (d, *J* = 8.8 Hz, 2H),
 4.91-4.89 (m, 2H), 4.76 (d, *J* = 5.6 Hz, 1H), 4.42 (t, *J* = 5.6 Hz, 1H), 4.00-3.95 (m, 5H),
 3.71-3.67 (m, 1H), 3.46-3.40 (m, 1H), 3.29-3.12 (m, 4H), 2.05 (s, 3H), 1.30 (t, *J* = 7.2
 Hz, 3H); [M+Na]⁺ 487.

EXAMPLE 078




(2S,3R,4R,5S,6R)-2-(5-(4-(Ethoxybenzyl)-4'-fluoro-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E078)

10 ¹H NMR (400 MHz, MeOD) δ 7.30-7.26 (m, 3H), 7.17-7.06 (m, 5H), 7.82 (dt, *J* = 8.8, 2.0 Hz, 2H), 4.14 (d, *J* = 9.2 Hz, 1H), 4.04-3.98 (m, 5H), 3.90 (d, *J* = 12.0 Hz, 1H), 3.73-3.69 (m, 1H), 3.49-3.37 (m, 3H), 2.07 (s, 3H), 1.37 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 505.

EXAMPLE 079

10




(2S,3R,4R,5S,6R)-2-(3-Bromo-5-(4-ethoxybenzyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E079)

15 ¹H NMR (400 MHz, MeOD) δ 7.56 (s, 1H), 7.23 (s, 1H), 7.02 (d, *J* = 8.4 Hz, 2H), 6.81 (d, *J* = 8.8 Hz, 2H), 4.09 (d, *J* = 9.6 Hz, 1H), 4.05-3.97 (m, 4H), 3.90 (d, *J* = 12.0 Hz, 1H), 3.73 (dd, *J* = 12.0, 5.6 Hz, 1H), 3.48-3.37 (m, 4H), 2.28 (s, 3H), 1.37 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 489.

20

EXAMPLE 081




(2S,3R,4R,5S,6R)-2-(5-(4-Ethoxybenzyl)-4',6-dimethylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E081)

5 ¹H NMR (400 MHz, MeOD) δ 7.25-7.21 (m, 3H), 7.17-7.14 (m, 3H), 7.08 (d, *J* = 8.8 Hz, 2H), 6.83 (d, *J* = 8.8 Hz, 2H), 4.14 (d, *J* = 9.2 Hz, 1H), 4.05-3.99 (m, 4H), 3.91 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.74-3.69 (m, 1H), 3.50-3.42 (m, 4H), 2.40 (s, 3H), 2.08 (s, 3H), 1.39 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 501.

10

EXAMPLE 083




(2S,3R,4R,5S,6R)-2-(4'-Chloro-5-(4-ethoxybenzyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E083)

15 ¹H NMR (400 MHz, MeOD) δ 7.39 (d, *J* = 8.4 Hz, 2H), 7.26-7.23 (m, 3H), 7.15 (d, *J* = 1.6 Hz, 1H), 7.05 (d, *J* = 8.8 Hz, 2H), 6.80 (d, *J* = 8.8 Hz, 2H), 4.12 (d, *J* = 9.2 Hz, 1H), 4.01-3.96 (m, 4H), 3.88 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.71-3.67 (m, 1H), 3.47-3.35 (m, 4H), 2.05 (s, 3H), 1.36 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 521.

20

EXAMPLE 084




(2S,3R,4R,5S,6R)-2-(5-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E084)

5 ¹H NMR (400 MHz, MeOD) δ 7.19-7.15 (m, 2H), 7.12-7.08 (m, 1H), 7.05-7.02 (m, 3H), 6.95 (d, *J* = 1.6 Hz, 1H), 6.50 (d, *J* = 8.4 Hz, 1H), 6.42-6.38 (m, 2H), 3.97 (s, 4H), 3.92 (d, *J* = 9.2 Hz, 1H), 3.74 (s, 2H), 3.67 (d, *J* = 12.0 Hz, 1H), 3.50-3.46 (m, 1H), 3.29-3.19 (m, 4H), 1.84 (s, 3H); [M+Na]⁺ 501.

10

EXAMPLE 085




(2S,3R,4R,5S,6R)-2-(3-Bromo-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E085)

15 ¹H NMR (400 MHz, MeOD) δ 7.34 (d, *J* = 1.6 Hz, 1H), 7.00 (d, *J* = 1.6 Hz, 1H), 6.49 (d, *J* = 8.0 Hz, 1H), 6.36-6.32 (m, 2H), 3.97 (s, 4H), 3.86 (d, *J* = 9.6 Hz, 1H), 3.73 (s, 2H), 3.68 (dd, *J* = 12.0, 2.0 Hz, 1H), 3.50 (dd, *J* = 12.0, 5.6 Hz, 1H), 3.25-3.18 (m, 4H), 2.05 (s, 3H); [M+Na]⁺ 503.

20

EXAMPLE 086




(2S,3R,4R,5S,6R)-2-(6'-Chloro-5-(4-ethoxybenzyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E086)

10 ¹H NMR (400 MHz, MeOD) δ 7.47-7.44 (m, 1H), 7.34-7.32 (m, 2H), 7.28 (dd, *J* = 14.4, 2.0 Hz, 1H), 7.23-7.22 (m, 1H), 7.10-7.04 (m, 3H), 6.80 (d, *J* = 8.8 Hz, 2H), 4.13 (d, *J* = 9.6 Hz, 1H), 4.01-3.96 (m, 4H), 3.90-3.86 (m, 1H), 3.71-3.66 (m, 1H), 3.47-3.38 (m, 4H), 1.93 (d, *J* = 2.8 Hz, 3H), 1.36 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 521.

10

EXAMPLE 087




3'-(4-Ethoxybenzyl)-2'-methyl-5'-(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)biphenyl-3-carbonitrile (E087)

15 ¹H NMR (400 MHz, MeOD) δ 7.70-7.68 (m, 1H), 7.64 (d, *J* = 1.2 Hz, 1H), 7.59-7.57 (m, 2H), 7.30 (d, *J* = 1.6 Hz, 1H), 7.17 (d, *J* = 1.6 Hz, 1H), 7.06 (d, *J* = 8.8 Hz, 2H), 6.80 (d, *J* = 8.8 Hz, 2H), 4.13 (d, *J* = 9.6 Hz, 1H), 4.01-3.96 (m, 4H), 3.90-3.86 (m, 1H), 3.72-3.68 (m, 1H), 3.50-3.35 (m, 4H), 2.06 (s, 3H), 1.35 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 512.

20

EXAMPLE 088




(2S,3R,4R,5S,6R)-2-(3-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-5-(4-ethylbenzyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E088)

5 ¹H NMR (400 MHz, MeOD) δ 7.22 (d, *J* = 1.6 Hz, 1H), 7.13 (d, *J* = 1.6 Hz, 1H),
7.07 (dd, *J* = 13.2, 8.4 Hz, 4H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.72 (d, *J* = 1.6 Hz, 1H), 6.69
(dd, *J* = 8.4, 2.0 Hz, 1H), 4.25 (s, 4H), 4.10 (d, *J* = 9.2 Hz, 1H), 4.02 (s, 2H), 3.88 (dd, *J*
= 12.0, 1.6 Hz, 1H), 3.71-3.67 (m, 1H), 3.49-3.38 (m, 4H), 2.59 (q, *J* = 7.6 Hz, 2H),
2.06 (s, 3H), 1.20 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 529.

10


EXAMPLE 089



(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-methyl-5-(thiophen-3-yl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E089)

15 ¹H NMR (400 MHz, MeOD) δ 7.42 (dd, *J* = 4.8, 3.2 Hz, 1H), 7.23-7.22 (m, 3H),
7.08-7.04 (m, 3H), 6.79 (d, *J* = 8.8 Hz, 2H), 4.11 (d, *J* = 9.2 Hz, 1H), 4.01-3.96 (m, 4H),
3.88 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.72-3.67 (m, 1H), 3.48-3.39 (m, 4H), 2.12 (s, 3H), 1.35
20 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 493.

EXAMPLE 090




(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-methyl-5-(thiophen-2-yl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E090)

5 ¹H NMR (400 MHz, MeOD) δ 7.39 (dd, *J* = 5.2, 1.2 Hz, 1H), 7.31 (d, *J* = 1.6 Hz, 1H), 7.26 (d, *J* = 1.6 Hz, 1H), 7.08-7.04 (m, 3H), 6.96 (dd, *J* = 3.6, 1.2 Hz, 1H), 6.80 (d, *J* = 8.4 Hz, 2H), 4.11 (d, *J* = 9.2 Hz, 1H), 4.01-3.96 (m, 4H), 3.88 (d, *J* = 11.2 Hz, 1H), 3.72-3.67 (m, 1H), 3.47-3.35 (m, 4H), 2.18 (s, 3H), 1.36 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 493.

10

EXAMPLE 091




15 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (E091)

To a suspension of compound **138** (50 mg, 0.09 mmol) in CH₃OH (5.0 mL) was added NaOMe (100 μL, 25% solution in CH₃OH) at room temperature. After 1 h, the resulting mixture was concentrated *in vacuo*. The crude was purified by preparative HPLC (reverse phase) to provide the title compound (29 mg, 74%) as a white solid.

20 ¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, *J* = 8.0 Hz, 1H), 7.19-7.14 (m, 2H), 6.75 (d, *J* = 8.8 Hz, 1H), 6.65-6.63 (m, 2H), 4.32 (d, *J* = 9.2 Hz, 1H), 4.16 (s, 4H), 4.09 (d, *J* = 8.8 Hz, 1H), 3.94 (ABq, Δv_{AB} = 23.1 Hz, *J*_{AB} = 15.4 Hz, 2H), 3.61-3.58 (m, 1H), 3.52-3.43 (m, 2H), 2.11 (s, 3H); [M+Na]⁺ 461.

25


EXAMPLE 092

5 (2S,3R,4R,5S,6S)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol (E092)

To a suspension of compound **140** (40 mg, 0.07 mmol) in CH₃OH (5.0 mL) was added NaOMe (100 μL, 25% solution in CH₃OH) at room temperature. After 1 h, the resulting mixture was concentrated *in vacuo*. The crude was purified by preparative HPLC (reverse phase) to provide the title compound (18 mg, 62%) as a white solid.

10 ¹H NMR (400 MHz, CDCl₃) δ 7.28-7.22 (m, 2H), 7.18 (d, *J* = 8.0 Hz, 1H), 6.73-6.70 (m, 1H), 6.63-6.61 (m, 2H), 4.19 (d, *J* = 7.2 Hz, 1H), 4.10 (s, 4H), 4.02 (d, *J* = 9.2 Hz, 1H), 3.91 (ABq, Δ*v*_{AB} = 27.6 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.54-3.51 (m, 1H), 3.46-3.37 (m, 2H), 3.35 (s, 3H); [M+Na]⁺ 445.

15

EXAMPLE 093

20 (2S,3R,4R,5S)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol (E093)


A solution of 0.35M HCl in CH₃OH was prepared by adding AcCl (25 μL, 0.35 mmol) to CH₃OH (1.0 mL) at 0 °C, and stirring for 15 min. Compound **136** (50 mg, 0.11 mmol) was treated with this solution for 2 h at 80 °C in a sealed vial. The reaction mixture cooled to room temperature, and quenched with K₂CO₃ until basic. The mixture was diluted with CH₂Cl₂, filtered, and concentrated *in vacuo*. The crude was purified by preparative HPLC (reverse phase) to provide the title compound (22 mg, 48%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, *J* = 8.4 Hz, 1H), 7.25-7.17 (m, 2H), 6.77-

6.74 (m, 1H), 6.67-6.65 (m, 2H), 4.79 (d, $J = 4.0$ Hz, 1H α), 4.38 (d, $J = 9.6$ Hz, 1H α), 4.27 (d, $J = 7.6$ Hz, 1H β), 4.17 (s, 4H), 4.10 (d, $J = 9.2$ Hz, 1H β), 4.03-3.91 (m, 2H), 3.81 (t, $J = 9.2$ Hz, 1H α), 3.64-3.58 (m, 1H), 3.50-3.40 (m, 1H), 3.46 (s, 3H β), 3.37 (s, 3H α); $[M+Na]^+$ 445.

5

EXAMPLE 094




10 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol (E094)

To a suspension of compound **143** (40 mg, 0.07 mmol) in CH_3OH (5.0 mL) was added NaOMe (100 μL , 25% solution in CH_3OH) at room temperature. After 1 h, the resulting mixture was concentrated *in vacuo*. The crude was purified by preparative HPLC (reverse phase) to provide the title compound (12 mg, 42%) as a white solid.

15 ^1H NMR (400 MHz, CDCl_3) δ 7.29-7.24 (m, 2H), 7.14-7.12 (m, 1H), 6.73-6.71 (m, 1H), 6.63-6.61 (m, 2H), 4.71 (d, $J = 2.8$ Hz, 1H), 4.34 (d, $J = 9.6$ Hz, 1H), 4.11 (s, 4H), 3.94-3.90 (m, 2H), 3.83-3.79 (m, 1H), 3.54 (d, $J = 8.0$ Hz, 1H), 3.39-3.34 (m, 1H), 3.28 (s, 3H); $[M+Na]^+$ 445.

20

EXAMPLE 095




25 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-(methylthio)-tetrahydro-2H-pyran-3,4,5-triol (E095)

^1H NMR (400 MHz, CD_3OD) δ 7.23 (s, 1H), 7.01 (s, 1H), 6.70 (d, $J = 8.8$ Hz, 1H), 6.64-6.63 (m, 2H), 4.63 (d, $J = 9.6$ Hz, 1H), 4.35 (d, $J = 9.6$ Hz, 1H), 4.18 (s, 4H),

3.92-3.91 (m, 2H), 3.82 (s, 3H), 3.53 (t, $J = 8.8$ Hz, 1H), 3.47 (t, $J = 8.8$ Hz, 1H), 3.37-3.32 (m, 1H), 2.11 (s, 3H); $[M+Na]^+$ 491.


5

EXAMPLE 096

(2S,3R,4R,5S,6S)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol (E096)

10 ^1H NMR (400 MHz, CD₃OD) δ 7.27 (s, 1H), 7.01 (s, 1H), 6.70 (dd, $J = 6.8, 2.4$ Hz, 1H), 6.65-6.63 (m, 2H), 4.64 (d, $J = 9.2$ Hz, 1H), 4.28 (d, $J = 7.6$ Hz, 1H), 4.18 (s, 4H), 3.92 (ABq, $\Delta\nu_{AB} = 8.1$ Hz, $J_{AB} = 15.2$ Hz, 2H), 3.82 (s, 3H), 3.52-3.42 (m, 2H), 3.46 (s, 3H), 3.28-3.25 (m, 1H); $[M+Na]^+$ 475.

15


EXAMPLE 097

(2S,3R,4R,5S,6S)-2-(7-Bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol (E097)

20 ^1H NMR (400 MHz, CDCl₃) δ 7.11-7.09 (m, 3H), 6.79 (d, $J = 8.4$ Hz, 2H), 4.29 (d, $J = 7.6$ Hz, 1H), 4.23 (d, $J = 8.8$ Hz, 1H), 4.03 (ABq, $\Delta\nu_{AB} = 21.2$ Hz, $J_{AB} = 15.4$ Hz, 2H), 3.75 (s, 3H), 3.65-3.61 (m, 2H), 3.52-3.47 (m, 1H), 3.51 (s, 3H), 3.18-3.09 (m, 1H), 3.05-2.99 (m, 1H), 2.96 (t, $J = 7.6$ Hz, 2H), 2.07 (m, 2H); $[M+Na]^+$ 501.

25

EXAMPLE 098




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-hydroxyphenyl)-6-(methylthio)-tetrahydro-2H-pyran-3,4,5-triol (E098)

5 ^1H NMR (400 MHz, CD₃OD) δ 7.14 (s, 1H), 6.79 (s, 1H), 6.70-6.68 (m, 1H),
 3.863.85 (m, 2H), 3.49-3.46 (m, 2H), 3.36-3.33 (m, 1H), 2.13 (s, 3H); [M+Na]⁺ 477.

EXAMPLE 099

10




(2S,3R,4R,5S,6R)-2-(3-(4-Ethylphenyl)-1,3-dihydroisobenzofuran-5-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E099)

To a suspension of **151** (380 mg, 0.68 mmol) in CH₃OH (5.0 mL) was added
 15 K₂CO₃ (65 mg, 0.47 mmol) at room temperature. After 1.5 h, the resulting mixture was
 filtered, and then purified by preparative HPLC (reverse phase) to provide the title
 compound (145 mg, 55%) as an off-white solid.

20 ^1H NMR (400 MHz, DMSO-d₆) δ 7.31-7.22 (m, 4H), 7.20-7.18 (m, 2H), 6.98 (d,
 J = 19.6 Hz, 1H), 6.09 (br s, 1H), 5.26 (dt, J = 12.4, 3.6 Hz, 1H), 5.08 (d, J = 11.6 Hz,
 1H), 4.81 (br s, 4H), 3.98 (dd, J = 9.2, 7.2 Hz, 1H), 3.67-3.63 (m, 1H), 3.44-3.35 (m,
 1H), 3.25-3.01 (m, 4H), 2.59 (q, J = 7.6 Hz, 2H), 1.17 (t, J = 7.6 Hz, 3H); [M+H]⁺ 387.

EXAMPLE 100

25




(2*R*,3*S*,4*R*,5*R*,6*S*)-2-(Hydroxymethyl)-6-(3-phenyl-1,3-dihydroisobenzofuran-5-yl)-tetrahydro-2*H*-pyran-3,4,5-triol (E100)

5 ¹H NMR (400 MHz, DMSO-d₆) δ 7.37-7.32 (m, 4H), 7.31-7.26 (m, 3H), 6.99 (d, J = 20.0 Hz, 1H), 6.13 (br s, 1H), 5.29 (dt, J = 12.4, 2.8 Hz, 1H), 5.10 (d, J = 11.6 Hz, 1H), 4.75 (br s, 4H), 3.98 (dd, J = 9.2, 7.6 Hz, 1H), 3.65 (ddd, J = 11.6, 4.8, 1.6 Hz, 1H), 3.44-3.35 (m, 1H), 3.25-3.01 (m, 4H); [M+H]⁺ 359.

10


EXAMPLE 101



15 (2*R*,3*S*,4*R*,5*R*,6*S*)-2-(Hydroxymethyl)-6-(3-(4-methoxyphenyl)-1,3-dihydroisobenzofuran-5-yl)-tetrahydro-2*H*-pyran-3,4,5-triol (E101)

15 ¹H NMR (400 MHz, DMSO-d₆) δ 7.31-7.22 (m, 4H), 6.97-6.89 (m, 3H), 6.07 (br s, 1H), 5.23 (dq, J = 12.6, 2.4 Hz, 1H), 5.06 (d, J = 11.6 Hz, 1H), 4.92-4.89 (m, 2H), 4.74-4.70 (m, 1H), 4.41 (br s, 1H), 3.98 (dd, J = 9.2, 7.6 Hz, 1H), 3.74 (s, 3H), 3.67-3.64 (m, 1H), 3.44-3.36 (m, 1H), 3.25-3.02 (m, 4H); [M+H]⁺ 389.

EXAMPLE 102




(2R,3S,4R,5R,6S)-2-(Hydroxymethyl)-6-(3-(4-(methylthio)phenyl)-1,3-dihydroisobenzofuran-5-yl)-tetrahydro-2H-pyran-3,4,5-triol(E102)

5 ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.30-7.22 (m, 6H), 6.98 (d, *J* = 18.4 Hz, 1H),
 6.09 (br s, 1H), 5.26 (dt, *J* = 11.6, 2.8 Hz, 1H), 5.08 (d, *J* = 11.6 Hz, 1H), 4.91 (br s, 2H),
 4.74 (br s, 1H), 4.42 (br s, 1H), 3.98 (dd, *J* = 9.2, 7.2 Hz, 1H), 3.66 (dd, *J* = 11.2, 3.6 Hz,
 1H), 3.45-3.36 (m, 1H), 3.25-3.02 (m, 4H), 2.46 (s, 3H); [M+H]⁺ 405.

10

EXAMPLE103




15 (2S,3R,4R,5S,6R)-2-(8-Chloro-7-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol(E103)

20 ¹H NMR (400 MHz, CD₃OD) δ 6.95 (s, 1H), 6.74-6.61 (m, 3H), 4.88 (s, 4H),
 4.61-4.56 (m, 1H), 4.37-4.32 (m, 2H), 4.31-4.24 (m, 2H), 4.20 (s, 3H), 3.92 (ABq, Δv_{AB}
 = 11.5 Hz, *J*_{AB} = 15.1 Hz, 2H), 3.88 (d, *J* = 11.2 Hz, 1H), 3.73-3.64 (m, 1H), 3.53-3.43
 (m, 2H), 3.41-3.31 (m, 3H); [M+Na]⁺ 503.

EXAMPLE104

25




(2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-methoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E104)

⁵ ¹H NMR (400 MHz, CD₃OD) δ 7.09 (d, *J* = 8.8 Hz, 2H), 6.95 (s, 1H), 6.80 (d, *J* = 8.7 Hz, 2H), 4.88 (s, 4H), 4.63-4.55 (m, 1H), 4.37-4.33 (m, 2H), 4.31-4.25 (m, 2H), 3.96 (ABq, Δ*v*_{AB} = 13.3 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.87 (d, *J* = 11.0 Hz, 1H), 3.77 (s, 3H), 3.73-3.64 (m, 1H), 3.52-3.45 (m, 2H), 3.41-3.35 (m, 2H); [M+Na]⁺ 475.

10

EXAMPLE105




(2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-ethylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E105)

¹⁵ ¹H NMR (400 MHz, CD₃OD) δ 7.10 (s, 4H), 4.86 (s, 5H), 4.62-4.54 (m, 1H), 4.37-4.32 (m, 2H), 4.31-4.25 (m, 2H), 4.01 (ABq, Δ*v*_{AB} = 11.8 Hz, *J*_{AB} = 15.1 Hz, 2H), 3.88 (d, *J* = 10.5 Hz, 1H), 3.73-3.63 (m, 1H), 3.54-3.44 (m, 2H), 3.41-3.36 (m, 2H), 2.61 (q, *J* = 7.6 Hz, 2H), 1.22 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 473.

EXAMPLE106

25




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E106)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.19 (s, 1H), 6.72 (d, *J* = 8.0 Hz, 2H), 6.68-6.64 (m, 2H), 4.21 (d, *J* = 9.2 Hz, 1H), 4.21 (s, 4H), 3.98 (ABq, Δ*v*_{AB} = 16.4 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.90 (d, *J* = 11.2 Hz, 1H), 3.72-3.65 (m, 1H), 3.52-3.46 (m, 2H), 3.43-3.38 (m, 2H), 3.23-3.14 (m, 1H), 3.09-3.02 (m, 1H), 2.98 (t, *J* = 7.4 Hz, 2H), 2.12 (m, 2H), 1.35 (t, *J* = 6.8 Hz, 3H); [M+Na]⁺ 485.

10

EXAMPLE 107




15 (2S,3R,4R,5S,6R)-2-(6-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E107)

15 ¹H NMR (400 MHz, CD₃OD) δ 7.08 (s, 1H), 6.70 (d, *J* = 8.0 Hz, 2H), 6.60 (dd, *J* = 8.4, 2.0 Hz, 1H), 6.55 (d, *J* = 2.0 Hz, 1H), 4.27 (d, *J* = 9.2 Hz, 1H), 4.20 (s, 4H), 3.93-3.89 (m, 3H), 3.73-3.67 (m, 1H), 3.59 (t, *J* = 7.0 Hz, 1H), 3.53-3.48 (m, 1H), 3.44-3.40 (m, 2H), 3.16-3.08 (m, 1H), 3.04-2.96 (m, 1H), 2.86 (t, *J* = 7.4 Hz, 2H), 2.12-2.05 (m, 5H); [M+Na]⁺ 465.

25

EXAMPLE 108




(2S,3R,4R,5S,6R)-2-(7-(Difluoromethyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E108)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.20 (s, 1H), 6.93 (t, *J* = 54.4 Hz, 1H), 6.74 (d, *J* = 8.4 Hz, 1H), 6.64-6.56 (m, 2H), 4.33 (d, *J* = 9.2 Hz, 1H), 4.22 (s, 4H), 4.06 (ABq, Δ*v*_{AB} = 12.0 Hz, *J*_{AB} = 16.0 Hz, 2H), 3.92 (d, *J* = 12.4 Hz, 1H), 3.74-3.70 (m, 1H), 3.56-3.50 (m, 2H), 3.47-3.42 (m, 2H), 3.19-3.08 (m, 3H), 3.03-2.95 (m, 1H), 2.17-2.08 (m, 2H); [M+Na]⁺ 501.

10

EXAMPLE 109




15 (2S,3R,4R,5S,6S)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol (E109)

1 ¹H NMR (400 MHz, CD₃OD) δ 7.26 (s, 1H), 7.08 (d, *J* = 6.8 Hz, 2H), 7.01 (s, 1H), 6.79 (d, *J* = 6.8 Hz, 2H), 4.63 (d, *J* = 9.6 Hz, 1H), 4.27 (d, *J* = 7.6 Hz, 1H), 4.01-3.95 (m, 4H), 3.82 (s, 3H), 3.51-3.42 (m, 5H), 3.28-3.24 (m, 1H), 1.36 (t, *J* = 6.8 Hz, 3H); [M+Na]⁺ 461.

25

EXAMPLE 110




(2S,3R,4R,5S,6R)-2-(2-(Allyloxy)-4-chloro-5-(4-methoxybenzyl)phenyl)-6-

(methylthio)tetrahydro-2H-pyran-3,4,5-triol (E110)

10 ^1H NMR (400 MHz, CD₃OD) δ 7.23 (s, 1H), 7.10 (d, $J = 8.8$ Hz, 2H), 7.01 (s, 1H), 6.81 (d, $J = 8.8$ Hz, 2H), 6.12-6.02 (m, 1H), 5.43 (dq, $J = 17.2, 1.6$ Hz, 1H), 5.26 (dq, $J = 10.8, 1.6$ Hz, 1H), 4.63 (d, $J = 10.0$ Hz, 1H), 4.58-4.57 (m, 2H), 4.35 (d, $J = 9.6$ Hz, 1H), 3.97 (br s, 2H), 3.75 (s, 3H), 3.59-3.56 (m, 1H), 3.46 (t, $J = 8.8$ Hz, 1H), 3.36-3.33 (m, 2H), 2.10 (s, 3H); [M+Na]⁺ 489.


EXAMPLE 111

10

**(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (E111)**


15 ^1H NMR (400 MHz, DMSO-d₆) δ 7.25 (s, 1H), 7.08 (d, $J = 8.4$ Hz, 2H), 7.04 (s, 1H), 6.82 (d, $J = 8.8$ Hz, 2H), 4.46 (d, $J = 9.6$ Hz, 1H), 4.26 (d, $J = 9.6$ Hz, 1H), 3.99-3.91 (m, 4H), 3.77 (s, 3H), 3.40-3.24 (m, 2H), 3.17-3.12 (m, 1H), 2.00 (s, 3H), 1.29 (t, $J = 6.8$ Hz, 3H); [M+Na]⁺ 477.

20

EXAMPLE 112**(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triol (E112)**

25 ^1H NMR (400 MHz, DMSO-d₆) δ 7.29 (s, 1H), 7.09-7.06 (m, 3H), 6.81 (d, $J = 6.8$ Hz, 2H), 4.60 (d, $J = 9.2$ Hz, 1H), 4.46 (d, $J = 9.6$ Hz, 1H), 3.99-3.92 (m, 4H), 3.78 (s, 3H), 3.64-3.59 (m, 1H), 3.43-3.38 (m, 2H), 2.90 (s, 3H), 1.30 (t, $J = 6.8$ Hz, 3H); [M+Na]⁺ 509.


30

EXAMPLE 113

- 5 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-5-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (E113)

¹H NMR (400 MHz, CD₃OD) δ 6.98 (d, *J* = 2.0 Hz, 1H), 6.88 (d, *J* = 1.6 Hz, 1H), 6.71-6.69 (m, 1H), 6.66-6.63 (m, 2H), 4.40 (d, *J* = 9.6 Hz, 1H), 4.18 (br s, 4H), 4.14 (d, *J* = 9.6 Hz, 1H), 3.97 (ABq, Δ*v*_{AB} = 13.0 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.89 (s, 3H), 3.46 (t, *J* = 8.8 Hz, 1H), 3.37 (t, *J* = 9.6 Hz, 1H), 2.15 (s, 3H); [M+Na]⁺ 491.


10

EXAMPLE 114

- 15 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (E114)

¹H NMR (400 MHz, CD₃OD) δ 7.09 (d, *J* = 8.8 Hz, 2H), 6.97 (d, *J* = 1.6 Hz, 1H), 6.87 (d, *J* = 1.6 Hz, 1H), 6.79 (d, *J* = 8.8 Hz, 2H), 4.39 (d, *J* = 9.6 Hz, 1H), 4.13 (d, *J* = 9.2 Hz, 1H), 4.06-3.96 (m, 4H), 3.88 (s, 3H), 3.47-3.42 (m, 1H), 3.38-3.34 (m, 2H), 2.14 (s, 3H), 1.35 (t, *J* = 6.8 Hz, 3H); [M+Na]⁺ 477.

20

EXAMPLE 115


25

(2S,3R,4R,5S,6S)-2-(2-(Allyloxy)-4-chloro-5-(4-methoxybenzyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol (E115)

5 ^1H NMR (400 MHz, CD₃OD) δ 7.27 (s, 1H), 7.10 (d, $J = 8.8$ Hz, 2H), 7.01 (s, 1H), 6.81 (d, $J = 8.4$ Hz, 2H), 6.12-6.03 (m, 1H), 5.44 (dq, $J = 17.2, 1.6$ Hz, 1H), 5.27 (dq, $J = 10.8, 1.6$ Hz, 1H), 4.65 (d, $J = 9.6$ Hz, 1H), 4.60-4.57 (m, 2H), 4.27 (d, $J = 7.6$ Hz, 1H), 3.97 (br s, 2H), 3.75 (s, 3H), 3.56 (t, $J = 9.2$ Hz, 1H), 3.48-3.41 (m, 4H), 3.29-3.25 (m, 2H); [M+Na]⁺ 473.

10

EXAMPLE 116




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(dimethylamino)benzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E116)

15 ^1H NMR (400 MHz, CD₃OD) δ 7.15 (s, 1H), 7.04 (d, $J = 8.8$ Hz, 2H), 6.71 (d, $J = 8.8$ Hz, 2H), 4.22-4.19 (m, 1H), 3.96 (ABq, $\Delta\nu_{AB} = 18.0$ Hz, $J_{AB} = 15.0$ Hz, 2H), 3.88-3.85 (m, 1H), 3.68-3.63 (m, 1H), 3.47-3.44 (m, 2H), 3.38-3.36 (m, 2H), 3.19-3.10 (m, 1H), 3.06-2.99 (m, 1H), 2.94 (t, $J = 7.2$ Hz, 2H), 2.86 (s, 6H), 2.12-2.04 (m, 2H); [M+H]⁺ 448.

20

EXAMPLE 117




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-vinylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E117)

25 ^1H NMR (400 MHz, CD₃OD) δ 7.30 (d, $J = 8.4$ Hz, 2H), 7.20 (s, 1H), 7.14 (d, $J = 8.0$ Hz, 2H), 6.68 (dd, $J = 17.6, 11.2$ Hz, 1H), 5.70 (dd, $J = 17.6, 0.8$ Hz, 1H), 5.15 (d, $J = 11.2$ Hz, 1H), 4.24-4.21 (m, 1H), 4.06 (ABq, $\Delta\nu_{AB} = 16.5$ Hz, $J_{AB} = 15.2$ Hz, 2H),

3.88-3.85 (m, 1H), 3.69-3.64 (m, 1H), 3.49-3.43 (m, 2H), 3.40-3.35 (m, 2H), 3.20-3.11 (m, 1H), 3.07-2.99 (m, 1H), 2.95 (t, $J = 7.2$ Hz, 2H), 2.12-2.05 (m, 2H); [M+Na]⁺ 453.


5

EXAMPLE 118

(2*S*,3*R*,4*R*,5*S*,6*R*)-2-(7-Chloro-6-(4-cyclopropylbenzyl)-2,3-dihydro-1*H*-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol (E118)


10 ¹H NMR (400 MHz, CD₃OD) δ 7.17 (s, 1H), 7.05 (d, $J = 8.0$ Hz, 2H), 6.94 (d, $J = 8.0$ Hz, 2H), 4.23-4.20 (m, 1H), 4.01 (ABq, $\Delta\nu_{AB} = 17.0$ Hz, $J_{AB} = 15.2$ Hz, 2H), 3.88-3.85 (m, 1H), 3.68-3.63 (m, 1H), 3.48-3.42 (m, 2H), 3.39-3.36 (m, 2H), 3.19-3.11 (m, 1H), 3.06-2.98 (m, 1H), 2.94 (t, $J = 7.6$ Hz, 2H), 2.12-2.05 (m, 2H), 1.87-1.80 (m, 1H), 0.92-0.87 (m, 2H), 0.63-0.59 (m, 2H); [M+Na]⁺ 467.

15

EXAMPLE 119


(2*S*,3*R*,4*R*,5*S*,6*R*)-2-(4-Chloro-5-(4-vinylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol (E119)

20 ¹H NMR (400 MHz, CD₃OD) δ 7.31 (d, $J = 8.4$ Hz, 2H), 7.14-7.12 (m, 3H), 6.68 (dd, $J = 17.6, 11.2$ Hz, 1H), 5.70 (dd, $J = 17.6, 0.8$ Hz, 1H), 5.15 (dd, $J = 11.2, 0.8$ Hz, 1H), 4.67-4.56 (m, 2H), 4.31 (d, $J = 9.6$ Hz, 1H), 4.01 (ABq, $\Delta\nu_{AB} = 10.4$ Hz, $J_{AB} = 15.4$ Hz, 2H), 3.87-3.83 (m, 1H), 3.67-3.63 (m, 1H), 3.61-3.56 (m, 1H), 3.45-3.41 (m, 1H), 3.39-3.35 (m, 2H), 3.23 (t, $J = 8.8$ Hz, 2H); [M+Na]⁺ 455.

EXAMPLE 120

5 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E120)


¹H NMR (400 MHz, CD₃OD) δ 7.11 (s, 1H), 7.04 (d, *J* = 8.0 Hz, 2H), 6.94 (d, *J* = 8.0 Hz, 2H), 4.64-4.57 (m, 2H), 4.29 (d, *J* = 9.6 Hz, 1H), 3.96 (ABq, Δ*v*_{AB} = 10.4 Hz, *J*_{AB} = 15.4 Hz, 2H), 3.86-3.83 (m, 1H), 3.67-3.63 (m, 1H), 3.60 (t, *J* = 8.8 Hz, 1H), 3.45-3.41 (m, 1H), 3.39-3.35 (m, 2H), 3.22 (t, *J* = 8.8 Hz, 2H), 1.87-1.81 (m, 1H), 0.92-10 0.87 (m, 2H), 0.63-0.59 (m, 2H); [M+Na]⁺ 469.

EXAMPLE 121

15 ((2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-cyclopropylbenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E121)

¹H NMR (400 MHz, CD₃OD) δ 7.19 (s, 1H), 7.04 (d, *J* = 8.0 Hz, 2H), 6.94 (d, *J* = 8.0 Hz, 2H), 4.63-4.60 (m, 1H), 4.18-4.08 (m, 2H), 3.96 (ABq, Δ*v*_{AB} = 13.6 Hz, *J*_{AB} = 20 15.2 Hz, 2H), 3.86-3.83 (m, 1H), 3.67-3.63 (m, 1H), 3.48-3.43 (m, 2H), 3.39-3.35 (m, 2H), 2.78 (t, *J* = 6.8 Hz, 2H), 2.04-1.98 (m, 2H), 1.87-1.80 (m, 1H), 0.92-0.87 (m, 2H), 0.63-0.58 (m, 2H); [M+Na]⁺ 483.

EXAMPLE 122




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-(trifluoromethyl)benzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E122)

1 H NMR (400 MHz, CD₃OD) δ 7.53 (d, *J* = 8.0 Hz, 2H), 7.36 (d, *J* = 8.0 Hz, 2H), 7.20 (s, 1H), 4.67-4.56 (m, 2H), 4.33(d, *J* = 9.6 Hz, 1H), 4.15-4.07 (m, 2H), 3.87-3.83 (m, 1H), 3.68-3.56 (m, 2H), 3.47-3.36 (m, 3H), 3.23 (t, *J* = 8.6 Hz, 2H); [M+Na]⁺ 497.

10

EXAMPLE 123




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-chlorobenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E123)

15 1 H NMR (400 MHz, CD₃OD) δ 7.24-7.21 (m, 2H), 7.17-7.14 (m, 3H), 4.67-4.56 (m, 2H), 4.31(d, *J* = 9.6 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 8.9 Hz, *J*_{AB} = 15.4 Hz, 2H), 3.86-3.83 (m, 1H), 3.68-3.56 (m, 2H), 3.46-3.36 (m, 3H), 3.23 (t, *J* = 8.8 Hz, 2H); [M+Na]⁺ 463.

20

EXAMPLE 124




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(trifluoromethyl)benzyl)-2,3-

dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E124)

¹H NMR (400 MHz, CD₃OD) δ 7.53 (d, *J* = 8.0 Hz, 2H), 7.37 (d, *J* = 8.0 Hz, 2H), 6.91 (s, 1H), 4.63 (t, *J* = 8.8 Hz, 2H), 4.17-4.13 (m, 3H), 3.89-3.86 (m, 1H), 3.70-3.65 (m, 1H), 3.48-3.41 (m, 3H), 3.38-3.34 (m, 3); [M+Na]⁺ 497.


5

EXAMPLE 125

10 (2S,3R,4S,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-methyltetrahydro-2H-pyran-3,4,5-triol (E125)

¹H NMR (400 MHz, CD₃OD) δ 7.09-7.06 (m, 2H), 6.79-6.76 (m, 3H), 4.61(t, *J* = 8.6 Hz, 2H), 4.11-4.09 (m, 1H), 4.01-3.95 (m, 4H), 3.44-3.36 (m, 4H), 3.11-3.07 (m, 1H), 1.35 (t, *J* = 7.0 Hz, 3H), 1.28 (d, *J* = 6.0 Hz, 3H); [M+Na]⁺ 457.

15


EXAMPLE 126

20 (2S,3R,4R,5S,6S)-2-(7-Chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(fluoromethyl)tetrahydro-2H-pyran-3,4,5-triol (E126)

¹H NMR (400 MHz, CD₃OD) δ 7.09-7.07 (m, 2H), 6.80-6.77 (m, 3H), 4.68-4.55 (m, 3H), 4.15 (d, *J* = 9.2 Hz, 1H), 4.00-3.95 (m, 3H), 3.53-3.39 (m, 4H), 3.26-3.24 (m, 1H), 1.35 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 475.

25

EXAMPLE 127




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(1-hydroxyethyl)tetrahydro-2H-pyran-3,4,5-triol (E127)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.10-7.06 (m, 2H), 6.88 (s, 1H), 6.79-6.76 (m, 2H), 4.60 (t, *J* = 8.8 Hz, 2H), 4.12-4.07 (m, 2H), 4.01-3.95 (m, 4H), 3.62 (t, *J* = 9.4 Hz, 1H), 3.47-3.40 (m, 3H), 3.47-3.34 (m, 1H), 3.15 (dd, *J* = 9.6, 2.0 Hz, 1H), 1.35 (t, *J* = 7.0 Hz, 3H), 1.24 (d, *J* = 6.4 Hz, 3H), 2:1 mixture; [M+Na]⁺ 487.

10

EXAMPLE 128




(2S,3R,4R,5S,6S)-2-(7-Chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(difluoromethyl)tetrahydro-2H-pyran-3,4,5-triol (E128)

15 ¹H NMR (400 MHz, CD₃OD) δ 7.09-7.07 (m, 2H), 6.80-6.76 (m, 3H), 6.04 (td, *J* = 54.0, 0.8 Hz, 1H), 4.61 (t, *J* = 8.8 Hz, 2H), 4.16 (d, *J* = 2.0 Hz, 1H), 4.01-3.95 (m, 4H), 3.66-3.34 (m, 6H), 3.29-3.27 (m, 1H), 1.35 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 493.

20

EXAMPLE 129




(2S,3R,4R,5S,6R)-2-(6-(4-Ethoxybenzyl)-7-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E129)

¹H NMR (400 MHz, CD₃OD) δ 7.01-6.99 (m, 2H), 6.77-6.75 (m, 3H), 4.51 (t, *J* = 8.8 Hz, 2H), 4.14 (d, *J* = 9.2 Hz, 1H), 3.98 (q, *J* = 7.0 Hz, 2H), 3.89-3.87 (m, 3H), 3.69-3.65 (m, 1H), 3.52-3.45 (m, 2H), 3.38-3.34 (m, 2H), 3.27-3.18 (m, 1H), 1.99 (s, 3H), 1.35 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 453.

5


EXAMPLE 130



- 10 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E130)
- 15 ¹H NMR (400 MHz, CD₃OD) δ 7.09 (d, *J* = 8.4 Hz, 2H), 6.82-6.78 (m, 3H), 5.00-4.94 (m, 1H), 4.11 (dd, *J* = 9.2, 3.6 Hz, 1H), 3.96 (ABq, Δ*v*_{AB} = 18.5 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.88-3.85 (m, 1H), 3.75 (s, 3H), 3.68-3.64 (m, 1H), 3.60-3.54 (m, 1H), 3.45-3.36 (m, 5H), 3.06-3.00 (m, 1H), 1.46 (d, *J* = 6.4 Hz, 3H) 1:1 mixture; [M+Na]⁺ 473.

EXAMPLE 131

20




- 15 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E131)

20 ¹H NMR (400 MHz, CD₃OD) 7.12-7.07 (m, 3H), 6.80-6.78 (m, 2H), 5.02-4.95 (m, 1H), 4.61 (t, *J* = 9.0 Hz, 1H), 3.93 (ABq, Δ*v*_{AB} = 13.7 Hz, *J*_{AB} = 15.4 Hz, 2H), 3.86-3.83 (m, 1H), 3.74 (s, 3H), 3.67-3.63 (m, 1H), 3.59-3.54 (m, 1H), 3.45-3.49 (m, 4H),

2.84-2.78 (m, 1H), 1.45 (d, $J = 6.2$ Hz, 3H) 1:1 mixture; $[M+Na]^+$ 473.

EXAMPLE 132

5




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E132)

¹H NMR (400 MHz, CD₃OD) 7.13 (s, 1H), 7.10-7.04 (m, 4H), 5.02-4.94 (m, 1H), 4.31 (dd, $J = 9.6, 8.4$ Hz, 1H), 3.97 (ABq, $\Delta\nu_{AB} = 8.4$ Hz, $J_{AB} = 16.8$ Hz, 2H), 3.86-3.83 (m, 1H), 3.67-3.62 (m, 1H), 3.59-3.54 (m, 1H), 3.46-3.37 (m, 3H), 2.85-2.79 (m, 1H), 2.58 (q, $J = 7.6$ Hz, 2H), 1.45 (d, $J = 6.2$ Hz, 3H), 1.19 (t, $J = 7.6$ Hz, 3H) 1:1 mixture; $[M+Na]^+$ 471.


15

EXAMPLE 133



(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-cyclopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E133)

¹H NMR (400 MHz, CD₃OD) 7.11 (s, 1H), 7.05-7.03 (m, 2H), 6.95-6.93 (m, 2H), 5.02-4.94 (m, 1H), 4.31 (dd, $J = 9.6, 8.4$ Hz, 1H), 3.95 (ABq, $\Delta\nu_{AB} = 12.0$ Hz, $J_{AB} = 16.4$ Hz, 2H), 3.86-3.83 (m, 1H), 3.67-3.63 (m, 1H), 3.59-3.54 (m, 1H), 3.45-3.42 (m, 1H), 3.39-3.35 (m, 4H), 2.85-2.79 (m, 1H), 1.87-1.80 (m, 1H), 1.45 (d, $J = 6.2$ Hz, 3H), 0.92-0.87 (m, 2H), 0.63-0.59 (m, 2H) 1:1 mixture; $[M+Na]^+$ 483.


EXAMPLE 134

5 (2S,3R,4R,5S,6R)-2-(4-Chloro-2-methyl-5-(4-propylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E134)

10 ¹H NMR (400 MHz, CD₃OD) 7.13 (s, 1H), 7.09-7.03 (m, 4H), 5.00-4.94 (m, 1H), 4.31 (dd, *J* = 9.6 , 8.4 Hz, 1H), 3.97 (ABq, Δ*v*_{AB} = 19.0 Hz, *J*_{AB} = 13.0 Hz, 2H), 3.86-3.83 (m, 1H), 3.67-3.63 (m, 1H), 3.59-3.54 (m, 1H), 3.45-3.42 (m, 1H), 3.39-3.35(m, 3H), 2.85-2.79 (m, 1H), 2.53 (t, *J* = 7.6 Hz, 2H), 1.65-1.56 (m, 2H), 1.45 (d, *J* = 6.0 Hz, 3H), 0.91 (t, *J* = 7.4 Hz, 3H) 1:1mixture; [M+Na]⁺ 485.

EXAMPLE 135

15




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E135)

20 ¹H NMR (400 MHz, CD₃OD) 7.09-7.07 (m, 2H), 6.82-6.77 (m, 3H), 5.00-4.94 (m, 1H), 4.11 (dd, *J* = 8.8 , 3.6 Hz, 1H), 4.00-3.95 (m, 4H), 3.90-3.86 (m, 1H), 3.69-3.64 (m, 1H), 3.60-3.54 (m, 1H), 3.45-3.40 (m, 2H), 3.39-3.34(m, 2H), 2.93-2.87 (m, 1H), 1.46 (d, *J* = 6.0 Hz, 3H), 1.35 (t, *J* = 7.0 Hz, 3H) 1:1mixture; [M+Na]⁺ 487.

25

EXAMPLE 136




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E136)

1 ¹H NMR (400 MHz, CD₃OD) 7.10-7.05 (m, 4H), 6.84 (s, 1H), 5.01-4.95 (m,
 5 1H), 4.11 (dd, *J* = 8.8 , 3.6 Hz, 1H), 3.99 (ABq, $\Delta\nu_{AB}$ = 19.5 Hz, *J_{AB}* = 15.0 Hz, 2H),
 3.89-3.86 (m, 1H), 3.68-3.64 (m, 1H), 3.60-3.54 (m, 1H), 3.46-3.35 (m, 4H), 2.93-2.87
 (m, 1H), 2.58 (q, *J* = 7.6 Hz, 2H), 1.46 (d, *J* = 6.4 Hz, 3H), 1.19 (t, *J* = 7.4 Hz, 3H)
 1:1 mixture; [M+Na]⁺ 471.

10


EXAMPLE 137



15 (2S,3R,4R,5S,6R)-2-(7-Chloro-2-methyl-6-(4-vinylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E137)

1 ¹H NMR (400 MHz, CD₃OD) 7.31 (d, *J* = 8.4 Hz, 2H), 7.14 (d, *J* = 8.0 Hz, 2H),
 6.86 (s, 1H), 5.71 (dd, *J* = 17.6, 0.8 Hz, 1H), 5.16 (dd, *J* = 10.8, 0.8 Hz, 1H), 5.02-4.95
 (m, 1H), 4.12 (dd, *J* = 8.8 , 3.6 Hz, 1H), 4.02 (ABq, $\Delta\nu_{AB}$ = 18.0 Hz, *J_{AB}* = 15.2 Hz, 2H),
 3.89-3.86 (m, 1H), 3.68-3.64 (m, 1H), 3.61-3.55 (m, 1H), 3.46-3.35 (m, 4H), 2.94-2.88
 20 (m, 1H), 1.46 (d, *J* = 6.0 Hz, 3H) 1:1 mixture; [M+Na]⁺ 469.

EXAMPLE 138




((2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E138)

5 ¹H NMR (400 MHz, CD₃OD) 7.05 (d, *J* = 8.0 Hz, 2H), 6.94 (d, *J* = 8.0 Hz, 2H),
 6.83 (s, 1H), 5.02-4.94 (m, 1H), 4.10 (dd, *J* = 8.8 , 3.6 Hz, 1H), 3.97 (ABq, $\Delta\nu_{AB}$ = 19.6
 Hz, *J_{AB}* = 15.2 Hz, 2H), 3.89-3.86 (m, 1H), 3.68-3.64 (m, 1H), 3.60-3.55 (m, 1H), 3.45-
 3.42 (m, 5H), 2.93-2.87 (m, 1H), 1.87-1.80 (m, 1H), 1.46 (d, *J* = 6.4 Hz, 3H), 0.93-0.88
 (m, 2H), 0.63-0.59 (m, 2H) 1:1 mixture; [M+Na]⁺ 483.

10

EXAMPLE 139




15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E139)

1H NMR (400 MHz; CD₃OD) 7.17 (s, 1H), 7.07-7.02 (m, 4H), 4.23-4.20 (m,
 1H), 4.02 (ABq, $\Delta\nu_{AB}$ = 16.8 Hz, *J_{AB}* = 14.8 Hz, 2H), 3.88-3.85 (m, 1H), 3.68-3.63 (m,
 1H), 3.48-3.43 (m, 2H), 3.40-3.35 (m, 2H), 3.19-3.11 (m, 1H), 3.06-2.98 (m, 1H), 2.95
 (t, *J* = 12.2 Hz, 2H), 2.27 (s, 3H), 2.12-2.04 (m, 2H); [M+Na]⁺ 441.

20

EXAMPLE 140




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(methylamino)benzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 2,2,2-trifluoroacetate (E140)

5 ¹H NMR (400 MHz, CD₃OD) 7.40-7.32 (m, 4H), 7.25 (s, 1H), 4.29-4.23 (m, 1H), 4.14 (s, 2H), 3.98-3.86 (m, 1H), 3.69-3.65 (m, 1H), 3.50-3.45 (m, 2H), 3.43-3.37 (m, 2H), 3.20-3.13 (m, 1H), 3.07-3.02 (m, 1H), 3.05 (s, 3H), 2.93 (t, *J* = 7.4 Hz, 2H), 2.13-2.06 (m, 2H); [M+Na]⁺ 456.

10

EXAMPLE 141




15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(methylamino)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 2,2,2-trifluoroacetate (E141)

1 ¹H NMR (400 MHz, CD₃OD) 7.41-7.34 (m, 4H), 6.91 (s, 1H), 4.62 (t, *J* = 8.8 Hz, 2H), 4.18-4.10 (m, 3H), 3.98-3.87 (m, 1H), 3.70-3.66 (m, 1H), 3.48-3.42 (m, 3H), 3.39-3.36 (m, 3H), 3.04 (s, 3H); [M+Na]⁺ 458.

20

EXAMPLE 142




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
(E142)

5 ¹H NMR (400 MHz, CD₃OD) 7.13-7.08 (m, 3H), 6.80 (d, *J* = 8.4 Hz, 2H), 4.10 (dd, *J* = 9.4, 4.2 Hz, 1H), 4.02-3.96 (m, 2H), 3.92-3.86 (m, 2H), 3.75 (s, 3H), 3.69-3.61 (m, 2H), 3.51-3.40 (m, 2H), 3.38-3.35 (m, 2H), 3.31-3.06 (m, 1H), 2.99-2.92 (m, 1H), 1.36 (d, *J* = 6.4 Hz, 3H) 1.5:1 mixture; [M+Na]⁺ 489.

10


EXAMPLE 143



15 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
(E143)

1 ¹H NMR (400 MHz, CD₃OD) 7.13-7.06 (m, 3H), 6.79 (d, *J* = 8.4 Hz, 2H), 4.10 (dd, *J* = 9.4, 4.4 Hz, 1H), 4.02-3.96 (m, 4H), 3.88-3.85 (m, 2H), 3.70-3.61 (m, 2H), 3.48-3.40 (m, 2H), 3.38-3.36 (m, 2H), 3.11-3.06 (m, 1H), 2.99-2.92 (m, 1H), 1.35 (d, *J* = 6.8 Hz, 3H), 1.35 (t, *J* = 7.0 Hz, 3H) 1.5:1 mixture; [M+Na]⁺ 503.

EXAMPLE 144




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E144)

5 ¹H NMR (400 MHz, CD₃OD) 7.13 (s, 1H), 7.08-7.04 (m, 4H), 4.09 (dd, *J* = 7.4, 2.2 Hz, 1H), 4.03-3.94 (m, 2H), 3.87-3.84 (m, 2H), 3.68-3.60 (m, 2H), 3.47-3.40 (m, 2H), 3.39-3.35 (m, 2H), 3.10-3.05 (m, 1H), 2.97-2.91 (m, 1H), 2.57 (q, *J* = 7.6 Hz, 2H), 1.35 (d, *J* = 6.8 Hz, 3H), 1.18 (t, *J* = 7.6 Hz, 3H) 2:1 mixture; [M+Na]⁺ 487.

10


EXAMPLE 145



15 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (E145)

1 ¹H NMR (400 MHz, CDCl₃) 7.08 (d, *J* = 8.4 Hz, 2H), 6.99 (s, 1H), 6.80 (d, *J* = 8.4 Hz, 2H), 5.05-4.94 (m, 1H), 4.44-4.35 (m, 2H), 3.99 (q, *J* = 7.0 Hz, 2H), 3.94-3.89 (m, 2H), 3.78-3.66 (m, 2H), 3.57-3.49 (m, 1H), 3.39-3.30 (m, 1H), 2.87-2.79 (m, 1H), 2.15 (d, *J* = 3.2 Hz, 3H), 1.45 (d, *J* = 7.4 Hz, 3H), 1.39 (t, *J* = 7.0 Hz, 3H) 2:1 mixture; [M+Na]⁺ 503.

EXAMPLE 146




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triol (E146)

5 ¹H NMR (400 MHz, CDCl₃) 7.04-7.02 (m, 3H), 6.73 (d, *J* = 7.2 Hz, 2H), 4.88-4.82 (m, 1H), 4.55-4.49 (m, 2H), 4.04-4.02 (m, 1H), 3.92-3.85 (m, 6H), 3.24-3.22 (m, 1H), 2.80 (s, 3H), 2.74-2.71 (m, 1H), 1.35-1.32 (m, 6H) 2:1 mixture; [M+Na]⁺ 535.

EXAMPLE 147

10




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-((S)-methylsulfinyl)tetrahydro-2H-pyran-3,4,5-triol (E147)

15 ¹H NMR (400 MHz, CDCl₃) 7.03-7.01 (m, 3H), 6.74 (d, *J* = 6.8 Hz, 2H), 4.92-4.88 (m, 1H), 4.51-4.45 (m, 1H), 4.23-4.08 (m, 1H), 3.95-3.80 (m, 6H), 3.34-3.22 (m, 1H), 2.78-2.74 (m, 1H), 2.64 (s, 3H), 2.48-2.44 (m, 1H), 1.37-1.33 (m, 6H) 2:1 mixture; [M+Na]⁺ 519.

20

EXAMPLE 148




(2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-ethoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (E148)

5 ^1H NMR (400 MHz, CDCl_3) 7.08 (d, $J = 8.4$ Hz, 2H), 6.81 (s, 1H), 6.79 (d, $J = 2.4$ Hz, 2H), 4.67 (d, $J = 9.6$ Hz, 1H), 4.38-4.34 (m, 3H), 4.31-4.25 (m, 2H), 4.02-3.97 (m, 4H), 3.70-3.62 (m, 2H), 3.55-3.51 (m, 1H), 2.78 (br.s, 1H), 2.49 (br.s, 1H), 2.14 (s, 3H), 2.10 (br.s, 1H), 1.39 (t, $J = 7.0$ Hz, 3H); $[\text{M}+\text{Na}]^+$ 505.

10

EXAMPLE 149




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E149)

15 ^1H NMR (400 MHz, CD_3OD) δ 7.11 (d, $J = 4.2$ Hz, 1H), 7.07 (s, 4H), 4.99-4.91 (m, 1H), 4.29 (t, $J = 9.2$ Hz, 1H), 3.94 (s, 2H), 3.83 (d, $J = 11.9$ Hz, 1H), 3.65-3.60 (m, 1H), 3.55 (t, $J = 9.2$ Hz, 1H), 3.45-3.39 (m, 1H), 3.37-3.30 (m, 3H), 3.28 (quint, $J = 1.6$ Hz, 4H), 2.84-2.76 (m, 2H), 1.42 (t, $J = 6.28$ Hz, 3H), 1.19 (d, $J = 6.9$ Hz, 6H); $\text{M}+\text{Na}^+$ 485.

20

EXAMPLE 150




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E150)

5 ^1H NMR (400 MHz, CD₃OD) δ 7.07 (s, 4H), 6.82 (d, $J = 7.0$ Hz, 1H), 4.09 (dd, $J = 8.8, 3.7$ Hz, 1H), 3.97 (ABq, $J = 15.26$ Hz, 2H), 3.85 (d, $J = 12.0$ Hz, 1H), 3.65-3.62 (m, 1H), 3.55 (q, $J = 8.1$ Hz, 1H), 3.40-3.37 (m, 2H), 3.33-3.98 (m, 2H), 3.05-2.99 (m, 1H), 2.91-2.78 (m, 2H), 1.44 (d, $J = 6.24$ Hz, 3H), 1.19 (d, $J = 6.9$ Hz, 6H); M+Na⁺ 485.

10

EXAMPLE 151




15 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2,3-dimethoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E151)

15 ^1H NMR (400 MHz, CD₃OD) δ 7.14 (s, 1H), 7.12 (d, $J = 8.8$ Hz, 2H), 7.82 (d, $J = 8.7$ Hz, 2H), 4.87 (s, 4H), 4.56 (d, $J = 9.2$ Hz, 1H), 4.13-3.94 (m, 4H), 3.93-3.84 (m, 7H), 3.67 (dd, $J = 11.9$ Hz, 5.7 Hz, 1H), 3.59-3.45 (m, 2H), 3.42-3.34 (m, 2H), 1.38 (t, $J = 7.0$ Hz, 3H); [M+Na]⁺ 491.

20

EXAMPLE 152



(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-3-hydroxy-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E152)

5 ^1H NMR (400 MHz, CD₃OD) δ 7.11 (d, $J = 8.6$ Hz, 2H), 6.86 (s, 1H), 6.82 (d, $J = 8.7$ Hz, 2H), 4.87 (s, 4H), 4.52 (d, $J = 9.6$ Hz, 1H), 4.06-3.97 (m, 4H), 3.91-3.83 (m, 4H), 3.66 (dd, $J = 12.0$ Hz, 5.6 Hz, 1H), 3.59 (t, $J = 9.2$ Hz, 1H), 3.50 (t, $J = 8.4$ Hz, 1H), 3.46-3.34 (m, 2H), 1.38 (t, $J = 7.0$ Hz, 3H); [M+Na]⁺ 477.

EXAMPLE 153

10




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethylbenzyl)-3-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E153)

15 ^1H NMR (400 MHz, CD₃OD) δ 7.13-7.07 (m, 4H), 6.98 (s, 0.7H), 6.92 (s, 0.3H), 4.87 (s, 4H), 4.68-4.55 (m, 1H), 4.33-4.24 (m, 2H), 4.08-3.98 (m, 2H), 3.90 (dd, $J = 12.7$ Hz, 0.9 Hz, 1H), 3.81-3.60 (m, 2H), 3.51-3.33 (m, 4H), 2.61 (q, $J = 7.6$ Hz, 2H), 1.39 (d, $J = 6.9$ Hz, 0.9H), 1.33 (d, $J = 7.0$ Hz, 2.1H), 1.22 (t, $J = 7.6$ Hz, 3H); [M+Na]⁺ 471.

20

EXAMPLE 154



25 (2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-(methylthio)benzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E154)


Similar procedure with preparation of E015 was used.

^1H NMR (400 MHz, CD₃OD) δ 7.24 (s, 1H), 7.18 (d, $J = 8.5$ Hz, 2H), 7.13 (d, $J = 8.6$ Hz, 2H), 4.85 (s, 4H), 4.68-4.60 (m, 1H), 4.21-4.11 (m, 2H), 4.01 (ABq, $\Delta\nu_{AB} =$

11.8 Hz, J_{AB} = 15.1 Hz, 2H), 3.91-3.84 (m, 1H), 3.71-3.64 (m, 1H), 3.52-3.46 (m, 2H), 3.41-3.35 (m, 2H), 2.82 (t, J = 6.6 Hz, 2H), 2.46 (s, 3H), 2.09-2.00 (m, 2H); $[M+Na]^+$ 489.


5

EXAMPLE 155




- (2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-cyclopropylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E155)
- ¹H NMR (400 MHz, CD₃OD) δ 7.08 (d, J = 8.2 Hz, 2H), 7.00 (s, 1H), 6.97 (d, J = 8.2 Hz, 2H), 4.90 (s, 4H), 4.43-4.37 (m, 1H), 4.38-4.16 (m, 2H), 4.03 (ABq, $\Delta\nu_{AB}$ = 10.0 Hz, J_{AB} = 15.0 Hz, 2H), 3.92-3.85 (m, 1H), 3.71-3.64 (m, 1H), 3.55-3.44 (m, 2H), 3.37-3.32 (m, 2H), 3.05-2.92 (m, 1H), 2.91-2.83 (m, 1H), 2.07-1.99 (m, 2H), 1.91-1.82 (m, 1H), 0.97-0.90 (m, 2H), 0.66-0.61 (m, 2H); $[M+Na]^+$ 483.

EXAMPLE 156



- (2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-methoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E156)


- ¹H NMR (400 MHz, CD₃OD) δ 7.12 (d, J = 8.7 Hz, 2H), 7.00 (s, 1H), 6.81 (d, J = 8.7 Hz, 2H), 4.91 (s, 4H), 4.42-4.36 (m, 1H), 4.25-4.19 (m, 2H), 4.01 (ABq, $\Delta\nu_{AB}$ = 10.0 Hz, J_{AB} = 15.1 Hz, 2H), 3.91-3.85 (m, 1H), 3.77 (s, 3H), 3.71-3.63 (m, 1H), 3.55-3.33 (m, 4H), 3.05-2.97 (m, 1H), 2.93-2.84 (m, 1H), 2.05-1.99 (m, 2H); $[M+Na]^+$ 473.

EXAMPLE 157

5 (2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-ethoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E157)

Similar procedure with preparation of E156 was used..


¹H NMR (400 MHz, CD₃OD) δ 7.11 (d, *J* = 8.7 Hz, 2H), 7.00 (s, 1H), 6.80 (d, *J* = 8.7 Hz, 2H), 4.95 (s, 4H), 4.42-4.37 (m, 1H), 4.26-4.19 (m, 2H), 4.06-3.95 (m, 4H), 3.92-3.85 (m, 1H), 3.71-3.63 (m, 1H), 3.55-3.45 (m, 2H), 3.43-3.37 (m, 2H), 3.07-2.97 (m, 1H), 2.94-2.83 (m, 1H), 2.07-1.99 (m, 2H), 1.38 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 487.

EXAMPLE 158

15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E158)

¹H NMR (400 MHz, CD₃OD) δ 7.07 (d, *J* = 8.2 Hz, 2H), 6.98 (d, *J* = 8.2 Hz, 2H), 6.88 (s, 1H), 6.06 (dd, *J* = 7.0 Hz, 1.0 Hz, 2H), 4.85 (s, 4H), 4.28 (d, *J* = 9.6 Hz, 1H), 3.98 (ABq, Δ*v*_{AB} = 10.9 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88 (d, *J* = 10.5 Hz, 1H), 3.72-3.63 (m, 1H), 3.60 (t, *J* = 9.2 Hz, 1H), 3.49-3.33 (m, 3H), 1.93-1.81 (m, 1H), 0.97-0.89 (m, 2H), 0.68-0.60 (m, 2H); [M+Na]⁺ 471.

EXAMPLE 159




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-isopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E159)

Similar procedure with preparation of E158 proceeded except for using compound 197 to obtain the compound E159.

¹H NMR (400 MHz, CD₃OD) δ 7.17-7.09 (m, 4H), 6.89 (s, 1H), 6.06 (dd, *J* = 7.4 Hz, 1.1 Hz, 2H), 4.87 (s, 4H), 4.28 (d, *J* = 9.6 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 9.6 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88 (dd, *J* = 12.0 Hz, 1.6 Hz, 1H), 3.71-3.63 (m, 1H), 3.64-3.55 (m, 1H), 3.52-3.23 (m, 3H), 2.94-2.79 (m, 1H), 1.24 (d, *J* = 6.9 Hz, 6H); [M+Na]⁺ 473.

10

EXAMPLE 160




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E160)

¹H NMR (400 MHz, CD₃OD) δ 7.10 (d, *J* = 8.8 Hz, 2H), 6.87 (s, 1H), 6.82 (d, *J* = 8.7 Hz, 2H), 6.06 (dd, *J* = 6.9 Hz, 1.1 Hz, 2H), 4.86 (s, 4H), 4.28 (d, *J* = 9.6 Hz, 1H), 4.02 (ABq, Δ*v*_{AB} = 12.1 Hz, *J*_{AB} = 7.0 Hz, 2H), 3.96 (d, *J* = 3.6 Hz, 2H), 3.89 (dd, *J* = 11.9 Hz, 1.6 Hz, 1H), 3.71-3.64 (m, 1H), 3.66-3.57 (m, 1H), 3.49-3.43 (m, 1H), 3.41-3.35 (m, 2H), 1.38 (t, *J* = 7.0 Hz, 3H); [M+Na]⁺ 473.

EXAMPLE 161

25




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-methoxybenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E161)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.12 (d, *J* = 8.8 Hz, 2H), 6.88 (s, 1H), 6.83 (d, *J* = 8.8 Hz, 2H), 6.06 (dd, *J* = 7.1 Hz, 1.1 Hz, 2H), 4.89 (s, 4H), 4.28 (d, *J* = 9.6 Hz, 1H), 3.97 (ABq, Δ*v*_{AB} = 11.1 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.92-3.85 (m, 1H), 3.77 (s, 3H), 3.73-3.63 (m, 1H), 3.62-3.55 (m, 1H), 3.49-3.32 (m, 3H); [M+Na]⁺ 461.

10

EXAMPLE 162




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E162)

15 ¹H NMR (400 MHz, CD₃OD) δ 7.10 (s, 4H), 6.89 (s, 1H), 6.06 (dd, *J* = 7.0 Hz, 1.1 Hz, 2H), 4.86 (s, 4H), 4.28 (d, *J* = 9.6 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 10.4 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.89 (dd, *J* = 12.0 Hz, 1.6 Hz, 1H), 3.71-3.63 (m, 1H), 3.64-3.55 (m, 1H), 3.51-3.43 (m, 1H), 3.41-3.35 (m, 2H), 2.62 (q, *J* = 7.6 Hz, 2H), 1.22 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 459.

20

EXAMPLE 163




(2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-cyclopropylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E163)

5 ^1H NMR (400 MHz, CD₃OD) δ 7.07 (d, $J = 8.2$ Hz, 2H), 6.97 (d, $J = 8.2$ Hz, 2H), 6.95 (s, 1H), 4.86 (s, 4H), 4.63-4.54 (m, 1H), 4.36-4.31 (m, 2H), 4.30-4.22 (m, 2H), 3.99 (ABq, $\Delta\nu_{AB} = 13.4$ Hz, $J_{AB} = 15.2$ Hz, 2H), 3.88 (d, $J = 11.5$ Hz, 1H), 3.72-3.63 (m, 1H), 3.53-3.43 (m, 2H), 3.40-3.35 (m, 2H), 1.90-1.82 (m, 1H), 0.96-0.89 (m, 2H), 0.66-0.59 (m, 2H); [M+Na]⁺ 485.

10

EXAMPLE 164




15 (2S,3R,4R,5S,6R)-2-(9-Chloro-8-(4-ethoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E164)

1 ^1H NMR (400 MHz, CD₃OD) δ 7.11 (d, $J = 8.8$ Hz, 2H), 7.07 (s, 1H), 6.82 (d, $J = 8.7$ Hz, 2H), 4.85 (s, 4H), 4.63-4.55 (m, 1H), 4.31-4.17 (m, 2H), 4.17-4.07 (m, 2H), 4.05-3.93 (m, 4H), 3.88 (dd, $J = 11.9$ Hz, 1.6 Hz, 1H), 3.71-3.64 (m, 1H), 3.49-3.43 (m, 2H), 3.41-3.34 (m, 2H), 2.29-2.10 (m, 2H), 1.38 (t, $J = 7.0$ Hz, 1H); [M+Na]⁺ 503.

20

EXAMPLE 165




25 (2S,3R,4R,5S,6R)-2-(9-Chloro-8-(4-ethylbenzyl)-3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E165)

1 ^1H NMR (400 MHz, CD₃OD) δ 7.10 (s, 4H), 4.86 (s, 4H), 4.63-4.56 (m, 1H), 4.31-4.19 (m, 2H), 4.17-4.07 (m, 2H), 4.01 (ABq, $\Delta\nu_{AB} = 11.8$ Hz, $J_{AB} = 15.1$ Hz, 2H),

3.88 (dd, $J = 11.9$ Hz, 1.4 Hz, 1H), 3.73-3.63 (m, 1H), 3.52-3.44 (m, 2H), 3.41-3.33 (m, 2H), 2.61 (q, $J = 7.6$ Hz, 2H), 2.31-2.11 (m, 2H), 1.22 (t, $J = 7.6$ Hz, 3H); $[M+Na]^+$ 487.


5

EXAMPLE 166

(2S,3R,4R,5S,6R)-2-(6-Benzyl-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E166)

10 ^1H NMR (400 MHz, CD_3OD) δ 7.28-7.24 (m, 2H), 7.22-7.15 (m, 3H), 6.89 (s, 1H), 4.65 (t, $J = 8.8$ Hz, 2H), 4.17 (d, $J = 8.8$ Hz, 1H), 4.07 (ABq, $\Delta\nu_{AB} = 18.0$ Hz, $J_{AB} = 14.8$ Hz, 2H), 3.92-3.89 (m, 1H), 3.72-3.68 (m, 1H), 3.52-3.42 (m, 3H), 3.40-3.38 (m, 2H), 3.36-3.30 (m, 2H); $[M+Na]^+$ 429.


15

EXAMPLE 168

20 1-(4-((7-Chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-yl)methyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)phenyl)ethanone (E168)

25 ^1H NMR (400 MHz, CD_3OD) δ 7.93 (dt, $J = 8.4, 1.6$ Hz, 2H), 7.36 (d, $J = 8.4$ Hz, 2H), 6.95 (s, 1H), 4.67 (t, $J = 8.8$ Hz, 2H), 4.21 (d, $J = 9.2$ Hz, 1H), 4.17 (d, $J = 5.2$ Hz, 2H), 3.94-3.91 (m, 1H), 3.75-3.70 (m, 1H), 3.55-3.47 (m, 3H), 3.45-3.38 (m, 3H), 2.61 (s, 3H); $[M+\text{H}]^+$ 449, $[M+\text{Na}]^+$ 471.

EXAMPLE 169




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(1-hydroxyethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E169)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.29 (d, *J* = 8.0 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 6.91 (s, 1H), 4.82 (q, *J* = 6.4 Hz, 1H), 4.66 (t, *J* = 8.8 Hz, 2H), 4.18 (d, *J* = 9.2 Hz, 1H), 4.07 (ABq, Δ*v*_{AB} = 17.5 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.92 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.74-3.69 (m, 1H), 3.54-3.44 (m, 3H), 3.42-3.31 (m, 3H), 1.45 (d, *J* = 6.4 Hz, 3H); [M+Na]⁺ 473.

10

EXAMPLE 170




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(1-fluoroethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E170)

15 ¹H NMR (400 MHz, CD₃OD) δ 7.28 (d, *J* = 8.0 Hz, 2H), 7.19 (d, *J* = 8.4 Hz, 2H), 6.91 (s, 1H), 4.81 (q, *J* = 6.4 Hz, 1H), 4.66 (t, *J* = 8.8 Hz, 2H), 4.18 (d, *J* = 9.2 Hz, 1H), 4.07 (ABq, Δ*v*_{AB} = 17.4 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.92 (d, *J* = 11.2 Hz, 1H), 3.74-3.69 (m, 1H), 3.54-3.44 (m, 3H), 3.42-3.39 (m, 3H), 1.45 (d, *J* = 6.4 Hz, 1H); [M+Na]⁺ 475.

EXAMPLE 171

25




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-vinylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E171)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.34 (d, *J* = 8.0 Hz, 2H), 7.18 (d, *J* = 8.0 Hz, 2H), 6.90 (s, 1H), 6.72 (dd, *J* = 17.6, 11.2 Hz, 1H), 5.74 (dd, *J* = 17.6, 1.2 Hz, 1H), 5.19 (dd, *J* = 10.8, 1.2 Hz, 1H), 4.66 (t, *J* = 8.8 Hz, 2H), 4.18 (d, *J* = 8.8 Hz, 1H), 4.07 (ABq, Δ*v*_{AB} = 17.4 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.91 (dd, *J* = 11.6, 1.2 Hz, 1H), 3.73-3.69 (m, 1H), 3.53-3.44 (m, 3H), 3.41-3.31 (m, 3H), 1.45 (d, *J* = 6.4 Hz, 1H); [M+Na]⁺ 455.

10


EXAMPLE 172



15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E172)

1 ¹H NMR (400 MHz, CD₃OD) δ 7.02 (d, *J* = 8.0 Hz, 2H), 6.92 (d, *J* = 8.0 Hz, 2H), 6.81 (s, 1H), 4.59 (t, *J* = 8.8 Hz, 2H), 4.11 (d, *J* = 9.2 Hz, 1H), 3.96 (ABq, Δ*v*_{AB} = 19.0 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.87-3.84 (m, 1H), 3.67-3.63 (m, 1H), 3.47-3.37 (m, 3H), 3.35-3.33 (m, 3H), 1.85-1.79 (m, 1H), 0.91-0.86 (m, 2H), 0.61-0.57 (m, 2H); [M+Na]⁺ 469.

EXAMPLE 173




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-cyclopropylbenzyl)benzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E173)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.37 (dd, *J* = 8.4, 0.8 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 7.08 (d, *J* = 8.0 Hz, 1H), 7.00 (d, *J* = 8.0 Hz, 1H), 6.87 (s, 1H), 4.42-4.41 (m, 1H), 4.01-4.36 (m, 1H), 4.31-4.29 (m, 1H), 4.15 (s, 2H), 4.12-4.10 (m, 1H), 3.92-3.88 (m, 1H), 3.77-3.73 (m, 1H), 1.92-1.85 (m, 1H), 0.97-0.92 (m, 2H), 0.68-0.64 (m, 2H); [M+Na]⁺ 467.

10


EXAMPLE 174



15 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-propylbenzyl)benzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E174)

1 ¹H NMR (400 MHz, CD₃OD) δ 7.38 (dd, *J* = 8.4, 0.8 Hz, 1H), 7.19 (d, *J* = 8.4 Hz, 1H), 7.10 (s, 4H), 6.96 (d, *J* = 0.8 Hz, 1H), 4.43 (d, *J* = 10.0 Hz, 1H), 4.17 (s, 2H), 3.92 (dd, *J* = 12.0, 2.0 Hz, 1H), 3.78 (dd, *J* = 9.6, 8.8 Hz, 1H), 3.71 (dd, *J* = 12.0, 5.2 Hz, 1H), 3.54-3.44 (m, 2H), 2.56 (t, *J* = 7.6 Hz, 2H), 1.63 (sect, *J* = 7.2 Hz, 2H), 0.94 (t, *J* = 7.6 Hz, 2H); [M+Na]⁺ 469.

EXAMPLE 175




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(2-hydroxypropan-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E175)

5 ^1H NMR (400 MHz, CD₃OD) δ 7.39 (d, $J = 8.4$ Hz, 2H), 7.16 (d, $J = 8.4$ Hz, 2H), 6.90 (s, 1H), 6.64 (t, $J = 8.8$ Hz, 2H), 4.17 (d, $J = 9.2$ Hz, 1H), 4.05 (ABq, $\Delta\nu_{AB} = 17.0$ Hz, $J_{AB} = 15.2$ Hz, 2H), 3.91 (d, $J = 11.6$ Hz, 1H), 3.72-3.68 (m, 1H), 3.48-3.45 (m, 3H), 3.40-3.38 (m, 3H), 1.53 (s, 6H); [M+Na]⁺ 487.

10

EXAMPLE 176




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(difluoromethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E176)

15 ^1H NMR (400 MHz, CD₃OD) δ 7.44 (d, $J = 8.0$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 2H), 6.92 (s, 1H), 6.72 (t, $J = 56.4$ Hz, 1H), 4.65 (t, $J = 8.8$ Hz, 2H), 4.18 (d, $J = 9.2$ Hz, 2H), 4.13 (d, $J = 6.0$ Hz, 2H), 3.93-3.89 (m, 1H), 3.73-3.68 (m, 1H), 3.51-3.45 (m, 3H), 3.43-3.37 (m, 3H); [M+Na]⁺ 479.

20


EXAMPLE 177



(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(1,1-difluoroethyl)benzyl)-2,3-

dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E177)

¹H NMR (400 MHz, CD₃OD) δ 7.43 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 8.8 Hz, 2H), 6.92 (s, 1H), 4.65 (t, *J* = 8.8 Hz, 2H), 4.18 (d, *J* = 8.8 Hz, 1H), 4.11 (d, *J* = 6.0 Hz, 2H), 3.92-3.89 (m, 1H), 3.73-3.68 (m, 1H), 3.53-3.45 (m, 3H), 1.90 (t, *J* = 18.4 Hz, 3H); 5 [M+Na]⁺ 493.

EXAMPLE 178


10

(2S,3R,4R,5S,6R)-2-(6-(4-Cyclopropylbenzyl)-7-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E178)


¹H NMR (400 MHz, CD₃OD) δ 7.01 (d, *J* = 8.4 Hz, 2H), 6.96 (d, *J* = 8.0 Hz, 2H), 6.78 (s, 1H), 4.54 (t, *J* = 8.8 Hz, 2H), 4.17 (d, *J* = 8.8 Hz, 1H), 3.92 (m, 2H), 3.93-3.89 (m, 1H), 3.72-3.68 (m, 1H), 3.55-3.47 (m, 2H), 3.43-3.37 (m, 4H), 2.01 (s, 3H), 1.90-1.83 (m, 1H), 0.95-0.90 (m, 2H), 0.65-0.61 (m, 2H); [M+Na]⁺ 449, [M+K]⁺ 465.

EXAMPLE 179

20

(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(2-hydroxybut-3-yn-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E179)

¹H NMR (400 MHz, CD₃OD) δ 7.51 (d, *J* = 8.4 Hz, 2H), 7.17 (d, *J* = 8.0 Hz, 2H), 6.87 (s, 1H), 4.62 (t, *J* = 8.8 Hz, 2H), 4.15 (d, *J* = 8.8 Hz, 1H), 4.04 (ABq, Δv_{AB} = 17.4 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.89-3.86 (m, 1H), 3.70-3.65 (m, 1H), 3.49-3.42 (m, 3H), 3.41-3.35 (m, 3H), 2.98 (s, 1H), 1.68 (s, 3H); [M+Na]⁺ 449, [M+K]⁺ 497.


EXAMPLE 180

5 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(prop-1-en-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E180)

10 ¹H NMR (400 MHz, CD₃OD) δ 7.35 (d, *J* = 8.8 Hz, 2H), 7.13 (d, *J* = 8.8 Hz, 2H), 6.85 (s, 1H), 5.31-5.30 (m, 1H), 5.01-5.00 (m, 1H), 4.60 (t, *J* = 8.8 Hz, 2H), 4.13 (d, *J* = 9.2 Hz, 1H), 4.02 (ABq, Δ*v*_{AB} = 17.4 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88-3.85 (m, 1H), 3.69-3.64 (m, 1H), 3.48-3.39 (m, 3H), 3.37-3.26 (m, 3H), 2.10-2.09 (m, 3H); [M+Na]⁺ 469.

EXAMPLE 181

15




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-isopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E181)

20 ¹H NMR (400 MHz, CD₃OD) δ 7.13 (s, 4H), 6.88 (s, 1H), 4.64 (t, *J* = 8.8 Hz, 2H), 4.17 (d, *J* = 9.2 Hz, 1H), 4.03 (ABq, Δ*v*_{AB} = 18.1 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.90 (dd, *J* = 12.0, 1.2 Hz, 1H), 3.72-3.68 (m, 1H), 3.52-3.42 (m, 3H), 3.40-3.33 (m, 3H), 2.87 (sept, 1H), 1.24 (d, *J* = 7.2 Hz, 6H); [M+Na]⁺ 471.

25

EXAMPLE 182




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethynylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E182)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.36 (d, *J* = 8.4 Hz, 2H), 7.19 (d, *J* = 8.4 Hz, 2H), 6.90 (s, 1H), 4.64 (t, *J* = 8.8 Hz, 2H), 4.18 (d, *J* = 9.2 Hz, 2H), 4.07 (ABq, Δ*v*_{AB} = 15.3 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.92-3.90 (m, 1H), 3.73-3.69 (m, 1H), 3.52-3.45 (m, 3H), 3.44-3.38 (m, 3H); [M+Na]⁺ 453.

10

EXAMPLE 183




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-((methylamino)methyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol trifluoroacetic acid salt (E183)

15

[M+H]⁺ 450, [M+Na]⁺ 472.

20




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-((dimethylamino)methyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol trifluoroacetic acid salt (E184)

$[M+H]^+$ 464, $[M+Na]^+$ 486.

EXAMPLE 185

5




(2S,3R,4R,5S,6R)-2-(6-(4-(Aziridin-1-ylmethyl)benzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol trifluoroacetic acid salt (E185)

10 ^1H NMR (400 MHz, CD₃OD) δ 7.38 (d, $J = 8.4$ Hz, 2H), 7.29 (d, $J = 8.0$ Hz, 2H), 6.89 (s, 1H), 4.62 (t, $J = 8.8$ Hz, 2H), 4.18 (s, 2H), 4.15 (d, $J = 9.2$ Hz, 2H), 4.09 (d, $J = 4.4$ Hz, 2H), 3.90-3.87 (m, 1H), 3.80-3.77 (m, 2H), 3.70-3.66 (m, 1H), 3.50-3.41 (m, 3H), 3.39-3.34 (m, 3H), 3.11-3.08 (m, 2H); $[M+H]^+$ 462, $[M+Na]^+$ 484.

15


EXAMPLE 186



20 4-((7-Chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-yl)methyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methylbenzonitrile (E186)

25 ^1H NMR (400 MHz, CD₃OD) δ 7.60 (d, $J = 8.4$ Hz, 2H), 7.36 (d, $J = 8.4$ Hz, 2H), 6.92 (s, 1H), 4.63 (t, $J = 8.8$ Hz, 2H), 4.17 (ABq, $\Delta v_{AB} = 24.7$ Hz, $J_{AB} = 36.0$ Hz, 2H), 4.14 (d, $J = 3.2$ Hz, 2H), 3.90-3.87 (m, 1H), 3.70-3.66 (m, 1H), 3.51-3.41 (m, 3H), 3.39-3.33 (m, 3H); $[M+Na]^+$ 454.

EXAMPLE 187



(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-propylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E187)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.07 (d, *J* = 8.0 Hz, 2H), 7.03 (d, *J* = 8.4 Hz, 2H), 6.84 (s, 1H), 4.60 (t, *J* = 8.8 Hz, 2H), 4.13 (d, *J* = 9.2 Hz, 2H), 3.99 (ABq, Δ*v*_{AB} = 18.4 Hz, *J*_{AB} = 14.8 Hz, 2H), 3.86 (dd, *J* = 11.6, 0.8 Hz, 1H), 3.68-3.64 (m, 1H), 3.48-3.38 (m, 3H), 3.36-3.25 (m, 3H), 2.52 (t, *J* = 7.2 Hz, 2H), 1.59 (sept, *J* = 7.2 Hz, 2H), 0.90 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 471.

10

EXAMPLE 188




15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol (E188)

15 ¹H NMR (400 MHz, CD₃OD) δ 7.07 (d, *J* = 8.4 Hz, 2H), 6.79 (d, *J* = 8.8 Hz, 2H), 6.76 (s, 1H), 4.63 (td, *J* = 8.0, 1.6 Hz, 2H), 3.95 (s, 2H), 3.92 (d, *J* = 3.6 Hz, 1H), 3.79-3.75 (m, 3H), 3.74 (s, 3H), 3.71 (d, *J* = 6.4 Hz, 1H), 3.56 (dd, *J* = 10.0, 8.8 Hz, 1H), 20 3.42-3.35 (m, 2H), 3.24-3.20 (m, 1H), 3.01-2.96 (m, 1H), 0.90 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 475.

EXAMPLE 189

25




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(methylthio)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E189)

5 ¹H NMR (400 MHz, MeOD) δ 7.17 (d, *J* = 8.4 Hz, 2H), 7.12 (d, *J* = 8.4 Hz, 2H), 6.87 (s, 1H), 6.65-6.60 (m, 2H), 4.16 (d, *J* = 9.2 Hz, 1H), 4.01 (ABq, Δ*v*_{AB} = 16.9 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.89 (d, *J* = 11.6 Hz, 1H), 3.71-3.66 (m, 1H), 3.48-3.36 (m, 6H), 2.44 (s, 3H); [M+Na]⁺ 475.

10

EXAMPLE 190




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(dimethylamino)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E190)

15 ¹H NMR (400 MHz, MeOD) δ 7.06 (d, *J* = 8.8 Hz, 2H), 6.85 (s, 1H), 6.73 (d, *J* = 8.8 Hz, 2H), 4.63 (t, *J* = 8.8 Hz, 2H), 4.16 (d, *J* = 8.8 Hz, 1H), 3.96 (ABq, Δ*v*_{AB} = 20.0 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.90 (dd, *J* = 12.4 Hz, 1.2 Hz, 1H), 3.72-3.67 (m, 1H), 3.51-3.383 (m, 6H), 2.88 (s, 6H); [M+H]⁺ 450.

20

EXAMPLE 191




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-

(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-hydroxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E191)

5 ¹H NMR (400 MHz, MeOD) δ 7.14 (s, 1H), 6.73-6.71 (m, 1H), 6.67-6.64 (m, 2H), 4.70-4.59 (m, 2H), 4.33 (d, *J* = 9.6 Hz, 1H), 4.21 (s, 4H), 3.92 (ABq, Δ*v*_{AB} = 8.6 Hz, *J*_{AB} = 11.8 Hz, 2H), 3.88 (dd, *J* = 12.0, 2.0 Hz, 1H), 3.71-3.66 (m, 1H), 3.63 (t, *J* = 9.2 Hz, 1H), 3.49-3.38 (m, 3H), 3.26 (t, *J* = 8.8 Hz, 2H); [M+Na]⁺ 487.

EXAMPLE 192

10




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-hydroxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E192)

15 ¹H NMR (400 MHz, MeOD) δ 7.01 (d, *J* = 8.6 Hz, 2H), 6.84 (s, 1H), 6.68 (d, *J* = 8.6 Hz, 2H), 4.63 (t, *J* = 8.6 Hz, 2H), 4.15 (d, *J* = 9.2 Hz, 1H), 3.95 (ABq, Δ*v*_{AB} = 19.4 Hz, *J*_{AB} = 14.8 Hz, 2H), 3.89 (dd, *J* = 12.2, 1.4 Hz, 1H), 3.71-3.67 (m, 1H), 3.50-3.38 (m, 6H); [M+Na]⁺ 445.

20

EXAMPLE 193




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(3-hydroxypropoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E193)

25 ¹H NMR (400 MHz, MeOD) δ 7.11 (d, *J* = 8.8 Hz, 2H), 6.86 (s, 1H), 6.83 (d, *J* = 8.8 Hz, 2H), 4.64 (t, *J* = 8.8 Hz, 2H), 4.16 (d, *J* = 9.2 Hz, 1H), 4.05 (t, *J* = 6.2 Hz, 2H), 4.00-3.94 (m, 2H), 3.90 (dd, *J* = 11.8, 1.4 Hz, 1H), 3.85-3.83 (m, 1H), 3.75 (t, *J* = 6.2 Hz, 2H), 3.71-3.67 (m, 1H), 3.51-3.38 (m, 5H), 2.01-1.95 (m, 2H); [M+Na]⁺ 503.

EXAMPLE 194

5




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-propoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E194)

¹H NMR (400 MHz, MeOD) δ 7.11 (d, *J* = 8.6 Hz, 2H), 6.87 (s, 1H), 6.82 (d, *J* = 8.6 Hz, 2H), 4.65 (t, *J* = 8.8 Hz, 2H), 4.17 (d, *J* = 9.2 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 18.1 Hz, *J*_{AB} = 15.1 Hz, 2H), 3.93-3.89 (m, 3H), 3.72-3.68 (m, 1H), 3.52-3.40 (m, 6H), 1.84-1.75 (m, 2H), 1.06 (t, *J* = 7.4 Hz, 3H); [M+Na]⁺ 487.

EXAMPLE 195

15




4-Chloro-5-(4-methoxybenzyl)-7-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one (E195)

¹H NMR (400 MHz, MeOD) δ 7.72 (s, 1H), 7.15 (d, *J* = 8.8 Hz, 2H), 6.85 (d, *J* = 8.8 Hz, 2H), 4.76 (s, 2H), 4.52 (d, *J* = 9.6 Hz, 1H), 4.09 (ABq, Δ*v*_{AB} = 20.1 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.89 (d, *J* = 11.6 Hz, 1H), 3.78 (s, 3H), 3.72-3.69 (m, 1H), 3.61-3.57 (m, 1H), 3.53-3.43 (m, 3H); [M+H]⁺ 451.

25

EXAMPLE 196




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-hydroxy-5-(4-methoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E196)

5 ^1H NMR (400 MHz, MeOD) δ 7.30 (s, 1H), 7.13 (d, $J = 8.4$ Hz, 2H), 6.82 (d, $J = 8.8$ Hz, 2H), 5.41-5.37 (m, 1H), 4.59-4.52 (m, 1H), 4.49-4.43 (m, 1H), 4.39-4.36 (m, 1H), 4.06-4.01 (m, 2H), 3.87 (d, $J = 10.8$ Hz, 1H), 3.77 (s, 3H), 3.70-3.66 (m, 1H), 3.61 (td, $J = 9.1, 2.7$ Hz, 1H), 3.49-3.39 (m, 3H); [M-H₂O]⁺ 434.

10

EXAMPLE 197




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-(dimethylamino)benzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E197)

15 ^1H NMR (400 MHz, MeOD) δ 7.12 (s, 1H), 7.05 (d, $J = 8.8$ Hz, 2H), 6.73 (d, $J = 8.8$ Hz, 2H), 4.66-4.57 (m, 2H), 4.31 (d, $J = 9.6$ Hz, 1H), 3.93-3.86 (m, 3H), 3.69-3.64 (m, 1H), 3.61 (d, $J = 9.6$ Hz, 1H), 3.48-3.37 (m, 3H), 3.25 (t, $J = 8.8$ Hz, 2H), 2.88 (s, 6H); [M+H]⁺ 450.

20

EXAMPLE 198




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(2-cyclopropoxymethoxy)benzyl)-2,3-

dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E198)

¹H NMR (400 MHz, MeOD) δ 7.10 (d, *J* = 8.6 Hz, 2H), 6.85 (s, 1H), 6.82 (d, *J* = 8.6 Hz, 2H), 4.62 (t, *J* = 8.6 Hz, 2H), 4.14 (d, *J* = 8.8 Hz, 1H), 4.073-4.05 (m, 2H), 3.98 (ABq, Δ*v_{AB}* = 18.0 Hz, *J_{AB}* = 15.0 Hz, 2H), 3.91 (d, *J* = 13.6 Hz, 1H), 3.84-3.82 (m, 2H), 3.70-3.65 (m, 1H), 3.50-3.36 (m, 7H), 0.59-0.54 (m, 2H), 0.53-0.47 (m, 2H); [M+Na]⁺ 529.


EXAMPLE 199

10

(2S,3R,4R,5S,6R)-2-(6-(4-(Azetidin-1-yl)benzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E199)

¹H NMR (400 MHz, MeOD) δ 6.97 (d, *J* = 8.6 Hz, 2H), 6.82 (s, 1H), 6.58 (d, *J* = 8.6 Hz, 2H), 4.62 (t, *J* = 8.8 Hz, 2H), 4.13 (d, *J* = 9.2 Hz, 1H), 3.96-3.86 (m, 3H), 3.69-3.66 (m, 3H), 3.49-3.39 (m, 6H), 3.16 (t, *J* = 7.0 Hz, 2H), 1.85-1.78 (m, 2H); [M+Na]⁺ 480.


20

EXAMPLE 200(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(trifluoromethoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E200)

¹H NMR (400 MHz, MeOD) δ 7.27 (d, *J* = 8.2 Hz, 2H), 7.14 (d, *J* = 8.2 Hz, 2H), 6.90 (s, 1H), 4.62 (t, *J* = 8.8 Hz, 2H), 4.16 (d, *J* = 8.8 Hz, 1H), 4.07 (ABq, Δ*v_{AB}* = 13.6 Hz, *J_{AB}* = 15.2 Hz, 2H), 3.88 (dd, *J* = 11.8, 1.4 Hz, 1H), 3.70-3.65 (m, 1H), 3.50-3.33 (m, 6H); [M+Na]⁺ 513.

EXAMPLE 201

5




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-methoxy-5-(4-methoxybenzyl)-2-methylbenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E201)

¹H NMR (400 MHz, MeOD) δ 7.24 (s, 1H), 7.12 (d, *J* = 8.6 Hz, 2H), 6.80 (d, *J* = 8.6 Hz, 2H), 4.60 (d, *J* = 9.6 Hz, 1H), 4.10 (ABq, Δ*v*_{AB} = 15.6 Hz, *J*_{AB} = 15.2 Hz, 2H), 10 3.87 (dd, *J* = 11.8, 1.4 Hz, 1H), 3.84 (s, 3H), 3.74 (s, 3H), 3.71-3.65 (m, 2H), 3.50 (t, *J* = 8.8 Hz, 1H), 3.44-3.42 (m, 2H), 2.40 (s, 3H); [M+H]⁺ 479.

EXAMPLE 202

15




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-methoxy-5-(4-methoxybenzyl)benzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E202)

¹H NMR (400 MHz, MeOD) δ 7.51 (s, 1H), 7.29 (s, 1H), 7.10 (d, *J* = 8.8 Hz, 2H), 6.80 (d, *J* = 8.8 Hz, 2H), 4.59 (d, *J* = 9.6 Hz, 1H), 4.10 (ABq, Δ*v*_{AB} = 17.5 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88-3.85 (m, 5H), 3.74 (s, 3H), 3.69-3.64 (m, 2H), 3.52-3.45 (m, 2H), 3.43-3.39 (m, 2H); [M+Na]⁺ 487.

25

EXAMPLE 203




2-(4-((7-Chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methyl)phenyl)acetonitrile (E203)

5 ¹H NMR (400 MHz, MeOD) δ 7.19 (q, *J* = 7.6 Hz, 4H), 6.84 (s, 1H), 4.58 (t, *J* = 8.8 Hz, 2H), 4.11 (d, *J* = 8.8 Hz, 1H), 4.01 (ABq, Δ*v*_{AB} = 15.8 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.86-3.83 (m, 1H), 3.80 (s, 2H), 3.66-3.61 (m, 1H), 3.46-3.11 (m, 6H); [M+H]⁺ 446.

10

EXAMPLE 204




15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(oxetan-3-yloxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E204)

1 ¹H NMR (400 MHz, MeOD) δ 7.07 (d, *J* = 8.6 Hz, 2H), 6.81 (s, 1H), 6.60 (d, *J* = 8.6 Hz, 2H), 5.21-5.16 (m, 1H), 4.95 (t, *J* = 6.8 Hz, 2H), 4.64-4.56 (m, 4H), 4.10 (d, *J* = 8.8 Hz, 1H), 3.94 (ABq, Δ*v*_{AB} = 16.4 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.84 (d, *J* = 11.6 Hz, 1H), 3.65-3.61 (m, 1H), 3.45-3.35 (m, 4H), 3.34-3.30 (m, 2H); [M+Na]⁺ 501.

20


EXAMPLE 205



(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-isopropoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E205)

10 ¹H NMR (400 MHz, MeOD) δ 7.04 (d, *J* = 8.8 Hz, 2H), 6.80 (s, 1H), 6.73 (d, *J* = 8.8 Hz, 2H), 4.57 (t, *J* = 8.8 Hz, 2H), 4.51-4.45 (m, 1H), 4.10 (d, *J* = 8.8 Hz, 1H), 3.92 (ABq, Δ*v*_{AB} = 18.0 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.84 (d, *J* = 11.2 Hz, 1H), 3.65-3.60 (m, 1H), 3.43-3.35 (m, 4H), 3.33-3.31 (m, 2H), 1.23 (d, *J* = 6.0 Hz, 6H); [M+Na]⁺ 487.

EXAMPLE 206




10 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopropylthio)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E206)

15 ¹H NMR (400 MHz, MeOD) δ 7.20 (d, *J* = 8.2 Hz, 2H), 7.03 (d, *J* = 8.2 Hz, 2H), 6.83 (s, 1H), 4.58 (t, *J* = 8.6 Hz, 2H), 4.11 (d, *J* = 9.2 Hz, 1H), 3.96 (ABq, Δ*v*_{AB} = 17.0 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.84 (d, *J* = 11.6 Hz, 1H), 3.66-3.61 (m, 2H), 3.45-3.31 (m, 5H), 2.18-2.12 (m, 1H), 1.02-0.98 (m, 2H), 0.56-0.52 (m, 2H); [M+Na]⁺ 501.


EXAMPLE 207

20




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((5-methoxythiophen-2-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E207)

25 ¹H NMR (400 MHz, MeOD) δ 6.88 (s, 1H), 6.37 (d, *J* = 4.0 Hz, 1H), 5.96 (d, *J* = 4.0 Hz, 1H), 4.61 (t, *J* = 8.6 Hz, 2H), 4.96 (d, *J* = 8.8 Hz, 1H), 4.01 (ABq, Δ*v*_{AB} = 18.6 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88-3.85 (m, 1H), 3.78 (s, 3H), 3.68-3.64 (m, 1H), 3.48-3.35 (m, 6H); [M+H]⁺ 443.

EXAMPLE 208


(2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-methoxybenzyl)chroman-8-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (**E208**)

¹H NMR (400 MHz, CDCL₃) δ 7.09 (d, *J* = 8.6 Hz, 2H), 7.07 (s, 1H), 6.81 (d, *J* = 8.6 Hz, 2H), 4.72 (d, *J* = 9.6 Hz, 1H), 4.23-4.18 (m, 1H), 4.13-4.08 (m, 1H), 3.99 (ABq, Δv_{AB} = 10.5 Hz, *J*_{AB} = 15.6 Hz, 2H), 3.78 (s, 3H), 3.71 (t, *J* = 9.0 Hz, 1H), 3.592-3.513 (m, 2H), 3.49 (brs, 1H), 2.82-2.78 (m, 2H), 2.52 (brs, 1H), 2.31 (brs, 1H), 2.14 (s, 3H), 2.06-2.02 (m, 2H); [M+Na]⁺ 489.

EXAMPLE 209

(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-methoxybenzyl)-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (**E209**)

¹H NMR (400 MHz, MeOD) δ 7.15 (s, 1H), 7.12 (d, *J* = 8.4 Hz, 2H), 6.84 (d, *J* = 8.4 Hz, 2H), 4.16 (d, *J* = 9.2 Hz, 1H), 4.01 (ABq, Δv_{AB} = 13.7 Hz, *J*_{AB} = 17.2 Hz, 2H), 3.92-3.89 (m, 1H), 3.78 (s, 3H), 3.74-3.67 (m, 2H), 3.50-3.39 (m, 5H), 3.37-3.36 (m, 2H); [M+Na]⁺ 475.




(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(diethylamino)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E210)

5 ¹H NMR (400MHz, CD₃OD₃) δ 7.49 (q, J=18.6, 8.6 Hz, 4H), 7.38 (d, J=8.0 Hz, 1H), 7.39-7.33 (m, 2H), 4.21 (s, 2H), 4.14 (d, J=9.6Hz, 1H), 3.90-3.87 (m, 1H), 3.72-3.68 (m, 2H), 3.48-3.44 (m, 1H), 3.41-3.39 (m, 2H), 1.29 (s, 4H), 1.13 (t, J=7.8Hz, 6H); [M+H⁺] 436.

10


EXAMPLE 211



15 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-morpholinobenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E211)

1 ¹H NMR (400MHz, CD₃OD₃) δ 7.35-7.26 (m, 3H), 7.09 (d, J=8.4 Hz, 2H), 6.87 (d, J=8.8 Hz, 2H), 4.08 (d, J=9.6 Hz, 1H), 4.01 (ABq, J=19.1 Hz, 2H), (dd, J=11.8, 1.8 Hz, 1H), 3.80 (t, J=4.8 Hz, 4H), 3.69 (dd, J=11.8, 5.4 Hz, 1H), 3.48-3.35 (m, 3H), 3.29-3.27 (m, 1H), 3.07 (t, J=4.8 Hz, 4H); [M+Na⁺] 472.

EXAMPLE 212




(2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-ethoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E212)

5 ¹H NMR (400MHz, CD₃OD₃) δ 7.08 (d, *J*=8.8 Hz, 2H), 6.78 (d, *J*=8.8 Hz, 2H),
6.68 (s, 1H), 4.60 (d, *J*=9.2 Hz, 1H), 4.22-4.15 (m, 2H), 3.98 (ABq, *J*=12.0 Hz, 2H),
3.92 (d, *J*=3.2 Hz, 2H), 3.86 (d, *J*=12.0 Hz, 1H), 3.68-3.64 (m, 1H), 3.52-3.48 (m, 2H),
3.44 (t, *J*=4.4 Hz, 2H), 3.38-3.37 (m, 2H), 1.36(t, *J*=7.0 Hz, 3H), 1.30 (s, 1H); [M+H⁺] 465.

10


EXAMPLE 213



15 (2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-ethoxybenzyl)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E213)

1 ¹H NMR (400MHz, CD₃OD₃) δ 7.08-7.06 (m, 3H), 6.77 (d, *J*=8.4 Hz, 2H), 4.64-
4.62 (m, 1H), 4.21-4.18 (m, 2H), 4.00-3.95 (m, 4H), 3.85 (d, *J*=12.0 Hz, 1H), 3.67-3.63
20 (m, 1H), 3.49-3.47 (m, 2H), 3.38-3.35 (m, 2H), 3.09 (q, *J*=2.8 Hz, 2H), 2.80 (s, 3H),
1.35 (t, *J*=7.0 Hz, 3H); [M+H⁺] 480.

EXAMPLE 214




(2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-ethylbenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E214)

5 ¹H NMR (400MHz, CD₃OD₃) δ 7.06 (d, J=2.4 Hz, 4H), 6.68 (s, 1H), 4.58 (d, J=9.2 Hz, 1H), 4.19-4.17 (m, 2H), 3.94 (d, J=2.0 Hz, 2H), 3.86-3.83 (m, 1H), 3.68-3.63 (m, 1H), 3.49-3.43 (m, 5H), 3.37-3.35 (m, 2H), 2.58 (d, J=7.6 Hz, 2H), 1.19 (t, J=7.6 Hz, 3H); [M+H⁺] 450.

10

EXAMPLE 215




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethylbenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E215)

15 ¹H NMR (400MHz, CD₃OD₃) δ 7.18 (d, J=4.0 Hz, 1H), 7.09 (s, 4H), 4.65-4.57 (m, 1H), 4.36 (t, J=10.8 Hz, 1H), 4.28-4.22 (m, 1H), 4.00 (ABq, J=10.4 Hz, 2H), 3.89-3.86 (m, 1H), 3.71-3.62 (m, 2H), 3.60-3.40 (m, 4H), 2.60 (q, J=7.6 Hz, 2H), 1.35 (d, J=6.8 Hz, 3H), 1.21 (t, J=7.6 Hz, 3H); [M+Na⁺] 471.

20

EXAMPLE 216




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-methoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E216)

¹H NMR (400MHz, CD₃OD₃) δ 7.14 (d, J=4.0 Hz, 1H), 7.08 (d, J=8.4 Hz, 2H), 6.79 (d, J=8.8 Hz, 2H), 4.63-4.55 (m, 1H), 4.36-4.30 (m, 1H), 4.25-4.19 (m, 1H), 3.94 (ABq, J=10.5 Hz, 2H), 3.85 (d, J=12.4 Hz, 1H), 3.72 (s, 3H), 3.69-3.60 (m, 2H), 3.56-3.35 (m, 4H), 1.32 (d, J=6.8 Hz, 3H); [M+Na⁺] 473.

5


EXAMPLE 217




10 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethylbenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E217)
¹H NMR (400MHz, CD₃OD₃) δ 7.18 (s, 1H), 7.10 (s, 4H), 4.37 d, J=9.6 Hz, 1H), 4.26 ABq, J=10.2 Hz, 2H), 4.01 ABq, J=11.1 Hz, 2H), 3.88 d, J=11.6 Hz, 1H), 3.71-3.60 (m, 2H), 3.40-3.50 (m, 3H), 2.61 (dd, J=15.2, 7.6 Hz, 2H), 1.48 (s, 6H), 1.22 (t, J=7.6 Hz, 3H); [M+Na⁺] 485.

20

EXAMPLE 218




20 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-methoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E218)
¹H NMR (400MHz, CD₃OD₃) δ 7.14 (s, 1H), 7.09 (d, J=8.8 Hz, 2H), 6.80 (d, J=8.4 Hz, 2H), 4.38 (d, J=9.6 Hz, 1H), 4.24 (ABq, J=8.9 Hz, 2H), 3.87-3.84 (m, 1H), 3.74 (s, 3H), 3.68-3.63 (m, 1H), 3.59 (t, J=9.4 Hz, 1H), 3.44-3.36 (m, 3H), 1.46 (s, 6H); [M+Na⁺] 487.

EXAMPLE 219


- 5 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-methoxybenzyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E219)
¹H NMR (400MHz, CD₃OD₃) δ 7.15 (s, 1H), 7.08 (d, J=7.2 Hz, 2H), 6.78 (d, J=7.2Hz, 2H), 4.34 (d, J=9.2 Hz, 1H), 3.93-3.84 (m, 3H), 3.71-3.66 (m, 4H), 3.57-3.46 (m, 2H), 3.42-3.35 (m, 2H), 3.02 (s, 2H), 1.46 (d, J=4.0 Hz, 6H); [M+Na⁺] 487.

10

EXAMPLE 220

- 15 (2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E220)
¹H NMR (400MHz, CD₃OD₃) δ 7.15 (s, 1H), 7.07 (d, J=8.4 Hz, 2H), 6.77 (d, J=8.4 Hz, 2H), 4.34 (d, J=9.2 Hz, 1H), 3.97-3.92 (m, 4H), 3.85 (d, J=11.6 Hz, 1H), 3.69-3.65 (m, 1H), 3.57-3.46 (m, 2H), 3.42-3.35 (m, 2H), 3.02 (s, 2H), 1.46 (d, J=5.2 Hz, 6H), 1.34 (t, J=6.8 Hz, 3H); [M+Na⁺] 501.

20

EXAMPLE 221


(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(pyrrolidin-1-yl)benzyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E221)

10 ¹H NMR (400 MHz, MeOD) δ 7.35-7.31 (m, 2H), 7.26 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 2H), 6.70 (br s, 2H), 4.08 (d, *J* = 9.6 Hz, 1H), 4.01 (d, *J* = 10.0 Hz, 5 1H), 3.87 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.71-3.66 (m, 1H), 3.49-3.27 (m, 9H), 2.07-2.04 (m, 4H); [M+Na]⁺ 456.

EXAMPLE 222

10


Step 1 : (3S,4R,5R,6R)-2-(2-(Allyloxy)-3-bromo-4-chloro-5-(4-ethoxybenzyl)phenyl)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran



To a solution of 2-bromo-3-chloro-4-(4-ethoxybenzyl)-6-((3S,4R,5R,6R)-3,4,5-15 tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenol (500 mg, 0.579 mmole) in acetone (15 mL) were added K₂CO₃ (120 mg, 0.869 mmole) and allyl bromide (75 µL, 0.869 mmole) continuously. The resulting solution was stirred at 60°C overni ght, diluted with a saturated NaHCO₃ and extracted with ethyl acetate. The organic layer was washed with water then brine, dried over MgSO₄, filtered, and 20 concentrated *in vacuo*. The crude residue was purified on Biotage® purification apparatus to yield the title compound (325 mg, 62 %) as a colorless gum.


[M+Na]⁺ 925.

Step 2 : 4-Chloro-5-(4-ethoxybenzyl)-3-methyl-7-((3S,4R,5R,6R)-3,4,5-25 tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran




To a solution of (3S,4R,5R,6R)-2-(2-(allyloxy)-3-bromo-4-chloro-5-(4-

ethoxybenzyl)phenyl)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2*H*-pyran (325 mg, 0.359 mmole) in toluene (15 mL) were added tributyltin hydride (0.29 mL, 1.08 mmole) and AIBN (5.9 mg, 0.0359 mmole) in one portion. The resulting solution was refluxed overnight. The reaction mixture was filtered on the KF pad followed by 5 concentrated *in vacuo*. The crude residue was purified on Biotage® purification apparatus to yield the title compound (102 mg, 34 %) as a colorless gum.



Step 3 : (2*S*,3*R*,4*R*,5*S*,6*R*)-2-(4-Chloro-5-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-3,4,5-triol




To a solution of 4-chloro-5-(4-ethoxybenzyl)-3-methyl-7-((3*S*,4*R*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2*H*-pyran-2-yl)-2,3-dihydrobenzofuran (102 mg, 0.124 mmol) in THF / MeOH (4 mL / 2 mL) was added 10% Pd/C (50 mg) at rt. The reaction mixture was stirred at r.t. for 15 hours under hydrogen and filtered off. The filtrate was concentrated *in vacuo* and the residue was purified using reverse phase preparative HPLC to provide the title compound (24 mg, 42%) as a white solid.

(2*S*,3*R*,4*R*,5*S*,6*R*)-2-(4-Chloro-5-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-3,4,5-triol (E222)
¹H NMR (400 MHz, MeOD) δ 7.12 (d, *J* = 4.0 Hz, 1H), 7.07 (d, *J* = 8.4 Hz, 2H), 6.78 (dd, *J* = 6.8, 2.0 Hz, 2H), 4.62 (dd, *J* = 18.4, 8.8 Hz, 1H), 4.31 (ABq, Δ*v*_{AB} = 6.4 Hz, *J*_{AB} = 9.6 Hz, 1H), 4.28-4.22 (m, 1H), 3.98 (q, *J* = 7.2 Hz, 2H), 3.95 (d, *J* = 4.0 Hz, 1H), 3.85 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.67-3.55 (m, 3H), 3.46-3.35 (m, 3H), 1.37-1.29 (m, 6H); [M+Na]⁺ 487.

Example 223 was synthesized as the same method of preparation of Example 222 using 3-bromo-2-methylpropene instead of allyl bromide.

30

EXAMPLE 223




(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E223)

5 ^1H NMR (400 MHz, MeOD) δ 7.13 (s, 1H), 7.07 (dd, $J = 6.8, 2.0$ Hz, 2H), 6.79 (dd, $J = 6.8, 2.0$ Hz, 2H), 4.33 (d, $J = 9.6$ Hz, 1H), 4.24 (ABq, $\Delta\nu_{AB} = 8.8$ Hz, $J_{AB} = 8.4$ Hz, 2H), 4.01-3.95 (m, 4H), 3.85 (dd, $J = 12.0, 1.6$ Hz, 1H), 3.67-3.56 (m, 2H), 3.49-3.36 (m, 3H), 1.46 (d, $J = 0.8$ Hz, 6H), 1.36 (t, $J = 7.6$ Hz, 3H); $[\text{M}+\text{Na}]^+$ 501.

10 Example 224 and 225 were synthesized as the same method of preparation of
Example 222 and 223 using 2-bromo-6-chloro-5-(4-ethoxybenzyl)-3-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenol instead of 2-bromo-3-chloro-4-(4-ethoxybenzyl)-6-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenol.

15

EXAMPLE 224




20 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E224)

1 ^1H NMR (400 MHz, MeOD) δ 7.10-7.08 (m, 2H), 6.93-6.87 (m, 1H), 6.79-6.77 (m, 2H), 4.63-4.55 (m, 1H), 4.30-4.22 (m, 2H), 4.01-3.96 (m, 4H), 3.87 (dd, $J = 12.0, 1.6$ Hz, 1H), 3.77-3.57 (m, 2H), 3.49-3.39 (m, 4H), 1.37-1.29 (m, 6H); $[\text{M}+\text{Na}]^+$ 487.

25

EXAMPLE 225




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E225)

5 ¹H NMR (400 MHz, MeOD) δ 7.10 (d, *J* = 8.8 Hz, 2H), 6.93 (s, 1H), 6.79 (d, *J* = 8.8 Hz, 2H), 4.45 (d, *J* = 9.6 Hz, 1H), 4.23 (ABq, Δ*v*_{AB} = 9.6 Hz, *J*_{AB} = 8.8 Hz, 2H), 4.01-3.96 (m, 4H), 3.84 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.66-3.61 (m, 2H), 3.49-3.45 (m, 1H), 3.39-3.37 (m, 2H), 1.46 (d, *J* = 10.0 Hz, 6H), 1.35 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 501.

10

EXAMPLE 226

Step 1 : Ethyl 2-(2-bromo-6-chloro-5-(4-ethoxybenzyl)-3-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenoxy)acetate




15

To a solution of 2-bromo-3-chloro-4-(4-ethoxybenzyl)-6-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenol (1.00 g, 1.16 mmole) in acetone (15 mL) were added K₂CO₃ (240 mg, 1.74 mmole) and allyl bromide (0.19 mL, 1.74 mmole) continuously. The resulting solution was stirred at 60°C overnight, diluted with a saturated NaHCO₃ and extracted with ethyl acetate. The organic layer was washed with water then brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude residue was purified on Biotage® purification apparatus to yield the title compound (1.09 g, 99 %) as a colorless gum.

[M+Na]⁺ 971.

25

Step 2 : 2-(2-Bromo-6-chloro-5-(4-ethoxybenzyl)-3-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenoxy)acetic acid




To a solution of ethyl 2-(2-bromo-6-chloro-5-(4-ethoxybenzyl)-3-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenoxy)acetate (1.09 g, 1.14 mmole) in a mixture of THF / MeOH / H₂O (12 mL / 4 mL / 4 mL) was added LiOH·H₂O (144 mg, 3.42 mmole). The resulting solution was stirred at rt overnight. The reaction mixture was concentrated *in vacuo* and diluted with water. The resulting solution was acidified with 1N-HCl solution followed by extraction with ethyl acetate. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo* to yield the title compound (1.03 g, 98 %) as a brown gum.

10 [M+Na]⁺ 943.

Step 3 : 2-(2-Bromo-6-chloro-5-(4-ethoxybenzyl)-3-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenoxy)-N-methoxy-N-methylacetamide

15




To a solution of 2-(2-bromo-6-chloro-5-(4-ethoxybenzyl)-3-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenoxy)acetic acid (1.03 g, 1.12 mmole) in DMF (20 mL) were added dimethylhydroxylamine, HCl (131 mg, 1.34 mmole), EDC (257 mg, 1.34 mmole), HOEt (181 mg, 1.34 mmole) and NMM (0.44 mL, 4.03 mmole) continuously. The resulting solution was stirred at rt overnight, diluted with a saturated NaHCO₃ and extracted with ethyl acetate. The organic layer was washed with water then brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude residue was purified on Biotage® purification apparatus to yield the title compound (1.02 g, 94 %) as a colorless gum.

[M+Na]⁺ 986.

Step 4 : 7-Chloro-6-(4-ethoxybenzyl)-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one

5




To a solution of 2-(2-bromo-6-chloro-5-(4-ethoxybenzyl)-3-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)phenoxy)-N-methoxy-N-methylacetamide (1.02 g, 1.06 mmole) in THF (15 mL) was added nBuLi (1.3 mL, 3.18 mmole, 2.5M in hexane) at -78 °C. The resulting solution was warmed up to rt and stirred overnight, diluted with a saturated NH₄Cl and extracted with ethyl acetate. The organic layer was washed with water then brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude residue was purified on Biotage® purification apparatus to yield the title compound (429 mg, 49 %) as a yellow gum.

15

[M+Na]⁺ 847.

Step 5 : 7-Chloro-6-(4-ethoxybenzyl)-4-(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one

20



25

To a solution of 7-chloro-6-(4-ethoxybenzyl)-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one (144 mg, 0.174 mmol) in THF / MeOH (4 mL / 2 mL) was added 10% Pd/C (14 mg) at rt. The reaction mixture was stirred at r.t. for 15 hours under hydrogen and filtered off. The filtrate was concentrated *in vacuo* and the residue was purified using reverse phase preparative HPLC to provide the title compound (32 mg, 39%) as a yellow solid.


7-Chloro-6-(4-ethoxybenzyl)-4-(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-

(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one (E226)

¹H NMR (400 MHz, MeOD) δ 7.25 (s, 1H) 7.13 (d, *J* = 8.8 Hz, 2H), 6.81 (d, *J* = 8.8 Hz, 2H), 5.06 (d, *J* = 9.2 Hz, 1H), 4.85-4.74 (m, 2H), 4.12 (ABq, Δ*v*_{AB} = 16.8 Hz, *J*_{AB} = 14.8 Hz, 2H), 3.99 (q, *J* = 7.2 Hz, 2H), 3.84 (dd, *J* = 12.0, 2.0 Hz, 1H), 3.68 (dd, *J* = 12.0, 2.8 Hz, 1H), 3.53-3.43 (m, 4H), 1.35 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 487.

EXAMPLE 227


10 Step 1 : 7-Chloro-6-(4-ethoxybenzyl)-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-3-ol



To a solution of 7-chloro-6-(4-ethoxybenzyl)-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one (285 mg, 0.345 mmole) in THF / MeOH (9 mL / 3 mL) was added NaBH₄ (39.2 mg, 1.04 mmole) at 0 °C. The resulting solution was stirred at 0 °C for 1 hr, diluted with 1N-HCl and extracted with ethyl acetate. The organic layer was washed with water then brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude residue was purified on Biotage® purification apparatus to yield the title compound (260 mg, 91 %) as a yellow gum.


[M+Na]⁺ 849.

Step 2 : 7-Chloro-6-(4-ethoxybenzyl)-3-methoxy-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran




To a mixture solution of 7-chloro-6-(4-ethoxybenzyl)-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-3-ol (260 mg, 0.314 mmole) and iodomethane (40 μL, 0.628

mmole) in DMF (10 mL) was added NaH (25.1 mg, 0.628 mmole) at 0°C. The resulting solution was stirred at rt overnight, diluted with sat. NaHCO₃ and extracted with ethyl acetate. The organic layer was washed with water then brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude residue was purified on 5 Biotage® purification apparatus to yield the title compound (238 mg, 90 %) as a yellow gum.



Step 3 : (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-3-methoxy-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-3,4,5-triol



To a solution of 7-chloro-6-(4-ethoxybenzyl)-3-methoxy-4-((3*S*,4*R*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2*H*-pyran-2-yl)-2,3-dihydrobenzofuran (124 mg, 0.147 mmol) in THF / MeOH (4 mL / 2 mL) was added 10% Pd/C (12 mg) at rt. The reaction mixture was stirred at r.t. for 15 hours under hydrogen and filtered off. The filtrate was concentrated *in vacuo* and the residue was purified using reverse phase preparative HPLC to provide the title compound (38 mg, 54%) as a white solid.

20

(2*S*,3*R*,4*R*,5*S*,6*R*)-2-(7-Chloro-6-(4-ethoxybenzyl)-3-methoxy-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-3,4,5-triol (E227)


¹H NMR (400 MHz, MeOD) δ 7.09 (d, *J* = 8.8 Hz, 2H), 6.93 (s, 1H), 6.76 (d, *J* = 8.4 Hz, 2H), 5.46 (dd, *J* = 6.0, 1.6 Hz, 1H), 4.66 (dd, *J* = 11.2, 1.6 Hz, 1H), 4.45 (dd, *J* = 10.8, 6.0 Hz, 1H), 4.26 (d, *J* = 9.6 Hz, 1H), 4.06-3.87 (m, 5H), 3.72 (dd, *J* = 12.0, 5.6 Hz, 1H), 3.55-3.50 (m, 1H), 3.46-3.37 (m, 3H), 3.36 (s, 3H), 1.35 (t, *J* = 7.6 Hz, 3H); [M+Na]⁺ 503.

30

EXAMPLE 228

Step 1 : 7-Cyclopropyl-6-(4-ethoxybenzyl)-4-((3*S*,4*R*,5*R*,6*R*)-3,4,5-


tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran



To a solution of 7-chloro-6-(4-ethoxybenzyl)-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran (235 mg, 0.290 mmole) in toluene (10 mL) were added cyclopropylboronic acid (49.8 mg, 0.580 mmole), Pd(OAc)₂ (19.5 mg, 0.0290 mmole), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (23.8 mg, 0.0580 mmole), and K₃PO₄ (246 mg, 1.16 mmole). The resulting solution was stirred at 110°C overnight, diluted with water and extracted with ethyl acetate. The organic layer was washed with water then brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude residue was purified on Biotage® purification apparatus to yield the title compound (102 mg, 43 %) as a yellow gum.

[M+Na]⁺ 839.

15 Step 2 : (2S,3R,4R,5S,6R)-2-(7-Cyclopropyl-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol




To a solution of 7-chloro-6-(4-ethoxybenzyl)-3-methoxy-4-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran (102 mg, 0.125 mmol) in THF / MeOH (4 mL / 2 mL) was added 10% Pd/C (10 mg) at rt. The reaction mixture was stirred at r.t. for 15 hours under hydrogen and filtered off. The filtrate was concentrated *in vacuo* and the residue was purified using reverse phase preparative HPLC to provide the title compound (17 mg, 29%) as a white solid.

(2S,3R,4R,5S,6R)-2-(7-Cyclopropyl-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E228)

¹H NMR (400 MHz, MeOD) δ 7.03 (d, *J* = 8.8 Hz, 2H), 6.77 (s, 1H), 6.75 (d, *J* = 9.2 Hz, 2H), 4.46 (t, *J* = 8.8 Hz, 2H), 4.13 (d, *J* = 9.2 Hz, 1H), 4.04 (d, *J* = 6.8 Hz, 2H), 3.97 (q, *J* = 6.8 Hz, 2H), 3.88 (dd, *J* = 12.0, 1.6 Hz, 1H), 3.69-3.64 (m, 1H), 3.50-3.43 (m, 2H), 3.37-3.35 (m, 2H), 3.20-3.12 (m, 2H), 1.49-1.42 (m, 1H), 1.35 (t, *J* = 7.2 Hz, 3H), 0.76-0.74 (m, 4H); [M+Na]⁺ 456.

Example 229 was isolated as byproduct in the course of preparation of Example 228.

10

EXAMPLE 229

(2S,3R,4R,5S,6R)-2-(6-(4-Ethoxybenzyl)-7-propyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E229)

15

¹H NMR (400 MHz, MeOD) δ 7.10-6.96 (m, 2H), 6.80-6.74 (m, 3H), 4.50 (t, *J* = 8.8 Hz, 2H), 4.14 (d, *J* = 9.2 Hz, 1H), 4.08-4.04 (m, 1H), 4.02-3.95 (m, 2H), 3.90-3.85 (m, 3H), 3.73-3.65 (m, 1H), 3.53-3.42 (m, 2H), 3.38-3.33 (m, 3H), 3.26-3.18 (m, 1H), 2.48-2.44 (m, 1H), 1.37-1.33 (m, 5H), 0.84 (t, *J* = 7.2 Hz, 3H); [M+Na]⁺ 481.

20

EXAMPLE 230

(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((1,2,3,4-tetrahydroquinolin-7-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E230)


25

¹H NMR (400 MHz, MeOD) δ 6.82 (s, 1H), 6.76 (d, *J* = 7.6 Hz, 2H), 6.41 (dd, *J* = 7.6, 1.2 Hz, 1H), 6.34 (d, *J* = 1.2 Hz, 1H), 4.61 (t, *J* = 8.8 Hz, 2H), 4.13 (d, *J* = 8.8 Hz, 1H), 3.87 (dd, *J* = 26.0, 14.8 Hz, 3H), 3.69-3.65 (m, 1H), 3.48-3.40 (m, 3H), 3.37-3.35 (m, 4H), 3.18 (t, *J* = 7.2 Hz, 2H), 2.68 (t, *J* = 6.4 Hz, 2H), 1.90-1.84 (m, 2H); [M+Na]⁺

484.

EXAMPLE 231

5




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E231)

10 ¹H NMR (400 MHz, MeOD) δ 6.82 (s, 1H), 6.55 (d, *J* = 8.0 Hz, 1H), 6.45-6.41 (m, 2H), 4.61 (t, *J* = 8.8 Hz, 2H), 4.15-4.12 (m, 3H), 3.91-3.85 (m, 4H), 3.69-3.65 (m, 2H), 3.49-3.35 (m, 7H); [M+Na]⁺ 486.

15

EXAMPLE 232




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(cyclopentyloxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E232)

20 ¹H NMR (400 MHz, MeOD) δ 7.07 (d, *J* = 8.8 Hz, 2H), 6.84 (s, 1H), 6.75 (d, *J* = 8.4 Hz, 2H), 4.75-4.73 (m, 1H), 4.61 (t, *J* = 8.8 Hz, 2H), 4.14 (d, *J* = 9.2 Hz, 1H), 3.96 (ABq, Δ*v*_{AB} = 18.4 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.88 (d, *J* = 10.8 Hz, 1H), 3.69-3.65 (m, 1H), 3.49-3.33 (m, 6H), 1.94-1.85 (m, 2H), 1.80-1.72 (m, 4H), 1.66-1.59 (m, 2H); [M+Na]⁺ 513.

25

EXAMPLE 233




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopentylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E233)

5 ¹H NMR (400 MHz, MeOD) δ 7.09 (dd, *J* = 13.6, 8.4 Hz, 4H), 6.85 (s, 1H), 4.62
 (t, *J* = 8.8 Hz, 2H), 4.14 (d, *J* = 9.2 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 18.4 Hz, *J*_{AB} = 15.2 Hz,
 2H), 3.87 (d, *J* = 10.8 Hz, 1H), 3.69-3.64 (m, 1H), 3.49-3.33 (m, 6H), 3.01-2.86 (m, 1H),
 2.05-1.99 (m, 2H), 1.85-1.76 (m, 2H), 1.75-1.63 (m, 2H), 1.60-1.51 (m, 2H); [M+Na]⁺
 497.

10

EXAMPLE 234




15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclobutoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol (E234)

1H NMR (400 MHz, MeOD) δ 7.06 (d, *J* = 8.4 Hz, 2H), 6.83 (s, 1H), 6.70 (d, *J*
 = 8.8 Hz, 2H), 4.63-4.59 (m, 3H), 4.13 (d, *J* = 8.8 Hz, 1H), 3.95 (ABq, Δ*v*_{AB} = 18.4 Hz,
*J*_{AB} = 14.8 Hz, 2H), 3.88 (d, *J* = 11.2 Hz, 1H), 3.69-3.65 (m, 1H), 3.47-3.35 (m, 6H),
 2.49-2.39 (m, 2H), 2.13-2.04 (m, 2H), 1.89-1.64 (m, 2H); [M+Na]⁺ 499.

20

EXAMPLE 235




(2S,3R,4R,5S,6R)-2-(6-(4-*tert*-Butylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-3,4,5-triol (E235)

10 ¹H NMR (400 MHz, MeOD) δ 7.27 (d, *J* = 8.4 Hz, 2H), 7.10 (d, *J* = 8.4 Hz, 2H), 6.86 (s, 1H), 4.62 (t, *J* = 8.8 Hz, 2H), 4.14 (d, *J* = 9.2 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 18.4 Hz, *J*_{AB} = 14.8 Hz, 2H), 3.87 (d, *J* = 10.8 Hz, 1H), 3.69-3.65 (m, 1H), 3.49-3.35 (m, 6H), 1.28 (s, 9H); [M+Na]⁺ 485.

EXAMPLE 236

10




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclobutylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-3,4,5-triol (E236)

15 ¹H NMR (400 MHz, MeOD) δ 7.09 (s, 4H), 6.84 (s, 1H), 4.61 (t, *J* = 8.8 Hz, 2H), 4.14 (d, *J* = 8.8 Hz, 1H), 4.00 (ABq, Δ*v*_{AB} = 18.2 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.87 (dd, *J* = 12.0, 1.2 Hz, 1H), 3.69-3.65 (m, 1H), 3.54-3.33 (m, 6H), 2.34-2.27 (m, 2H), 2.16-1.95 (m, 3H), 1.89-1.80 (m, 1H); [M+Na]⁺ 483.

20

EXAMPLE 237




(2S,3R,4R,5S,6R)-2-(7-(Difluoromethyl)-6-(4-methoxybenzyl)-2,3-dihydro-1*H*-inden-4-yl)-6-(hydroxymethyl)-tetrahydro-2*H*-pyran-3,4,5-triol (E237)

25 ¹H NMR (400 MHz, CD₃OD) δ 7.21 (s, 1H), 7.07 (d, *J* = 8.8 Hz, 2H), 6.88 (d, *J* = 54.4 Hz, 1H), 6.84 (d, *J* = 8.8 Hz, 2H), 4.33 (d, *J* = 9.2 Hz, 1H), 4.11 (ABq, Δ*v*_{AB} = 12.7 Hz, *J*_{AB} = 16.0 Hz, 2H), 3.92 (d, *J* = 11.2 Hz, 1H), 3.79 (s, 3H), 3.74-3.69 (m, 1H), 3.56-3.49 (m, 2H), 3.46-3.41 (m, 2H), 3.16-3.08 (m, 3H), 3.03-2.95 (m, 1H), 2.17-2.07

(m, 2H); [M+Na]⁺ 473.

EXAMPLE 238

5




(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E238)

¹H NMR (400 MHz, CD₃OD) δ 7.21 (s, 1H), 7.11 (d, *J* = 3.2 Hz, 4H), 4.26 (d, *J* = 9.2 Hz, 1H), 4.06 (ABq, Δ*v*_{AB} = 15.9 Hz, *J*_{AB} = 15.2 Hz, 2H), 3.90 (d, *J* = 12.8 Hz, 1H), 3.73-3.67 (m, 1H), 3.53-3.46 (m, 2H), 3.43-3.39 (m, 2H), 3.21-3.15 (m, 1H), 3.11-3.02 (m, 1H), 2.98 (t, *J* = 3.2 Hz, 2H), 2.62 (q, *J* = 3.2 Hz, 2H), 2.16-2.07 (m, 2H), 1.23 (t, *J* = 7.6 Hz, 3H).

15


EXAMPLE 239



(2S,3R,4R,5S,6R)-2-(7-(Difluoromethyl)-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E239)

¹H NMR (400 MHz, CD₃OD) δ 7.21 (s, 1H), 7.13-7.10 (m, 2H), 7.08-7.04 (m, 2H), 6.87 (d, *J* = 54.4 Hz, 1H), 4.33 (d, *J* = 12.0 Hz, 1H), 4.14 (ABq, Δ*v*_{AB} = 12.3 Hz, *J*_{AB} = 16.8 Hz, 2H), 3.91 (d, *J* = 12.4 Hz, 1H), 3.74-3.68 (m, 1H), 3.54-3.48 (m, 2H), 3.44-3.41 (m, 2H), 3.17-3.09 (m, 3H), 3.03-2.94 (m, 1H), 2.62 (q, *J* = 7.5 Hz, 2H), 2.16-2.07 (m, 2H), 1.23 (t, *J* = 9.0 Hz, 3H); [M+Na]⁺ 471.

EXAMPLE 240




(2S,3R,4R,5S,6R)-2-(6-(4-(Azetidin-1-yl)benzyl)-7-chloro-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E240)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.14 (s, 1H), 6.95 (d, *J* = 8.4 Hz, 2H), 6.56 (d, *J* = 8.4 Hz, 2H), 4.20 (d, *J* = 9.0 Hz, 1H), 3.92 (ABq, Δ*v*_{AB} = 18.9 Hz, *J*_{AB} = 14.8 Hz, 2H), 3.86 (d, *J* = 11.2 Hz, 1H), 3.66 (t, *J* = 6.2 Hz, 2H), 3.65-3.63 (m, 1H), 3.48-3.42 (m, 2H), 3.38-3.35 (m, 2H), 3.18-3.10 (m, 3H), 3.05-2.97 (m, 1H), 2.93 (t, *J* = 7.6 Hz, 2H), 2.11-2.04 (m, 2H), 1.83-1.77 (m, 2H); [M+NH₄]⁺ 478.

10

EXAMPLE 241




15 (2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzo[b]thiophen-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E241)

20 ¹H NMR (400 MHz, CD₃OD) δ 7.07 (d, *J* = 8.8 Hz, 2H), 7.04 (s, 1H), 6.78 (d, *J* = 8.4 Hz, 2H), 4.20 (d, *J* = 8.8 Hz, 1H), 3.91 (ABq, Δ*v*_{AB} = 15.8 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.86 (d, *J* = 11.2 Hz, 1H), 3.73 (s, 3H), 3.68-3.63 (m, 1H), 3.60-3.52 (m, 1H), 3.47-3.39 (m, 3H), 3.38-3.32 (m, 4H); [M+Na]⁺ = 475.

25

EXAMPLE 242




(2S,3R,4R,5S,6R)-2-(8-Chloro-7-(4-methoxybenzyl)thiochroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (E242)

5 ¹H NMR (400 MHz, CD₃OD) δ 7.15 (s, 1H), 7.07 (d, *J* = 8.8 Hz, 2H), 6.79 (d, *J* = 8.8 Hz, 2H), 4.48 (d, *J* = 8.8 Hz, 1H), 3.98 (ABq, Δ*v*_{AB} = 9.6 Hz, *J*_{AB} = 15.0 Hz, 2H), 3.86 (d, *J* = 12.0 Hz, 1H), 3.74 (s, 3H), 3.67-3.62 (m, 1H), 3.51-3.44 (m, 2H), 3.41-3.36 (m, 2H), 3.07-2.96 (m, 3H), 2.94-2.86 (m, 1H), 2.12-2.06 (m, 2H); [M+Na]⁺ = 489.

10

EXAMPLE 243



(2R,3S,4R,5R,6S)-2-(Hydroxymethyl)-6-(3-(4-methoxybenzyl)-4-methyl-5,6,7,8-tetrahydronaphthalen-1-yl)tetrahydro-2H-pyran-3,4,5-triol (E243)

15 ¹H NMR (400 MHz, CD₃OD) δ 7.20 (s, 1H), 7.05 (d, *J* = 8.8 Hz, 2H), 6.82 (d, *J* = 8.8 Hz, 2H), 4.53 (d, *J* = 9.6 Hz, 1H), 3.98 (s, 2H), 3.91 (d, *J* = 11.6 Hz, 1H), 3.78 (s, 3H), 3.72-3.67 (m, 1H), 3.66 (t, *J* = 9.2 Hz, 1H), 3.57-3.52 (m, 1H), 3.46-3.42 (m, 2H), 3.03-2.85 (m, 2H), 2.69 (t, *J* = 5.8 Hz, 2H), 2.07 (s, 3H), 1.88-1.77 (m, 4H); [M+Na]⁺ = 451.

20

In vitro assay

Test 1: Cloning and cell line construction for human SGLT2

25


Human SGLT2 (hSGLT2) gene was amplified by PCR from cDNA-Human Adult Normal Tissue Kidney (Invitrogen). The hSGLT2 sequence was cloned into pcDNA3.1(+) for mammalian expression and stably transfected into Chinese hamster

ovary (CHO) cells. SGLT2-expressing clones were selected based on resistance to G418 antibiotic (Geneticin) and activity in the ^{14}C - α -methyl-D-glucopyranoside (^{14}C -AMG) uptake assay.

5 Test 2: Inhibitory effects on human SGLT2 activities

For sodium-dependent glucose transport assay, cells expressing hSGLT2 were seeded into a 96-well culture plate at a density of 5×10^4 cells/well in RPMI medium 1640 containing 10% fetal bovine serum. The cells were used 1 day after plating. They were incubated in pretreatment buffer (10 mM HEPES, 5 mM Tris, 140 mM choline chloride, 2 mM KCl, 1 mM CaCl₂, and 1 mM MgCl₂, pH 7.4) at 37 °C for 10 min. They were then incubated in uptake buffer (10 mM HEPES, 5 mM Tris, 140 mM NaCl, 2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, and 1 mM ^{14}C -nonlabeled AMG pH 7.4) containing ^{14}C -labeled AMG (8 μM) and the inventive compound or dimethyl sulfoxide (DMSO) vehicle at 37 °C for 2 h. Cells were washed twice with washing buffer (pretreatment buffer containing 10 mM AMG at room temperature) and then the radioactivity was measured using a liquid scintillation counter. IC₅₀ was determined by nonlinear regression analysis using GraphPad PRISM [Katsuno, K. et al. *J. Pharmacol. Exp. Ther.* **2007**, 320, 323-330; Han, S. et al. *Diabetes*, **2008**, 57, 1723-1729]. The inventive compounds and their IC₅₀ are shown in following Table 1.

Table 1. hSGLT2 Inhibitory Activity









Compound	Structure	Name	IC ₅₀ (nM)
E001		(2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.15
E002		(2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	9.00

E003		(2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.738
E004		(2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.661
E005		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.681
E006		(2S,3R,4R,5S,6R)-2-(7-fluoro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.03
E007		(2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(6-(4-methoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran-3,4,5-triol	0.793
E008		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.551
E009		(2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.18
E010		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.884
E011		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.28

		triol	
E012		(2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.55
E013		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.27
E016		(2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-methoxybenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.978
E017		(2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethylbenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.845
E019		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.53
E020		(2S,3R,4R,5S,6R)-2-(6-(4-ethylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.715
E021		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.72
E022		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.833

E023		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.753
E024		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.52
E025		(2S,3R,4R,5S,6R)-2-(4-chloro-3-(quinolin-6-ylmethyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.85
E026		(2S,3R,4R,5S,6R)-2-(4-chloro-3-(quinoxalin-6-ylmethyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	8.63
E029		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	4.38
E030		(2S,3R,4R,5S,6R)-2-(3-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	9.62
E031		(2S,3R,4R,5S,6R)-2-(3-(benzo[b]thiophen-5-ylmethyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.865
E032		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydrobenzo[b]thiophen-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.16

E033		(2S,3R,4R,5S,6R)-2-(3-((1-benzyl-1H-indazol-5-yl)methyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.39
E034		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((1-methyl-1H-indol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.98
E035		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((1-methyl-1H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.72
E036		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((2-methyl-2H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.31
E037		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((1-ethyl-1H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.58
E038		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((2-ethyl-2H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.76
E039		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((1-isopropyl-1H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.76
E040		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((2-isopropyl-2H-indazol-5-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	4.44

E043		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-5-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.68
E044		(2S,3R,4R,5S,6R)-2-(5-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.65
E045		(2S,3R,4R,5S,6R)-2-(7-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.37
E046		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)benzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	275
E047		(2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol	4.17
E048		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol	2.62
E049		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	1.23
E052		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-hydroxyphenyl)-6-(hydroxymethyl)-	1.64

		tetrahydro-2H-pyran-3,4,5-triol	
E054		(2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	2.02
E056		(2S,3R,4R,5S,6R)-2-(3-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	2.58
E057		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydro-1H-inden-5-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	2.15
E060		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((5,6,7,8-tetrahydronaphthalen-2-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	2.99
E061		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(thiochroman-6-ylmethyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	3.35
E064		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,2-dimethyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	5.78
E065		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2-methyl-2,3-dihydrobenzofuran-5-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	7.62
E066		(2S,3R,4R,5S,6R)-2-(3-(Benzo[d][1,3]oxathiol-5-ylmethyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	3.67

E068		(2S,3R,4R,5S,6R)-2-(3-((4H-Benzo[d][1,3]dioxin-6-yl)methyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	9.47
E069		(2S,3R,4R,5S,6R)-2-(3-((4H-Benzo[b][1,4]dioxin-6-yl)methyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	0.788
E072		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]oxathiin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	1.75
E073		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((1,1-dioxo-2,3-dihydrobenzo[b][1,4]oxathiin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	78.5
E076		(2S,3R,4R,5S,6R)-2-(5-(4-(Ethylbenzyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	9.63
E077		(2S,3R,4R,5S,6R)-2-(5-(4-(Ethoxybenzyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	3.84
E078		(2S,3R,4R,5S,6R)-2-(5-(4-(Ethoxybenzyl)-4'-fluoro-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	93.3
E084		(2S,3R,4R,5S,6R)-2-(5-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	5.30









E085		(2S,3R,4R,5S,6R)-2-(3-Bromo-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	1.82
E086		(2S,3R,4R,5S,6R)-2-(6'-Chloro-5-(4-ethoxybenzyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	15.4
E087		3'-(4-Ethoxybenzyl)-2'-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)biphenyl-3-carbonitrile	38.9
E089		(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-methyl-5-(thiophen-3-yl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	2.55
E090		(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-methyl-5-(thiophen-2-yl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	3.73
E091		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol	0.629
E092		(2S,3R,4R,5S,6S)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol	8.65
E093		(2S,3R,4R,5S)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol	16.8

E094		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol	53.9
E095		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-(methylthio)-tetrahydro-2H-pyran-3,4,5-triol	0.628
E096		(2S,3R,4R,5S,6S)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol	18.5
E097		(2S,3R,4R,5S,6S)-2-(7-Bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol	3.83
E098		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-hydroxyphenyl)-6-(methylthio)-tetrahydro-2H-pyran-3,4,5-triol	0.454
E099		(2S,3R,4R,5S,6R)-2-(3-(4-Ethylphenyl)-1,3-dihydroisobenzofuran-5-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	56.2
E102		(2R,3S,4R,5R,6S)-2-(Hydroxymethyl)-6-(3-(4-(methylthio)phenyl)-1,3-dihydroisobenzofuran-5-yl)-tetrahydro-2H-pyran-3,4,5-triol	75.7
E103		(2S,3R,4R,5S,6R)-2-(8-chloro-7-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.82

E104		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.00
E105		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.923
E106		(2S,3R,4R,5S,6R)-2-(7-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.616
E107		(2S,3R,4R,5S,6R)-2-(6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.860
E108		(2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.26
E109		(2S,3R,4R,5S,6S)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol	29.1
E110		(2S,3R,4R,5S,6R)-2-(2-(Allyloxy)-4-chloro-5-(4-methoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol	0.504









E111		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol	0.783
E112		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triol	7.44
E113		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-5-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol	0.551
E114		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol	0.308
E115		(2S,3R,4R,5S,6S)-2-(2-(Allyloxy)-4-chloro-5-(4-methoxybenzyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol	7.06
E116		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(dimethylamino)benzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.475
E117		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-vinylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.742
E118		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopropylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.678

E119		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-vinylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.38
E120		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.09
E121		((2S,3R,4R,5S,6R)-2-(5-Chloro-6-(4-cyclopropylbenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.851
E122		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-(trifluoromethyl)benzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.97
E123		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-chlorobenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.82
E124		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(trifluoromethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.25
E125		(2S,3R,4S,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-methyltetrahydro-2H-pyran-3,4,5-triol	0.728
E126		(2S,3R,4R,5S,6S)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(fluoromethyl)tetrahydro-2H-pyran-3,4,5-triol	3.21









E127		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(1-hydroxyethyl)tetrahydro-2H-pyran-3,4,5-triol	1.35
E128		(2S,3R,4R,5S,6S)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(difluoromethyl)tetrahydro-2H-pyran-3,4,5-triol	-
E129		(2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-7-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.28
E130		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.78
E131		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.02
E132		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.706
E133		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-cyclopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.11
E134		(2S,3R,4R,5S,6R)-2-(4-chloro-2-methyl-5-(4-propylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.885

E135		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.65
E136		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.835
E137		(2S,3R,4R,5S,6R)-2-(7-chloro-2-methyl-6-(4-vinylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.00
E138		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.13
E139		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.808
E140		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(methylamino)benzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 2,2,2-trifluoroacetate	1.34
E141		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(methylamino)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 2,2,2-trifluoroacetate	2.82

E142		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.09
E143		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.03
E144		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.976
E145		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol	0.685
E146		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triol	3.45
E147		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-((S)-methylsulfinyl)tetrahydro-2H-pyran-3,4,5-triol	5.40
E148		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol	-

E149		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.80
E150		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.44
E151		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2,3-dimethoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	-
E152		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-3-hydroxy-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	-
E153		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-3-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.721
E154		(2S,3R,4R,5S,6R)-2-(5-chloro-6-(methylthio)benzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.01
E155		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-cyclopropylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.881
E156		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.09

E157		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.28
E158		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.366
E159		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.872
E160		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.08
E161		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.15
E162		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.404
E163		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-cyclopropylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.651
E164		(2S,3R,4R,5S,6R)-2-(9-chloro-8-(4-ethoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.28







E165		(2S,3R,4R,5S,6R)-2-(9-chloro-8-(4-ethylbenzyl)-3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.08
E166		(2S,3R,4R,5S,6R)-2-(6-Benzyl-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	4.22
E168		1-(4-((7-Chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methyl)phenyl)ethanone	0.960
E169		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(1-hydroxyethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.12
E170		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(1-fluoroethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.46
E171		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-vinylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.366
E172		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.463
E173		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-cyclopropylbenzyl)benzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	18.1

E174		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-propylbenzyl)benzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	574
E175		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(2-hydroxypropan-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.03
E176		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(difluoromethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.14
E177		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(1,1-difluoroethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.910
E178		(2S,3R,4R,5S,6R)-2-(6-(4-Cyclopropylbenzyl)-7-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.16
E179		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(2-hydroxybut-3-yn-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	5.20
E180		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-(prop-1-en-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.574

E181		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-isopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.794
E182		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethynylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.03
E183		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((methylamino)methyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol trifluoro acetic acid salt	122
E184		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((dimethylamino)methyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol trifluoro acetic acid salt	162
E185		(2S,3R,4R,5S,6R)-2-(6-(4-(Aziridin-1-ylmethyl)benzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol trifluoro acetic acid salt	164
E186		4-((7-Chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methyl)benzonitrile	6.06
E187		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-propylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.17
E188		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(methoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol	-









E189		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methylthio)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	-
E190		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(dimethylamino)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.11
E191		(2S,3R,4R,5S,6R)-2-(4-chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.57
E192		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(hydroxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.63
E193		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-hydroxypropoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.87
E194		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(propoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.22
E195		4-chloro-5-(4-methoxybenzyl)-7-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one	35.1

E196		(2S,3R,4R,5S,6R)-2-(4-chloro-3-hydroxy-5-(4-methoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	3.56
E197		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(dimethylamino)benzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	3.22
E198		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(2-cyclopropoxymethoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.02
E199		(2S,3R,4R,5S,6R)-2-(6-(4-(azetidin-1-yl)benzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	3.49
E200		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(trifluoromethoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.08
E201		(2S,3R,4R,5S,6R)-2-(4-chloro-3-methoxy-5-(4-methoxybenzyl)-2-methylbenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	49.4
E202		(2S,3R,4R,5S,6R)-2-(4-chloro-3-methoxy-5-(4-methoxybenzyl)benzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	42.3





E203		2-(4-((7-chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methyl)phenyl)acetonitrile	1.81
E204		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(oxetan-3-yloxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	5.05
E205		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(isopropoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.96
E206		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(cyclopropylthio)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.88
E207		(2S,3R,4R,5S,6R)-2-(7-chloro-6-((5-methoxythiophen-2-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	3.75
E208		(2S,3R,4R,5S,6R)-2-(5-chloro-6-(methoxybenzyl)chroman-8-yl)-6-(methylthiomethyl)tetrahydro-2H-pyran-3,4,5-triol	-
E209		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(methoxybenzyl)-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	-

E210		(2S,3R,4R,5S,6R)-2-(4-chloro-3-(diethylamino)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	89.3
E211		(2S,3R,4R,5S,6R)-2-(4-chloro-3-(morpholinobenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	9.08
E212		(2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	2.42
E213		(2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	6.12
E214		(2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethylbenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	3.17
E215		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.891
E216		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.22

E217		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.76
E218		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	4.66
E219		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.61
E220		(2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.27
E221		(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(pyrrolidin-1-yl)benzyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	2.17
E222		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	1.99
E223		(2S,3R,4R,5S,6R)-2-(4-Chloro-5-(4-ethoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	4.16

E224		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	0.867
E225		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	1.82
E226		7-Chloro-6-(4-ethoxybenzyl)-4-(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one	10.5
E227		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-ethoxybenzyl)-3-methoxy-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	8.99
E228		(2S,3R,4R,5S,6R)-2-(7-Cyclopropyl-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	13.8
E229		(2S,3R,4R,5S,6R)-2-(6-(4-Ethoxybenzyl)-7-propyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	5.60
E230		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((1,2,3,4-tetrahydroquinolin-7-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	2.49
E231		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	5.56

		3,4,5-triol	
E232		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopentyloxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	1.60
E233		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclopentylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	1.16
E234		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclobutoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	2.82
E235		(2S,3R,4R,5S,6R)-2-(6-(4-tert-Butylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	-
E236		(2S,3R,4R,5S,6R)-2-(7-Chloro-6-(4-cyclobutylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	-
E237		(2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.734
E238		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.627
E239		(2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.718

E240		(2S,3R,4R,5S,6R)-2-(6-(4-(azetidin-1-yl)benzyl)-7-chloro-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	1.75
E241		(2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzo[b]thiophen-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.902
E242		(2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)thiochroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	0.552
E243		(2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(3-(4-methoxybenzyl)-4-methyl-5,6,7,8-tetrahydronaphthalen-1-yl)tetrahydro-2H-pyran-3,4,5-triol	-

* Reference compound dapagliflozin $IC_{50} = 1.35 \pm 0.15 \text{ nM}$ (in-house assay).

** These data were obtained by single determinations.

5

In vivo assay

Test 3: Urinary glucose excretion in normal animals

10 Animals

Male Sprague-Dawley (SD) rats were purchased by Charles River Laboratory. All animals were housed at $23 \pm 2^\circ\text{C}$ under a 12-h light/dark cycle (light on 7:00) and were fed a standard chow and water *ad libitum*.

15

Urinary glucose excretion in normal animal

For glucosuria assessment, overnight-fasted SD rats (5 weeks of ages) were placed into metabolism cages for baseline urine collection over 24 h. Rats were weighed,


randomized into experimental groups ($n = 4$) and orally administered with 50% aqueous glucose solution (2 g/kg) and the inventive compound (E005, E010, and E020). Rats were returned to metabolism cages for 24 h urine collection. After the urine volume had been measured, the glucose concentration in the urine was determined using a 5 LabAssayTM (Wako Pure Chemicals). These data were normalized per 200g body weight [Katsuno, K. *et al.* *J. Pharmacol. Exp. Ther.* **2007**, *320*, 323-330; Han, S. *et al.* *Diabetes*, **2008**, *57*, 1723-1729].

The results were shown in Fig. 2. Fig. 2 represents effects of single oral administration of dapagliflozin, and the inventive compounds (E005, E010, and E020) 10 on urinary glucose excretion (A) and urine volume (B) in normal SD rats. All results are expressed as means \pm S.E.M. The statistical analysis was performed using a one-way ANOVA followed by Dunnett's post hoc test. * $P < 0.05$, ** $P < 0.01$ versus vehicle.

As shown above, the inventive compounds exhibited inhibitory activities against 15 sodium-dependent glucose cotransporter 2 (SGLT2) and are thus effective as SGLT2 inhibitors.

WHAT IS CLAIMED IS:

1. A compound of formula I, or a pharmaceutically acceptable salt or a prodrug thereof:




wherein,

X is oxygen or sulfur;

Y is C₁₋₇ alkyl, C₂₋₇ alkenyl, C₂₋₇ alkynyl, C₁₋₇ alkoxy, C₁₋₇ alkoxy-C₁₋₇ alkyl, C₁₋₇ alkylsulfinyl, C₁₋₇ alkylsulfonyl, or C₁₋₇ alkylthio;

ring A is



said R_{1a}, R_{1b}, R_{4a}, R_{4b} and W being each independently selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, cyano, nitro, amino, carboxy, C₁₋₇ alkyl, C₂₋₇ alkenyl, C₂₋₇ alkynyl, C₁₋₇ alkoxy, C₁₋₇ alkoxy-C₁₋₇ alkyl, C₂₋₇ alkenyl-C₁₋₇ alkyloxy, C₂₋₇ alkynyl-C₁₋₇ alkyloxy, C₃₋₁₀ cycloalkyl, C₅₋₁₀ cycloalkenyl, C₃₋₁₀ cycloalkyloxy, phenyl-C₁₋₇ alkoxy, mono- or di-C₁₋₇ alkylamino, C₁₋₇ alkanoyl, C₁₋₇ alkanoylamino, C₁₋₇ alkoxycarbonyl, carbamoyl, mono- or di-C₁₋₇ alkylcarbamoyl, C₁₋₇ alkylsulfonylamino, phenylsulfonylamino, C₁₋₇ alkylsulfanyl, C₁₋₇ alkylsulfinyl, C₁₋₇ alkylsulfonyl, C₆₋₁₄ arylsulfanyl, C₆₋₁₄ arylsulfonyl, C₆₋₁₄ aryl, 5 to 13-membered heteroaryl, or 5 to 10-membered heterocycloalkyl,


said R₂ being each independently hydroxy, C₁₋₇ alkyl, or C₁₋₇ alkoxy,

said n being an integer of 0 to 3,


said Z_1 , Z_2 , and Z_3 being each independently $-CH_2-$, $-CH=$, $-(CO)-$, $-O-$, $-S-$, $-NH-$, or $-N=$, and

said p being an integer of 1 to 3;

ring B is



B-1



B-2

with the proviso that when ring A is A-1, then ring B is B-2,
wherein,


said R_{5a} , R_{5b} , R_{6a} , and R_{6b} being each independently selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, cyano, nitro, amino, carboxy, oxo, C_{1-7} alkyl, C_{1-7} alkylthio, C_{2-7} alkenyl, C_{2-7} alkynyl, C_{1-7} alkoxy, C_{1-7} alkoxy- C_{1-7} alkyl, C_{2-7} alkenyl- C_{1-7} alkyloxy, C_{2-7} alkynyl- C_{1-7} alkyloxy, C_{3-10} cycloalkyl, C_{3-7} cycloalkylthio, C_{5-10} cycloalkenyl, C_{3-10} cycloalkyloxy, C_{3-10} cycloalkyloxy- C_{1-7} alkoxy, phenyl- C_{1-7} alkyl, C_{1-7} alkylthio-phenyl, phenyl- C_{1-7} alkoxy, mono- or di- C_{1-7} alkylamino, mono- or di- C_{1-7} alkylamino- C_{1-7} alkyl, C_{1-7} alkanoyl, C_{1-7} alkanoylamino, C_{1-7} alkylcarbonyl, C_{1-7} alkoxy carbonyl, carbamoyl, mono- or di- C_{1-7} alkylcarbamoyl, C_{1-7} alkylsulfonylamino, phenylsulfonylamino, C_{1-7} alkylsulfinyl, C_{6-14} arylsulfanyl, C_{6-14} arylsulfonyl, C_{6-14} aryl, 5 to 13-membered heteroaryl, 5 to 10-membered heterocycloalkyl, 5 to 10-membered heterocycloalkyl- C_{1-7} alkyl, or 5 to 10-membered heterocycloalkyl- C_{1-7} alkoxy, and


said ring C being C_{3-10} cycloalkyl, C_{5-10} cycloalkenyl, C_{6-14} aryl, 5 to 13-membered heteroaryl, or 5 to 10-membered heterocycloalkyl;

said alkyl, alkenyl, alkynyl, or alkoxy is optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, mercapto, C_{1-7} alkyl, and C_{2-7} alkynyl; and


said cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocycloalkyl is optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, mercapto, C_{1-4} alkyl, and C_{1-4} alkoxy.

2. The compound of claim 1, wherein said ring A-2 is selected from the group consisting of:






3. The compound of claim 1, wherein said ring B-1 is selected from the group consisting of:



in which R_7 is hydrogen, or C₁₋₇ alkyl, and R_{8a} and R_{8b} are each independently C₁₋₇ alkyl, or R_{8a} and R_{8b} are connected to form

a 5 to 10-membered heterocycloalkyl.

4. The compound of claim 1, wherein said ring B-2 is selected from the group consisting of:



5. The compound of claim 1, wherein said ring A is a benzene, indane, indene, dihydrobenzofuran, dihydroisobenzofuran, benzofuran, dihydrobenzothiophene, benzothiophene, tetrahydronaphthalene, dihydronaphthalene, chroman, chromene, isochroman, isochromene, benzodioxole, benzodioxane, benzoazazine, tetrahydroquinoline, tetrahydroquinoxaline, tetrahydroisoquinoline, indazole, indole, indoline, benzoimidazole, benzooxazole, benzothiazole, benzotriazole, quinazoline, quinoxaline, cinnoline, phthalazine, or benzotriazine ring, which is optionally substituted with a substituent as defined in claim 1.

6. The compound of claim 1, wherein said ring B is a quinoline, quinoxaline, 3,4-dihydro-2H-benzo[b][1,4]dioxepine, 2,3-dihydrobenzo[b]thiophene, indazole, indole, 2,3-dihydrobenzo[b][1,4]dioxine, benzodioxole, indane, tetrahydronaphthalene, 3,4-dihydro-2H-thiochromene, dihydrobenzofuran, benzo[d][1,3]oxathiole, tetrahydroquinoline, or 3,4-dihydro-2H-benzo[b][1,4]oxazine ring, which is optionally substituted with a substituent as defined in claim 1.

7. The compound of claim 1, which is selected from the group consisting of:

(1) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

- (2) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (3) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (4) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (5) (2S,3R,4R,5S,6R)-2-(7-fluoro-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (6) (2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(6-(4-methoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)tetrahydro-2H-pyran-3,4,5-triol;
- (7) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
- (8) (2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (9) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (10) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (11) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (12) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (13) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-methoxybenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (14) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethylbenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (15) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (16) (2S,3R,4R,5S,6R)-2-(6-(4-ethylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (17) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (18) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (19) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

- (20) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (21) (2S,3R,4R,5S,6R)-2-(5-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (22) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (23) (2S,3R,4R,5S,6R)-2-(5-(4-(ethoxybenzyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (24) (2S,3R,4R,5S,6R)-2-(5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-6-methylbiphenyl-3-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (25) (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-methyl-5-(thiophen-3-yl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (26) (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-methyl-5-(thiophen-2-yl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (27) (2S,3R,4R,5S,6S)-2-(7-bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-methoxy-tetrahydro-2H-pyran-3,4,5-triol;
- (28) (2S,3R,4R,5S,6R)-2-(8-chloro-7-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (29) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (30) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (31) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (32) (2S,3R,4R,5S,6R)-2-(6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-7-methyl-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (33) (2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (34) (2S,3R,4R,5S,6R)-2-(2-(allyloxy)-4-chloro-5-(4-methoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;
- (35) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;

- (36) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methoxyphenyl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triol;
- (37) (2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-5-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;
- (38) (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)-5-methoxyphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;
- (39) (2S,3R,4R,5S,6S)-2-(2-(allyloxy)-4-chloro-5-(4-methoxybenzyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol;
- (40) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(dimethylamino)benzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (41) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-vinylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (42) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (43) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-vinylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (44) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (45) ((2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-cyclopropylbenzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (46) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-(trifluoromethyl)benzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (47) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-chlorobenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (48) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(trifluoromethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (49) (2S,3R,4S,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-methyltetrahydro-2H-pyran-3,4,5-triol;
- (50) (2S,3R,4R,5S,6S)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(fluoromethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (51) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(1-hydroxyethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (52) (2S,3R,4R,5S,6S)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(difluoromethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (53) (2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-7-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

- (54) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (55) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (56) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (57) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-cyclopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (58) (2S,3R,4R,5S,6R)-2-(4-chloro-2-methyl-5-(4-propylbenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (59) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (60) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (61) (2S,3R,4R,5S,6R)-2-(7-chloro-2-methyl-6-(4-vinylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (62) ((2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (63) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (64) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(methylamino)benzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 2,2,2-trifluoroacetate
- (65) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(methylamino)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 2,2,2-trifluoroacetate
- (66) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (67) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (68) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-methyl-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (69) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;
- (70) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(methylsulfonyl)tetrahydro-2H-pyran-3,4,5-triol;
- (71) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2-methyl-2,3-

dihydrobenzofuran-7-yl)-6-((S)-methylsulfinyl)tetrahydro-2H-pyran-3,4,5-triol;

(72) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;

(73) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(74) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(75) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2,3-dimethoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(76) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-3-hydroxy-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(77) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-3-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(78) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-(methylthio)benzyl)chroman-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(79) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-cyclopropylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(80) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(81) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethoxybenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(82) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(83) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(84) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(85) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(86) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(87) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-cyclopropylbenzyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

(88) (2S,3R,4R,5S,6R)-2-(9-chloro-8-(4-ethoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

- (89) (2S,3R,4R,5S,6R)-2-(9-chloro-8-(4-ethylbenzyl)-3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (90) (2S,3R,4R,5S,6R)-2-(6-benzyl-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (91) 1-((4-((7-chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methyl)phenyl)ethanone;
- (92) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(1-hydroxyethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (93) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(1-fluoroethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (94) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-vinylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (95) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (96) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-cyclopropylbenzyl)benzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (97) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(2-hydroxypropan-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (98) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(difluoromethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (99) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(1,1-difluoroethyl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (100) (2S,3R,4R,5S,6R)-2-(6-(4-cyclopropylbenzyl)-7-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (101) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(2-hydroxybut-3-yn-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (102) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(prop-1-en-2-yl)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (103) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (104) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethynylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (105) 4-((7-chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl)tetrahydro-2H-pyran-2-yl)-2,3-dihydrobenzofuran-6-yl)methyl)benzonitrile;

- (106) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-propylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (107) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol;
- (108) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(methylthio)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (109) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(dimethylamino)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (110) (2S,3R,4R,5S,6R)-2-(4-chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (111) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-hydroxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (112) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(3-hydroxypropoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (113) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-propoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (114) 4-chloro-5-(4-methoxybenzyl)-7-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one;
- (115) (2S,3R,4R,5S,6R)-2-(4-chloro-3-hydroxy-5-(4-methoxybenzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (116) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-(dimethylamino)benzyl)-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (117) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(2-cyclopropoxyethoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (118) (2S,3R,4R,5S,6R)-2-(6-(4-(azetidin-1-yl)benzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (119) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(trifluoromethoxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (120) 2-(4-((7-chloro-4-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-yl)methyl)phenyl)acetonitrile;
- (121) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(oxetan-3-yloxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (122) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;

- (123) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-(cyclopropylthio)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (124) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((5-methoxythiophen-2-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (125) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-methoxybenzyl)chroman-8-yl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;
- (126) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2,3-dihydrobenzo[b]thiophen-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (127) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (128) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethoxybenzyl)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (129) (2S,3R,4R,5S,6R)-2-(5-chloro-6-(4-ethylbenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (130) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (131) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (132) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (133) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (134) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-methoxybenzyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (135) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (136) (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(pyrrolidin-1-yl)benzyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (137) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (138) (2S,3R,4R,5S,6R)-2-(4-chloro-5-(4-ethoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (139) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-3-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (140) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-3,3-dimethyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;


- (141) 7-chloro-6-(4-ethoxybenzyl)-4-(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)benzofuran-3(2H)-one
- (142) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-3-methoxy-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (143) (2S,3R,4R,5S,6R)-2-(7-cyclopropyl-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (144) (2S,3R,4R,5S,6R)-2-(6-(4-ethoxybenzyl)-7-propyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (145) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((1,2,3,4-tetrahydroquinolin-7-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (146) (2S,3R,4R,5S,6R)-2-(7-chloro-6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (147) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopentyloxy)benzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (148) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopentylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (149) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclobutoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (150) (2S,3R,4R,5S,6R)-2-(6-(4-tert-butylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (151) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclobutylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;
- (152) (2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (153) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (154) (2S,3R,4R,5S,6R)-2-(7-(difluoromethyl)-6-(4-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (155) (2S,3R,4R,5S,6R)-2-(6-(4-(azetidin-1-yl)benzyl)-7-chloro-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (156) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-methoxybenzyl)-2,3-dihydrobenzo[b]thiophen-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;
- (157) (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-methoxybenzyl)thiochroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;


(158) (2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(3-(4-methoxybenzyl)-4-methyl-5,6,7,8-tetrahydronaphthalen-1-yl)tetrahydro-2H-pyran-3,4,5-triol;

(159) (2S,3R,4R,5S,6R)-2-(4-chloro-5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methoxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol; and

(160) (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-isopropylbenzyl)-2-methyl-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.


8. A method for preparing a compound of formula **I-a**, comprising:
- reacting a compound of formula **II** with a compound of formula **III** to obtain a compound of formula **IV**; and
 - deprotecting and reducing the compound of formula **IV** to obtain a compound of formula **I-a**,




**I-a**

wherein, X, ring A and ring B are same as defined herein, Hal is halogen, and PG is trimethylsilyl or benzyl.

9. The method of claim 8, wherein step (b) is carried out by deprotecting the compound of formula IV to obtain a compound of formula V, and reducing the compound of formula V to obtain the compound of formula I-a, when PG is trimethylsilyl:

**V**

10. The method of claim 8, wherein step (b) is carried out by reducing the compound of formula IV to obtain a compound of formula VI, and deprotecting the compound of formula VI to obtain the compound of formula I-a, when PG is benzyl:

**VI**


11. A pharmaceutical composition for preventing or treating a metabolic disorder, comprising as an active ingredient the compound of formula **I** of claim 1 or a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutically acceptable carrier.

12. A method for preventing or treating a metabolic disorder in a mammal, which comprises administering the compound of formula **I** of claim 1 or a pharmaceutically acceptable salt or a prodrug thereof to the mammal.


13. A method for inhibiting sodium-dependent glucose cotransporter 2 (SGLT2) in a mammal, which comprises administering the compound of formula **I** of claim 1 or a pharmaceutically acceptable salt or a prodrug thereof to the mammal.

14. A use of the compound of formula **I** of claim 1 or a pharmaceutically acceptable salt or a prodrug thereof for the manufacture of a medicament for preventing or treating a metabolic disorder.

1/2

FIG. 1

2/2

FIG. 2**A.****B**